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Abstract 
Injury to the peripheral nervous system (PNS) stimulates a finely regulated regenerative response 
that generally leads to some recovery of function. In contrast, the response to injury in the adult 
mammalian central nervous system (CNS) is abortive and adult CNS neurons do not normally 
regenerate. We used a microarray approach to identify putative regeneration-associated changes 
in gene expression in the L4 dorsal root ganglion (DRG) in rat models of PNS and CNS injury. 
Our models included crush injury to both branches of the bifurcating axon of sensory neurons with 
cell bodies in the DRG (DRGNs). Injury to the peripheral branch at the level of the spinal nerve 
(SN) results in axonal regeneration and reinnervation. Crush injury of the central branch in the 
dorsal root (DR) results in active regeneration up to the point of CNS entry at the DR entry zone 
(DREZ) and subsequent arrest of further growth, while transection injury within the CNS at the level 
of the dorsal columns (DC) results in abortive and unsuccessful regeneration attempts. These 
DRGN injury models therefore allowed us to compare the gene expression programmes elicited 
during active, arrested and abortive regeneration. 
Following a pilot microarray experiment to optimize experimental parameters and tract tracing and 
electrophysiological experiments to confirm time points for harvest of DRGs after DR and SN 
injury, respectively, male Sprague-Dawley rats underwent an L4 SN crush, an L4 DR crush or a 
bilateral DC transection at the L3/L4 spinal segment boundary. L4 DRGs were collected at 2 weeks 
(active regeneration) and 6 weeks (arrested regeneration) after DR crush. DRGs were harvested at 
6 weeks after SN crush and 2 weeks after DC transection.   DRGs harvested from naïve rats 
served as a control group.   
Microarray analysis (Affymetrix Rat genome 230 2.0 array) identified genes showing differential 
expression (5% FDR) in regenerating and non-regenerating conditions. Selected genes chosen for 
validation by qRT-PCR included WISP2 and TFPI2- genes that were regulated specifically in the 
regenerating conditions. These genes could represent putative regeneration-associated genes and 
may suggest novel therapeutic interventions to encourage regeneration of the spinal cord following 
injury. Additionally, we have identified genes upregulated in the DR active regeneration state 
relative to DR arrested state, which have relevance to root avulsion injury and may provide insight 
into the mechanisms that prevent regeneration of DR axons through the DREZ to re-enter the 
spinal cord. We also present evidence that a transcriptional programme consistent with 
regeneration is mounted within the DRG following DC transection. This lends support to the idea 
that CNS neurons have intrinsic regenerative capability and that manipulations of the CNS 
environment may be sufficient to permit regeneration of CNS axons. 
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Definitions 
ºC    Degrees Celsius 
µ    Micro (10
6) 
ANOVA  Analysis of variance 
b    Base 
bp    Base pair 
cDNA   Complementary deoxyribonucleic acid 
CAP    Compound action potential 
CDP    Cord dorsum potential 
CNS    Central nervous system 
dATP    2’-Deoxyadenosine-5’-triphosphate 
dCTP   2’-Deoxycytidine-5’-triphosphate 
dGTP   2’-Deoxyguanine-5’-triphosphate 
dTTP    2’-Deoxythymidine-5’-triphosphate 
DEPC   Diethylpyrocarbonate 
DNA    Deoxyribonucleic acid   
dNTP   Deoxyribonucleotidetriphosphate 
DREZ   Dorsal root entry zone 
DRG    Dorsal root ganglion 
DTT    Dithiotheitol 
EDTA   Ethylenediaminetetracetic acid 
EtBr    Ethidium bromide 
g    Gram 
K    Kilo (10
3) 
l    Litre 
L4    Lumbar 4 
L5    Lumbar 5 
m    Milli (10
-3) 
M    Molar 
mRNA    Messenger ribonucleic acid 
MW    Molecular weight 
N    Nano (10
-9) 
P    Pico (10
-12) 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PFA    Paraformaldehyde 
PNS    Peripheral nervous system 
RNA    Ribonucleic acid 
RT    Reverse transcriptase 
TBS    Tris-buffered saline 
Tm    Melting temperature 
Tris    Tris(hydroxymethyl)amino methane 
U    Unit 
UV    Ultraviolet 
v    Volume 
V    Volt 
w    Weight 
W    Watt 
  16 
 
 
 
In  adult  centres  the  nerve  paths  are  something  fixed,  ended,  immutable.  
Everything may die, nothing may be regenerated.  It is for the science of the future 
to change if possible, this harsh decree. 
Santiago Ramon y Cajal, 1911.  17 
 
1  Introduction 
1.1 Regeneration in the central and peripheral nervous 
systems 
Injury to the peripheral nervous system (PNS) stimulates a complex and finely regulated 
regenerative response that generally leads to some recovery of function. In contrast, in the adult 
mammalian central nervous system (CNS), the response to injury is abortive and in normal 
circumstances, adult CNS neurons do not regenerate. Thus damage to the CNS has permanent 
and debilitating consequences such as paralysis (in the case of spinal cord injury (SCI)).    It is 
therefore of significant clinical importance to elucidate the molecular mechanisms underlying the 
failure of CNS regeneration, and to explore ways in which they can be manipulated to stimulate 
regeneration.  This project aims to compare and contrast the transcriptional response of dorsal root 
ganglion (DRG) neurons to injuries to their central or peripheral branch and to gain insight into the 
molecular mechanisms that dictate their respective injury response programmes. 
1.2 Injury to the PNS 
1.2.1 Aetiology 
Aetiologically, a number of factors including malignancy, toxins, connective tissue diseases (e.g. 
Systemic Erythematosus Lupus), metabolic factors (e.g. as in diabetes mellitus) and thermal and 
mechanical disruption can cause injury to peripheral nerves.  Of most relevance to this project and 
of wider clinical significance is mechanical injury, which can result from a number of primary 
injuries, including laceration, fracture, surgery and gunshot wounds.    
The clinical prognosis following any peripheral nerve injury will depend on the nature of the primary 
injury.  For example, the probability of functional recovery following a crush lesion is much greater 
than following a transection lesion as in nerve crush the preserved basal lamina (a layer of 
extracellular matrix on which epithelia sits) provides guidance for regenerating axons from the 
proximal nerve stump to their targets.  In contrast, the proximal and distal stumps are completely 
separated in transection injuries and thus reinnervation of targets is impeded and a swelling of the 
nerve, called a neuroma, may form.  Despite these differences in clinical outcome, the initial 
regenerative response elicited by peripheral nerve crush and peripheral nerve transection follows 
the same characteristic pattern.  
  18 
1.2.2 Wallerian Degeneration and regeneration 
In the PNS, the response to injury comprises a degenerative and subsequent regenerative phase 
that has been described in detail in a number of reviews (Stoll and Muller 1999; Stoll et al. 2002; 
Burnett and Zager 2004; Rodiguez et al. 2004).  The degenerative phase was first described by 
Augustus Waller, who in the transected hypoglossal and glossopharyngeal nerves of frogs, 
observed histological alterations in the ‘medulla’ of the nerve and in the nerve-tubes of the papillae 
(Waller 1850).  It is now recognised that these early observations describe a process that applies 
to all peripheral and central nerve lesions and is widely known as ‘Wallerian Degeneration’ (WD). 
WD (Figure 1-1) serves to create a microenvironment favouring axonal regeneration.  It begins 
within hours of injury with fragmentation of microtubules and degradation of the axoplasm and 
axolemma in the distal nerve segment.  This is mediated by increased calcium influx (George et al. 
1995) and the subsequent activation of ubiquitin-regulatory enzymes and axonal proteases such as 
calpain (Glass et al. 2002; Zhai et al. 2003; Ehlers 2004).  Zhai et al. (2003) demonstrated, using 
pharmacological methods, a critical role for the Ubiquitin-Proteasome System (UPS) in the early 
stages of WD. UPS inhibitors retarded the development of the early signs of WD and more 
specifically, microtubule fragmentation.     Modification of proteins by addition of ubiquitin can target 
them for destruction by the proteosome and thus ubiquitinisation may be a suitable candidate 
mechanism for the destruction of cellular structures as seen in WD. 
Schwann cells (the myelin producing cells of the PNS) play a pivotal role in WD and subsequent 
axonal elongation.  In response to axonal loss, Schwann cells proliferate in the distal section of the 
injured nerve to form daughter cells that upregulate genes involved in the degenerative and 
regenerative processes, and down-regulate steady-state mRNA levels for the myelin components 
(LeBlanc and Poduslo 1990).  As will be discussed later, the downregulation of myelin-associated 
components in the PNS may contribute to the creation of an environment permissive to neural 
regeneration, as such molecules are known to be growth inhibitory.  Schwann cells fragment their 
own myelin sheaths and have a role in the removal of the debris of WD by sequestration of small 
coils of myelin debris for phagocytosis.  Phagocytosis of the myelin debris is achieved partly 
through the action of the Schwann cells themselves but also through haematogenous 
macrophages that infiltrate the injured area.  Following phagocytosis of their myelin and axonal 
components, the basal lamina of Schwann cells (the endoneurial tubes) collapse and form stacked 
processes called bands of Büngner.  The bands of Büngner later serve as guidance tubes for the 
regenerating nerve fibres.  19 
 
 
 
Figure 1-1: Wallerian degeneration. a) Fragmentation of myelin occurs in the distal stump. b) 
Schwann cells proliferate in the distal stump and macrophages engulf debris. c) Axons bud and 
grow along schwann cells d) Schwann cells collapse to form bands of Büngner which guide 
regenerating nerve fibres. Adapted from www.iupucanatomy.com. 
The regenerative phase of the peripheral response to injury may begin after completion of WD (in 
the case of severe nerve injuries), or almost immediately after injury (following milder injuries), and 
can continue for a number of months.  The first signs of regeneration are seen in the neuronal cell 
body where there are visible changes marking the reversal of chromatolysis (the dissolution and 
breaking up of chromatin).  Chromatolysis is a hallmark feature of the PNS response to injury, 
occurring immediately following injury and marking a shift from synaptic transmission to cellular 
repair.  With initiation of regeneration, the cell nucleus returns to the cell centre, nucleoproteins 
reorganise into compact Nissl granules and subcellular metabolic functions that were altered during 
chromatolysis revert to their original states. 
Regeneration of the axon tip proceeds from the proximal stump of the injured nerve fibre into the 
distal nerve and relies on an increase in protein and lipid synthesis in the cell body and an 
adequate supply of trophic and tropic factors, provided by reactive Schwann cells, macrophages 
and the extracellular matrix.  Axotomised neurons express growth cones on their axon tips and 
these structures are essential to dictate the direction of axonal outgrowth.  
1.2.2.1  Growth cones 
Growth cones are dynamic actin-supported motile organelles which extend fine finger-like 
(filopodia) and web-like (lamellopodia) sensory processes that detect and allow the growth cone to 
respond to signals in their local environment (Morris and Tiveron 1994) (Figure 1-2).   A number of 
a)  c) 
b)  d)  20 
molecules have been identified that influence growth cone guidance chemotactically and these 
may be repellent or attractant in nature. These molecules include: netrins (acting through DCC and 
UNC5 receptors), Ephrins (acting through Ephrin receptor tyrosine kinases) and Slits (acting 
through Robo receptors).  In particular, a large body of research has concentrated on the 
elucidation of the role of the large semaphorin gene family in axonal guidance (Section 1.2.2.2). 
Contact guidance is also an important component of growth cone guidance and 
filopodia/lammelapodia adhere to the basal lamina of Schwann cells, using it as a guide for 
outgrowth. 
 
Figure  1-2:  Examples  of  primarily  filopodial  and  primarily  lamellopodial  growth  cones.  
Growth  cones  possess  functionally  defined  zones;  P:  The  peripheral  domain  which  primarily 
consists  of  an  actin  based  cytoskeleton.    This  region  contains  the  motile  filopodia  and 
lammelopodia;  T:  the  transitional  domain  is  the  thin  band  between  the  central  and  peripheral 
domains and C: the central domain, the region of the growth cone nearest the axon which consists 
of a microtubule based cytoskeleton and contains many organelles and vesicles (Taken from  Dent 
and Gertler (2003). 
Early observations of Aplysia axon growth in vitro indicated that axonal outgrowth occurs through a 
cycle of protrusion, engorgement and consolidation (Goldberg and Burmeister 1986) (Figure 1-3).  
Protrusion relies on the polymerisation of actin filaments, leading to the elongation of filopodia and 
lamellipodia.  Engorgement occurs when microtubules invade the protrusions and populate them 
with membranous vesicles and organelles.  Consolidation, the final stage of the cycle, involves 
depolymerisation of F-actin in the neck of the growth cone.  This allows the axonal membrane to 
shrink around the microtubules forming a new, cylindrical section of axon shaft. Dent and Gertler 
(2003) proposed that growth cone repellents and attractants in the local environment can bias one 
side of a growth cone to pass through the described stages of growth and thus influence the 
directionality of axon outgrowth.  In addition, they presented a model for cytoskeletal regulation of 
axon outgrowth and guidance involving local stabilization/destabilization of the microtubule array.  
They suggest that in normal circumstances, protrusion is in balance across the growth cone and 
thus the growth cone remains in a straight trajectory.  However, when an attractant is detected on 
one side of the growth cone, F-actin-driven protrusion is favoured on that side while retraction is 
favoured on the contralateral side. Ena/VASP proteins, a conserved family of actin-regulatory  21 
proteins that are found concentrated at filopodial tips, are implicated in translating guidance cues 
into changes in cytoskeletal dynamics and filopodial formation (Drees and Gertler 2008). 
 
Figure 1-3: Stages of axon growth.  Axons undergo a cycle of protusion, engorgement and 
consolidation whereby polymerisation of the actin meshwork in the lamellopodia of the growth cone 
results in its fillopodia that then become engorged with microtubules, vesicles and organelles. 
Depolymerisation of F-actin and membrane shrinkage in the neck of the growth cone is the final 
step in the cycle leading to axon outgrowth. Taken from Dent and Gertler (2003). 
 
 
1.2.2.2  Semaphorins in growth cone guidance 
The semaphorins comprise a family of secreted or membrane-associated proteins that can signal 
growth cone repulsion and/or attraction and can thus influence the trajectory of axonal outgrowth 
(Dodd and Schuchardt 1995; Pasterkamp et al. 2001; Pasterkamp and Verhaagen 2001).  The 
semaphorin family has been categorised according to sequence and structural similarity into eight 
classes, classes 3-7 being the vertebrate semaphorins (Figure 1-4a).   In development, 
semophorins have a mainly repulsive role in axon guidance and act by altering the axonal 
cytoskeleton by modification of actin and microtubule dynamics through a neurophilin/plexin/CAM 
receptor complex or through direct interaction with plexin or integrins (Figure 1-4b) (Rohm et al. 
2000). Semaphorin 3a, the most studied member of the semaphorin family, has been shown to 
play a key role in developmental axonal guidance by causing growth cone collapse by  22 
depolymerisation and loss of F-actin (Luo et al. 1993) through intracellular collapsin response 
mediator prioteins (CRMPS) and G-proteins (Nakamura et al. 2000; Hotta et al. 2005; 
Rosslenbroich et al. 2005; Schmidt and Strittmatter 2007). A role for membrane-bound semaphorin 
6a in the appropriate segregation of the CNS and PNS during development has also been 
suggested (Mauti et al. 2007). The role of the semaphorins is not howerver limited to the 
developing nervous system and there is a sustained expression of semaphorins and their effectors 
(such as CRMPs) during adulthood (Giger et al. 1998; Bretin et al. 2005; Sahay et al. 2005).  In the 
adult nervous system semaphorins act to prevent abberant axonal sprouting by limiting structural 
plasticity (de Wit and Verhaagen 2003). 
 
 
Figure 1-4: The vertebrate semaphorins and their receptors. a) Semaphorins have a 
conserved N-terminal signal sequence and semaphorin domain. b) Semaphorins classes 4-7 and 
a)           
 
 
 
b)  23 
semaphorin 3E can interact directly with plexins. c) Semaphorin class 3 signals though a 
neurophilin/plexin/CAM complex and c) Sema7A requires β1-integrin.  Adapted from Pasterkamp 
and Verhaagen (2006). 
1.3 Injury to the CNS 
In contrast to PNS damage, injuries to the CNS (brain and spinal cord) are almost always 
irrevocable and can lead to permanent loss of function.   Spinal cord injury has particularly 
debilitating consequences and affects approximately 40000 people in the UK alone (The Spinal 
Injuries Association (SIA), 2008. (www.spinal.co.uk)).  It is thus the focus of a large body of 
research directed towards the development of putative therapies to reinstate lost function.    
1.3.1 The anatomy of the spinal cord 
The spinal cord is the extension of the central nervous system outside the cranium and forms a 
gateway for transfer of sensory, motor and proprioceptive information between the body and brain.  
It begins immediately below the brain stem and extends to the first lumbar vertebra where it blends 
with the conus medularis to become a group of nerves resembling a horse’s tail (cauda equina).  
Three membranes (Figure 1-5) collectively known as the meninges cover the spinal cord (and also 
the brain).  The innermost membrane, the pia mater, is extremely delicate and closely covers the 
surface of the spinal cord. A weblike membrane called the arachnoid lies between the pia mater 
and the tough outermost membrane, the dura mater.  The space between the arachnoid and pia 
meninges (subarachnoid space) is filled with cerebrospinal fluid (CSF), forming a fluid filled sack 
around the brain and spinal cord.    
The spinal cord is housed and protected within the vertebral (spinal column) which has a 
segmental organisation and consists of 7 cervical, 12 thoracic, 5 lumbar, 5 sacral and 4 coccygeal 
vertebrae. 31 pairs of spinal nerves exit along the length of the spinal column through the 
intervertebral foramen (small hollows between each vertebra).  The spinal nerves branch to form 
the peripheral nerves that are responsible for movement and sensation of the extremities and 
trunk.  The origins of the spinal nerves, as they emerge from the spinal cord are called the nerve 
roots (Figure 1-5).  Each spinal nerve is formed by the merging of two roots: the dorsal root; which 
contains axons entering the spinal cord and has cell bodies in the dorsal root ganglion (DRG), and 
a ventral root; which contains axons exiting the cord. Figure 1-6 illustrates the segmental 
organisation of the spine and the relationship between the spinal nerve roots and vertebrae.   
The spinal cord itself contains a central core of grey matter which is butterfly shaped in transverse 
section (Figure 1-5).  The grey matter contains the spinal neurons and can broadly be divided into 
the dorsal (sensory) and the ventral (motor) horns.  The sensory neurons (primary afferents) 
entering the spinal cord through the dorsal roots synapse onto the spinal neurons in the dorsal 
horn and also project rostrocaudally in axon tracts in the white matter that surrounds the grey  24 
matter (see also section 1.5.2.2 and Figure 1-14).  The white matter contains ascending and 
descending axon tracts which are arranged in columns, the dorsal columns being the principle 
axon tract through which sensory information is transmitted.  
 
Figure 1-5: Diagramatic representation of the spine in transverse section (lumbar region) 
viewed from the ventral aspect.  Adapted from a diagram published by McGraw-Hill Companies, 
Inc. 
 
Figure 1-6: The relationship between the spinal nerves and vertebrae. 
(www.apparalyzed.com). 
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1.3.2 Spinal cord injuries 
Spinal cord injury causes the spinal nerves below the level of the injury to be partially or completely 
isolated from the brain.  This leads to a loss of sensory function and motor paralysis below the level 
of injury.  Depending on the level of the injury, quadriplegia/tetraplegia or paraplegia may occur 
(Figure 1-7).  Quadriplegia/tetraplegia occurs with injury above the first thoracic vertebra and 
describes paralysis that affects all four limbs.  In this type of paralysis there is further discomfort as 
the abdominal and chest muscles are also affected, resulting in weakened breathing and an 
inability to clear the chest by coughing.  Paraplegia occurs when the level of injury is below the first 
thoracic spinal nerve and can vary in severity from impairment in leg movement to complete 
paralysis of the legs and abdomen to nipple level. 
 
 
 
Figure 1-7: Injury outcomes at different levels of spinal cord injury.  The area of paralysis is 
indicted in red. 
 
Injury to the spinal cord is most common at the C5-C7 and T12-L1 levels and may be due to 
concussion, contusion, laceration, compression or complete transection.  Hyperextension and the 
resultant dorsal column contusion and posterior dislocation of the vertebrae is often seen in motor 
accidents due to the victim being thrown against the windshield or steering wheel.  Compression 
injuries are frequently seen following jumps or falls in which the individual lands on their feet or 
buttocks.  The force of the impact fractures the vertebrae and compresses the cord, most 
commonly at the lumbar and lower thoracic level. Traumatic injuries to the spine and brachial 
plexus can result in avulsion of the dorsal and ventral roots whereby the roots are damaged or are 
ripped from the spinal cord.  Although this is not a direct injury to the spinal cord, this injury, which 
is commonly caused by motor cycle accidents, often results in indirect spinal cord damage and lost 
sensory function because of the inability of the sensory fibres contained within the dorsal root to  26 
regenerate across the PNS/CNS border of the dorsal root entry zone (DREZ), despite an initial 
regenerative response (Zhang et al. 2001).  
 
1.4 Why doesn’t the CNS regenerate? 
Spinal cord injury, along with other CNS injuries such as stroke and optic nerve damage, carries an 
extremely poor prognosis because of the lack of regeneration in CNS nerves.    The investigation 
of the reasons for this lack of regeneration has found fundamental differences in the CNS response 
to injury compared to that in the PNS and a number of factors are now known to play an 
instrumental part in creating an environment that is conducive or inhibitory to neuronal 
regeneration.  This knowledge has led to the development of a number of approaches to promote 
CNS regeneration in vivo.  
The profound morphological and metabolic changes in the cell body (chromatolysis) and beneficial 
inflammatory mechanisms that occur following PNS injury are diminished or absent following an 
equivalent injury to the CNS (Lieberman 1971); WD and clearance of debris is significantly slower 
in the CNS and is incomplete (Vargas and Barres 2007). The CNS does however undergo a brief 
period of regeneration immediately following injury.  Cajal (1928) was first to confirm histologically 
that following injury, the CNS undergoes a phase of abortive sprouting around the injury site 
whereby the newly formed axons were often hypertrophied, branched and irregular and ended in 
clubs, points or rings.  In addition, he demonstrated growth of CNS cortical axons through pre-
degenerated peripheral nerve graft and hypothesised that the failure of CNS regeneration was due 
to the absence of a number of extrinsic growth promoting and neurotrophic factors that are present 
in the PNS.  Indeed, David and Aguayo (1981) showed that neurons in the adult mammalian CNS 
were capable of long distance axon regeneration if provided with an appropriate glial environment 
and a number of extrinsic factors have been identified that contribute to the CNS injury response.  
Conversely, there is evidence that PNS myelin is not permissive to axonal growth (Bahr and 
Przyrembel 1995) and manipulation of extrinsic factors is insufficient to promote axonal outgrowth 
in the CNS (Dusart et al. 2005) This, along with the observation that there is variation in intrinsic 
regenerative potential between PNS and CNS neurons and also within different classes and ages 
of neurons in the CNS (Chen et al. 1995; Ng and Lozano 1999), suggests that PNS neurons 
possess intrinsic properties that allow them to regenerate.   The failure of CNS axonal regeneration 
is therefore multifactorial, involving extrinsic and intrinsic factors.  27 
1.4.1 Extrinsic factors and how they are targeted 
1.4.1.1  Myelin-associated inhibitors of regeneration 
Myelin-associated inhibitors and the formation of a glial scar are two major obstacles to CNS axon 
regeneration (Figure 1-8) and have been targeted therapeutically (see reviews (Fawcett and Asher 
1999; Gurgo et al. 2002; Batchelor and Howells 2003; Spencer et al. 2003; Profyrus et al. 2004)).  
Myelin-associated inhibitors are localised predominately on the innermost lamella of the myelin 
sheath (McKerracher and Winton 2002) and are exposed during axonal damage.  They are thus 
the principle obstacles to axonal regeneration in the acute phase of CNS injury.  Three such 
inhibitors have been identified (Figure 1-9); myelin-associated glycoprotein (MAG) (McKerracher et 
al. 1994), oligodendrocyte-myelin glycoprotein (OMgp) (Kottis et al. 2002) and Nogo-A (Prinjha et 
al. 2000), the antigen for IN-1, a monoclonal antibody previously shown to permit some CNS 
regeneration and functional recovery in rats (Caroni and Schwab 1988; Bregman et al. 1995).  
Myelination is key to limiting plasticity and thus preventing aberrant sprouting within the adult CNS 
(Schwegler et al. 1995).   The limited regenerative capacity of the CNS is therefore a necessary 
consequence of this restricted plasticity.  This is supported by the observation that the loss of 
regenerative capacity in the mammalian CNS is concurrent with myelination (Ghooray and Martin 
1993).  
 
 
Figure 1-8: Barriers to axonal regeneration- myelin-associated inhibitors of regeneration are 
exposed on damage to myelin and a glial scar that forms a physical barrier to regeneration is 
formed.  Taken from Spencer et al. (2003). 
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Figure 1-9:  Structural features of the myelin associated inhibitors and their receptors.  MAG 
has a large extracellular domain and an intracellular C-terminus.  Nogo-A has a short extracellular 
domain (Nogo-66) that can induce growth cone collapse by binding to NgR, its C- and N-terminus 
domains are internalised.  OMgp is a cell adhesion molecule that is linked to the membrane by a 
GPI-anchor.  It has a leucine rich repeat (LRR) domain that binds NgR causing growth cone 
collapse.  p75
NTR acts as a co-receptor with the Nogo receptor (NgR) interacting with the C-terminal 
end of the LRR.  Small GTPase adaptor proteins bind the death domain of p75NTR  and mediate 
growth cone collapse via activation of RhoA.  (adapted from (Profyrus et al. 2004).  
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The myelin associated inhibitory molecules are juxtaposed at the myelin-axon interface to the Nogo 
receptor (NgR), and all three (with exception of the N-terminal region of Nogo-A, the amino-nogo 
domain, whose receptor is unknown but which appears to function via inhibition of integrin 
signalling (Hu and Strittmatter 2008), exert their effects via this receptor (Wang et al. 2002) (Figure 
1-10).  NgR, a glycosylphosphatidylinositol (GPI)-linked protein, lacks transmembrane and 
cytosolic domains and utilises the neurotrophin receptor p75 (p75
NTR) as a transducing partner 
(Yamashita et al. 2002).  Thus, despite distinct structural features, OMgp, the extracellular region 
of Nogo-A (Nogo-66) and MAG bind the NgR receptor with similar affinities and consequently 
activate common intracellular signalling pathways. In particular, the Rho signalling pathway has 
emerged playing a particularly important role in the inhibition of axonal outgrowth by several myelin 
components. 
The Rho family of small GTPases are key regulators of cytoskeletal dynamics and cell motility (Hall 
1998).  Specific inactivation of RhoA by C3 transferase has been shown to block myelin-induced 
inhibition of neurite outgrowth and growth cone collapse (Jin and Strittmatter 1997) and to promote 
axon regeneration in vivo (Lehmann et al. 1999; Dergham et al. 2002).  The Rho GTPases cycle 
between the GTP-bound (active) and guanosine diphosphate (GDP)-bound (inactive) states as 
regulated by guanine nucleotide exchange factors.  Binding of myelin inhibitory factors to the NgR 
results in activation of Rho GTPases, which ultimately leads to growth cone collapse (Figure 1-10).  
Elevation of neuronal cAMP levels has been shown to prevent Nogo-A and MAG induced RhoA 
activation (Bandtlow 2003).   Intracellular cAMP levels are raised by a conditioning lesion (see also 
1.4.2.1) in the PNS prior to CNS injury (Qiu et al. 2002) and such conditioning lesions have been 
shown to allow regeneration of the axotomised central processes of DRG neurons inside the spinal 
cord (Neumann and Woolf 1999).   
Strategies to encourage CNS regeneration in vivo have targeted the myelin-associated inhibitors 
and their receptors (extrinsic approaches) or their intracellular signalling pathways (intrinsic 
approaches).  As already discussed, the monoclonal antibody IN-1 has been successful in 
encouraging CNS regeneration by blocking the effects of Nogo-A in vivo.  Antibodies against the 
other inhibitory myelin components may therefore be of some therapeutic benefit. However the 
difficulties in delivery of such antibodies to the CNS has not yet been fully addressed.   A vaccine 
approach whereby the patient’s immune system is stimulated to produce antibodies against myelin-
associated inhibitors would overcome problems with antibody delivery and has had some degree of 
success in vivo (Huang et al. 1999).  Antagonistic peptides, such as NEP1-40, that block NgR have 
also had limited success in vivo (GrandPre et al. 2002).  The identification of the receptor for 
Amino-Nogo will allow for a more complete blockade of the effects of the myelin-associated 
inhibitors. 
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Figure 1-10: Molecular mechanisms of growth cone collapse following myelin-associated 
inhibitor binding with NgR. Guanine triphosphate exchange factors (GEFs) activate RhoA which 
then associates with the plasma membrane and binds serine-threonine kinase Rho-kinase (ROK), 
rendering ROK’s kinase active.  ROK phosphorylates the regulatory light chain of the major 
cytoplasmic myosin (myosin II), thus increasing myosin II’s activity of actin-activated ATPase.  
Activation of this ATPase hydrolyses myosin ATP and initiates contraction between myosin within 
the growth cone and actin filaments of the filopodia.  This contraction pulls the actin filaments 
towards the centre of the growth cone, which culminates in growth cone collapse. Taken from 
Profyrus et al. (2004)  31 
1.4.1.2  Glial scar 
The other major barrier to CNS regeneration, the glial scar, is an evolving structure that forms over 
several days (Buss et al. 2004).  It is composed of a number of cell types (oligodendrocytes, 
microglia/macrophages, meningeal cells and oligodendrocyte precursors) but consists mainly of a 
meshwork of astrocyte processes bound together by tight and gap junctions (Fawcett and Asher 
1999). Reactive astrocytes have been shown to be inhibitory to axon growth in vitro (Fawcett et al. 
1989) and this is due to secretion of certain extracellular matrix components of which the 
chondroitin sulphate proteoglycans (CSPGs) and to a lesser extent, the tenascins, have emerged 
as being particularly important (Eddleston and Mucke 1993).  In vitro treatment of reactive 
astrocytes with Chondroitinase ABC (that removes the chondroitin sulphate GAG chains from 
CSPG) has been successful in neutralising the inhibitory activity of the CSPGs (Rudge and Silver 
1990). Furthermore, recent evidence has suggested that a CSPG (Versican V2) exerts its inhibitory 
effects on axonal regeneration via the Rho signalling pathway (Sweigreiter et al. 2004).  There is 
potential therefore for combined block of inhibitory molecules associated with the scar and those 
associated with myelin at this common point of signal convergence.   
Another approach to overcome the glial scar as a physical barrier to regeneration is the use of 
cellular substrates to bridge the injury site.  Cell grafts of olfactory ensheathing cells (OECs), 
macrophages, embryonic and bone marrow stem cells and Schwann cells, as well as PNS nerve 
grafts, have all been investigated.  Seemingly one of the most promising of these strategies is the 
use of OECs, specialised glial cells that guide primary olfactory axons from the neuroepithelium in 
the nasal cavity to the brain.  OECs used in isolation have however had limited success in 
promoting regeneration across the transplant (Riddell et al. 2004; Collazos-Castro et al. 2005) 
although there is electrophysiological evidence that they improve functional recovery after dorsal 
column transection injury (Toft et al. 2007). The potential and limitations for the use of OECs in 
spinal cord injury have been discussed in a number of recent reviews (Barnett and Riddell 2004; 
Barnett and Riddell 2007; Radtke et al. 2008; Yuan 2008). The limited success of this and other 
similar strategies again highlights the multifactorial nature of CNS regenerative failure and the need 
for a multi-faceted approach to promote regeneration in vivo. 
Neurotrophic factors have also been used in an effort to overcome growth inhibitory effects of 
molecules associated with the glial scar and myelin (Romero et al. 2001; Ramer at al. 2002). They 
include the family of neurotrophins (nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6), ciliary neurotrophic factor (CNTF) and glial 
derived neurotrophic factor (GDNF).  The neurotrophin family bind specifically to one of three 
membrane bound trk receptor tyrosine kinases and to the p75 neurotrophin receptor (Figure 1-11) 
and induce axonal extension and dendritic arborisation by acting on cytoskeletal proteins (Chao 
2003).   32 
1.4.1.3  Inhibitory molecules in the DREZ 
Dorsal root avulsion injury (section 1.3.2) is an intractable injury because sensory fibres are 
prevented from regenerating across the CNS/PNS interface of the DREZ.   Zhang et al. (2001) 
observed that dorsal root axons regenerate as far as the DREZ where they grow no further or turn 
back towards the ganglion suggesting the presence of repellent molecules in the DREZ.      They 
found two molecules, tenascin-R and chondroitin sulfate proteoglycan 4 (CSPG4 or NG2) to be 
highly expressed in the DREZ suggesting that these may contribute to the inhibition of regeneration 
at the DREZ.  Ramer et al. (2001) have proposed a two-tiered inhibition at the DREZ. The first 
barrier is astrogliotic and surmountable by treatment with neurotrophins whilst the second barrier is 
caused by spinal cord degeneration with infiltration of phagocytes and cannot be overcome by 
neurotrophin treatment. This is supported by another study in which delayed NT-3 treatment was 
not sufficient to overcome the barrier caused by the protracted myelin clearance in the CNS 
(McPhail et al. 2007).  This study suggested facilitation of the elimination of myelin in combination 
with neurotrophin treatment could constitute an effective therapeutic approach for treatment of 
dorsal root avulsion and again highlights the multiplicity of the extrinsic barriers to regeneration and 
the requirement for tailored interventions to overcome them. 
 
1.4.2 Intrinsic determinants of regeneration 
Evidence points to there being multiple intrinsic factors involved in the regenerative failure of the 
CNS. Firstly, attempts to neutralise the inhibitory extrinsic factors within the CNS have not been 
sufficient to encourage regeneration (Schwab 1993) whilst different types of neuron have been 
reported to have different responses to injury despite existing in the same environment and hence 
having exposure to the same extrinsic factors (Dusart et al. 2005).  Furthermore, intrinsic growth 
capacity is reduced with age such that embryonic neurons have a greater intrinsic capacity for 
growth than adult neurons. Finally, it has been demonstrated both in vivo (Jacob and McQuarrie 
1993; Chong et al. 1999; Neumann and Woolf 1999) and in vitro (Smith and Skene 1997) that 
‘conditioning’ peripheral nerve lesions increase the ability of the associated primary afferent central 
processes to regenerate successfully.   
1.4.2.1  Clues from conditioning lesions 
Injury to peripheral branch neurons elicits a very different cell body response than injury to central 
branch neurons (Smith and Skene 1997). The expression of regeneration-associated genes 
(RAGs) such as growth associated proteins (GAP43 and CAP23) and the immediate-early gene c-
jun is induced after peripheral nerve injury while their induction is reduced or absent after a central 
lesion (Chong et al. 1994; Broude et al. 1997; Andersen and Schreyer 1999) (see also section 
1.5.2).  The conditioning peripheral nerve lesion acts to encourage central regeneration by priming 
the cell body with the activation of an intrinsic transcriptional programme within the cell body that 
marks a switch of function away from synaptic transmission and towards regeneration. In order to  33 
sustain axonal elongation a neuron must synthesize structural components for newly formed 
processes and activate signal transduction pathways that decode external guidance cues and is 
associated with dramatic changes in gene expression.  The identification of genes associated with 
the intrinsic regenerative ability of the PNS and the corresponding lack of regeneration in the CNS 
has thus become the aim of a number of global gene expression studies (section 1.5).  
The transcriptional effects of the conditioning lesion are downstream of a primary elevation of 
intracellular cAMP. cAMP also has a transcription-independent local effect on the growth cone 
cytoskeleton through type II PKA, which is enriched in filopodia (Han et al. 2007).  Indeed, 
intraganglionic injection of cAMP can mimic the effect of a conditioning lesion to increase 
regeneration of the central branch of lesioned neurons (Neumann et al. 2002; Qiu et al. 2002). The 
transcription-dependent effect of cAMP requires activation of the cAMP response element binding 
protein (CREB) (Gao et al. 2004) and leads to the upregulation of, among other genes, arginase I 
(ArgI), and subsequent increased synthesis of polyamines (Cai et al. 2002) (Figure 1-11). It has 
been shown that increased intracellular cAMP can help axons to overcome the inhibitory molecules 
associated with myelin and can even convert negative growth cues to positive ones (Song et al. 
1998; Spencer and Filbin 2004).  This demonstrates how the intrinsic state of the neuron can 
modulate its response to extrinsic factors.   CREB may be central to this effect but is however 
multifunctional and is therefore not an attractive target for therapeutic manipulation.  The 
identification of CREB-regulated transcriptional events could however lead to pharmacological 
manipulation of the intrinsic regenerative potential of CNS neurons. 
The observation that conditioning lesions are less effective in the sensory neurons of LIF null 
(Cafferty et al. 2001) and Il-6 null mice (Cafferty et al. 2004) has led to the suggestion that these 
genes play an important role in the mitigation of the conditioning lesion effect.  Both these 
cytokines signal via the JAK-STAT pathway and activate signal transducer and activator of 
transcription 3 (STAT3) (Horvath 2004; O'Brien and Nathanson 2007) (Figure 1-11).  STAT3 can 
induce transcription of SPRR1A, a protein known to be involved in growth cone dynamics and that 
promotes axon outgrowth (Bonilla et al. 2002) (see also section 1.5.2.3). 
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Figure 1-11: Signalling molecules involved in mediating intrinsic regenerative potential.  
Intrinsic regenerative capacity is conferred by cAMP- CREB and cytokine-STAT3 mediated 
activation of transcription and production of growth promoting gene products such as ARG1 and 
SPRR1A which overcome Rho activation by myelin associated inhibitors.  The transcription of 
growth promoting genes can be enhanced by BCL-2 which activates CREB and modulates calcium 
signalling.  Adapted from Teng and Tang (2006)    
1.4.2.2  Clues from embryonic neurons 
Embryonic CNS neurons have a greater intrinsic capacity for growth than adult CNS neurons and 
can therefore provide information as to which genes are important in providing a neuron with 
intrinsic regenerative ability.  Loss of regenerative potential is concominant with a dramatic 
decrease in the expression of Bcl-2 (Chen et al. 1997) (Figure 1-11).  Furthermore, Bcl-2 
overexpression overcomes loss in intrinsic regenerative capacity with development by enhancing 
Ca
2+ signalling and activating CREB (Jiao et al. 2005). Bcl-2 expression is maintained in the PNS 
in adulthood further supporting a role for this protooncogene in the regenerative capacity of trhe 
PNS and the corresponding lack of regeneration in the adult CNS (Merry et al. 1994). 
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Another group of molecules that appear to decline with development are receptors for the adhesive 
molecules L1/NgCAM, Integrins (Figure 1-11) and cadherins that embryonic neurons use to extend 
axons in the spinal cord (Blackmore and Letourneau 2006).  This raises the possibility that the 
reduced expression of these receptors contribute to the low-regenerative capacity of adult neurons.  
Transected peripheral axons undergo adhesive changes and these are essential for their 
regeneration. Werner et al. (2000) demonstrated impaired axonal regeneration in α7 Integrin-
deficient mice.  α7 Integrin is strongly upregulated in neurons and axons following peripheral but 
not central nerve injury and has been shown to be involved in the conditioning lesion effect (section 
1.4.2.1) by increasing axon responsiveness to laminin (Ekstrom et al. 2003).  Similarly, L1/NgCAM 
and its homologue CHL1 are upregulated at 2-5 weeks following sciatic nerve injury while dorsal 
root transection elicited only transient upregulation of CHL1 and minimal upregulation of L1 (Zhang 
et al. 2000).  CHL1 was also strongly upregulated by dorsal root Schwann cells that support 
regeneration, but not by CNS glia in the DREZ where regeneration is blocked.  Taken together, this 
suggests an important role for adhesion molecules in the creation of an environment that is 
conducive to axonal regeneration.   
That cAMP plays an important role in the intrinsic regenerative potential of neurons is further 
supported by the fact that there is a decline in developing neuronal cAMP which renders adult 
mammalian CNS neurons more susceptible to myelin associated inhibitors (Fawcett 1992) (see 
also section 1.4.1.1).  The role of CREB in cAMP signalling has already been discussed (see 
section 1.4.2.1).  More recently cAMP has been shown to enhance neurite outgrowth through 
activation of Rap guanine nucleotide exchange factor (Epac) which can act independently of PKA 
through the MAPK/ERK1/ERC2 signalling casade (Bos 2003) (Figure 1-11). Epac is 
developmentally regulated and can enhance neurite outgrowth and growth cone turning in vitro 
(Murray and Shewan 2008).  It is therefore an attractive target to increase intrinsic growth ability by 
overcoming extrinsic inhibitory molecules. 
 
 
1.5 Genome-wide approaches to investigating neuronal 
regeneration  
The  growth  programme  initiated  by  peripheral  axotomy  provides  adult  DRG  neurons  with  both 
intrinsic growth capacity and the ability to overcome a hostile environment.  In recent years there 
has been an explosion of research centred on identifying genes that are key to this regenerative 
response and the corresponding lack of regeneration in the adult CNS.  While some researchers 
have chosen a focused study of the expression of one particular gene or a small set of genes, the 
birth  of  DNA  microarray  technology  (section  1.6.2)  has  allowed  researchers  to  obtain  vast 
quantities of information from a single experiment and hundreds of genes are now known to be 
differentially expressed in nerves following various experimental models of PNS (Araki et al. 2001; 
Costigan et al. 2002; Schmitt et al. 2003) and CNS (Tachibana et al. 2002; Di Giovanni et al. 2003; 
Schmitt et al. 2003; Aimone et al. 2004; Kury et al. 2004; Velardo et al. 2004) injury.    These  36 
studies have examined gene expression changes at the lesion site or in the neuronal cell body 
itself. 
 
 
1.5.1 Gene expression changes at the lesion site  
1.5.1.1  CNS lesion site studies 
The majority of microarray studies that have addressed the mammalian CNS response to injury 
have examined gene changes at the spinal cord lesion zone (Carmel et al. 2001; Song et al. 2001; 
Nesic et al. 2002; Tachibana et al. 2002; Bareyre and Schwab 2003; Di Giovanni et al. 2003; Liu et 
al. 2003; Aimone et al. 2004; Resnick et al. 2004; Zhang et al. 2004; De Biase et al. 2005; Di 
Giovanni et al. 2005; Hashimoto et al. 2005; Xiao et al. 2005; Schmitt et al. 2006).  These studies, 
with the exception of a couple, (Resnick et al. 2004; Schmitt et al. 2006), have concentrated on 
acute changes occurring within hours to a few days of the injury. 
The gene changes observed at the lesion site following a primary injury to the spinal cord are 
consistent with a number of vascular, metabolic, biochemical and cellular alterations that together 
form the pathophysiology or secondary injury of SCI. Immediately after injury (within 6 hours), there 
is downregulation of ion channels (K+, Na+ and Ca2+) and transporters (GABA and glutamate) 
involved in cell excitability (Carmel et al. 2001; Song et al. 2001; Tachibana et al. 2002; Di 
Giovanni et al. 2003). In addition, there is a strong upregulation of interleukins and other 
inflammation-related factors (Carmel et al. 2001; Di Giovanni et al. 2003) reflecting recruitment of 
peripherally derived immune cells to the lesion zone (Schnell et al. 1999; Bethea and Dietrich 
2002).  At high concentrations pro-inflammatory molecules can lead to the activation of 
transcription factors that lead to cell death.  Indeed, there is a strong induction of transcription 
factors involved in cell damage and death in the acute stage of SCI (Song et al. 2001).   (Song et 
al. 2001) also reported an elevation in immediate early gene expression with c-jun showing a 
particularly dramatic upregulation.  
Studies that have examined gene expression changes at 12-72 hours after SCI have shown that 
many of the changes seen in the acute stage after SCI are sustained or augmented.  In addition, 
there is downregulation of synaptic molecules and cytoskeletal proteins (Carmel et al. 2001) 
reflecting the compromised functional integrity of the spinal cord at this time point and suggesting 
impaired synaptic function. There is however elevated expression of growth factors such as VGF, 
BDNF and IGF (Song et al. 2001, Carmel et al. 2001) suggesting that the spinal cord makes an 
attempt at regeneration. 
Less is known from microarray studies about gene expression in the lesion zone during the chronic 
phase of SCI.  There are however phenomena, such as neuropathic pain, that develop some 
weeks to months following injury suggesting that biochemical and functional changes are still 
taking place at this late time point after injury (Hulsebosch et al. 2000).  In support of this (Resnick  37 
et al. 2004) noted changes occurring at the molecular level at 42 days following SCI in rat.  Among 
these changes was a reduction in myelin-associated glycoprotein (MAG), a change that was not 
seen during the acute phase of SCI.  A more recent study by the same authors suggests that the 
gene expression in chronic SCI varies between rat stains which show differing potential for 
functional recovery after SCI (Schmitt et al. 2006) providing evidence for a link between intrinsic 
genetic background and regenerative capacity.   
 
1.5.1.2  PNS lesion site studies 
Following peripheral nerve injury changes occur at the lesion site that allow axonal regeneration 
(Section 1.2.2).  An important aspect of this is the proliferation of Schwann cells in the distal nerve 
segment.  In order to identify genes involved in Schwann cell activation (Araki et al. 2001) 
examined gene changes in the distal stumps of sciatic nerve lesioned rats at several time points 3 
hours to 56 days post-lesion. They identified four distinct groups of genes that clustered together 
according to their temporal regulation, each cluster potentially representing a different biological 
process. One cluster corresponded to early induction of IEGs.  Another group of genes that were 
induced early and peaked around 7 days contained gene associated with macrophage infiltration 
and proliferation (KI67 and MAC1).  A third cluster of genes was induced at around 3 days and 
peaked 7-14 days post-injury.  The cluster contained genes such as GFRα1 which is known to be 
expressed by Schwann cells during Wallerian degeneration and to be negatively regulated by axon 
contact (Taniuchi et al. 1988) suggesting that regenerating axons contact the distal segment at 7-
14 days post injury.  The final cluster of genes, containing neurotrophic and growth factors such as 
BDNF and GDNF, was induced at 7 days post-lesion and peaked at 14 days consistent with 
phenotypic changes in Schwann cells to promote neurite outgrowth. 
(Kubo et al. 2002) examined changes in the distal stump 7 days after sciatic injury in mice, a time 
point at which many genes had been shown to peak (Araki et al. 2001).  They showed a number of 
similarities and differences in gene regulation at the PNS lesion zone from that seen in the CNS, 
the main difference being the absence of the induction of proinflammatory mediators in the PNS 
lesion zone.  This revealed important differences between peripheral and central immune 
responses after injury that may influence potential to regenerate. 
1.5.2 The cell body response to injury 
1.5.2.1  How is injury signalled to the cell body? 
The cell body of a neuron is often some distance from the site of nerve injury yet the neuron 
responds to injury to its axon with changes in gene expression.  Injury is signalled in three ways 
(Figure 1-12). Immediately after damage to the axon the first indication of injury is a rapid burst of 
action potentials called ‘injury discharge’ that propagates to the cell body (Berdan et al. 1993)  38 
(Figure 1-12a).  From hours to days after injury there are ‘positive signals’ that are conveyed to the 
cell body by retrograde transport.  These are de novo activated proteins emanating from the injury 
site (Figure 1-12c).  In addition to these positive signals, termination of normal trophic support 
constitutes a ‘negative signal’ to the cell body  (Figure 1-12b) (Ambron and Walters 1996; Perlson 
et al. 2004).  
 
 
Figure 1-12a-c: Retrograde signalling of axonal injury. Injury is initially signalled by rapid bursts of 
action potentials. Termination of normal trophic support causes disinhibition of gene transcription 
whilst locally translated positive cues cause activation of gene transcription.   Taken from Rossi et 
al. (2007). 
1.5.2.2  Studying the cell body response using the dorsal root ganglion neuron 
The dorsal root ganglion neuron (DRGN) is a pseudounipolar neuron that has an axon that 
bifurcates from a cell body contained within the DRG (Figure 1-13). Peripheral branch DRG axons 
form the peripheral nerves and serve as sensory receptors in various organs while the central 
branch DRG axons course though the dorsal root and make synaptic connections on neurons, 
largely within the dorsal horn, and also project rostrocaudally in axon tracts in the dorsal columns. 
Central axotomy thus deprives the DRG cell of a different set of target-defined interactions than 
does peripheral axotomy.  In addition, while the peripheral branch generally regenerates and  39 
reforms functional connectivity with its innervating organs, the central branch sprouts through the 
dorsal root but is growth arrested at the CNS-dorsal root junction (dorsal root entry zone (Quaglia 
et al. 2008). If the injury is within the CNS at the level of the dorsal columns, attempts to regenerate 
are abortive.  This presents the opportunity to explore, in the same nerve cell body, gene 
expression associated with regeneration of the peripheral and central branches and also that 
associated with blocked or abortive regeneration.   
To date, most of the microarray studies examining gene expression changes in the DRG have 
examined changes associated with sciatic or spinal nerve injury.  Only one (Stam et al. 2007) has 
been comparative in nature, comparing gene expression after injury to the dorsal root with that 
after sciatic nerve crush.  To the best of my knowledge, there have been no published microarray 
studies of gene expression changes in the DRG after spinal cord injury. 
 
Figure 1-13:  Schematic diagram illustrating the primary sensory neurons located within the 
dorsal root ganglion.  Laminae I-VI (marked on the left of the diagram) constitute that dorsal horn 
and many of the sensory neurons entering from the dorsal root terminate here while others form 
ascending sensory pathways in the dorsal columns. Taken from Hochman (2007). 
 
1.5.2.3  The neuronal response to sciatic and spinal nerve injury 
Much of what we know about the neuronal response to peripheral nerve injury comes from studies 
that aim to elucidate the molecular mechanisms of neuropathic pain rather than the mechanisms of 
regeneration per se.  Studies that have examined gene expression changes in the DRG 
accompanying neuropathic pain caused by spinal nerve ligation (Wang et al. 2002; Valder et al. 
2003) have found changes in immediate early genes, in ion channels and signalling molecules 
associated with excitability of neurons and in genes indicative of neuroinflammation.  
Costigan et al. (2002) used triplicate microarrays to examine  changes in gene expression in the L4 
and L5 dorsal root ganglion of rats 3 days following sciatic nerve transection by comparing 
expression levels with non-injured DRGs. The microarray data were validated using northern blots,  40 
quantitative slot blots and in situ hybridisation.  While only a small number of genes were validated, 
the authors gave a conservative estimate of 240 regulated genes and functional classification of 
these genes indicated an up-regulation of genes expressed by immune and inflammatory cells and 
a down-regulation of those genes involved in neurotransmission.  This is consistent with the notion 
that peripheral nerve injury initiates an inflammatory response in the cells of the DRG, migration of 
inflammatory cells into the DRG and a phenotypic switch away from neurotransmission. 
Bonilla et al. (2002) examined global gene expression changes in the DRG 1 week after sciatic 
nerve transection in the mouse.  They found the highest level of upregulation in the muscle stretch 
sensor protein, small proline-rich repeat protein 1A (SPRR1A) and this was verified by Northern 
blot.  SPRR1A is expressed in sensory and motor fibres and the authors show that it colocalises 
with F-actin axonal growth cones, consistent with a role in axonal outgrowth by modification of actin 
dynamics.  Indeed, they showed that acute overexpression of SPRR1A can promote axonal 
outgrowth of adult neurons and can increase axonal outgrowth of embryonic neurons on inhibitory 
substrates whilst blockade of SPRR1A expression decreases adult outgrowth of adult neurons.  
This demonstrates the potential for promoting axonal outgrowth through manipulation of proteins 
that affect F-actin driven growth cone dynamics.  
In a more recent study using chips covering a higher proportion of the mouse genome (Tanabe et 
al. 2003) performed a more complete survey of DRG gene expression changes 1 week following 
sciatic nerve transection in the mouse.  They identified a novel regeneration-associated gene, 
fibroblast growth factor-inducible 14 (FN14) and showed that this induces neurite outgrowth, 
filopodial and lamellopodial formation and growth cone formation in PC12 cells.  Furthermore, they 
show that FN14 interacts with the Rho family GTPase Rac1.  The Rho family of GTPases are 
known to have a role in modulating F-actin structures (Hall 1998) and hence influence growth cone 
motility. This suggests that, like SPRR1A, FN14 may act upon F-actin structures in the growth cone 
to enhance neurite extension.  It also demonstrates that there are multiple components active at 
the level of the growth cone. 
A comparison of these three sciatic nerve studies reveals eleven consistently regulated genes; 
neuropeptides (NPY and GAL), cytoskeletal proteins (GAP43 and SPRR1A), calcium signalling 
(calcium channel alpha-2-delta subunit), development (SOX11), cell death (GADD45, annexin-1 
(ANXA1), HSP27, cytochrome P450 1bl1 (CYP1B1)) and extracellular matrix (MMP9).  All these 
genes may play an important role in the regenerative response of the PNS to injury.  The 
microarray studies thus far have however only covered a small proportion of the mouse or rat 
genome and as such many putative regeneration associated genes could be still undiscovered.  
1.5.2.4  The neuronal response to dorsal root axotomy 
Wong and Oblinger (1990) presented the first information regarding changes in mRNA levels in 
mammalian DRG cells in response to dorsal root axotomy and showed that these cells are capable 
of mounting a specific molecular response to central axotomy.  Their study also documented 
differences between the response of DRG cells to central and peripheral axotomy with a focus on  41 
the cytoskeletal proteins β-tubulin and neurofilament protein NF-1.  Peripheral crush produced a 
change in NF-1 and β-tubulin expression that was greater in magnitude and of longer duration than 
central crush.  In addition, β-tubulin mRNA levels were down-regulated at 8 weeks following dorsal 
root crush, by which time the DRG axons had failed to reconnect to their original targets.  In 
contrast, β-tubulin mRNA levels had returned to control levels 8 weeks after sciatic nerve crush 
following reconnection with appropriate target cells.  β-tubulin expression therefore appears to be 
regulated by signals generated by or at the end of the axon.  NF-1 did not show this pattern of 
regulation, initially decreasing in the large DRG neurons and then increasing to control levels 
during 4-8 weeks after both CNS and PNS nerve crush.  This suggests that the aberrant contact of 
dorsal root axons on astroglial cells in the DREZ generates sufficient signals to enable NF-1 gene 
expression but not that of β-tubulin to recover.   This study also demonstrated the importance of 
the interaction between axons and their targets in the regulation of cytoskeletal gene expression. 
1.5.2.5  Comparative studies 
The first microarray study of the DRG response to more than one injury type was conducted by 
(Stam et al. 2007) who identified transcriptional factors involved in successful regeneration by 
comparing gene expression changes in the DRG at a number of timepoints 2 hours-14 days after a 
sciatic nerve or dorsal root crush.  They showed that injuries to the peripheral or central branch 
lead to very different transcriptional responses in the DRG, differences that are evident from as 
early as 6 hours.  At this time point dorsal root fibres will not yet be under inhibitory influence at the 
DREZ suggesting that the intrinsic differences in the central and peripheral branch response are 
not purely due to the inhibitory factors at the DREZ that act upon the dorsal root.   Furthermore, the 
authors identify the muscle stretch sensor Ankrd1 as a novel candidate transcriptional regulator of 
neuroregeneration and show that knock-down of this gene results in decreased adult DRG neuron 
outgrowth in vitro.   They hypothesise the involvement of multiple stretch-sensitive proteins in 
regenerating neurons as other muscle stretch sensor proteins such as SPRR1A (Bonilla et al. 
2002) have been identified as mediators of axonal outgrowth by past studies.  
1.5.2.6  The neuronal response to CNS lesions 
As yet, there have been no genome-wide studies of the DRG response to injuries within the spinal 
cord.  There have however been two studies of the neuronal response to a postcomissural fornix 
(an axon bundle located in the brain with cell bodies in an area called the subiculum) transection in 
rat.  Abankwa et al. (2002) examined gene expression changes in the subiculum following a fornix 
transection at three timepoints corresponding to the degenerative, spontaneous sprouting and 
abortive phases  (1 day, 7 days and 3 weeks, respectively) of the CNS response to injury.  They 
found dramatic differences in the transcriptional programmes that are illicited at the three time 
points and even found some genes to be antagonistically regulated between the time points 
corresponding to degeneration and spontaneous outgrowth.  Three genes were particularly highly 
induced during the sprouting phase.  One such gene, gastric inhibitory peptide (GIP) is known to 
enhance intracellular cAMP production (Usdin et al. 1993) and may thus stimulate the short 
regenerative phase of the CNS injury response by cAMP-mediated processes (Section 1.4.2.1).    42 
The other two genes that showed high induction during axon outgrowth but not during the 
degerative and abortive phases were transcription factors EAR2/NRSF6 and CDP2/Cux.  EAR2 
belongs to a family of nuclear receptors that are widely expressed during neuronal development 
(Qiu et al. 1994) and members of this family have been shown to induce GAP43 (Neuman et al. 
1995) and enhance axon outgrowth (Adam et al. 2000).  CDP2 is thought to be involved in the 
Notch signalling pathway (de Celis and Bray 1997) working antagonistically on the positive 
feedback mechanisms that act on Notch.  Activation of the Notch pathway results in inhibition of 
neurite growth (Franklin et al. 1999; Sestan et al. 1999) and as such CDP2 may act to remove this 
inhibition, promoting regenerative sprouting. 
In their more recent study (Kury et al. 2004) compared gene expression in the subiculum 3 weeks 
after fornix axotomy with gene expression changes in the lesion site to identify gene expression 
changes associated with axonal regenerative failure.  The lesion site showed upregulation of 
multiple inhibitory factors whilst the subiculum showed upregulation of genes that can be 
associated with axonal growth or synaptic potential suggesting a residual potential for regeneration 
that is repressed by inhibitory signals from the lesion zone.  Evidence from these studies therefore 
suggests that the CNS retains some intrinsic ability for regeneration but that regenerative attempts 
may be thwarted by inhibitory factors originating from the lesion.   
 
1.6 Experimental rationale 
Injuries to the spinal cord and dorsal root avulsion injury result in functional deficits because of the 
limited ability of the CNS to regenerate.  We wished to investigate the intrinsic factors that are 
involved in successful/unsuccessful regeneration and identify putative regeneration-associated 
genes by performing a genome-wide screen of gene expression in regenerating and non-
regenerating conditions using microarrays.  Injuries to the sciatic (Carroll et al. 1997; Yang et al. 
2004), facial (Werner et al. 2000) and spinal nerves (Gaudet et al. 2004)  have been utilised as 
models in order to investigate neuronal regeneration in the PNS while injuries to the dorsal column, 
dorsal root, inner ear hair cells (Morest and Cotanche 2004) and optic nerves (Werner et al. 2000) 
have been used as models of CNS injury.   Our study takes advantage of the unique features of 
the dorsal root ganglion neuron (section 1.5.2) to compare gene expression in regenerating and 
non-regenerating conditions. 
1.6.1  The injury models used in this study 
Sciatic nerve transection (Figure 1-15a) has been commonly used as the peripheral injury in the 
DRG model as it can be accessed at the mid-thigh level and thus requires a fairly simple surgical 
procedure (Broude et al. 1997; Gallinat et al. 1998; Antunes Bras et al. 1999; Fan et al. 2001; 
Bloechlinger et al. 2004.).  The DRG response to this injury is therefore fairly well characterised.  43 
This injury was used as the basis of a pilot microarray experiment to optimise experimental 
parameters before the larger main microarray experiment in which a spinal nerve injury is used as 
the PNS injury model (Figure 1-15b).  Spinal nerve crush is a more difficult procedure to conduct 
than sciatic nerve lesion but has the advantage of affecting only the DRG from which it has 
originated and is more likely to affect all the cells within a given DRG. This contrasts sciatic nerve 
injury, which does not affect all the neurons in any one DRG.   For the CNS injury model, dorsal 
root injury (where there is regeneration (Figure 1-15c) then blocked regeneration at the dorsal root 
entry zone (Figure 1-15d) and dorsal column injury (Figure 1-15d) (where regeneration is blocked) 
was employed.  Several comparisons could therefore be made by examination of DRGs from a 
combination of the two types of CNS lesion, spinal nerve lesion and control animals.    The crush 
lesion was favoured over complete transection in the case of the spinal nerve and dorsal root 
lesions in order to preserve the basal lamina and stimulate a stronger regenerative response. A 
transection injury using an optimised wire knife technique that produces a consistent lesion without 
disruption of the overlying blood vessels was used to produce the dorsal column lesion. 
 
 
 
 
 
 
Figure 1-14: Schematic diagram of the spinal cord in cross section with anatomical features 
relevant to the injury models labelled (not to scale).  The parallel dotted lines show the position 
of cross section for Figure 1-15 b-c.  
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Figure 1-15: Schematic diagram illustrating the position of injury models used in the study.  
a) sciatic nerve transection (regeneration), b) dorsal root crush (DREZ marked in red) 
(regeneration until the point of CNS entry at the DREZ where it is blocked), c) spinal nerve crush 
(regeneration) d) dorsal column transection (abortive regeneration).  Dark dotted lines represent 
axon outgrowth.  See Figure 1-14 for anatomical labelling. 
a) 
b) 
c) 
d) 
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1.6.2 Microarray technology 
1.6.2.1  The principle of microarrays 
DNA microarray technology, pioneered by Affymetrix Inc. (Santa Clara, CA), and first described in 
a seminal paper in Science in 1991 (Fodor et al. 1991), is a powerful and relatively new molecular 
genetics technique that allows the expression analysis of a large number of genes simultaneously.  
DNA microarrays consist of a small membrane or glass slide onto which thousands of DNA probes 
are attached at high density and at precise and fixed locations. There are three main types of 
microarray available; filter arrays and spotted glass slides (both of which can be produced in 
academic facilities to produce custom arrays), and in situ synthesised oligonucleotide arrays 
(produced commercially using photolithographic masks).  The choice of microarray will depend on 
the aims of the experiment in question, budget and available facilities.  For example, custom arrays 
can be less costly and may be favoured in situations where the number of genes of interest has 
been narrowed.  However, although expensive, commercially produced arrays carry many 
advantages.  Commercial arrays are manufactured with built-in process controls at each synthesis 
step thus ensuring they produce accurate and reproducible results.  In addition, most commercially 
available arrays form part of an integrated system of microarray chips, reagents, scanning 
instruments and data analysis software.  Furthermore, evidence from a number of studies has 
suggested that the Affymetrix GeneChip, the choice of array for the current project, performs more 
reliably compared to custom made and other commercially available arrays (Li et al. 2002; Park et 
al. 2004).   
In sample preparation for microarray experiments, mRNAs from the sample of interest are used as 
templates to generate fluorescently labelled cDNA. Incubation of the microarray with this 
fluorescently labelled cDNA causes hybridisation of the cDNA to complementary DNA sequences 
on the microarray and fluorescence emission at defined regions when excited by a laser scanner. 
Where the sample yields limiting amounts of RNA, it may be necessary to increase the 
fluorescence signal by amplification processes, which include the binding of highly branched 
molecules (dendrimers) carrying fluorescent tags to each hybridised molecule.  Alternatively, the 
sample may be amplified by means of polymerase chain reaction (PCR) or linear amplification 
(Livesey 2003).  It is also generally accepted that the minimum number of replicates per 
experiment for statistical reliability should be at least three and this is now the usual minimum 
standard demanded for journal publications (Lee et al. 2000) and was the number of replicates 
used for each of the conditions in this study. 
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Figure 1-16:  Schematic diagram summarising the steps of a microarray experiment. 
 
 
1.6.2.2  Validation of microarrays 
Validation of microarray data is a necessary step in microarray data quality control as array results 
can be influenced by each step of the complex assay, from array manufacture to sample 
preparation and analysis (Rajeevan et al. 2001; Chuaqui et al. 2002).  Validation can be achieved 
via an in silico or laboratory-based analysis.  The in silico method compares microarray results with 
information from literature or from public and private expression databases.  Laboratory-based 
methods provide an independent means of validating array results and commonly used techniques 
include: semi-quantitative reverse transcription PCR (RT-PCR), quantitative RT-PCR, northern 
blot, ribonuclease protection assay and in situ hybridisation or immunohistochemistry for tissue 
microarrays.  Real-Time PCR was utilised in the validation step for the current project, being rapid, 
relatively inexpensive and requiring minimal starting template (Rajeevan et al. 2001). 
1.7 Conclusions and aims 
Axonal injury initiates a transcriptional response within the cells of the DRG leading to a temporally 
orchestrated gene expression programme.  This project aimed to identify putative regeneration 
associated genes that are expressed at a late timepoint post-injury using more comprehensive 
microarrays than previously used that cover the majority of the rat genome.  Implementation of a 
combination of injury models allowed for a more thorough investigation of the DRG injury response 
and allowed us to better evaluate when gene redundancy may account for the differences 
observed.  Indeed, this is the first microarray study that addresses the neuronal response after 
dorsal column transection injury.   It is hoped that the data provided by this study will gain further 
insight into the signalling processes associated with regeneration, thus allowing potential methods 
of increasing the intrinsic growth state of injured CNS neurons to be identified.   47 
1.7.1 Chapter summaries 
The aims and objectives of the project were: 
  To optimise tissue collection and processing protocols for microarray and qRT-PCR by 
completing and validating a pilot microarray experiment (Chapter 3) 
  To determine appropriate time points at which to harvest DRGs after dorsal root and spinal 
nerve crush (Chapter 4). 
  To compare and contrast gene expression changes in regenerating and non-regenerating 
conditions using various analysis methods (Chapter 5). 
-  Do axotomised CNS neurons respond to remote injury by altering their gene 
expression programmes? 
 
-  Do such genetic programmes include regeneration associated genes, perhaps re-
activating developmental processes? 
   
-  What are the intrinsic differences between injured peripheral and central neurons? 
 
 
  To validate using qRT-PCR a number of genes which demonstrate an interesting pattern of 
regulation in the microarrays or have been implicated in regeneration previously (Chapter 
6). 
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2  Materials and Methods 
2.1 Solutions used for in vivo work 
4% Paraformaldehyde solution 
4% w/v paraformaldehyde in 0.1M phosphate buffer 
 
Mammalian ringer 
130 mM NaCl,
 4 mM KCl, 1 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, 18 mM glucose,
 20 mM 
HEPES-Tris in DEPC-treated water, pH 7.4. 
 
Phosphate buffered saline (PBS) 
0.08 % w/v NaCl, 0.002% w/v KCl, 0.0144% w/v Na2HPO4, 0.0024% w/v KH2PO4 
in DEPC-treated water, pH 7.4. 
 
0.1% Toluidine Blue stain 
0.1% w/v toluidine blue in DEPC-treated water 
 
2.2 Injury Models  
2.2.1 Pre-operative Medication and Anaesthesia 
Adult male Sprague Dawley rats (Harlan, Loughborough, UK) were used in all the operations 
described below. Animals were housed in groups of 2-3 in standard solid bottomed cages with 
woodchip bedding and had free access to food and water.  Anaesthesia was induced with 4% 
halothane and maintained with 1.5-2.5% (as appropriate) halothane in oxygen delivered via a mask 
following transfer to the operating table.  Depth of anaesthesia was assessed by monitoring pedal 
withdrawal reflexes.  Rectal temperature was monitored and regulated via a homeothermic heating 
blanket connected to a rectal thermister.  Pre-operative medication consisted of antibiotics 
(Amfipen, 0.3ml 100 mg/ml, Intervet, UK) and analgesics (Vetergesic, 0.05 mg/kg, Alstoe Ltd., UK) 
administered subcutaneously.  The incision area was shaved and swabbed with ethanol.  Dr J S 
Riddell carried out all operations using sterile precautions and in accordance with the UK Animals 
(Scientific Procedures) Act 1986. 
2.2.2 Post-operative care 
Animals were monitored visually during recovery on a fleece covered heat mat.  Animals were 
offered chocolate mousse to encourage appetite and administered with a further dose of analgesic  49 
(Vetergesic, 0.05 mg/kg) on the morning following the surgery.  Saline (0.2-0.4 ml/0.1 kg) was 
administered 2-3 times daily for up to 3 days following surgery via the oral or subcutaneous route 
to compensate for fluid loss during surgery. 
2.2.3 Sciatic Nerve Transection 
The left sciatic nerve was exposed at mid thigh level and a tight ligature (6/0 silk) was placed 
around the nerve.  The nerve was transected distal to this ligature and a 1 cm length was removed.  
The wound was sutured in two layers and the rat was allowed to recover.  The animal’s hind legs 
were examined daily for signs of autophagia (nibbling of own toes).  Animals exhibiting autophagia 
were euthanased humanely. 
2.2.4 Dorsal Root Crush 
The lumbar spinal cord was exposed by a hemi laminectomy at the L4 vertebral level.  The bone 
was thinned using a dental drill then removed using bone rongeurs to expose the L4 DRG and 
proximal roots and the dura was opened.  The L4 dorsal root was identified and a loop of 10/0 
suture was placed loosely around the root to allow post mortem confirmation of its identity (Figure 
2-1 a).   The root was then crushed ~5 mm proximally to the DRG with watchmaker’s forceps 
(Figure 2-1 b). The dura was closed with 10/0 suture and the overlying tissues were sutured in 
layers with 3/0 vicryl. 
2.2.5 Spinal Nerve Crush 
The lumbar spine was exposed and the lateral processes at the L4 vertebral level were removed 
using bone ronguers.  The L4 spinal nerve was identified and crushed using watchmaker’s forceps 
(~6 mm distal to the DRG) for approximately 20 seconds until translucent.  A loose ligature of 6/0 
silk was placed around the nerve at the lesion site and the overlying tissues were sutured in layers 
with 3/0 vicryl. 
2.2.6 Lumbar Dorsal Column Transection 
The lumbar spinal cord was exposed by laminectomy at the L1/rostral T13 vertebral junction.  The 
T13 vertebra was clamped to immobilise the vertebrae.  The dorsal columns were then lesioned at 
the border between the L3 and L4 spinal segments using a wire knife  (David Kopf Instruments, 
Tujunga, USA).  The knife within its cannula was inserted through a small slit made in the dura with 
a fine hypodermic needle at the dorsal root entrance zone on left side of the cord.  The cannula 
was lowered into the cord to a depth of approximately 950um (Figure 2-2a) and the knife was 
protruded to form an arc of approximately 1.5 mm inside diameter, encompassing the dorsal 
columns (Figure 2-2b).  A glass rod (1 mm diameter) was then positioned at the surface of the 
dorsal columns and the wire knife was raised until it pressed firmly against the rod (Figure 2-2c).  50 
The wireknife was then retracted and withdrawn (Figure 2-2d).   A 10/0 ligature was stitched into 
the dura at the lesion site to allow confirmation at post mortem that the lesion was at the L3/L4 
border. The tissues were then sutured in layers and the animal was allowed to recover. 
2.2.7 Sham operations 
In the case of a sham operation, animals underwent all stages of the operation (including, where 
appropriate, removal of bone, cutting of dura and placement of marking ligature) but did not receive 
a lesion. 
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Figure  2-1:  Dorsal  root  crush.  a)  The  L4  dorsal  root  is  exposed  and  a  loose  ligature  is  tied 
around it.  b) The root is crushed using watchmaker’s forceps (the crush is marked by an arrow).  
c) The dura is closed with 10/0 suture. 
 
 
a) 
b) 
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Figure 2-2: Lumbar dorsal column transection. a) A wire knife within a cannula is inserted 
through a small slit in the dura. b) The wire knife is protracted under the dorsal columns.  c) The 
wire knife is raised, cutting through the dorsal columns, until it is pressed against a glass rod.  d) 
The wire knife is retracted and withdrawn. 
a)  b) 
c)  d)  53 
 
2.3 Neuroanatomy 
2.3.1 Spinal Nerve Injection of biotin dextran amine (BDA) 
The left sciatic nerve was exposed and the tract tracer biotin dextran amine (BDA; 10,000MW, 
product no. D-1956, Molecular probes) was injected into the nerve in a sterile operation under 
halothane anaesthesia.  A solution of 20% BDA dissolved in 0.1 M phosphate buffer (PB) with 2% 
(v/v) fast green dye (to detect spillage; R.A Lamb Supplies, UK; product 42053) was injected 
through a glass pipette with a bevelled tip (internal diameter approximately 45 µm) using a PV30 
pneumatic PicoPump (World Precision Instruments).  A total of approximately 3-4 µl of BDA was 
injected over ~4 mins (approx 1 µl/min) using repeated 40 ms pressure pulses.  Wounds were 
closed in layers with 3/0 vicryl and post-operative analgesia administered.   
2.3.2 Sciatic Nerve Injection of cholera toxin B (CTB) 
The left sciatic nerve was exposed and approximately 3-4 µl 1% CTB (List Biological Laboratories) 
dissolved in 0.1 M PB with 2% (v/v) fast green was injected into the sciatic nerve as proximally as 
possible and approximately level with the sural nerve branch using a PV830 pneumatic PicoPump 
(World Precision Instruments) as in Section 2.3.1.  The overlying muscles and skin were sutured in 
layers with 3/0 vicryl and post-operative analgesia was administered.  
2.3.3 Histological processing 
Animals were deeply anaesthetised with intraperitoneal sodium pentobarbital (200 mg/ml Euthatal, 
Vericone Ltd, UK) and perfused through the left ventricle with 50 ml mammalian ringer’s solution 
followed by 500 ml 4% paraformaldehyde in mammalian ringer 0.1M, pH 7.4. 
The animal was dissected to expose the lumbar spinal cord, L4 and L5 dorsal roots, ganglia and 
spinal nerves and sciatic nerves and where appropriate, the position of the lesion was confirmed by 
virtue of a loose 10/0 ligature placed at the lesion site at the time of surgery.  The L4 and L5 
ganglia were removed for inspection in the CTB experiment.  In addition to the DRGs, the L4 and 
L5 dorsal roots, L4 spinal nerve, sciatic nerve and L4 and L5 spinal cord segments were removed 
for the BDA experiment.  The tissue was post-fixed overnight with 30% sucrose added to the 
fixative solution and then transferred to 30% sucrose in phosphate buffered saline (PBS). 
Blocks corresponding to the L4 spinal segment were cut into 70 µm transverse sections while the 
L4 and L5 DRG and 3 mm lengths of dorsal root and spinal/sciatic nerve were cut into 70 µm 
longitudinal sections on a freezing microtome.  Sections were immersed in 50% ethanol for 30 
minutes to improve antibody penetration and then incubated in primary antibodies (Table 2-1).   54 
Sections were subsequently incubated for 2-4 hours in secondary antibodies (Table 2-1).  All 
antibodies were diluted in PBS with 0.3% triton X-100 (Sigma) to aid tissue penetration.  Sections 
were mounted on plain slides in Vectashield (Vector Labs, UK) and stored at  -20°C. 
Table 2-1: Primary and secondary antibodies used in histological processing (Colours 
indicate colour of fluorescence emitted). 
PRIMARY ANTIBODIES  SECONDARY ANTIBODIES 
Mouse anti-neurofilament (NF200: 1:1000, 
clone N52, Sigma) 
Donkey anti-mouse IgG conjugated to 
rhodamine (RRX 1:100, Jackson 
Immuoresearch Laboratories Inc.) 
Rabbit anti-CGRP (calcitonin gene-related 
peptide) 
Donkey anti-rabbit IgG conjugated to cyanine5 
(Cy5; 1:100, Jackson Immunoresearch 
Laboratories Inc.) 
Goat anti-CTB   Donkey anti-goat IgG conjugated to FITC (RRX 
1:100, Jackson Immunoresearch Laboratories 
Inc.) 
  Streptavidin conjugated to DTAF to detect BDA 
(1:1000, Jackson Immunoresearch Laboratories 
Inc.) 
 
2.3.4 Microscopy 
Sections were initially examined on a Nikon Eclipse E600 epi-fluorescence microscope through dry 
(x10 and x20) objectives. Selected sections were serially scanned at 2 µm intervals through dry 
objectives on a Bio-Rad MRC 1024 confocal microscope equipped with a Krypton-Argon laser (Bio-
Rad, Hemel-Hempstead, UK).  Projections of confocal image stacks were formed using Confocal 
Assistant software (Todd Clark Brelje, University of Minnesota).   
2.4 Removal of DRGs for Microarray 
Animals were deeply anaesthetised with intraperitoneal sodium pentobarbital (200 mg/ml Euthatal, 
Vericone Ltd, UK) and perfused through the left ventricle for 30 seconds with freshly prepared, ice-
cold mammalian ringer’s solution (this flushes out the blood which can hinder dissection and which 
is a potential source of tissue contamination) and rapidly dissected to expose the lumbar spinal 
cord, dorsal roots and DRGs.  Where appropriate, the location of the lesion was confirmed by 
visual inspection, under a dissecting microscope, of the position of a loose ligature placed at the 
lesion site at the time of surgery.  DRGs were freed carefully from surrounding tissues, and 
removed into ice-cold saline with their corresponding roots and spinal nerve (Figure 2-3).  DRGs 
were trimmed to remove roots, spinal nerve and any excess tissue surrounding the DRG, 
transferred individually into screwcap tubes and flash frozen in liquid nitrogen.  The removal of the 
L4 and L5 DRGs from both sides of one animal took typically, under 15 minutes.   55 
           
 
 
 
 
Figure 2-3: Removal of DRG for microarray.  In this case, from a dorsal root lesioned animal. a)  
L4 DRG (orange arrows) and intact ventral root.  The position of the crush is marked by a loose 
ligature (black arrows). b) The L4 dorsal root is cut before the DRG is freed carefully from the 
surrounding tissue. c) The L4 DRG, dorsal and ventral roots (green and yellow arrows, 
respectively) are removed to ice cold saline for trimming before being flash frozen in liquid nitrogen. 
a) 
b) 
c) 
←caudal 
←caudal  rostral→ 
rostral→ 
saline on ice  56 
 
2.5 Human patient material 
DRGs from three patients who had suffered a dorsal root avulsion injury were removed by Mr 
Timothy Hems during brachial plexus surgery. DRGs were subject to histopathological examination 
in order to confirm the identity and extent of damage and remaining tissue was frozen in liquid 
nitrogen.  Samples were stored at -80°C in the Department of Neuropathology at the Southern 
General Hospital, Glasgow before transfer in liquid nitrogen and storage at -80°C in our lab until 
use. 
2.6 Electrophysiology 
2.6.1 Surgical Preparation 
Male Sprague Dawley rats that had previously undergone a left L4 spinal nerve crush (5-8 mm 
distal to DRG) were anaesthetised in halothane gas and maintained with sodium pentobarbitone 
(10mg/kg i.v), given as required. The trachea, left jugular vein and left carotid artery were 
cannulated to enable artificial respiration, the administration of drugs and solutions, and the 
recording of systemic blood pressure, respectively.  Body temperature was maintained at 38ºC by 
an electric heating mat with feedback control from a rectal probe thermistor.  Mean blood pressure 
was always greater that 80 mm Hg and pCO2 was maintained within 4-4.5%. 
The left sciatic nerve was exposed as far proximally (40mm from crush) and distally (66 mm from 
crush) as possible and freed from surrounding connective tissue along its length.  A laminectomy 
(L3-L5 segments) was performed to expose the spinal cord and the cauda equina at the level of 
the L4 and L5 dorsal root ganglia.  Once preparative surgery was complete, the rat was 
administered the neuromuscular blocker Pancuronium (Faulding Pharmaceuticals PLC, 
Warwickshire, U.K.; 0.1mg i.v at 40 minute intervals) to prevent movement artefacts and was 
artificially ventilated.  The depth of anaesthesia was then monitored and maintained such that no 
precipitate changes in blood pressure were observed on the application of a noxious stimulus. The 
animal was transferred to a rigid spinal frame and supported by clamping the L2 and L6 vertebrae.  
The exposed tissues were bathed in paraffin oil to prevent short- circuiting of the electrodes and 
drying out of tissues.   Surgical preparation and positioning of electrodes was performed by Dr 
Dugald Scott. 
2.6.2 Orthodromic Mapping 
The sciatic nerve was placed on cathodes placed proximally and stimulated supramaximally (1mA-
10mA) at 2 mm intervals down its exposed length (24-62 mm from crush- see table) and 
monopolar recordings were made from the L4 and L5 dorsal roots using a silver wire electrode. 
Loose ligatures were placed at the recording sites on the L4 and L5 dorsal roots and at the most  57 
distal point at which a response could still be detected upon stimulation.   Recordings were 
amplified and filtered and displayed on an oscilloscope during the experiment.  Between 10 and 20 
responses to each stimulus were recorded and averaged with use of CED 1401+ interface and 
Signal software (Cambridge Electronic Design, Cambridge, UK). The amplitudes and latencies of 
the CAPs recorded at each location were measured off-line using Signal software (Figure 2-4).  
Following the experiment the animal was overdosed with anaesthetic and perfused transcardially 
with 3% PFA. The L4 and L5 dorsal roots, DRGs and sciatic nerve were removed carefully and the 
distance between the crush site and the stimulation sites was noted to allow calculation of 
conduction velocities (CV) using Equation 1.  
Equation 1: Calculation of conduction velocity. 
CV= distance ÷ latency 
 
 
 
 
 
 
 
 
Figure 2-4: Schematic diagram of a CAP illustrating the points from which the latency and 
amplitude parameters are measured in Signal.
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2.7 Materials and general molecular methods 
2.7.1 Solutions  
2% agarose gel: 2% agarose (w/v) in 1XTBE 
0.1% Diethyl pyrocarbonate (DEPC) (v/v) in dH2O, mixed thoroughly, left overnight at room 
temperature and autoclaved. 
70% ethanol: 70% absolute ethanol (v/v) in dH2O 
Ethidium bromide: Stock solution (10 mg/ml in H2O).  Working solution (200 ng/ml). 
1XTAE: 0.04 M Tris base, 0.04 M acetic acid, 0.001 M EDTA, pH 8.0. 
1XTBE: 0.09 M Tris base, 0.09 M boric acid, 0.001 M EDTA, pH 8.0. 
 
 
2.8 RNA analysis 
2.8.1 Precautions for RNA handling 
All RNA handling was carried out in a laboratory dedicated to RNA work and using a dedicated set 
of pipettes.  Care was taken to minimise RNase and DNase contamination by use of DEPC treated 
and autoclaved plastics and DNAse/RNAse free pipette tips (Greiner Bio-one).  Total RNA samples 
were stored at -80°C and freeze/thawing was minimised to avoid RNA degradation. 
2.8.2 Disruption and homogenisation of rat DRG 
Frozen tissue was weighed (DRGs weighed 9-14 mg) and transferred to a volume (350 or 600 ul) 
of either Trizol (Invitrogen) or buffer RLT (Qiagen) in bead filled tubes (Lysing matrix D,) and 
simultaneously disrupted and homogenised in a Ribolyser™ cell disrupter (Hybaid) (3x 20s runs, 
6000g).  Homogenates were frozen on dry ice and stored at -70°C until use.  59 
2.8.3 Disruption and homogenisation of fibrous tissues 
Fibrous tissues (20-30 mg) such as skeletal muscle and heart were homogenised as in section 
2.8.2 then transferred to an eppendorf and incubated with 10 µl proteinase K (Qiagen) for 10 mins 
at 56°C.  The homogenates were then centrifuged at 10000g for 3 mins to pellet cellular debris and 
the supernatant was removed and stored at -70°C until use. 
2.8.4 Isolation of total RNA 
2.8.4.1  Tissue homogenised in Trizol 
Following thawing at room temperature, 200 µl chloroform was added to each of the Trizol 
homogenates which were then shaken vigorously and incubated at room temperature for 10 mins.  
Following incubation on ice for 2 mins and centrifugation (10,000 g) for 15 mins, the aqueous layer 
was removed to a fresh eppendorf.  Another 400 µl chloroform was added to the aqueous layer 
and the incubation and centrifugation steps were repeated.  The aqueous layer was again removed 
to a fresh eppendorf and RNA isolation proceeded according to manufacturer’s guidelines for 
isolation of total RNA from animal tissue using the RNeasy mini kit (Qiagen). RNA was eluted in a 
volume of 20-50 µl. 
 
2.8.4.2  Tissue homogenised in buffer RLT 
Homogenates were thawed at room temperature and RNA was isolated using the RNeasy micro kit 
(Qiagen) according to the manufacturer’s protocol for isolation of total RNA from animal tissue. The 
optional on-column DNase digestion was used.  RNA was eluted in a volume of 14 µl. 
2.8.5 Laser capture microdissection (LCM) 
2.8.5.1  Poly-L-lysine coating of sides 
Plain glass slides were dipped in Poly-L-lysine solution (Sigma) freshly diluted 1:10 in DEPC H2O 
and processed according to manufacturer’s guidelines. 
2.8.5.2  Preparation of fresh-frozen sections 
DRGs were removed from storage at -70°C and allowed to equilibrate in a cryostat at -20°C for 10-
15 mins prior to mounting.  The DRG was mounted on a chuck with Cryomatrix (Shandon). 10 µm 
serial longitudinal sections were cut with a cryostat and thaw mounted onto uncoated or poly-L- 60 
lysine (Sigma) coated glass slides (Section 2.8.5.1).  The sections were allowed to dry and then 
stored at -70°C. 
2.8.5.3  Toluidine blue staining of frozen sections 
Slides of serial DRG sections were transferred directly from -70°C storage to ice cold acetone for 3 
minutes.  1% Toluidine blue stain was dropped onto slides and sections were left to stain for 3 
minutes.  Slides then underwent 2x 30 s washes in DEPC treated water before dehydration in a 
series of ethanol rinses of 30 s each (70%, 95% then 100%) and finally a 2 min xylene rinse. Slides 
were then air dried and placed in a slide box with silica gel desiccant for use in LCM within 1 hour. 
2.8.5.4  Capture of cells 
Cells were laser dissected from DRG using the Pix-Cell II LCM (Arcturis) and collected on HS 
CapSure caps.  Capture was performed using a laser power of 70-100 mW, a spot size of 10 µm 
and a duration of 750 ms. Sensory cells were identified based on morphology (large, light staining) 
and ~2000 were captured onto each cap.  RNA was prepared using the Qiagen RNeasy micro kit 
according to the manufacturer’s protocol. 
2.8.6 Assessment of RNA quality using the Bioanalyzer 
Quality of total RNA for microarray analysis was assessed using the Agilent 2100 Bioanalyzer 
(Agilent Technologies).  1µl total RNA was used to generate an electropherogram (Figure 2-5) that 
allowed an estimate of RNA concentration and ribosomal ratio to be obtained.   High quality RNA 
showed the following features on a electropherogram:  
-  clear 18S and 28S rRNA peaks 
-  A low small RNAs (5S, transfer RNA and miRNA) presence relative to the rRNA peaks 
-  A flat base line in the fast-migrating region 
-  A flat inter-rRNA peak regions 
-  A return to the baseline after the ribosomal RNA peaks 
 
In addition to visual inspection of the electropherogram, integrated software generated an RNA 
integrity number (RIN) by analysis of the entire electrophoretic trace.  This number provides a de 
facto standard for RNA integrity with an RIN >7 indicating a sample of sufficient quality for 
microarray.  All our RNA samples from whole, buffer RLT homogenised DRG fulfilled this minimum 
RIN criterion.  61 
 
Figure 2-5: Features of a total RNA bioanalyzer electropherogram. 
 
2.8.7 Assessment of RNA quality and quantity using the 
Nanodrop 
Total RNA was quantified by an ND-1000 Spectrophotometer (ND-1000 spectrophotometer; 
Nanodrop Technologies, Wilmington, DE) using the nucleic acid function which uses the 
absorbance at 260 nm to calculate concentration using Beer’s law.  The ratio of absorbance at 260 
nm and 280 nm was used to assess purity of the RNA with a ratio of ~2 indicating sample purity. 
The 260/280 ratios for RNA samples were all in the acceptable range of 1.8-2.1. 
2.8.8 Assessment of RNA quality using gel electrophoresis 
When yields of RNA were adequate, gel electrophoresis was used to assess RNA quality.  1 µg 
total RNA and 1Kb+ ladder was loaded onto a 1 % (w/v) TAE agarose gel with ethidium bromide to 
a final concentration of 0.25 µM. Gels were electrophoresed for 20-30 minutes in Sub Cell-GT 
electrophoresis tanks (Biorad) at 40-120 volts at room temperature using power packs (PowerPAC-
300, Biorad).  Agarose gels were visualised under UV light (260 nm) using the UVP Dual Density 
transilluminator and photographed with the UVP ImageStore 7500 system. 
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Figure 2-6: Example of an RNA gel with total RNA extracted from different tissues.  1 µg total 
RNA was loaded in each well. 
 
2.8.9 Complementary DNA (cDNA) synthesis 
2.8.9.1  Random Prime method 
500 ng-1 µg total RNA was treated with DNase I (Invitrogen) according to the manufacturer’s 
instructions before being reverse transcribed by Superscript II (Invitrogen) in a total volume of 20 
µl according to the manufacturer’s recommendations.  
 
2.8.9.2  Quantitect reverse transcription kit 
500 ng total RNA was used in cDNA synthesis according to the manufacturer’s instructions 
(Qiagen).  This method incorporates an initial DNase digestion step to eliminate contaminating 
gDNA. 
2.8.9.3  Reverse transcriptase negative (RT-) controls 
Where RT- controls were included, total RNA was subject to conditions as described in section 
2.8.9.1 or section 2.8.9.2 above but RT was substituted with an equivalent volume of RNase- free 
H2O. 
 
1Kb+  
28s rRNA 
18s rRNA  63 
2.8.9.4  cDNA storage 
cDNA samples  were diluted 1 in 20 and stored at –80°C.  The cDNA was stored in 12 ul aliquots 
(sufficient for triplicate reactions) to minimise freeze-thaw degradation. 
2.8.10  Reverse transcriptase polymerase chain reaction (RT-
PCR) 
2.8.10.1  Primer design 
Primers for standard RT-PCR were designed using the Primer3 website 
(http://fokker.wi.mit.edu/primer3/input.htm).  Default parameters were used for primer picking 
except for the TM parameters which were set to as follows: minimum 50°C, maximum 66°C, 
optimum 55°C and a maximum of 1°C difference between primers.  Primer sequences were 
subject to a BLAST against the nr database. Primers with significant similarities to regions other 
than the target sequence and in close proximity to one another were re-designed to reduce the 
possibility of non-specific amplification.  Primers were purchased from Sigma-Genosys. 
Table 2-2: Primers used in RT-PCR 
GENE  EXONS  FORWARD PRIMER SEQUENCE  
(5’ TO 3’) 
REVERSE PRIMER SEQUENCE  
(5’ TO 3’) 
PRODUCT 
SIZE (BP) 
TA 
(°C) 
MX2  3/4  GAGAGGAGTGGAAAGGCAAAGT  GGTCAATCAGAGTCAGGTCTGG  171  66 
ECEL1  1/2  GACATGCGTGAGATCGAGAGG  TTCTCTCTGGCAGGGTGAGC  253  61 
TGM1  7/8  GCAGAGTTGAAGTTGGTGACAG  TACCTACGCACCGGCTATTC  119  58 
NPTX1  4/5  CAAGCTGCCCTTTGTAATCAAC  GGTCCCAGATGTTGAAATGG  250  65 
SEMA6A  12/13  GGCCATATGAGAATCACACT  GGCACCTTTATCACACAAGT  244  58 
 
2.8.10.2  Reagents and cycling conditions 
PCR optimisations were performed in a Biometra Tgradient machine.  Standard PCRs were carried 
out on a GeneAmp PCR system 9700 (Applied Biosystems). 
PCR was carried out in thin-walled 0.2 ml PCR tubes (ABgene) in a volume of 10 µl using 
1xThermo-Start PCR master Mix (ABgene) with 1 µM of each primer.  For reverse transcriptase 
PCR (RT-PCR) cDNA was synthesised as in section 2.8.9.1 and 1 µl was added to each reaction.  
The thermal cycling conditions were; 95°C for 15 minutes, (95°C for 30 seconds, TA°C for 30 
seconds, 72°C for 30 seconds) x 30 cycles, 72°C for 10 mins and 4°C hold.  64 
2.8.10.3  Gel electrophoresis 
qRT-PCR products were resolved with a 1Kb+ ladder on 2% (W/V) TBE agarose gels (section 
2.7.1) with ethidium bromide to a final concentration of 0.25 µM.  Gels were electrophoresed and 
visualised as in section 2.8.8. 
2.9 Microarray experiment 
2.9.1 Design 
2.9.1.1  Pilot experiment  
The pilot experiment consisted of a well-studied injury model (sciatic nerve transection), naïve and 
sham control.  The design of the experiment is described in chapter 3.  
 
2.9.1.2  Main Experiment 
The microarray consisted of four experimental conditions (spinal nerve crush, 2 and 6 week dorsal 
root crush and dorsal column transection) and a naïve control.  The design if the experiment is 
described in chapter 5.  Equal masses of total RNA from the L4 DRGs of three animals was pooled 
and used to generate biotin labelled cDNAs for each of 15 chips (3 chips/condition).   
2.9.2 Hybridisation  
Total RNA of RIN of >7 was prepared according to the Affymetrix standard (pilot experiment) or 
Affymetrix small sample protocol (main experiment) and hybridised to Affymetrix 230_A chips (pilot 
experiment) or Affymetrix 230 2.0 rat arrays (main experiment). The Affymetrix small sample 
protocol consists of two rounds
 of amplification (TwoRA) and is
 a well-established T7-based 
method for the preparation of biotin-labelled cRNA
 targets from nanogram amounts of RNA.  
Hybridisation was performed by Dr Jing Wang of the Sir Henry Wellcome Functional Genomics 
Unit (SHWFGU), Glasgow. 
2.9.3 Statistical Analysis 
2.9.3.1  FunAlyse Pipeline Analysis (Performed by the SHWFGU) 
2.9.3.1.1  Low Level Normalisation 
The Robust Multichip Average (RMA) method of normalisation (Irizarry et al. 2003) was 
implemented through the Affy module of the Bioconductor microarray analysis suite.  RMA  65 
performs probe specific background correction to compensate for non-specific binding using PM 
distribution rather than PM-MM values, probe-level multichip quantile normalisation to normalise 
PM distributions across all chips and robust probe-set summary of the log-normalised probe-level 
data by median polishing. 
2.9.3.1.2  Identification of differentially expressed genes using Rank Products analysis 
Identification of differentially expressed genes was achieved using the RankProducts (RP) 
approach (Breitling et al. 2004).  RP sorts all the genes in a data set according to their expression 
changes and assigns statistical confidence levels to each change in the form of false discovery 
rates (FDRs) with a 5% FDR corresponding to a p value of 0.05.  This method is more powerful 
than many other techniques used to find differentially expressed genes (such as significance of 
microarrays (SAM)) (Breitling et al. 2004) and is particularly useful for small and noisy data sets. 
2.9.3.1.3  Identification of differentially expressed genes using Genespring 
Affymetrix cel. files were imported into Genespring GX 7.3 (Agilent technologies) and normalised 
using RMA.  Data was then filtered by error to remove genes that have a large spread around the 
mean and are thus less likely to be reliable.  If it assumed that the data follow a normal distribution, 
then 68% of the values lie within one SD of the mean and 97% of the values lie within two SD of 
the mean.  A stringent standard deviation filter was set to select genes whose values were within 1 
standard deviation of the mean in 5 out of 5 conditions. 
An expression filter was applied to remove non-changing genes.  To remove genes with a smaller 
than 2-fold change in all conditions parameters were set thus; min=0.667 max=1.334 in 5 out of 5 
conditions. To remove genes with a smaller than 1.5-fold change parameters were set to; min=0.8 
and max=1.2 in 5 out of 5 conditions. 
A search was carried out for Affymetrix control genes (find gene seach term ‘AFFX’).  The 57 
control genes that were found were also removed from the list of genes used in further analyses. 
2.9.3.1.4  Functional interpretation of microarray data 
Functional interpretation of the data was aided by Iterative Group Analysis (iGA), a method for 
identification of differentially expressed functional gene classes (Breitling et al. 2004).  iGA 
provides  biological summary of the physiological processes affected in a particular experiment 
whilst providing statistical confidence levels. 
 
2.9.3.2  Ingenuity Pathways Analysis 
Data were analysed through the use of Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, 
www.ingenuity.com). 
2.9.3.2.1  Network Generation  66 
A data set of genes (differentially expressed in each of the injury models relative to control) 
containing gene identifiers and corresponding expression fold changes and FDRs were uploaded 
into the application.  Each gene identifier was mapped to its corresponding gene object in the 
Ingenuity Pathways Knowledge Base.  A FDR cut-off of 5% was set to identify genes whose 
expression was significantly differentially regulated.  These genes, called focus genes, were 
overlaid onto a global molecular network developed from information contained in the Ingenuity 
Pathways Knowledge Base.  Networks of these focus genes were then algorithmically generated 
based on their connectivity. 
2.9.3.2.2  Functional analysis 
Functional Analysis identified the biological functions that were most significant to the data set.  
Genes from the dataset that met the FDR cut-off of 5% and were associated with biological 
functions in the Ingenuity Pathways Knowledge Base were considered for the analysis.  Fischer’s 
exact test was used to calculate a p-value determining the probability that each biological function 
assigned to that data set is due to chance alone. 
2.9.3.2.3  Canonical Pathway Analysis 
Canonical pathways analysis identified the pathways from the Ingenuity Pathways Analysis library 
of canonical pathways that were most significant to the data set.  Genes from the data set that met 
the FDR cut-off of 5% and were associated with a canonical pathway was measured in 2 ways: 1) 
A ratio of the number of genes from the data set that map to the pathway divided by the total 
number of genes that map to the canonical pathway is displayed. 2) Fischer’s exact test was used 
to calculate a p-value determining the probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance alone. 
 
2.10 Quantitative Real time PCR (qRT-PCR) 
2.10.1  SYBR Green I chemistry 
In qRT-PCR, the quantity of amplification product is measured during every PCR cycle.  SYBR 
green I, a minor groove binding dye, was used for the quantitative detection of the amplification 
product.   Figure 2-7 illustrates the principle of qRT-PCR using SYBR Green I chemistry.  The 
fluorescence measured at the end of every extension phase can be plotted as an amplification 
graph (Figure 2-8) and the cycle at which the fluorescence rises above threshold (threshold cycle, 
Ct) is related to the starting template amount.  Since the quantity of DNA doubles every cycle 
during the exponential phase, relative amounts of DNA can be calculated e.g. a sample whose Ct 
is 2 cycles earlier than another has 2
2=4 times more template.  67 
 
Figure 2-7: Schematic diagram illustrating SYBR Green I chemistry.  During the denaturation 
(stage 1) and annealing (stage 2) process, the SYBR Green I molecule does not bind the single-
stranded DNA and consequently does not fluoresce.  Upon primer extension (stage 3), the DNA 
target is now present as a double-stranded template which now binds SYBR Green I.  This causes 
the bound SYBR Green I to fluoresce (blue lightning symbol) The cycle is repeated and the 
fluorescence is ‘read’ at the end of each extension reaction with the total amount of fluorescence 
being proportional to the concentration of the amplified product.  
 
 
Figure 2-8:  Diagram illustrating the features of an amplification plot. Threshold and cycle 
threshold (Ct) are shown. 
2.10.2  Two-step qRT-PCR 
Real-time RT-PCR was performed using the DNA Engine Opticon-2
 (MJ Research Inc, Boston. 
MA). Real-time fluorescence detection was performed
 in 96-well plates using Quantitect SYBR 
Green PCR mastermix (Qiagen).
 Samples were assayed in triplicate. Each 20-µl reaction
 contained 
cycle number 
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cDNA (equivalent to 5 ng RNA) and a final concentration of 1x Quantitect primer assay (Qiagen) 
and 1x Quantitect SYBR green master mix. After the initial 15-min.
 incubation at 95°C for activation 
of the Hot Start Taq DNA
 polymerase, all templates were amplified for 45 cycles using
 the following 
protocol: denaturation for 15 s at 94°C, primer
 annealing for 30 s at 55°C, and elongation for 30 s at 
72°C.
 Fluorescence data were acquired at the end of each elongation
 phase. After the amplification 
program, melting curves were
 generated by measuring the fluorescence as the temperature was
 
raised from 60°C to 90°C in 1°C increments to
 verify specificity of fluorescence detection. 
Specificity of
 amplification products was further verified by gel electrophoresis
 and ethidium 
bromide staining (Section 2.8.10.3). Threshold cycle (Ct) values were determined by automated 
threshold analysis (3x S.D. of the global minimum across all primers and samples in a plate).  
Positive (no template reaction) controls were run in triplicate and
 included in each PCR assay.
   
Negative (no RT) controls were deemed unnecessary for the majority of the assays as Quantitect 
Primer assays are designed, where possible, to span exon/exon boundaries to prevent 
coamplification of genomic DNA (gDNA).  Negative controls were included for YWAZ, ATP5B and 
BDNF as these assays co-amplify gDNA.  In addition, a plate calibrator (described in section 
2.10.4.2) was run in triplicate on each plate. 
Table 2-3: Qiagen primer assays used in qRT-PCR.  * Number of exons according to Ensembl 
Transcript. ** Indicates a primer assay that may potentially amplify gDNA. 
TARGET GENE SYMBOL  QIAGEN CATALOG NUMBER  *EXONS 
AMPLIFIED 
PRODUCT SIZE (BP) 
Sema6a   QT01603791  8/9  98 
Top1  QT00193718  10/11  87 
B2m  QT00176295  1/2  61 
Canx  QT00177975  12/13  92 
Ywhaz **  QT01083992  ---  97 
Atp5b **  QT00434385  ---  104 
Ankrd1  QT01083845  5/6  69 
Bdnf **  QT00375998  ---  143 
Notch4  QT01626415  12/13  126 
Gapdh  QT00199633  1/3  149 
Ptpn5  QT01081458  8/10  120 
Atf3  QT00183883  3/4  76 
Wisp2  QT00189840  3/4  101 
 Igf1  QT00996247  3/4  118 
Tfpi2  QT00183190  3/4  86 
Tgm1  QT00178948  8/9  94 
 
 
2.10.3  Assessment of Experimental Precision   
2.10.3.1  Intra and inter-run precision 
To quantify inter-run variation, two identical runs were carried out using the same cDNA template, 
reagents and RT-PCR conditions on two different days. Each run consisted of 15 replicates of the 
same cDNA sample.  A master mix of reagents was aliquoted into each well such that each well 
contained 5 ng cDNA (RNA equivalents) in a total volume of 20 µl.   As qRT-PCR data are  69 
logarithmic Ct values were first linearised (using 2
-CT) and CVexp (CV=SD/mean x100) was 
calculated for both runs to give the intra-run variation.  The difference between these CVs gave the 
inter-run variation. 
 
2.10.3.2  Operator precision 
Operator precision was assessed by a third run consisting of 15 replicates of the same template 
cDNA as above.  The cDNA was added separately to each well and run under the same conditions 
as before. Again, the Ct values were linearised and the CVexp (CV= SD/mean x 100) for the run was 
calculated.  Operator associated variation was calculated as (mean CVexp Run 1 and Run 2 ) – 
CVexp Run 3). 
 
2.10.4  Analysis of qRT-PCR data 
2.10.4.1  Validation of reference genes: geNorm and NormFinder. 
6 housekeeping genes were assessed for stability and hence, suitability for use as reference genes 
in the sciatic nerve transection injury paradigm.  The three most stable of these genes were used in 
conjunction in generation of a normalisation factor in qRT-PCR analysis software REST-MCS 
(Section 2.10.4.5). 
Briefly, geNorm (Vandesompele et al. 2002) calculates the gene expression stability value M for a 
reference gene as the pairwise variation V of that gene with all other reference genes tested.  
Stepwise exclusion of the least stable gene (with the highest M value) allows ranking of the tested 
genes according to their expression stability and thus the most stable genes can be identified.  
Since co-regulated genes lead to stable expression ratios, care was taken that the genes chosen 
for consideration as reference genes were not co-regulated. 
Like geNorm, NormFinder (Andersen et al. 2004) ranks a panel of potential reference genes on the 
basis of their stability but uses a model-based approach to estimate expression variation instead of 
a pairwise comparison approach.  NormFinder assigns a stability value to each gene having first 
estimated both intra- and inter-group variation.  This stability value represents a practical measure 
of the systematic error that will be introduced if the gene were to be used. 
2.10.4.2  Plate to plate calibrator 
As the samples for any one gene were split between 3- 5 plates, a plate to plate calibrator was 
included in each run as a quality control measure (Godfrey and Kelly 2005). The calibrator was a  70 
cDNA sample from RNA originating from several different tissues (DRG, heart, liver, spleen and 
spinal cord dissected from rats used for other purposes) that was amplified in triplicate on each 
plate.  Ct values obtained for the calibrator sample were relatively invariant with differences 
between plates of typically <0.8 cycles.  Where CVs could be calculated (in the case of genes run 
over 4 or 5 plates) they were in the range of 0.6072-1.042%.  
2.10.4.3  Identification of outliers 
Within triplicates, an outlier was defined as having a Ct >0.5 cycles different from the other Cts in 
the triplicate.  These triplicate outliers were removed before calculation of the triplicate means from 
the remaining 2 values. 
Within group outliers were identified by subjecting the triplicate mean Ct values to a Grubb’s test 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm) (Burns et al. 2005).  Significant outliers (p≤ 
0.05) were eliminated before further analysis. 
2.10.4.4  Calculation of well-well reaction efficiencies with LinRegPCR 
Raw fluorescence data for each qRT-PCR run was exported as Excel spreadsheets from MJR 
Opticon Software and analysed using LinRegPCR software tool (Ramakers et al. 2003).  
LinRegPCR calculates reaction efficiencies by linear regression on the Log(fluorescence)/cycle 
number data and allows assay-specific PCR efficiency to be determined.  Subsequent data 
analysis is therefore not based on the erroneous assumption of 100% reaction efficiency and the 
need for standard curves is removed.  
2.10.4.5  Relative expression quantification using Relative Expression Software Tool (REST-
MCS) 
Mean triplicate Ct values were analysed in REST-MCS relative expression software (Pfaffl et al. 
2002).  REST-MCS employs a non-parametric method to assess the statistical differences between 
experimental groups. It calculates P values on the basis of the pair-wise fixed reallocation 
randomisation test which jointly reallocates the Ct values for reference and target genes to control 
and sample groups then calculates the resulting expression ratios on the basis of the mean values.  
In the course of each test 2000 such randomisations are performed.  The method avoids the 
reduction in power that is encountered when using parametric tests and avoids assumptions about 
data distribution that may be encountered in non-parametric tests that employ measurements of 
rank (Pfaffl et al. 2002).  The software also takes into account gene-specific reaction efficiencies.  
Mean reaction efficiencies were therefore calculated from the well reaction efficiencies calculated 
by LinRegPCR (section 2.10.4.4) and these gene-specific reaction efficiencies were integrated into 
the REST-MCS analysis.  
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3  Pilot microarray experiment, analysis and qRT-PCR 
validation 
3.1 Introduction and aims 
A conditioning lesion to the peripheral branch of a DRG neuron facilitates regenerative sprouting 
after a lesion to the central branch (Neumann and Woolf 1999) (see also section 1.4.2.1).  This is 
thought to be due to a priming effect whereby intracellular cAMP is elevated within the nerve cell 
body (Neumann et al. 2002) and the slow component of axonal transport that carries cytomatrix 
proteins to the site of injury is accelerated (Jacob and McQuarrie 1991; McQuarrie and Jacob 
1991).  Additionally, it has been shown that sciatic nerve transection, a well-studied conditioning 
lesion, induces changes in gene expression within the cells of the DRG (Costigan et al. 2002).  It is 
therefore likely that the priming effect of a conditioning lesion is partly due to a regeneration-
permissive transcriptional programme being activated within the nerve cell bodies in the DRG. 
Here we aimed to optimise parameters for a large microarray experiment by conducting an 
experiment to examine gene changes at 8 days following sciatic nerve transection  using 
microarray technology.  Use of such a well-studied injury model allowed us to confirm that our 
experimental methods could yield biologically valid results that are consistent with other 
experiments of this type.  In addition, it allowed optimisation of various technical aspects of the 
experiment such as tissue collection and homogenisation, RNA extraction, cDNA synthesis and 
qRT-PCR. In addition, laser capture micro-dissection (LCM) was explored as a method to obtain a 
homogenous population of DRG cells as an alternative to extracting RNA from whole DRG. 
 
3.2 The microarray 
The left (ipsilateral) L4 and L5 DRGs from 6 rats (310-380 g) that had undergone a left sciatic 
nerve transection 8 days before (section 2.2.3) were homogenised in pairs in Trizol (section 2.8.2) 
and total RNA extracted (section 2.8.4.1). L4 and L5 DRGs from 4 naïve control animals and a 
further 2 sham control rats (250-360g) were also processed. Figure 3-1 illustrates the design of the 
pilot microarray experiment.  Briefly, RNA from 2 rats was pooled and biotinylated cDNA was 
synthesized, fragmented and hybridized to RAE 230A GeneChips (Affymetrix, Santa Clara, CA).  
Three chips were used for each condition according to MIAME guidelines (Brazma et al. 2001). 
Tissue collection and processing for 5 of the 6 chips was completed before my arrival by a final 
year undergraduate project student, Miss Virginia Bound.  I observed surgery and completed tissue 
collection and processing for the third in the triplicate of sciatic transection chips (chip F).  It should 
be noted that chip F was hybridized separately and at a later date than the other 5 chips.  72 
 
 
 
 
 
                      
 
          
                           
  
 
                                  
 
 
                                        
 
        
                                                 
   
      
                         
 
   
 
  
 
 
   
 
 
Figure 3-1: Schematic diagram illustrating the design of the pilot microarray experiment that 
investigated gene changes in the DRG 8 days after a sciatic nerve transection injury. 
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3.2.1 Low level analysis for QC 
3.2.1.1  Internal controls 
Internal controls provide a measure of RNA sample quality by showing the 3’/5’ ratios for a set of 
specific probe sets.  Ratios of greater than 3 can indicate sample degradation.  The 6 chips in this 
pilot microarray showed elevated 3’/5’ ratios for the hexokinase control in all but chip F (Table 3-1).  
Since this chip was hybridized separately from the other chips it is possible that the difference in 
internal controls for this chip could be due to differences in the extraction of the RNA and in the 
RNA/cDNA handling.  
 
Table 3-1: RNA sample quality assessed by 3’/5’ ratios in probe sets for internal controls. 
Hexokinase shows elevated 3'/5' ratios in all but chip F. 
CHIP  BETA-ACTIN  GAPDH  HEXOKINASE 
A  2.030334  1.1738755  3.6950305 
B  2.070120  1.2229369  4.1672587 
C  1.871972  1.2387062  3.2658498 
D  1.787989  1.1488721  3.531362 
E  2.020886  1.3364604  3.7674406 
F  2.815433  2.1557865  2.5883071 
 
 
3.2.1.2  Hybridisation controls 
Affymetrix chips have integral hybridisation controls to allow assessment of hybridisation quality.  
Hybridisation controls are composed of a mixture of biotin-labelled cRNA transcripts (bioB (1.5 
pM), bioC (5 pM), bioD (25 pM) and cre (100 pM)).  This mixture was spiked into the hybridisation 
cocktail.  BioB is at the level of assay sensitivity and should thus be present 50% of the time while 
bioC, bioD and cre should appear in increasing concentrations.  
Figure 3-2 shows the hybridisation control profiles for all 6 chips.  All the hybridisation controls are 
present in increasing concentrations on all the chips.  There is a close clustering of profiles for all 
chips apart from chip F.  The separation is unsurprising as chip F was hybridized at a later time-
point than the other chips that were hybridized together.  All the profiles are however roughly 
parallel to each other suggesting a high quality, uniform hybridization across chips.  74 
3.2.1.3  Principal components analysis 
Principal component analysis (PCA) is a decomposition technique that can be used to check data 
quality.  It allows projection of complex data sets onto an easily visualized, 2-dimensional or 3-
dimensional space.  Replicates within a condition should cluster together and separately from 
arrays in other conditions.  Principal components are numbered according to their decreasing 
significance.  Principal components 1 and 2 for the pilot microarray experiment are illustrated in 
Figure 3-3.  Control chips cluster together indicating a similarity in gene behaviour on these chips.  
Chip F separates from the other experimental chips suggesting that this chip differs in its global 
gene expression from the other chips in the triplicate. 
 
 
Figure 3-2: Hybridisation control profiles. The x axis represents the hybridisation controls 
present at 1.5, 5, 25 and 100 pM, respectively.  The log of the normalised signal values is plotted 
on the Y-axis.   
 
 
 
 
Figure 3-3: Principal components analysis (PCA) for pilot experiment chips: PCA Component 
1 is plotted against PCA component 2. 
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3.2.2 Differentially expressed genes 
Rank products analysis (section 2.9.3.1.2) was used to identify genes that were up or 
downregulated 8 days after sciatic nerve transection.   Table 3-2 presents the descriptive statistics 
for this analysis while Figure 3-4 illustrates the proportion of probes that were up and 
downregulated.  At the 5% level there are roughly 50% more downregulated genes than 
upregulated genes.   There are however more dramatic fold changes to be seen amongst the 
upregulated genes with neuropeptide Y (NPY) showing a massive 45-fold upregulation. Table 3-3 
and Table 3-4 below show the top 20 up and downregulated genes.  A list of ranked genes to 1% 
FDR is presented in appendix A while ranked genes to 50% FDR are presented on the 
accompanying CD.  
Table 3-2:  Pilot microarray descriptive statistics. 
HIGHEST FOLD CHANGES   UPREGULATED GENES  DOWNREGULATED 
GENES 
Up  Down  1% FDR  5% FDR  1% FDR  5% FDR 
45.88  -3.60  44  86  57  138 
 
 
Figure 3-4: Pie chart showing the percentage of probe sets regulated within 5% FDR. The 
chips contained 15924 probes sets covering 15700 genes.  The proportion of upregulated probe 
sets is denoted by the red slice while the green slice indicates downregulated probe set.  76 
Table 3-3: Top 20 genes upregulated after sciatic nerve transection ranked by fold change  
PROBESET ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1387154_at  Npy  neuropeptide Y  NM_012614  45.88  0.00 
1377146_at  Vip  vasoactive intestinal polypeptide  AI412212  28.51  0.00 
1369268_at  Atf3  activating transcription factor 3  NM_012912  14.32  0.00 
1387088_at  Gal  Galanin  NM_033237  12.00  0.00 
1398243_at  Vsnl1  Visinin-like 1  NM_057144  8.71  0.00 
1368238_at  Pap (Reg2)  pancreatitis-associated protein  NM_053289  8.82  0.00 
1371248_at  Sprr1a  small proline-rich protein 1A (predicted)  BI286387  7.15  0.00 
1376601_at  Sema6a  Similar to semaphorin 6A1; semaphorin 6A-1  BF397526  6.35  0.00 
1368224_at  Spin2c  Serine protease inhibitor  NM_031531  6.62  0.00 
1387396_at  Hamp  hepcidin antimicrobial peptide  NM_053469  5.80  0.00 
1369202_at  Mx2  myxovirus (influenza virus) resistance 2  NM_017028  5.35  0.00 
1377334_at  RT1-Ba  RT1 class II, locus Ba  BG378249  4.80  0.00 
1388451_at  Cacna2d1  V-dependant calcium channel  AA817802  3.76  0.00 
1370883_at  RT1-Da  Antigen processing and presentation  Y00480  4.03  0.07 
1368947_at  Gadd45a  growth arrest and DNA-damage-inducible 45 alpha  NM_024127  4.12  0.07 
1368266_at  Arg1  arginase 1  NM_017134  3.69  0.06 
1370315_a_at  Stmn4  stathmin-like 4  AF026530  3.56  0.06 
1371450_at  Sox11  SRY-box containing gene 11  BE117330  3.02  0.11 
1367973_at  Ccl2  chemokine (C-C motif) ligand 2  NM_031530  3.20  0.11 
1372734_at  Smagp  small cell adhesion glycoprotein  AI408095  3.44  0.10 
Table 3-4: Top 20 genes downregulated 8 days after sciatic nerve transection ranked by fold 
change 
PROBESET ID  GENESYMBOL  GENE NAME 
   
ACC. NO.  FC   FD
R 
1368751_at  Kcns3  potassium voltage-gated channel, delayed-rectifier, 
subfamily S, member 3 
NM_031778  -3.60  0.00 
1393933_at  RGD:1310938  sortilin-related receptor, L(DLR class) A repeats-
containing (predicted) 
AW144823  -3.25  0.00 
1371108_a_at  Atp1a1  ATPase, Na+/K+ transporting, alpha 1 polypeptide  M74494  -3.82  0.00 
1374046_at  Hs3st2  Heparin sulfate (glucosamine)-3-0 sulfotransferase 2  BG376092  -3.03  0.00 
1368506_at  Rgs4  regulator of G-protein signaling 4  U27767  -3.37  0.00 
1368821_at  Fstl1  follistatin-like 1  BI290885  -3.23  0.00 
1370556_at  Vamp1  Vesicle-associated membrane protein  M24104  -3.06  0.00 
1370517_at  Nptx1  neuronal pentraxin 1  U18772  -2.88  0.00 
1377457_a_at  Sorl1  sortilin-related receptor, L(DLR class) A repeats-
containing (predicted) 
AA850618  -2.8  0.00 
1377095_at  LOC287847  similar to ataxin 2-binding protein 1 isoform 1  BG380409  -2.91  0.00 
1369390_a_at  Dpp6  dipeptidylpeptidase 6  NM_022850  -2.82  0.00 
1371077_at  Htr3b  5-hydroxytryptamine (serotonin) receptor 3b  AI575989  -2.63  0.00 
1369428_a_at  Htr3a  5-hydroxytryptamine (serotonin) receptor 3a  U28430  -2.65  0.00 
1371211_a_at  Nrg1  neuregulin 1  U02315  -2.78  0.00 
1369001_at  Chrna3  cholinergic receptor, nicotinic, alpha polypeptide 3  NM_052805  -2.57  0.00 
1388000_at  Slc24a2  solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 2 
AF021923  -2.65  0.00 
1369116_a_at  Calca  calcitonin/calcitonin-related polypeptide, alpha  NM_017338  -2.5  0.00 
1370572_at  Gpr149  G protein-coupled receptor 149  AY030276  -2.43  0.00 
1375242_at  Cadm1  Cell adhesion molecule 1  BI296440  -2.39  0.05 
1384132_at  RGD:1310999  immunoglobulin superfamily, member 4A (predicted)  H31111  -2.63  0.05 
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3.2.3 Comparison with past studies 
A number of studies have examined gene changes in the DRG after sciatic nerve transection.  A 
comparison of our data with past studies was performed whereby the microarray data was 
searched (by gene symbol and all known gene symbol aliases) for the presence of genes whose 
regulation is already known.  Studies included in the comparison have examined gene changes in 
the DRG at various time points after sciatic nerve transection in rodents using various techniques.  
The results of this comparison are presented in Table 3-5.  On the whole, the microarray showed 
good concordance with past studies and where a gene was identified as regulated, the direction of 
change was, in general, the same as previously reported (see genes highlighted in bold).  Only one 
gene showed regulation in the opposite direction to previously reported (ROBO2, highlighted in 
red). A number of genes that have been previously reported as regulated after sciatic nerve injury 
were unchanged at the 50% FDR level in our microarray.  These were mainly encoding G protein 
coupled receptors that are in low abundance.  Whilst this may indicate a problem with sensitivity of 
the microarray, it is possible that these genes are simply not regulated at this relatively late time 
point after injury.  There is also evidence that the mRNA for a number of proteins, such as the κ-
opioid receptor, undergoes axonal transport and local translation (Willis et al. 2005; Bi et al. 2006; 
Bi et al. 2007) and as such would only be detected as increased in the DRG at a very early 
timepoint after injury. 
Table 3-5: Comparison of microarray and known regulation data for genes whose 
expression within the DRG following nerve injury has been studied previously.  Genes that 
show the same regulation in our microarray as past studies are highlighted in bold.  Where 
information is unavailable cells are shaded in grey.  NC= no change (for past studies) or no change 
within 50% FDR (for our pilot microrray), A= absent on all chips.  
CATEGORY  GENE 
SYMBOL 
KNOWN REGULATION  (Costigan 
et al. 2002) 
3 days 
post-lesion 
FC  FDR 
ADRA2A  Up (Birder and Perl 1999; Shi et al. 2000)  A  NC  --- 
ADRA2C  Down (Shi et al. 2000)  A  -1.25  48.66 
AGTR1  Up (Gallinat et al. 1998)  A  NC  --- 
AGTR2  Up (Gallinat et al. 1998)  A  NC  --- 
BDKRB1  Up (Levy and Zochodne 2000)  -1.6  NC  --- 
BDKRB2  Up (Levy and Zochodne 2000)  A  NC  --- 
CCKBR  Up (Zhang et al. 1993; Antunes Bras et al. 1999)  -1.1  NC  --- 
GALR1  Down (Xu et al. 1996; Zhang et al. 1998)  A  NC  --- 
GALR2  Down (Sten Shi et al. 1997; Zhang et al. 1998)  A  NC  --- 
NPY1R  Down (Zhang et al. 1994; Landry et al. 2000)  -1.3  NC  --- 
OPRM1  Down (Zhang et al. 1998)  -3.2  NC  --- 
G protein coupled 
receptors 
OPRD1  Down (Zhang et al. 1998)  A  NC  --- 
GABRA2  NC (Fukuoka et al. 1998)  -1.6  NC  --- 
GABRG2  down (Bradbury et al. 1998)  -1.5  NC  --- 
P2RX3  Down (Bradbury et al. 1998; Yiangou et al. 
2000) 
-1.1  -1.73  15.02 
Ligand gated ion 
channel receptors 
TRPV1  Down (Michael and Priestley 1999)  -1.8  -2.07  1.41 
Receptor tyrosine 
kinases 
NGFR  Down (Krekoski et al. 1996)  A  -1.73  9.43  78 
Table 3-5 continued. 
GFRA1  Up (Bennett et al. 2000)  2.00  2.42  1.1 
GFRA2  Down (Bennett et al. 2000)  -1.7  -1.31  34.82 
 
TRKA  Down (Kashiba et al. 1998; Bergman et al. 
1999) 
-1.3  -2.23  0.91 
BDNF  Up (Cho et al. 1997; Kashiba and Senba 1999)  1.6  NC  --- 
CALCB  Down (Noguchi et al. 1990)  -1.6  -1.51  19.98 
CALCA  Down (Noguchi et al. 1990)  -1.6  -1.64  7.31 
CCK  Up (Verge et al. 1993)  A  NC  --- 
FGF2  Up (Ji et al. 1995)  A  NC  --- 
GAL  Up (Hokfelt et al. 1994; Tanabe et al. 2003)  28.8  12  0 
IL1B  Up (Murphy et al. 1995)  1.1  NC  --- 
IL6  Up (Murphy et al. 1995)  A  1.81  8.21 
NPY  Up (Hokfelt et al. 1994; Tanabe et al. 2003)  9.7  45.88  0 
ADCYAP1  Up (Jongsma et al. 2000)  3.5  2.88  0.25 
SST  Down (Alvares and Fitzgerald 1999)  -1.5  -1.82  4.28 
TAC1  Down (Noguchi et al. 1990; Zhang et al. 1995; 
Alvares and Fitzgerald 1999)  
-2.2  -1.78  6.83 
TNF  Up (Murphy et al. 1995)  A  NC  --- 
DAP  Down (Mulder et al. 1997)  -4.7  NC  --- 
REG2 (PAP)  Up (Livesey et al. 1997)  18.5  8.82  0 
ROBO2  Up (Bloechlinger et al. 2004; Yi et al. 2006)    -1.53  16.61 
SLIT1  Up (Yi et al. 2006)    NC  --- 
STAT3  Up (Qiu et al. 2005)    NC  --- 
PACAP  Up (Pettersson et al. 2004)    2.88  0.25 
Cytokine/growth 
factors/neuropeptides 
NTS  Up (Tanabe et al. 2003)    A   
Receptor- associated 
proteins 
RBP1  Up (Karchewski et al. 2004)    1.55  18.7 
BNC1  Up (Waxman et al. 1994) (Dib-Hajj et al. 1996)  1.4  NC  --- 
KCNA7, 
KCNA2 
Down (Ishikawa et al. 1999; Park et al. 2003)  -1.1  NC  ---- 
KCNA4  Down (Park et al. 2003)    -1.37  22.76 
KCND2  Down (Park et al. 2003)    NC  --- 
SCN10A  Down (Dib-Hajj et al. 1996; Okuse et al. 1997) 
(Sleeper et al. 2000) 
-1.9  -1.96  1.71 
CACNA2D1  Up (Luo et al. 2001)  3.4  2.46  1.84 
NaN alpha 
subunit 
Down (Dib-Hajj et al. 1998; Sleeper et al. 2000)  -2.1  ??   
TRPC1  NC (Wu et al. 2008)    NC  --- 
TRPC3  NC (Wu et al. 2008)    -1.48  22.53 
TRPC4  Up (Wu et al. 2008)    NC  --- 
TRPC6  NC (Wu et al. 2008)    NC  --- 
Ion channels 
TRPC7  NC (Wu et al. 2008)    NC  --- 
ACTB  Up (Lund and McQuarrie 1996)  -1.1  NC  --- 
GAP43  Up (Chong et al. 1994)  1.8  2.77  0.08 
GFAP  Up (Woodham et al. 1989)  3.8  2.06  2.74 
NEFH  Down (Oblinger et al. 1989; Wong and 
Oblinger 1990)  
-1.2  -1.35  33.85 
NEFM  Down (Oblinger et al. 1989; Wong and 
Oblinger 1990) 
-1.1  -1.39  31.98 
NEFL  Down (Oblinger et al. 1989; Wong and 
Oblinger 1990) 
1  -1.42  23.95 
PRPH  Up (Wong and Oblinger 1990; Chadan et al. 
1994) 
-1.1  NC  --- 
TUB  Up (Moskowitz et al. 1993; Jiang et al. 1994)  -1.3  1.9  8.22 
LASP1?  Up  (Newton et al. 2000)  4  NC  --- 
SPRR1A  Up (De Leon et al. 1995)  3.6  7.15  0 
MYO10  Up (Tanabe et al. 2003)    NC  --- 
Cell cytoskeleton 
ITGA6  Up (Wallquist et al. 2004)    NC  ---  79 
Table 3-5 continued. 
ITGA7  Up (Wallquist et al. 2004)    NC  --- 
ITGB1  Up (Wallquist et al. 2004)    1.51  31.61 
ATF3  Up (Tsujino et al. 2000; Tanabe et al. 2003)  11.4  14.32  0 
c-jun  Up (Herdegen et al. 1992; De Leon et al. 1995; 
Kenney and Kocsis 1997) 
7.3  2.68  0.26 
jun-D  Up (Herdegen et al. 1992; De Leon et al. 1995; 
Kenney and Kocsis 1997) 
A  NC  --- 
SOX11  Up (Tanabe et al. 2003)    1.68  15.74 
RGS3  Down (Costigan et al. 2003)    -1.88  4.22 
RGS4  Down (Costigan et al. 2003)    -3.37  0 
Transcription factors 
TNFRSF12A 
(FN14) 
Up (Tanabe et al. 2003)    NC  --- 
AEG  Up (Newton et al. 2000)  7.5  NC  --- 
ITGA7  Up (Werner et al. 2000)  1.5  NC  --- 
NCAM  Up (Daniloff et al. 1986)  A  NC  --- 
L1CAM  NC (Zhang et al. 2000)  1.2  NC  --- 
NRP1  Up (Gavazzi et al. 2000)  -1.2  NC  --- 
NINJ1  Up (Araki and Milbrandt 1996)  1  NC  --- 
CSPG4  NC (Rezajooi et al. 2004)    NC  --- 
Cell 
surface/extracellular 
matrix 
GPC1  Up (Bloechlinger et al. 2004)    NC  --- 
Transmembrane 
proteins 
FLRT3  Up (Tanabe et al. 2003)    NC  --- 
NOS1  Up (Shi et al. 1998; Gonzalez-Hernandez and 
Rustioni 1999)  
A  NC  ---- 
RHOA  Up (Cheng et al. 2008)    NC  --- 
Enzymes 
ECEL1  Up (Kato et al. 2002; Kiryu-Seo 2006)    2.42  1 
Chaperone proteins  TOR1A  Up (Zhao et al. 2008)    NC  --- 
BAX alpha  NC (Gillardon et al. 1994; Gillardon et al. 
1996) 
1  NC  --- 
BCL2  Down (Gillardon et al. 1994; Alberi et al. 1996)  -1.1  NC  --- 
SOD2  Up (Fernandes and Tetzlaff 2001)  1.1  1.51  29.6 
HSP27  Up (Tandrup et al. 2000)  2.9  1.8  9.22 
Cell death/survival 
SOD  NC (Fernandes and Tetzlaff 2001)  1  NC  --- 
FABP  Up (De Leon et al. 1996)  1.5  1.64  18.68  Metabolism 
PPI  NC (Tandrup et al. 2000)  -1.1  NC  --- 
Immune and 
inflammation 
C1QA  Up (Tanabe et al. 2003)    2.39  1.67 
SLC17A7  Down (Brumovsky et al. 2007)    -1.29  41.45  Vesicular transport 
proteins  SLC17A6  Down (Brumovsky et al. 2007)    NC  --- 
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3.2.4 Functional analysis of differentially expressed genes 
Iterative group analysis (IGA) (section 2.9.3.1.4) was used to aid in the functional interpretation of 
the pilot microarray data.  Ontological analyses such as this simplify microarray data by identifying 
the ontological groups that are most changed in a data set.  The top represented up and down 
regulated ontological groups are presented in Table 3-6 and Table 3-7.  IGA can operate in a 
‘classic’ mode whereby multiple probe sets for one gene can contribute or in a ‘representative’ 
mode, whereby only one probeset per gene is included in the analysis.  I have chosen to present 
data from IGA analysis in the latter mode as it avoids overrepresentation of ontological groups 
because of genes with more than one probe set. 
Table 3-6: Top upregulated groups as determined by IGA (representative mode). 
TOP CHANGED GROUPS  NO. OF 
GROUP 
MEMBERS  
NO. OF 
CHANGED 
MEMBERS 
P VALUE  % 
MEMBERS 
CHANGED 
GENES 
INVOLVED 
1664 - G-protein-coupled receptor binding  14  3  3.6e-06  21.43  Npy 
Gal 
Ccl2 
42613 - MHC class II protein complex  4  3  5.9e-06  75.00  RT1-Ba 
RT1-Bb 
RGD:735096 
IPR000971 - Globin  8  3  1.1e-04  37.50  Hba-a1 
LOC287167 
Hbb 
IPR000375 - Dynamin central region  6  2  1.3e-04  33.33  Mx2 
Mx1 
IPR003130 - Dynamin GTPase effector  6  2  1.3e-04  33.33  Mx2 
Mx1 
IPR000353 - Class II histocompatibility 
antigen, beta chain, beta-1 domain 
2  2  1.3e-04  100.00  RT1-Bb 
RGD:735096 
5525 – GTP binding  78  5  1.5e-04  6.41  Mx2 
Rhoq 
Mx1 
RGD:621810 
Rasd1 
IPR000532 - Glucagon/GIP/secretin/VIP  6  2  1.6e-04  33.33  RGD:621647 
Adcyap1 
5833 - hemoglobin complex  2  2  1.7e-04  100.00  Hba-a1 
Hbb 
IPR001401 - Dynamin  7  2  1.8e-04  28.57  Mx2 
Mx1 
6956 - complement activation  10  3  2.1e-04  30.00  C1qb 
C3 
C4a 
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Table 3-7: Top downregulated groups as determined by IGA (representative mode) 
TOP CHANGED GROUPS  NO. OF 
GROUP 
MEMBERS 
NO. OF 
CHANGED 
MEMBERS 
P VALUE  % 
MEMBERS
CHANGED 
GENES 
INVOLVED 
5261 - cation channel activity  30  8  2.2e-09  26.67  Kcns3 
Kcnd3 
Grik1 
RGD:628841 
RGD:3629 
Kcns1 
Kcnb1 
Kcnc2 
 
IPR003131 - K+ channel tetramerisation  23  7  7.5e-09  30.43  Kcns3 
Kcnd3 
Kcns1 
Kcnv1 
Kcna1 
Kcnb1 
Kcnc2 
IPR005821 - Ion transport protein  76  9  8.7e-09  11.84  Kcns3 
Kcnd3 
Scn1a 
Scn11a 
RGD:3629 
Kcns1 
Kcnv1 
Kcna1 
Kcnb1 
6812 - cation transport  53  7  2.0e-07  13.21  Kcns3 
Kcnd3 
Scn1a 
Scn11a 
RGD:3629 
Kcns1 
Kcnb1 
IPR006202 - Neurotransmitter-gated ion-
channel ligand binding domain 
36  4  6.0e-06  11.11  Htr3b 
Htr3a 
Chrna3 
Glrb 
IPR010526 - Sodium ion transport-
associated 
10  3  2.4e-05  30.00  Scn1a 
Scn11a 
RGD:3629 
Calcium_regulation_in_cardiac_cells - 
GenMAPP 
96  7  5.0e-05  7.29  Rgs4 
RGD:628732 
Rgs10 
Gnai1 
Rgs3 
Atp2b3 
Gnaq 
IPR001990 - Chromogranin/secretogranin  4  2  1.6e-04  50.00  Scg2 
Chga 
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3.3 qRT-PCR validation of microarray results 
Changes observed in the microarray for selected genes were validated by qRT-PCR on separate 
samples from those used in the microarray (n=6/group (transected, sham ctrl. and naïve ctrl.) using 
SYBR green chemistry (see section 2.10.1).  The inclusion of sham controls allowed us to test the 
hypothesis that the changes were a result of the transection injury and not a non-specific response 
to surgery and/or anaesthesia.  Genes chosen for validation are described in section 3.3.3. 
 
3.3.1 Validation of qRT-PCR reference genes  
qRT-PCR data was normalised against stably expressed reference genes, the purpose of 
normalisation being to correct for non-specific variation, such as differences in cDNA quantity and 
quality which can affect efficiency of the PCR reaction. There have however been several reports 
of variation in supposedly stable housekeeping genes (Schmittgen and Zakrajsek 2000; Selvey et 
al. 2001) and it has been demonstrated that errors of up to 20-fold can be generated through 
normalization to a single housekeeping gene (Vandesompele et al. 2002).  Consequently, 
normalization to a single reference gene is thought to be insufficient and it is recommended that 
potential reference genes are validated for stability when subject to the specific experimental 
manipulations in question (Thellin et al. 1999; Dheda et al. 2004). A panel of 6 housekeeping 
genes; 18s rRNA, GAPDH, TOP1, B2M, RPL13 and UBC were therefore assessed with Genorm 
(Vandesompele et al. 2002) and NormFinder (Andersen et al. 2004) to validate their stability in the 
sciatic nerve transection injury paradigm and hence their suitability for use as reference genes for 
relative quantification. The genes were chosen from separate functional pathways (with guidance 
from Primer Design Ltd.) in order to minimise the possibility of co-regulation.   Both Genorm and 
NormFinder found the most stable three genes to be GAPDH, TOP1 and B2M in both transected 
vs. naïve and transected vs. sham samples (Figure 3-5 and Figure 3-6) and these genes were 
used to calculate a composite normalisation factor for analysis of subsequent experiments.  83 
 
 
Figure 3-5:  Genorm analysis of HKG stability.  TOP1, GAPDH and B2M were most stable in 
transected vs. naive and transected vs. sham conditions.  A low M value represents high stability 
with an M value of >1.5 indicating a gene that is unsuitable for use a reference gene 
(Vandesompele et al. 2002). 
 
Figure 3-6: Normfinder analysis of HKG stability. TOP1, GAPDH and B2M were most stable in 
transected vs. naive and transected vs. sham conditions. 
← decreasing stability        increasing stability→ 
           
← decreasing stability           increasing stability→ 
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3.3.2 PCR efficiency testing using raw fluorescence data 
LinReg-PCR (Ramakers et al. 2003) was used to calculate well-to-well reaction efficiencies from 
the amplification of target genes.  Raw fluorescence data from each well were analysed and gene-
specific PCR efficiencies calculated using 4-6 fluorescence data points within the log-linear phase 
with a correlation coefficient of r>0.99.   Figure 3-7 illustrates the calculation of well-to-well reaction 
efficiencies for one gene.  
The average PCR efficiencies obtained from LinReg-PCR for each of the reference and target 
genes are recorded in Table 3-8.  These PCR efficiencies are significantly lower than those 
assumed by the 2
-ΔΔCt quantification method (one sample t-test, two tailed, p<0.0001). This is 
consistent with previous findings that indicate that the 2
-ΔΔCt method tends to overestimate reaction 
efficiencies (Ramakers et al. 2003) and thus may lead to erroneous gene expression data.  Assay-
specific reaction efficiencies were therefore used in subsequent data analysis with REST-MCS, a 
software tool that allows estimation of up and down-regulation for gene expression studies (Pfaffl et 
al. 2002) (section 3.3.3).  All primer sets appeared to be functioning with similar mean efficiency 
(70-85 %). 
 
Table 3-8: Mean gene specific reaction efficiencies and standard deviations as calculated by 
LinRegPCR. 
GENE  MEAN REACTION EFFICIENCY  STANDARD DEVIATION 
GAPDH  1.793  0.289 
TOP1  1.713  0.185 
B2M  1.789  0.258 
NPTX1  1.733  0.162 
ATF3  1.794  0.159 
ECEL1  1.743  0.159 
MX2  1.709  0.165 
SEMA6A  1.848  0.200 
TGM1  1.757  0.195 
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Figure 3-7: Example of determination of PCR efficiency using LinReg-PCR tool.  a) 
Amplification plots generated from raw fluorescence data from a group of 60 samples and b) for a 
single sample, highlighting the points used for the linear regression c) Calculated efficiencies, d) R
2 
values and e) number of points included in linear regression calculation for each sample. 
a) 
 
b) 
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3.3.3 Quantification of relative gene expression levels using 
REST-MCS 
Figure 3-9 compares microarray and qRT-PCR expression data of the 6 genes chosen for 
validation.  The expression of 5 of these genes in spinal cord, skeletal muscle, heart, spleen, lung 
and kidney was also investigated using standard RT-PCR (section 2.8.10) (Figure 3-8). The qRT-
PCR results for each gene are described in the ensuing sections (3.3.3.1 to 3.3.3.6).  Gene 
positions are for rat and according to Ensembl release 49. 
3.3.3.1  Endothelin converting enzyme-like 1 (ECEL1) 
ECEL1 (or DINE) has been mapped to position 85,939,300 - 85,945,981 on chromosome 9 in rat.   
It is a CNS-specific metallopeptidase and this is supported by RT-PCR that shows its expression 
only in CNS tissue (Figure 3-8). It undergoes an extreme transcriptional response to a variety of 
injury types both in the central and peripheral NS and in response to LIF and NGF deprivation 
(Kato et al. 2002).  It is upregulated mainly in small-sized DRG cells after sciatic nerve transection 
where it has a similar regulatory pattern to galanin and as such has been suggested to share a 
common transcriptional machinery and neuroprotective role with this gene (Kato et al. 2002; Kiryu-
Seo 2006).  It has been shown that ECEL1 can be regulated by interaction of ATF3, c-JUN and 
STAT3 with the general transcription factor SP1 (Kiryu-Seo et al. 2008). ECEL1 (probe set 
1368923_at) had a 2.42 fold-change in the microarray (FDR=1%). qRT-PCR confirmed this 
upregulation and this was significant for both the transection vs. naive ctrl. (p=0.001) and 
transection vs. sham ctrl. (p= 0.001) comparisons.  There was no significant difference in 
expression of this gene between the naïve and sham ctrl. (p=0.716). 
3.3.3.2  Activating transcription factor 3 (ATF3) 
ATF3 (also known as LRFI and LRF1) maps to position 107,191,622 - 107,223,850 on 
chromosome 13 and has been previously associated with neuronal injury (Tsujino et al. 2000; 
Kataoka et al. 2007).  It has been suggested that this gene contributes to neurite outgrowth by 
orchestrating gene expression in the injured neuron (Seijffers et al. 2006).  There is also evidence 
of an antiapoptotic role for the gene (Francis et al. 2004; Hamdi et al. 2008).  ATF3 (probe set 
1369268_at) showed a large upregulation in the microarray (14.32-fold, FDR<0.01%).  qRT-PCR 
detected a similar degree of upregulation in this gene in both the transection vs. naïve and 
transection vs. sham comparisons  (p=0.001 in both cases).  Again, sham and naïve controls 
showed no significant difference in expression of this gene (p=0.851).  87 
3.3.3.3  Interferon-induced GTP-binding protein (MX2) 
MX2 is located on chromosome 11, position 37,548,833 - 37,611,797. It is expressed upon 
interferon treatment when it localizes to the cytoplasm and has an antiviral role (Jin et al. 1999); 
(Stark et al. 1998). There is however support for MX2 also having an inflammatory role within the 
CNS as its expression has been shown to be concurrent with astrocytosis and microglial activation 
in rodent brain (Stobart et al. 2007).  RT-PCR indicates that MX2 is expressed constitutively in 
normal spleen and lung as previously reported (Asano et al. 2003), also in kidney, skeletal muscle 
and spinal cord but not in heart (Figure 3-8).  MX2 (probe set 1369202_at) was upregulated 5.35-
fold (FDR<0.01%) in the microarray and dominated the IGA ontological analysis.  qRT-PCR 
confirmed this upregulation in comparisons of transection with both the control groups and was 
significant for the transection vs. sham comparison (p=0.007) although the transection vs. naïve 
comparison misses significance (p=0.074).  There was however no significant difference between 
the sham and naïve groups (p=0.973). 
3.3.3.4  Neuronal pentraxin 1 (NPTX1) 
NPTX1, mapped to position 108,918,661 - 108,927,625 on chromosome 10, has been reported to 
be localized exclusively to the nervous system where it may mediate the uptake of synaptic 
material (Omeis et al. 1996).  This is contrary to the results of the standard RT-PCR that suggested 
a fairly ubiquitous expression in all tissues examined apart from spinal cord (Figure 3-8).  NPTX1 is 
also thought to be involved in extracellular matrix reorganization and its expression was shown to 
be increased following a treatment that led to decreased collagen content in the male reproductive 
tract (Yasuhara et al. 2008).  NPTX1 (probe set 1370517_at) was downregulated in the microarray 
(-2.88-fold, FDR<0.01%).  qRT-PCR analysis of this gene also showed downregulation in this gene 
in comparisons with both the naïve and sham ctrl groups although insignificant  (p=0.414 and 
p=0.743, respectively).  These changes were however significant before normalization  (p=0.005 
for transection vs. naïve and p=0.046 for transection vs. sham). There was no significant difference 
between the two ctrl. groups (p=0.743). 
3.3.3.5  Semaphorin 6A (SEMA6A) 
SEMA6A, mapped to chromosome 18, position 41,545,337 - 41,666,255, is one of the less well 
characterized members of the large semaphorin family of axonal guidance molecules (see also 
section 1.2.2.2). As well as its role in axon guidance, SEMA6A is expressed in the cytoskeleton in 
association with beta-actin and has thus been suggested to have a role in modulating tubulin 
isotype composition (Prislei et al. 2008).  During spinal cord development SEMA6A expression is 
localized to the cells at the PNS/CNS interface and is thought to be necessary for prevention of the 
emigration of motoneurons out of the ventral spinal cord and for correct segregation of the dorsal 
roots (Bron et al. 2007; Mauti et al. 2007).  RT-PCR did however suggest a fairly ubiquitous 
expression of the gene in all the tissues examined (Figure 3-8). SEMA6A (probe set 1376601_at) 
exhibited a fairly large upregulation in the microarray (6.35 fold, FDR<0.01%).  This change was 
validated in the transection vs. sham comparison (p=0.004) and was of a similar magnitude.   88 
Upregulation of this gene was also seen in the transection vs. naïve comparison although this was 
insignificant (p=0.162).  No significant difference was found between the control groups (p= 0.422). 
3.3.3.6  Transglutaminase 1 (TGM1) 
TGM1 (also known as TGR) is located on chromosome 15, position 33,846,335 - 33,859,759 
where it encodes a cross-linking enzyme.  Its expression has been most well characterised in 
keratinocytes where mutations in this gene cause a skin disorder called lamellar ichthyosis 
(Boeshans et al. 2007).  RT-PCR provided evidence for a ubiquitous expression of this gene in all 
tissues examined with highest expression in heart, spleen and lung (Figure 3-8).  There is evidence 
for a role for this gene in axonal regeneration as TGM1 promotes axonal elongation at the surface 
of retinal ganglion cells after optic nerve injury (Sugitani et al. 2006).  TGM1 (probe set 
1370051_at) showed a 2.83 fold change in the microarray (FDR 0.36%).  qRT-PCR validated this 
change with significant upregulation of this gene seen in both the transected vs. naïve and 
transected vs. sham comparisons (p=0.002 and p=0.003, respectively).  There was no significant 
difference between the sham and naïve groups (p=0.922). 
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Figure 3-8: Expression of selected genes in normal rat tissues.  2 µl PCR product was loaded 
in each well of a 2% agarose gel. 
 
Figure 3-9:  Validation of microarray by qRT-PCR.  Log2expression ratio (± S.E.M, n=5-6).  *= 
p<0.01 for the plotted qRT-PCR comparison or FDR <5% in the case of the microarray experiment. 
*=p<0.05 before normalization to housekeeping genes. 
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3.3.4 Correlation between fold changes determined by 
microarray and qRT-PCR 
Microarray fold changes for each gene were plotted against the fold changes obtained by qRT-
PCR for the qRT-PCR.  Although direction of change was the same in the qRT-PCR as the 
micrarray, fold changes tended to be greater in the qRT-PCR leading to a weak correlation (R= 
0.267 and R=0.460, p>0.05 (d.f=4) when microarray was compared to qRT-PCR using naïve and 
sham ctrl, respectively).  This is consistent with past studies that have shown qRT-PCR to provide 
larger fold change estimates than microarray due to greater sensitivity of the assay.  In addition, it 
has been demonstrated that microarray fold change estimates arising from RMA normalized data 
are significantly lower than nominal fold changes calculated from spiked in controls (Cope et al. 
2004). 
 
 
Figure 3-10: Correlation between qRT-PCR and microarray fold change data. a) microarray 
vs. qRT-PCR with naive ctrl, b) microarray vs. qRT-PCR with sham ctrl.  
a) 
b)  91 
3.4 Further optimisation of experimental parameters  
3.4.1 Laser capture microdissection 
The DRG is a heterogeneous tissue containing schwann cells, satellite cells, fibroblasts, 
inflammatory cells and vascular endothelium/smooth muscle cells, as well as the sensory neuron 
cell bodies that are of interest to this study.  LCM was investigated as a method to obtain a 
homogeneous population of sensory cells from which RNA could be extracted for microarray 
purposes, the advantage of a pure population of sensory cells being that gene expression changes 
in these cells of interest will be neither exaggerated nor obscured by changes in other cell types. 
Sensory nerve cells were successfully captured from thin, toluidine-blue stained DRG sections 
mounted on poly-L-lysine coated slides following unsuccessful attempts to capture cells from plain 
slides (Figure 3-11).  Approximately 2000 cells were captured onto each cap and subjected to lysis 
and subsequent total RNA isolation (Section 2.8.5.4).   
Total RNA yield/2000 cells ranged from 0-50 ng and was thus insufficient quantity for use in 
microarray experiments using the Affymetrix standard protocol.  Whilst there have been reports in 
previous studies of LCM successfully producing material for microarray experiments (Luo et al. 
1999) this hasn’t been without the subsequent use of several rounds of T7 amplification (Eberwine 
method).  The small sample protocol for Affymetrix requires >100 ng of good quality RNA as 
starting material.  Although this quantity of RNA may have been achievable with the use of 
additional animals, the high 260/280 ratios (2.35- 3.21) of the RNA originating from laser captured 
cells suggested the presence of degraded RNA and it can be envisioned that RNA damage may 
have occured in the DRG sections during staining, fixing, dehydration or use of the laser itself.    
Since high quality, intact RNA is key to the quality of microarray experiments, LCM was pursued no 
further and whole DRG were again used in the main microarray experiment.   92 
 
                         
                          
                          
Figure 3-11:  Laser capture microdissection of DRG cells. a) Toluidine blue stained DRG 
section. DRG cells captured from sections mounted on b) plain slides and c) Poly-L-Lysine coated 
slides.  The arrow in a) indicates a cell of correct morphology for capture. 
a) 
b) 
c)  93 
3.4.2 Homogenisation in buffer RLT improves RNA integrity  
RNA extraction for the pilot microarray had been carried out using TriReagent as a lysis buffer.  
RNA obtained using this method showed an unusual bioanalyser profile, showing only one peak 
and also only one band when run on an agarose gel.  An alternative method of RNA extraction 
using buffer RLT (Qiagen) was investigated and this appeared to improve RNA integrity (Figure 
3-12).  All subsequent homogenisations for the main microarray experiment were therefore carried 
out in buffer RLT and total RNA obtained had an RIN of >7 (Schroeder et al. 2006).     
 
 
Figure 3-12:  Typical bioanalyser traces for RNA extracted after a) trizol homogenisation and 
b) buffer RLT homogenisation. Trizol homogenized RNA shows an absence of the 28s peak. 
 
 
 
 
a)  b)  94 
3.5 Discussion and summary 
Sciatic nerve transection elicits changes in the regulation of hundreds of genes in the DRG 
(Costigan et al. 2002; Tanabe et al. 2003). The pilot microarray was successful in detecting gene 
expression changes in the DRG at 8 days following a sciatic nerve transection (~1.5 % of probes, 
<5%FDR) and many of these changes were consistent with those already reported in past studies 
(Table 3-5) providing in silico validation of the data in addition to the qRT-PCR validation. 
3.5.1 Sample and experiment quality 
RNA quality is of paramount importance to microarray experiments and our method of rapid 
isolation and freezing of DRGs in liquid nitrogen after perfusion of the rat with ice cold mammalian 
ringer yielded good quality RNA as indicated by high RINs.  An alternative method of DRG isolation 
has since come to light that may further improve RNA quality and could be considered for future 
projects.  (LeDoux et al. 2006) perfusion fixed rats with RNAlater before isolation of DRGs.  This 
avoids the potential for introduction of RNases during the perfusion step and eliminates the need 
for freezing of tissue, hence reducing freeze-thaw degradation of RNA.  
Although LCM was investigated as a method to obtain a pure population of sensory nerve cells for 
the main microarray it was decided that whole DRG would again be used allowing higher quality 
total RNA to be obtained with a reduction in animal numbers.  In addition, it can be argued that the 
inflammatory response after injury of non-neuronal cells within the DRG is inextricably linked to 
regeneration and therefore gene responses in these cells are also of interest to this study.  Indeed, 
it has been suggested that inflammation near the nerve cell body enhances axon outgrowth and 
that axotomy-induced mitosis of glial satellite cells is a mechanism by which conditioning lesions 
facilitate regeneration after a subsequent injury to the central branch (Lu and Richardson 1991).  
Microarray analysis of whole DRG has value in that it gives an overall picture of gene expression 
changes in the neuronal cells and also the non-neuronal cells in close proximity to them.  Further 
investigation of individual genes and their gene products using in situ hybridisation and 
immunohistochemistry will allow their spatial expression within the DRG to be disseminated.   
Quality control assessment of the microarray data suggested that experimental chip F showed 
slightly different sample quality (Table 3-1), hybridization profile (Figure 3-2) and distribution of 
gene changes (Figure 3-3) than the ctrl chips and more importantly, the other two chips in the 
sciatic transection triplicate. The other chips were hybridized separately from chip F, and using 
material collected and processed by a different experimenter than chip F, highlighting the 
importance of consistency in the preparation of material for microarray and also the importance of 
hybridizing all chips for one experiment together using chips from a single batch. Whilst there is 
argument to exclude chip F from the analyses, bioinformatics advice was sought and the decision 
was taken to include this final chip.  In addition, RP lists generated with and without inclusion of this 
chip did not differ greatly in the genes regulated at <5% FDR.  95 
3.5.2 Consistency with past studies and biological validity 
3.5.2.1  Expression of regeneration and pain associated genes 
The microarray yielded data that was consistent with past studies of the DRG response to sciatic 
nerve injury.  It is known that the sciatic nerve undergoes a regenerative response to injury and is 
associated with neuropathic pain.  Gene regulation reflected this with changes in expression of 
several known regeneration- associated genes (RAGs) and neurotrophic factors and in 
neuropeptides known to modulate pain transmission.  Among the top upregulated genes (Table 
3-3) were genes previously implicated in axonal regeneration (ARG1, SPRR1A and ATF3) or 
neuronal development. ARG1 (3.69-fold upregulated) and SPRR1A (7.15-fold upregulated) have 
been shown to be downstream effectors of the cAMP-mediated conditioning lesion effect (see also 
section 1.4.2.1). ATF3 showed a 14.32-fold upregulation which was confirmed by qRT-PCR (Figure 
3-9) and is an attractive candidate RAG as not only is it upregulated in all DRG cells after a 
peripheral but not a central axonal injury (Tsujino et al. 2000), but it also enhances neurite 
outgrowth in culture (Pearson et al. 2003; Seijffers et al. 2006). Furthermore, in mice 
overexpressing ATF3 the rate of peripheral nerve regeneration was increased to an extent 
comparable to a conditioning lesion although overexpression was not sufficient to overcome the 
inhibitory effects of myelin to promote regeneration in the spinal cord in vivo (Seijffers et al. 2007).  
The upregulation of growth associated genes such as SPRR1A in these ATF3 overexpressing 
mice also suggests that ATF3 can regulate expression of regeneration enhancing genes and thus 
increases the intrinsic growth state of neurons. The neurotrophic factor PAP (REG2) (upregulated 
8.82-fold in our study) is upregulated in axons and DRG cells after sciatic nerve injury and is 
thought to have a mitogenic effect on Schwann cells and a proregenerative effect on sensory and 
motor neurons (Livesey et al. 1997).   More recently (Averill et al. 2002) showed REG2 to have a 
dynamic expression in DRG neurons after injury, with expression moving from small to large size 
DRG cells.   
Expression of genes with a putative neuroprotective role was also increased. GADD45a, which 
showed a 4.12-fold upregulation in our study, is not constitutively expressed in adult or embryonic 
DRG neurons but has been previously shown to be upregulated after peripheral nerve injury but 
not after dorsal rhizotomy (Costigan et al. 2002; Befort et al. 2003).  The function of this gene is 
unclear but its upregulation after various lesions has led to the suggestion that it has a role in 
neuroprotection after injury (Jin et al. 1996; Uberti et al. 2002).  
Also among the top upregulated genes were genes involved in nervous system development, 
consistent with the theory that regeneration may in part recapitulate developmental gene 
expression.  The transcription factor SOX11, 3.02-fold upregulated in our microarray, has been 
shown to be upregulated after sciatic nerve injury (Tanabe et al. 2003) and is expressed during 
neuronal development although its role in regeneration is not well characterised (Uwanogho et al. 
1995; Jankowski et al. 2006; Kim et al. 2008).  SEMA6A, a member of the large semaphorin family 
of axon guidance molecules expressed in development and thought to limit plasticity in the adult  96 
CNS was 6.35-fold upregulated.  While it may seem paradoxical that a molecule that limits 
plasticity in the CNS is re-expressed during axonal regeneration in the PNS, a new role for this 
molecule in modulating microtubule dynamics has been suggested (Prislei et al. 2008) and it is 
conceivable that the upregulation of SEMA6A could therefore reflect a need for microtubule 
remodeling during axonal outgrowth. 
Another gene involved in microtubule modulation was also upregulated. The expression of 
microtubule disassembly molecules such as stathmins has been shown to be upregulated during 
regeneration (Iwata et al. 2002) and STMN4, upregulated 3.56-fold in our microarray, has been 
previously shown to be upregulated following optic nerve axotomy (Nakazawa et al. 2005).  
Stathmins have a role in tubulin regulation (Jourdain et al. 2004; Ravelli et al. 2004) and stathmin 
deficient mice develop axonopathy indicating that stathmin is important for maintenance of axonal 
integrity (Liedtke et al. 2002).  
Also consistent with past studies, the neuropeptides VIP, GAL and NPY, known to contribute to the 
mechanisms of neuropathic pain, were among the top upregulated genes (Ma and Bisby 1998). 
These neuropeptides are thought to be upregulated by the activation of c-jun, which is also 
upregulated following sciatic nerve injury (Son et al. 2007). Galanin (GAL) showed a 12-fold 
upregulation after axotomy as has already been reported (Kashiba et al. 1994; Sun and Zigmond 
1996; Sun and Zigmond 1996; Ma and Bisby 1999).  GAL has been shown to have a complex role 
in the modulation of pain with facilitatory and inhibitory effects (reviewed in (Xu et al. 2000) as well 
as a role in nerve regeneration and knock-out mice have significantly reduced axonal regeneration 
after sciatic nerve injury (Holmes et al. 2000).  The IL-6 and LIF cytokines positively regulate Gal 
expression suggesting an involvement of the JAK/STAT (Figure 1-11) pathway in its regulation 
(Thompson et al. 1998).  Besides neuropeptides, upregulation was also seen in the chemokine 
CCL2 (3.2-fold upregulation). Mice overexpressing CCL2 have enhanced nociceptive responses 
suggesting that this gene has a role in modulation of pain (Menetski et al. 2007). 
Many of the downregulated genes have also been reported in past studies of this type. RGS4 
encodes a GTPase boosting protein that is expressed constitutively at high levels in adult sensory 
DRG neurons and is downregulated by axotomy (Costigan et al. 2003).  This downregulation is 
therefore likely to cause an increase in G-protein coupled receptor sensitivity and RGS4 has been 
upregulated in sciatic nerve ligation and is thought to contribute to neuropathic pain via attenuation 
of opioid signaling via G protein coupled receptors (Garnier et al. 2003). 
There was also a generalized depression in the expression of various ion channels and 
neurotransmitter receptors suggesting a transcriptional switch away from neurotransmission 
following injury.  The downregulation of voltage-gated potassium channels dominated the IGA 
ontological analysis (Table 3-7) and the delayed rectifier, subfamily S, member 3 (KCNS3) was the 
top ranked downregulated gene according to RPA (Table 3-4).  This has been previously reported 
following chronic constriction (Kim et al. 2002) and transection (Park et al. 2003) of the sciatic 
nerve. This reduction of K+ current is thought to contribute to the electrical abnormalities in primary 
sensory neurons that are involved in the generation and maintenance of neuropathic pain and  97 
allodynia.  There was also downregulation of serotonin receptors and although 5-HT3 receptor 
expression has been shown to be downregulated in motor neurons of the spinal cord after sciatic 
nerve lesion (Rende et al. 1999), there have been to my knowledge no reports of how type 3 
serotonin receptor are regulated in the DRG after injury.   5-HT3a and 3b are constitutively 
expressed on small medium and large size DRG neurons (Morales et al. 2001; Nicholson et al. 
2003) and decreased expression of these receptors is likely to result in a reduction in the 
excitability of afferent neurons. 
3.5.2.2  Immunological and inflammatory gene changes 
The DRG is known to undergo inflammatory and immunological changes as a result of peripheral 
nerve injury, such as infiltration of macrophage and lymphocytes (Hu and McLachlan 2002).  
Inflammation is thought to both enhance regeneration (Lu and Richardson 1991; Golz et al. 2006) 
and contribute to neuropathic pain (Znaor et al. 2007). We would therefore expect there to be 
upregulation of genes involved in inflammation and immune response.  Indeed, ontological analysis 
(Table 3-6) shows upregulation of genes involved in activation of complement and presentation of 
antigens.  The presence of Mx2 and Mx1 which dominate the ontological analysis and which are 
interferon-inducible genes (Asano et al. 2003) provides indirect evidence for there being activation 
of interferon-expressing glia (Cameron et al. 2003).   Additionally, Reg-2, mentioned above and 
upregulated in our microarray has been shown to be upregulated when inflammation is induced in 
DRGs (Averill et al. 2008). 
 
3.5.3 qRT-PCR successfully validated microarray gene 
expression changes  
Six genes were selected and confirmed as being regulated thus further validating the microarray 
and optimising the qRT-PCR assay for use later in the project. Furthermore, to our knowledge, this 
is the first report of the thorough evaluation of housekeeping genes for use as reference genes in 
the sciatic nerve transection experimental paradigm.  The importance of the use of appropriate 
reference genes in relative quantification of qRT-PCR has already been discussed (section 3.3.1) 
and given that this injury model is widely used in studies of neuropathic pain and neuronal 
regeneration it is of significant value that a set of stably expressed HKGs is established. The 
combined use of TOP1, GAPDH and B2M for normalization of qRT-PCR data in future studies of 
this kind is recommended. 
For the six validated genes there was no significant difference between their expression in the 
sham operated and naïve controls suggesting that their regulation was a genuine response to 
transection injury and not due to non-specific effects of surgery.   All genes, with the exception of 
NPTX1 were significantly increased after transection in both the microarray and qRT-PCR and may 
therefore contribute to the regenerative response of the sciatic to injury. The downregulation of  98 
NPTX1 after sciatic injury may represent removal of a plasticity-limiting factor or simply 
downregulation of an unneeded synaptic protein. 
Whole DRG were used in the microarray and thus we cannot be certain as to which cells 
expressed these genes, however, MX2 is most likely to be induced as part of an inflammatory 
response to injury through the proliferation of non-neuronal astrocytic and glial cells that exist in the 
DRG as its expression is concominant with microglial activation (Stobart et al. 2007). Further 
investigation using in situ hybridization techniques on DRG sections could elucidate the locus of 
the gene expression changes. 
3.5.3.1  Summary 
In summary, the pilot microarray generated data that was both biologically valid as well as 
consistent with past studies of sciatic nerve transection. LCM was investigated but did not provide 
RNA of a sufficient quantity or quality for use in our main experiment.  Finally, qRT-PCR with an n 
of 5-6 successfully validated changes in six genes that were regulated in the microarray 
experiment and identified suitable reference genes for future use in experiments of this kind. 
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4  Determination of time points to study regeneration 
4.1 Introduction and Aims 
In order that putative regeneration-associated genes could be identified from our microarray study, 
a key prerequisite was that neuronal regeneration was occurring at our chosen time points.  
Examination of past studies of nerve regeneration following peripheral nerve injury in the rat 
revealed a confusing range of estimates of regenerative rate (2.5- 5 mm/day) (McQuarrie 1975; 
Forman and Berenberg 1978; Forman et al., 1979; Bisby 1985; Danielsen et al., 1986; Mandys et 
al., 1991; Verdu and Navarro 1997; Kamijo et al., 2003; Lozeron et al., 2004) In addition, whilst a 
large number of studies have focussed on regeneration following sciatic nerve crush or transection 
injury, few have examined regeneration following the spinal nerve and dorsal root crush injuries 
that are relevant to this study.  We aimed therefore, to obtain our own estimate of the rate of 
neuronal regeneration in the rat following dorsal root and spinal nerve crush to allow us to choose 
a time point at which fibres are actively regenerating (i.e. have not reached distal targets in the hind 
limb in the sciatic nerve or have not reached the dorsal root entry zone (DREZ) in the case of the 
dorsal root).  We also wished to choose a later time point for the dorsal root by which time its fibres 
will have reached the DREZ and ceased to regenerate.  We hoped that this would allow 
comparison of gene expression during regeneration and at a time when regeneration is blocked in 
the dorsal root.  To determine these time points we employed two main approaches; a tract tracing 
approach using Cholera Toxin B (CTB) or Biotin Dextran Amine (BDA) and an electrophysiological 
approach. 
4.2 Tract tracing with CTB 
4.2.1 Introduction  
Cholera toxin subunit B (CTB) is commonly used as a tool for the retrograde and anterograde 
labelling of neurons.  CTB binds via the pentasaccharide chain of the ganglioside GM1 and is thus 
selectively taken up by and transported in the large diameter myelinated neurons that express this 
ganglioside.  The sciatic nerve contains the afferents of the L4 and L5 DRGs.  Therefore, it was 
expected that in an intact animal, injection of CTB into the proximal sciatic nerve would cause 
labelling of the large diameter cells of the L4 and L5 DRGs.  In contrast, it was expected that for a 
certain time period following a complete spinal nerve crush, no CTB labelling would be seen in the 
corresponding DRG, indicating that the nerve had yet to reinnervate distal targets and was thus still 
regenerating. 
Male SD rats (244-284 g) underwent a spinal nerve crush 5-8 mm distal to the DRG (section 2.2.5) 
and a second operation two weeks (n=3) or one week (n=3) later to inject CTB into the proximal 
sciatic nerve (section 2.3.2). CTB labelling in the L4 and L5 DRGs was examined using indirect  100 
immunofluorescence three days following CTB injection.  CTB labelling in the L4 and L5 DRGs was 
also examined after CTB injection in control rats (n=3) that had not undergone a crush injury.  
Again, three days was allowed for transport of the CTB following its injection into the proximal 
sciatic nerve.  The animals were then perfused with fixative and tissues removed for histological 
processing (section 2.3.3).  Labelling of longitudinal DRG sections with anti-NF200 and anti-CGRP 
allowed visualisation of myelinated and unmyelinated fibres respectively and identification of cell 
types containing CTB. 
4.2.2 Three days is adequate for CTB transport and DRG labelling 
Three days following CTB injection into the proximal sciatic nerve of normal nerve intact animals, 
CTB labelling was detected mainly in the large diameter cells of the L4 and L5 DRGs (Figure 4-1).  
As expected, CTB staining mainly co-localised with NF200 fluorescence but not CGRP indicating 
that CTB was transported in the large, NF200 expressing myelinated axons. 
4.2.3 Absence of CTB labelling in spinal nerve crushed animals 
confirms efficacy of crush injury. 
1 week following L4 spinal nerve crush and CTB injection into the distal sciatic nerve (~52mm distal 
to crush site), CTB labelling was present within the L5 DRG. CTB labelling was absent within the 
L4 DRG (Figure 4-2), confirming to the extent possible using this approach, that the crush was 
indeed complete. 
4.2.4 CTB tract tracing may overestimate rate of regeneration 
after spinal nerve crush 
2 weeks following L4 spinal nerve crush and CTB injection into the distal sciatic nerve (~52mm 
distal to crush site) it was expected that there would be an absence of CTB labelling within the L4 
DRG (based on an estimate that peripheral nerves regenerate at a rate of 1mm/day) and CTB 
labelling within the L5 DRG (the internal control). CTB labelling was however observed in the large 
diameter cells of both the L4 and L5 DRGs.  Additionally, CTB labelling was observed within small 
diameter cells in the L4 DRG and is presumed to be a consequence of GM1 ganglioside expression 
in damaged small unmyelinated fibres (Figure 4-3). 
The high level of labelling within the L4 was surprising, and suggested a faster rate of regeneration 
(>3.7 mm/day) than estimates from some previous studies. However, it is likely that CTB may have 
diffused proximally encountering regenerating fibres further up the nerve and hence overestimating 
regenerative rate (Shehab et al., 2003), led to investigation of another tract tracer approach using 
BDA.   101 
Figure 4-1: CTB, NF200 and CGRP labelling within an L4 DRG of an intact  
control animal.  Yellow cells within the merged image indicate where CTB 
staining is colocalised with NF200 (arrow indicates an example).  Scale bar = 100 
µm. 
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Figure 4-2: CTB labelling of DRG cells 1 week post- L4 spinal nerve crush.  CTB was injected 
at 52 mm from the crush site.   There was an absence of CTB labelling in the L4 DRG (top panel). 
CTB labelling in L5 DRG of same animal  (bottom panel) acts as a positive control indicating that 
CTB has had adequate time to travel the length of the nerve.  The absence of CTB labelling in the 
L4 DRG therefore indicates a complete crush of all L4 spinal nerve fibres.   Scale bar = 200 µm. 
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Figure  4-3:  CTB  labelling  in  DRG  cells  2  weeks  following  spinal  nerve  crush.    CTB  was 
injected at 52 mm from crush site. CTB labelling is present in both the L4 DRG (top panel) and the 
L5 DRG that served as an internal control (bottom panel).  Scale bar = 200 µm. 
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4.3 Tract tracing with BDA 
4.3.1 Introduction and Aims 
The results from the experiments using CTB to determine the rate of regeneration within the 
spinal/sciatic nerve following spinal nerve crush suggested that the rate of regeneration was at 
least 3.7 mm/day. This supported the findings of Lozeron et al. (2004), who, using a retrograde 
tracer method, showed that the axonal growth rate for unmyelinated and myelinated sensory fibres 
following sciatic nerve crush was 3.7 mm/day.  However, neither this study nor our experiment 
could show to what extent the result was attributed to distal diffusion of the tracer within the nerve 
fascicle, as has been reported previously (Shehab et al., 2003). 
To test the findings of the CTB experiments, we used Biotin Dextran Amine (BDA) to visualise the 
progress of the regenerating nerve fibres.  BDA (10kD) is a neuroanatomical tracer that is taken up 
endocytically by intact nerves and diffuses laterally within the plane of the cell membrane in a 
predominantly anterograde direction.  These transport properties mean that unlike CTB, that 
undergoes vesicular transport and which produces a granular appearance within the cell soma, 
BDA produces a much smoother labelling of the complete nerve fibre.  BDA is however transported 
more slowly than CTB and it was therefore necessary to check that BDA’s transport rate was 
sufficient (at least 3.7 mm/day) to test the findings of the previous experiments.  
Male SD rats (263-316 g, n=2) underwent an operation to inject BDA into the L4 spinal nerve 
(section 2.2.5) and perfused with fixative seven days later.  BDA progress both centrally and 
peripherally was examined by indirect immunofluorescence (section 2.3.3). BDA labelling was then 
used to assess L4 dorsal regeneration at the proposed microarray time points 2 weeks (n=2) and 6 
weeks (n=2) after a dorsal root crush injury (section 2.2.4).  In each case BDA was injected seven 
days prior to sacrifice to allow adequate time for transport of the tracer. 
4.3.2 Seven days is sufficient for BDA to label the whole dorsal 
root in a control animal 
At 7 days post-BDA injection, BDA labelling was observed along the entire length of the L4 dorsal 
root (20 mm) and within the L4 segment of the spinal cord suggesting that the tracer would be 
useful in tracking the progress of regenerating fibres within the dorsal root.  Labelling could be 
seen within the left dorsal horn and also within the motor neurons in the left ventral horn suggesting 
that the injection had successfully labelled the majority of fibres, both sensory and motor (Figure 
4-4)   105 
4.3.3 BDA transport rate and quality of labelling is insufficient to 
track regeneration following spinal nerve crush 
Poorer BDA labelling was observed in the sciatic nerve up until ~24mm from the injection site 
within the sciatic nerve suggesting that BDA travels through the spinal/sciatic nerve at a rate of 
approximately 3.43 mm/day.  BDA was therefore unsuitable to trace the progress of a regenerating 
peripheral nerve as the results from the CTB experiments suggested that nerve fibres within the 
sciatic nerve regenerate at a rate of >3.7 mm/day following spinal nerve crush.  
4.3.4 Dorsal root fibres have not yet reached the DREZ two weeks 
post-dorsal root crush. 
At 2 weeks following L4 dorsal root crush, BDA labelled nerve fibres could be observed along the 
majority of the dorsal root but not in the dorsal rootlets at the DREZ (Figure 4-5 top panels). This 
suggested that at 2 weeks following dorsal root crush, the nerve fibres are yet to reach the DREZ 
and are thus still regenerating and confirmed 2 weeks as a suitable early time point for our study. 
4.3.5 Dorsal root fibres have reached the DREZ six weeks post-
dorsal root crush 
At 6 weeks post dorsal root crush, more extensive BDA labelling was observed along the whole 
length of the dorsal root and also in the dorsal rootlet at the entry to the spinal cord (Figure 4-5 
bottom panels).   This suggested that the fibres had regenerated as far as the DREZ and, as such, 
6 weeks was a suitable late time point at which to examine genes involved in arrested 
regeneration. 
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Figure 4-4: BDA labelling in the dorsal root and spinal cord of a control animal 7 days after 
injection.  Labelling could be seen in the L4 dorsal root (top panel), dorsal rootlet and in sensory 
fibres entering the dorsal horn of the spinal cord (middle panel) and motor neurons in the ventral 
horn (bottom panel) indicating efficacy of the injection.  Scale bars = 100 µm. 
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Figure 4-5: BDA labelling in dorsal root and rootlet at 2 (a and b) and 6 (c and d) weeks after 
dorsal root crush.  Panels a and c show a longitudinal section of dorsal root that corresponds to 
the 3 mm block which ended ~ 2 mm away from the DREZ. Panels b and d show in transverse 
section the dorsal rootlet still attached to the dorsal horn of the spinal cord (Scale bars= 100 µm). 
 a) 
c) 
d) 
b)  108 
 
4.4 Electrophysiological investigation of peripheral nerve 
regeneration 
 
4.4.1 Introduction and aims 
Evidence from some past studies and our CTB tract tracer experiment has suggested that 
peripheral nerves regenerate at a much faster rate than classic estimates and observations by 
surgeons of regeneration in human patients suggest (up to 5 mm/day as opposed to 1 mm/day).  
However, many experiments that have aimed to estimate the rate of peripheral nerve regeneration 
have provided the rate of growth of the fastest growing lead nerve fibres which may not necessarily 
be in the majority. In addition, differences in choice of experimental method may account for the 
discrepancies in growth rate estimates obtained. For example, those experiments that use tract 
tracers do not necessarily take into consideration diffusion of the tracer within the nerve fascicle 
and thus may overestimate nerve growth rates. Experiments that utilise the pinch reflex test 
measure the regenerative rate of unmyelinated and finely myelinated afferents and not large 
myelinated motor and sensory axons, the latter of which are the focus of this study. For the 
purposes of our microarray experiment we wished to evaluate the rate at which the majority of 
large myelinated sensory nerve fibres regenerate.  In order to answer this question, we carried out 
orthodromic electrophysiology experiments to determine the extent of regeneration at three 
timepoints following an L4 spinal nerve crush.  
4.4.2 Experimental Rationale 
In a control animal stimulation of the sciatic nerve will provoke a response (detectible as a C.A.P) 
in the L4 and L5 dorsal roots that are upstream from the spinal nerves that contribute to the sciatic.  
Following an L4 spinal nerve crush, it was expected that stimulation to the sciatic would only 
provoke a response in the L4 dorsal root if the nerve fibres originating from the L4 spinal nerve had 
regenerated as least as far as the stimulation site.  A response should however be detectible in the 
L5 dorsal root as the fibres downstream from this root are uninterrupted. We therefore assessed 
progress of regeneration in five male SD rats (305-410 g) that had under-gone an L4 spinal nerve 
crush (section 2.2.5) at 4 (n=2), 6 (n=2) or 8 (n=1) weeks previously.  The sciatic nerve was 
stimulated at increasing distances from the spinal nerve crush and recordings were made from the 
L4 and L5 dorsal roots, with the latter acting as an internal control (section 2.6) (Figure 4-6).  109 
 
 
 
 
 
Figure 4-6: Schematic diagram illustrating the setup for electrophysiology (not to scale).  
The dorsal roots are cut and mounted on silver biolar recording electrodes.  The sciatic nerve is 
mounted on a stimulating electrode and stimulated at 2 mm intervals distally to proximally. 
 
4.4.3 Results and discussion 
4.4.3.1  Interpretational caveats and stimulus spread 
Interpretation of the data from this experiment was complicated by a number of factors.  There was 
a large degree of biological variation between animals in the amplitude of the response of the L5 
dorsal root (internal control). This made comparison of the results from separate experiments 
difficult.  This was partly overcome by expressing the L4 dorsal root response amplitude as a 
percentage of the amplitude of the L5 control in each case (Figure 4-9a).  This approach is 
however hampered by the fact that the regenerating L4 fibres are less excitable than the normal L5 
fibres and thus often require higher stimulus intensities for activation.  Such high stimulus 
intensities can result in the phenomena of anodal block in the L5 fibres, decreasing their response 
amplitude. High stimulus intensity also carries the risk of causing stimulus spread and hence 
artefactual responses within the crushed nerve.   In a test for stimulus spread in which the nerve 
was crushed and stimulated distally at increasing intensity, C.A.Ps could only be detected 1mm 
proximal to the crush when the nerve was stimulated at over 4mA (Figure 4-7). Therefore to 
eliminate as far as possible stimulus spread and anodal block, records at 2mA stimulus intensity 
were used for further analysis. 
crush 
spinal 
nerves  stimulating 
electrode 
recording 
electrodes 
regenerating nerve 
fibre 
      L5 DRG  
      
L5 dorsal root 
sciatic 
nerve 
L4 DRG      L4 dorsal root  110 
Figure 4-8 illustrates some representative C.A.Ps at selected distances along the sciatic nerve. 
Compound action potentials (C.A.P.s) were always recorded in the L5 dorsal root and were of a 
higher amplitude than those recorded in the L4 dorsal root. This contrasts with what we would 
expect to see in a normal animal. The sciatic nerve has a higher contribution from the L4 spinal 
nerve than the L5 spinal nerve and we would thus expect to detect a higher response amplitude in 
the L4 DR than in the L5 DR. This test is therefore conservative for our purposes in that it is likely 
to overestimate the proportion of nerve fibres that have regenerated to any given point. 
4.4.3.2  Regeneration proceeds at <1.43 mm/day following a spinal nerve crush 
At 4 weeks post-injury, a small number of fibres have reached the most proximal stimulation site as 
indicated by a small C.A.P (40 mm) but not the most distal stimulation site (60 mm). This indicates 
that the majority of fibres are regenerating at <1.43 mm/day. At 6 weeks post crush only a very 
small C.A.P could be detected at the most distal stimulation site indicating again that most of the 
fibres are regenerating at <1.43 mm/day.  By 8 weeks a large C.A.P could be detected at the distal 
stimulation site, and as this position corresponded to the point at which fibres entered the muscle, 
this suggested that a substantial proportion of fibres may be reinnervating target tissues at this time 
point. At 4 weeks post-crush the C.A.P.s recorded in the L4 dorsal root are of a considerably 
smaller amplitude and area (Figure 4-9 a & b) than those recorded in the L5 dorsal root such that 
by the most distal recording point they are hardly detectible.  In addition, those fibres that have 
reached the most distal recording point have a much higher response latency (Figure 4-10).  This 
may be due to differences in the electrical properties of regenerating nerve fibres due to immature 
ion channels etc.  At 8 weeks post crush, there appears to be less difference in amplitude between 
the L4 and L5 C.A.Ps and in latency of response.  In addition, conduction velocities calculated from 
the regenerating nerve at 8 weeks are significantly higher than those calculated for 4 and 6 weeks 
p<0.05 (1 way ANOVA) (Figure 4-11) suggesting that a large proportion of fully functional axons 
had reached the most distal stimulation site. 
 
These data suggested that 4 weeks was a suitable time point at which to study regeneration in the 
sciatic nerve as little or no fibres were likely to have reached their distal targets.  This was also the 
case for the 6 week time point. At 8 weeks however nerve fibres may be reconnecting with target 
tissues and thus ceasing to regenerate.  We chose 6 weeks as our peripheral branch time point as 
it allowed us to draw a direct comparison between it and the 6 week dorsal root crush injury.  The 
data also suggested that CTB tract tracing provided an overestimation of regenerative rate in the 
sciatic nerve. 
  111 
 
 
  
Figure 4-7:  Stimulus spread in the sciatic nerve occurs at >4mA stimulus intensity.  The 
sciatic nerve was crushed and stimulated at increasing intensity just distal to the crush.  
Recordings were made at 1 mm proximal to the crush and stimulus spread (indicated by the 
presence of a C.A.P) could be detected at >4mA stimulus intensity.  * indicates presence of C.A.P. 
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Figure 4-9a) Amplitude and b) Area of C.A.Ps recorded in the L4 dorsal root 4, 6 and 8 
weeks post L4 spinal nerve crush expressed as a % of the response in the L5 dorsal root 
(internal control).  Each line represents data from a single animal. 
a) 
b)  114 
 
 
 
Figure 4-10: Latency to responses recorded from L4 and L5 dorsal roots at a) 4 weeks, b) 6 
weeks and c) 8 weeks post- L4 spinal nerve crush.  Each line represents data from a single 
animal. 
a) 
b) 
c)  115 
 
Figure 4-11: Conduction velocity of L4 and L5 nerve fibres 4, 6 and 8 weeks post- spinal 
nerve crush (± S.D).  Conduction velocities measured at 8 weeks post spinal nerve crush were 
significantly greater than those measured at both 4 (p<0.05) and 6 weeks (p<0.05) (1-way 
ANOVA).  Each pair of columns represents data from one animal.  Conduction velocities were 
calculated from each point at which a response could be detected and the mean calculated. 
 
4.5 Chapter summary 
Anatomical and electrophysiological studies allowed us to determine suitable time points for our 
microarray experiment.  Evidence from BDA tract tracing suggests that at 2 weeks following DR 
crush, nerve fibres are yet to reach the DREZ and are thus still regenerating whilst at 6 weeks they 
have reached the point of CNS entry.  Evidence from electrophysiology suggests that at 6 weeks 
post L4 spinal nerve crush, the majority of fibres within the sciatic nerve have not reached distal 
targets in the hind limb and are thus still regenerating.  The time points for our microarray were 
thus confirmed as 2 and 6 weeks post dorsal root crush and 6 weeks post spinal nerve crush.   
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5  Microarray analysis of DRG gene expression after 
axonal injury 
5.1 Introduction and Aims 
We aimed to identify putative regeneration-associated genes using a microarray approach. Having 
identified appropriate time points to harvest DRGs after dorsal root and spinal nerve crush 
(Chapter 4), gene expression changes in the DRG after injuries in which regeneration is expected 
to occur (2DR and 6SN) were compared with that after injuries where regeneration is blocked or 
abortive (6DR and 2DC respectively).   
The first part of this chapter deals with quality control issues and low-level statistical analysis of the 
microarray experiments.  The remainder of the chapter tackles the more difficult task of making 
sense of the data in a biological context.  Two main approaches to higher-level analysis was taken.  
Firstly, an ontology-based approach whereby the whole of each data set was interrogated and 
interpreted according to existing ontological information using IGA and IPA analyses. There was a 
particular focus on genes involved in the development of the nervous system and in embryological 
development in general as these may constitute plasticity-related genes that could have a role in 
remodelling in the damaged CNS.  Simple filtering and sorting of the data on the fold change 
and/or FDR criterion using Venn diagrams and Excel spreadsheets followed by a focussed search 
of literature and gene databases, allowed a second, question-led investigation of the data.  The 
main question that informed this investigation was: What features do the regenerating conditions 
have in common that are not shared by the non-regenerating conditions?  Secondary to this, this 
study has relevance to studies of neuropathic pain.  Regulated genes were therefore investigated 
with the various mechanisms of pain generation in mind.  
5.2 The microarray 
The left L4 DRG was harvested from rats that had undergone a left spinal nerve crush (section 
2.2.5) (n=9) or a dorsal column transection (section 2.2.6) (n=9) at 6 or 2 weeks, respectively.  
DRGs were also harvested 2 and 6 weeks after a dorsal root crush (n=9/group) and from a naïve 
control group that had not undergone any surgery (n=9).  Total RNA was extracted (section 
2.8.4.2) and for each condition RNA from 3 animals was pooled before synthesis of biotinylated 
cDNA and hybridisation to Affymetrix® chips.  Each condition was replicated on three chips, each 
of which containing material from 3 animals.   Figure 5-1 illustrates the design of the experiment.  117 
   
 
 
 
 
 
 
 
 
                            
 
            
                                      
 
 
                                                             
 
 
 
 
 
 
 
 
 
                   
 
 
 
 
   
 
          
 
 
Figure 5-1: Schematic diagram illustrating microarray design.  a) Generalised scheme that 
applies to each of the conditions. b) Illustration of conditions and the main comparisons that are 
possible. 
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5.3 Low level analysis: results and discussion 
5.3.1 Quality control on samples assessed by Genespring 
5.3.1.1  Internal controls 
Internal controls provide a measure of RNA sample quality by showing the 3’/5’ ratios for a set of 
specific probe sets.  Ratios of greater than 3 can indicate sample degradation.  The 9 chips in our 
main microarray experiment showed ratios of less than 3 for 2 out of the 3 internal controls.  Given 
that the total RNA showed little indication of degradation with high RNA integrity numbers it is likely 
that the elevated ratios for beta-actin are due to the use of the small sample amplification protocol 
that may have lead to the generation of targets skewed to the 3’ end.   
 
Table 5-1: RNA sample quality assessed by internal controls.  3’/5’ ratios of greater than 3 
suggest sample degradation. Beta-Actin shows elevated 3'/5' ratios. 
 
 
5.3.1.2  Hybridisation controls 
Affymetrix chips have integral hybridisation controls to allow assessment of hybridisation quality 
(described in section 3.2.1.2). Figure 5-2 shows the hybridisation control profiles for all 15 chips.  
All the hybridisation controls are present in increasing concentrations in all the chips.  This, along 
with the close clustering of the hybridisation profiles, indicates a high quality, uniform hybridisation 
across chips. 
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Figure 5-2: Hybridisation control profiles for all chips.  The x axis represents the hybridisation 
controls present at 1.5, 5, 25 and 100 pm, respectively.  The log of the normalised signal values is 
plotted on the Y-axis.  All hybridisation controls were present in increasing concentrations in all 
chips. 
 
 
5.3.1.3  Principal component analysis scores  
Principal component analysis (PCA) is a decomposition technique that can be used to check data 
quality.  Replicates within a condition should cluster together and separately from arrays in other 
conditions.  Principal components are numbered according to their decreasing significance.  Figure 
5-3 illustrates the principal components for the main microarray experiment coloured by condition, 
time point and regenerative state.  In general, replicates within each of the injury conditions cluster 
together and ctrl separates from all the conditions. However, 2DR, 6DR and SN do not have a high 
degree of separation from one another.  The 2DC condition separates from all the other conditions 
and control.  The regenerating conditions appear to roughly cluster while the non-regenerating 
conditions do not and samples do not cluster according to time point.  This perhaps suggests that 
the regenerative state of a neuron is more important than the time since injury in dictating its 
transcriptional status and that mixed regenerating conditions share more in common than mixed 
non-regenerating conditions. 
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Figure 5-3:  Principal components analysis of main microarray experiment.  Replicates are 
coloured by a) conditions, b) time point and c) regenerative state. 
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5.3.1.4  Across-array correlation analysis 
Calculation of a correlation coefficient for each pair of arrays can give a measure of how arrays 
correlate with each other.  Arrays within a condition should correlate highly with each other.  On the 
whole, arrays were well correlated (R
2=0.989-1).  The dorsal column chips showed the least 
correlation with chips from other conditions and out of all the conditions correlated least well with 
the control chips.  This suggests that dorsal column injury elicits a transcriptional programme that is 
distinct from that elicited by the other injuries.  
 
 
 
Figure 5-4: Heatmap showing across-array correlations illustrating lack of correlation 
between dorsal column injury and other conditions.  Each chip is compared to every other 
chip.  A perfect correlation of 1 can be seen when chips are compared to self whilst the lowest 
correlation is seen between DC chips and chips from other conditions. 
0.989 
1.000  122 
 
5.4 Identification of differentially expressed genes 
Two approaches were taken to identify differentially expressed genes, Rank Product Analysis 
(RPA), which allows a cut-off for significant regulation to be set according to false discovery rate 
(FDR) and, for comparison, ANOVA, which was implemented in Genespring.  Use of Genespring 
also enabled enhanced visualisation of the data using volcano plots. 
5.4.1 Rank products analysis 
Rank products analysis is described in section 2.9.3.1.2.  Each condition was compared to control 
as well as to every other condition.  The descriptive statistics from this analysis are presented in 
Table 5-2 and Figure 5-5 illustrates the percentage of probe sets changed after each injury.  Dorsal 
column transection elicited many more changes in gene expression than the other injuries and 
unlike other injuries, more genes were downregulated than upregulated.  In addition, when each 
condition was compared to every other condition, comparisons with the dorsal column transection 
injury yielded the highest number of gene differences.  This again indicates that dorsal column 
injury elicits a transcriptional programme within the DRG that is distinct to that initiated by either 
spinal nerve or dorsal root crush.  This is consistent with the principle components and correlation 
analyses that showed a separation of dorsal column transection from these injuries (sections 
5.3.1.3 and 5.3.1.4).  The top 20 up and downregulated genes for each condition compared to 
control are presented in Table 5-3 to Table 5-10.  Regulated genes (<1% FDR) are presented in 
appendix A, while a full list of regulated genes (<50% FDR) is presented on the accompanying CD. 
Table 5-2: Descriptive statistics for all microarray comparisons. 
LARGEST FOLD 
CHANGE  
NO. GENES 
UPREGULATED 
NO. GENES 
DOWNREGULATED 
COMPARISON 
Up  Down  1% FDR  5% FDR  1% FDR  5% FDR 
2DR vs. ctrl  13.64  -2.44  172  403  34  146 
6DR vs. ctrl  2.67  -14.12  44  150  30  84 
6SN vs. ctrl  3.26  -8.89  72  222  25  90 
2DC vs. ctrl  87.59  -9.97  208  502  279  627 
6DR vs. 2DR  2.63  -15.89  12  39  74  163 
6DR vs. 6SN  1.87  -2.77  11  63  20  69 
6DR vs. 2DC   4.32  -81.94  204  483  160  321 
2DR vs. 6SN   16.58  -2.68  43  106  12  56 
2DR vs. 2DC  4.31  -91.65  188  441  144  254 
6SN vs. 2DC  4.02  -84.02  231  544  169  292 
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Figure 5-5: Pie charts showing the percentage of all probe sets regulated within 5% FDR for 
each condition.  The chips contained 31000 probe sets covering 28700 genes.  The red slice 
denotes the proportion of upregulated probe sets while the green slice indicates downregulated 
probe sets for each injury vs. naïve control. 
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Table 5-3: Top 20 genes identified by RPA as upregulated 2 weeks after dorsal root crush  
PROBESET ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1368238_at  Pap  pancreatitis-associated protein  NM_053289  13.64  0 
1387930_at  Reg3a  regenerating islet-derived 3 alpha  L10229  4.55  0 
1368187_at  Gpnmb  glycoprotein (transmembrane) nmb   NM_133298  3.71  0 
1387154_at  Npy  neuropeptide Y  NM_012614  3.18  0 
1368677_at  Bdnf  brain derived neurotrophic factor  NM_012513  2.86  0 
1368359_a_at  Vgf  VGF nerve growth factor inducible  NM_030997  2.83  0 
1375010_at  Cd68  CD68 antigen  AI177761  2.53  0 
1384063_at  Cthrc1  collagen triple helix repeat containing 1   AA958001  2.49  0 
1395126_at  Msr2_predicted  macrophage scavenger receptor 2 (predicted)  AI011393  2.45  0 
1369268_at  Atf3  activating transcription factor 3   NM_012912  2.45  0 
1373386_at  Gjb2  gap junction membrane channel protein beta 2  AI179953  2.49  0 
1390119_at  Sfrp2  secreted frizzled-related protein 2  BF396602  2.41  0 
1376750_at  Thbs2  thrombospondin 2  AA963477  2.32  0 
1385751_at  Thbs2  thrombospondin 2  BF408413  2.38  0 
1377092_at  Socs3  suppressor of cytokine signaling 3  BF389682  2.33  0 
1368224_at  Serpina3n 
serine (or cysteine) peptidase inhibitor, clade A, 
member 3N   NM_031531  2.34  0 
1392965_a_at  Smoc2_predicted 
SPARC related modular calcium binding 2 
(predicted)  AI028877  2.25  0 
1385248_a_at  Ogn_predicted  osteoglycin (predicted)  AA997590  2.25  0 
1370892_at  C4a /// C4-2 
complement component 4a /// complement 
component 4, gene 2  BI285347  2.27  0 
1367973_at  Ccl2  chemokine (C-C motif) ligand 2  NM_031530  2.33  0 
Table 5-4: Top 20 genes identified by RPA as downregulated 2 weeks after dorsal root crush 
Probeset id  Gene Symbol  Gene name  Acc. NO  FC  FDR 
1387133_at  Calb2  calbindin 2  NM_053988  -2.44  0 
1394297_at  Hoxd1_predicted  homeo box D1 (predicted)  BG670107  -2.31  0 
1390881_at  Abra  actin-binding Rho activating protein  AI172339  -2.25  0 
1370900_at  Myh4  myosin, heavy polypeptide 4, skeletal muscle  BM391169  -9.32  0.25 
1367962_at  Actn3  actinin alpha 3   NM_133424  -7.31  0.4 
1384269_at  Mterf  mitochondrial transcription termination factor  BF386887  -1.77  0.5 
1377163_at  Inhbb  inhibin beta-B   BM385741  -1.74  0.57 
1372195_at  Tnnc2  troponin C type 2 (fast)  BG663128  -6.72  0.5 
1370033_at  Mlc3  fast myosin alkali light chain  NM_020104  -5.55  0.44 
1391575_at  Hapln4  Hyaluronan and proteoglycan link protein 4  BG380566  -1.67  0.4 
1380306_at  ---  Transcribed locus  AW435415  -1.96  0.36 
1367626_at  Ckm  creatine kinase, muscle  NM_012530  -5.3  0.42 
1391305_at  ---  ---  AI576233  -1.62  0.46 
1387787_at  Myl2  myosin, light polypeptide 2   NM_012605  -5.11  0.43 
1368585_at  Cart  cocaine and amphetamine regulated transcript  NM_017110  -1.66  0.53 
1395714_at  ---  ---  AT005664  -1.53  0.5 
1388349_at  Ckm   creatine kinase, muscle  AA799557  -1.75  0.71 
1367762_at  Sst  somatostatin   NM_012659  -1.58  0.67 
1371247_at 
Ap2a1_predicted /// 
Ptov1 /// 
Med25_predicted 
Adaptor protein complex AP-2, alpha 1 subunit 
(predicted) /// Prostate tumor over expressed 
gene 1 /// Mediator of RNA polymerase II 
transcription, subunit 25 homolog (yeast) 
(predicted)  BF521859  -4.33  0.68 
1370198_at  Trdn  triadin  AJ243304  -2.86  0.65  125 
Table 5-5: Top 20 genes identified by RPA as upregulated 6 weeks after dorsal root crush 
PROBESET ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1387902_a_at  LOC500180 /// LOC500183 
similar to IG KAPPA CHAIN V-V REGION K2 
PRECURSOR /// similar to NGF-binding Ig light 
chain   L22655  2.67  0 
1371447_at  Plac8_predicted  placenta-specific 8 (predicted)  BG378630  1.98  0 
1368187_at  Gpnmb  glycoprotein (transmembrane) nmb   NM_133298  2.11  0 
1371245_a_at  LOC689064  similar to Hemoglobin beta-2 subunit   BI287300  1.94  0 
1390798_at  Ptprc  protein tyrosine phosphatase, receptor type, C   BF288130  1.87  0 
1373386_at  Gjb2  gap junction membrane channel protein beta 2  AI179953  2.05  0 
1367553_x_at  Hbb  hemoglobin beta chain complex  NM_033234  1.81  0 
1371102_x_at  MGC72973  beta-glo  X05080  1.8  0 
1387125_at  S100a9  S100 calcium binding protein A9 (calgranulin B)   NM_053587  2.29  0 
1388602_at  Cfd  complement factor D (adipsin)  AI237358  1.87  0 
1369705_at  Xtrp3  X transporter protein 3  AI169634  2.03  0 
1370967_at  Cldn10_predicted  Claudin 10 (predicted)   BG374683  1.71  0.08 
1382083_at  Coch_predicted 
coagulation factor C homolog (Limulus 
polyphemus) (predicted)  BF287593  1.82  0.15 
1391446_at  Ms4a1_predicted 
membrane-spanning 4-domains, subfamily A, 
member 1 (predicted)  AA817742  1.68  0.29 
1374334_at  Igha_mapped  immunoglobulin heavy chain (alpha polypeptide)   AI412189  1.87  0.27 
1382305_at  Zfp364_predicted  Zinc finger protein 364 (predicted)  AI236814  1.65  0.25 
1368422_at  Meox2  Mesenchyme homeobox 2   NM_017149  1.7  0.24 
1395126_at  Msr2_predicted  macrophage scavenger receptor 2 (predicted)  AI011393  1.71  0.28 
1367985_at  Alas2  Aminolevulinic acid synthase 2   NM_013197  1.65  0.26 
1397999_at  Irs2  Insulin receptor substrate 2  BF386502  1.61  0.5 
Table 5-6: Top 20 genes identified by RPA as downregulated 6 weeks after dorsal root crush 
#GENE NAME  GENE SYMBOL  GENE TITLE  ACC. NO.  FC  FDR 
1387133_at  Calb2  calbindin 2  NM_053988  -1.86  0 
1367962_at  Actn3  actinin alpha 3   NM_133424  -9.27  0 
1387787_at  Myl2  myosin, light polypeptide 2   NM_012605  -8.39  0 
1370033_at  Mlc3  fast myosin alkali light chain  NM_020104  -9.08  0 
1384269_at  Mterf  mitochondrial transcription termination factor  BF386887  -1.72  0 
1370900_at  Myh4  myosin, heavy polypeptide 4, skeletal muscle  BM391169  -14.12  0 
1377106_at  ---  Transcribed locus  AW533050  -5.94  0 
1372195_at  Tnnc2  troponin C type 2 (fast)  BG663128  -8.73  0 
1378252_at  Chodl_predicted  Chondrolectin (predicted)  AI029745  -1.66  0 
1370971_at  Myh1 /// LOC691644  myosin, heavy polypeptide 1, skeletal muscle, adult   BI277545  -6.99  0 
1388604_at  LOC679341 /// LOC686019 similar to Calsequestrin-1 precursor   BI276959  -3.1  0 
1369928_at  Acta1  actin, alpha 1, skeletal muscle   NM_019212  -4.79  0.08 
1367626_at  Ckm  creatine kinase, muscle  NM_012530  -6.48  0.08 
1387414_at  Duox2  dual oxidase 2  NM_024141  -1.58  0.07 
1390881_at  Abra  actin-binding Rho activating protein  AI172339  -1.66  0.4 
1370198_at  Trdn  Triadin  AJ243304  -3.15  0.38 
1390355_at  Ryr1  ryanodine receptor 1, skeletal muscle  AI575442  -2.21  0.41 
1368554_at  Pnlip  pancreatic lipase   NM_013161  -1.58  0.39 
1395327_at  ---  Transcribed locus, weakly similar to XP_580018.1   AW522341  -3.09  0.37 
1371247_at 
Ap2a1_predicted /// Ptov1 
/// Med25_predicted 
Adaptor protein complex AP-2, alpha 1 subunit 
(predicted) /// Prostate tumor over expressed gene 
1 /// Mediator of RNA polymerase II transcription, 
subunit 25 homolog (yeast) (predicted)  BF521859  -5.61  0.45  126 
Table 5-7: Top 20 genes identified by RPA as upregulated 6 weeks after spinal nerve crush 
PROBESET ID.  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1387125_at  S100a9  S100 calcium binding protein A9 (calgranulin B)   NM_053587  3.26  0 
1371245_a_at  LOC689064  similar to Hemoglobin beta-2 subunit   BI287300  2.88  0 
1367553_x_at  Hbb  hemoglobin beta chain complex  NM_033234  2.58  0 
1370913_at  Best5  Best5 protein   AI409634  2.57  0 
1368494_at  S100a8  S100 calcium binding protein A8 (calgranulin A)   NM_053822  2.85  0 
1371102_x_at  MGC72973  beta-glo  X05080  2.51  0 
1382031_at  ---  Transcribed locus  AA859079  2.38  0.14 
1370240_x_at  Hba-a1 /// LOC360504  hemoglobin alpha, adult chain 1   AI179404  2.32  0.12 
1367985_at  Alas2  aminolevulinic acid synthase 2   NM_013197  2.34  0.11 
1368021_at  Adh1  alcohol dehydrogenase 1 (class I)  NM_130780  2.23  0.1 
1370239_at  Hba-a1 /// LOC360504 
hemoglobin alpha, adult chain 1  /// hemoglobin 
alpha 2 chain   AI179404  2.28  0.09 
1375519_at  LOC287167  globin, alpha   AI237401  2.26  0.08 
1371447_at  Plac8_predicted  placenta-specific 8 (predicted)  BG378630  2.1  0.08 
1388142_at  Cspg2  chondroitin sulfate proteoglycan 2  AA850991  2.05  0.14 
1385248_a_at  Ogn_predicted  osteoglycin (predicted)  AA997590  2.38  0.13 
1370791_at  Hgfac  Hepatocyte growth factor activator  U16683  2.46  0.12 
1385229_at  Pcdh20_predicted  protocadherin 20 (predicted)  AW524146  2.42  0.18 
1388608_x_at  Hba-a1 /// LOC360504 
hemoglobin alpha, adult chain 1 /// hemoglobin 
alpha 2 chain  AI577319  2.07  0.17 
1387943_at  Defa  defensin, alpha 5, Paneth cell-specific  U16686  2.19  0.16 
1374334_at  Igha_mapped  immunoglobulin heavy chain (alpha polypeptide)  AI412189  2.21  0.2 
Table 5-8 Top 20 genes identified by RPA as downregulated 6 weeks after spinal nerve 
crush 
PROBESET ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1367962_at  Actn3  actinin alpha 3   NM_133424  -6.41  2 
1377106_at  ---  Transcribed locus  AW533050  -5.79  1 
1370900_at  Myh4  myosin, heavy polypeptide 4  BM391169  -6.6  0.67 
1372195_at  Tnnc2  troponin C type 2 (fast)  BG663128  -6.89  0.5 
1370033_at  Mlc3  fast myosin alkali light chain  NM_020104  -5.94  0.4 
1383827_at  Tlk1_predicted  tousled-like kinase 1 (predicted)  AI059119  -1.61  0.5 
1387787_at  Myl2  myosin, light polypeptide 2   NM_012605  -6.72  0.43 
1370971_at  Myh1 /// LOC691644  myosin, heavy polypeptide 1   BI277545  -5.37  0.62 
1370198_at  Trdn  triadin  AJ243304  -3.27  0.56 
1384717_at  ---  ---  AA894199  -1.55  0.7 
1367626_at  Ckm  creatine kinase, muscle  NM_012530  -5.08  0.64 
1370550_at  Lsamp 
limbic system-associated membrane 
protein  U31554  -1.5  0.75 
1388604_at  LOC679341/// LOC686019  similar to Calsequestrin-1 precursor   BI276959  -2.82  0.69 
1385491_at  RGD1560435_predicted  similar to KIAA1183 protein (predicted)  BF403514  -1.71  0.64 
1371247_at 
Ap2a1_predicted /// Ptov1 
/// Med25_predicted 
Adaptor protein complex AP-2, alpha 1 
subunit /// Prostate tumor over expressed 
gene 1 /// Mediator of RNA polymerase II 
transcription, subunit 25 homolog (yeast)   BF521859  -5.01  0.6 
1369928_at  Acta1  actin, alpha 1, skeletal muscle   NM_019212  -4.4  0.62 
1399073_at  Otub1_predicted  OTU domain, ubiquitin aldehyde binding 1  BI274378  -1.55  0.65 
1387133_at  Calb2  calbindin 2  NM_053988  -1.48  0.61 
1374677_at  LOC684425 
similar to Adenylosuccinate synthetase 
isozyme 1   AI577508  -3.21  0.68 
1368108_at  Atp2a1 
ATPase, Ca++ transporting, cardiac 
muscle, fast twitch 1  NM_058213  -4.04  0.75  127 
Table 5-9: Top 20 genes identified by RPA as upregulated 2 weeks after dorsal column 
transection 
PROBESET ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1377146_at  Vip  vasoactive intestinal polypeptide  AI412212  87.59  0 
1387154_at  Npy  neuropeptide Y  NM_012614  29.13  0 
1368238_at  Pap (Reg2)  pancreatitis-associated protein  NM_053289  13.01  0 
1369268_at  Atf3  activating transcription factor 3   NM_012912  11.13  0 
1398243_at  Vsnl1  Visinin-like 1  NM_057144  9.65  0 
1384035_at 
LOC685277 /// 
LOC686794 
similar to liver-specific bHLH-Zip transcription 
factor   AW536030  7.67  0 
1387088_at  Gal  galanin   NM_033237  6.14  0 
1368266_at  Arg1  arginase 1   NM_017134  5.87  0 
1392863_at  Flrt3_predicted 
fibronectin leucine rich transmembrane protein 
3   AA817953  5.69  0 
1393573_at  Pde6b_predicted 
phosphodiesterase 6B, cGMP, rod receptor, 
beta polypeptide   AI575628  5.23  0 
1381070_at  Synpr  Synaptoporin   AI233106  4.99  0 
1371450_at  Sox11  SRY (sex determining region Y)-box11  BE117330  5.03  0 
1383210_at  Sox11  SRY (sex determining region Y)-box11  BF554576  4.95  0 
1375661_at  Sox11  SRY (sex determining region Y)-box11  BE104180  4.76  0 
1371248_at  SPRR1A 
similar to Cornifin A (Small proline-rich protein 
1A)   BI286387  4.8  0 
1382868_at  Sema6a_predicted  semaphorin 6A   BM387083  4.33  0 
1378057_at  Flrt3_predicted 
fibronectin leucine rich transmembrane protein 
3   BE103354  4.24  0 
1392862_at  Sema6a_predicted  semaphorin 6A  AA859389  4.25  0 
1378700_at  ---  Transcribed locus  BF403674  3.85  0 
1376601_at  Sema6a_predicted  semaphorin 6A  BF397526  3.85  0 
Table 5-10: Top 20 genes identified by RPA as downregulated 2 weeks after dorsal column 
transection  
PROBESET 
ID  GENE SYMBOL  GENE NAME  ACC. NO.  FC  FDR 
1387133_at  Calb2  calbindin 2  NM_053988  -4.94  0 
1388349_at  Ckmt2  Creatine kinase, muscle  AA799557  -5.16  0 
1374787_at  Vgkc  V-gated potassium channel  BI282169  -4.04  0 
1377163_at  Inhbb  inhibin beta-B /// inhibin beta-B  BM385741  -3.81  0 
1376980_at  Htr2c  5-hydroxytryptamine  BF285539  -3.72  0 
1391575_at  Hapln4  Hyaluronon and proteoglycan link  BG380566  -3.49  0 
1382914_at  Adra1a  Alpha1 adrenergic receptor  AA924097  -3.36  0 
1370900_at  Myh4 
myosin, heavy polypeptide 4, skeletal 
muscle  BM391169  -9.97  0 
1368407_at  Hpse  heparanase  NM_022605  -3.09  0 
1374035_at  Rem2  rad and gem-related GTP  BI296482  -3.08  0 
1385731_at  Cntn3  Contactin3  BE113552  -3.07  0 
1390530_at  ---  Transcribed locus  AI169239  -3.14  0 
1387065_at  Plcd4  phospholipase C, delta 4   NM_080688  -2.95  0 
1371077_at  Htr3b 
5-hydroxytryptamine (serotonin) receptor 
3b  AI575989  -2.92  0 
1394297_at  Hoxd1_predicted  homeo box D1 (predicted)  BG670107  -3.03  0 
1396366_at  Chd12  cadherin 12  BF409020  -3.07  0 
1370214_at  Pvalb  parvalbumin  AI175539  -2.83  0 
1391563_at  RGD1565148_predicted 
similar to melanoma associated antigen 
(mutated) 1-like 1 (predicted)  AA963184  -2.95  0 
1384269_at  Mterf  Mitochondrial transcription term. factor  BF386887  -2.93  0 
1377106_at  ---  Transcribed locus  AW533050  -6.9  0  128 
5.4.2 ANOVA (Genespring) 
Following normalisation and filtering of probe-level raw data (from Affymetrix cel. files) (section 
2.9.3.1.3) differentially expressed genes were also identified using 1-way ANOVA in Genespring 
(Agilent).  Volcano plots generated by Genespring illustrate the distribution of fold changes in each 
of the injury models and genes that are changed significantly (p<0.05, uncorrected) and have a fold 
change >1.5 are coloured in red.  The number of differentially expressed genes identified by 
ANOVA in Genespring and by RPA is compared in Table 5-11.  ANOVA identifies approximately 
twice the number of differentially expressed genes than RPA indicating that the latter method of 
analysis is more conservative and is less likely to generate false positives. The number of genes 
changed at p<0.05 and greater than 1.5-fold is detailed in the final column of Table 5-11.  The 
numbers of genes generated using these two filters together are considerably smaller than those 
generated by rank products at 5% FDR.  This reflects the fact that many of the genes identified by 
rank products are less than 1.5-fold regulated, even at 5% FDR and also illustrates how the 
criterion used to choose differentially expressed genes can dramatically affect the outcome of a 
microarray experiment.   
 
Table 5-11: Comparison of numbers of differentially expressed genes identified by Rank 
products and ANOVA. 
NO. DIFFERENTIALLY EXPRESSED GENES AT:  COMPARISON 
  5% FDR (RANK 
PRODUCTS) 
P<0.05 
(ANOVA) 
P<0.05 
(ANOVA) and 
over 1.5-fold 
changed 
2DR vs. ctrl  549  1011  218 
6SN vs. ctrl  312  573  69 
6DR vs. ctrl.  231  466  41 
2DC vs. ctrl.  1129  2303  1016 
6DR vs. 2DR  202  403    52  
2DR vs. 6SN  162  473   36  
6DR vs. 6SN  132  240    15 
6DR vs. 2DC  802  1936   619 
2DR vs. 2DC  695  1827    491   
6SN vs. 2DC  836  1836    632  
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a) 2DR (218 genes) 
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Figure 5-6: Volcano plots displaying mean fold differences for each probe set in the a) 2w 
DR crush, b) 6w DR crush, c) SN crush and d) DC transection relative to control as a 
function of P value.  Genes showing greater than 1.5-fold differential expression with p values 
<0.05 are depicted with red dots.  Other genes are represented with yellow dots.  The vertical line 
represents a 1.5-fold difference in gene expression whereas the horizontal line corresponds to a P 
value of 0.05.  The data was first filtered on error to remove genes with high variability within 
conditions (leaving 31028 out of 31099 genes). 
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5.5 Ontological analysis 
Ontological analysis was used to extract the main transcriptional themes associated with each 
condition.  Again for comparison, two different analysis methods were used, Iterative Group 
Analysis (IGA) that relies on ‘GO’ classifications, and Ingenuity Pathways Analysis (IPA), which 
relies upon a recently curated information database based on peer-reviewed papers.  IPA also 
includes a number of visualisation tools that aid in the interpretation of the analysis.  Genes that 
were ranked by false discovery rate using RPA were used in both the ontological analyses 
methods.   
5.5.1 Iterative group analysis (IGA) 
IGA was described in (section 2.9.3.1.4).  The top changed ontological groups identified by IGA for 
each condition compared to control and sorted by p-value are presented in Table 5-12 to Table 
5-19. 
  131 
Table 5-12: Top upregulated ontological groups identified by IGA 2 weeks after dorsal root 
crush 
TOP CHANGED GROUPS    NO. GROUP 
MEMBERS  
 NO. CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
CHANGED 
GENES INVOLVED 
6953 - acute-phase response  26  5  4.4e-09  19.23  PAP, REG3A, A2M, LBP, 
FN1 
8201 - heparin binding  51  6  2.7e-07  11.76  GPNMB, THBS2, FN1, 
POSTN, ADAMTS1, 
THBS4 
31012- extracellular matrix  13  4  1.4e-06  30.77  CSPG2, COL15A1, 
ADAMTS1, COL18A1 
5529 - sugar binding  96  7  4.9e-06  7.29  PAP, REG3A, LY49, 
CSPG2, COLEC12, 
THBD, CLECSF6 
IPR008435 - Corticotropin-
releasing factor binding 
2  2  2.2e-05  100.00  LOC689064, MGC72973 
6956 - complement activation  10  3  4.7e-05  30.00  C4A, C1A, C2 
5184 - neuropeptide hormone 
activity 
19  2  4.8e-05  10.53  NPY, VGF 
7631 - feeding behavior  24  2  5.2e-05  8.33  NPY, BDNF 
IPR000961 - Protein kinase C-
terminal domain 
3  2  6.7e-05  66.67  LOC689064, MGC72973 
IPR002075 - Nuclear transport 
factor 2 (NTF2) 
3  2  6.7e-05  66.67  LOC689064, MGC72973 
16023 - cytoplasmic membrane-
bound vesicle 
30  2  8.2e-05  6.67  GPNMB, BDNF 
6817 - phosphate transport  50  5  8.4e-05  10.00  CTRC1, COL15A1, 
COLEC12, COL5A2, 
COL3A1 
4866 - endopeptidase inhibitor 
activity 
52  3  1.3e-04  5.77  SERPINA3N, C4A, A2M 
16049 - cell growth  29  4  1.4e-04  13.79  CSRP2, TNN, XM2, EMP1 
Table 5-13: Top downregulated ontological groups identified by IGA 2 weeks after dorsal 
root crush 
TOP CHANGED GROUPS    NO. GROUP 
MEMBERS  
 NO. CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
 % 
CHANGED 
GENES INVOLVED 
Striated_muscle_contraction – 
GenMAPP 
26  7  3.6e-11  26.92  ACTN3, MYL2, TPM1, 
TTN, TNNI2, MYH1, 
MYBPC1 
6941 - striated muscle contraction  22    7  2.5e-10  31.82  MYH4, MYH1, MYBPC1, 
PGAM2, KBTBD10, 
SMPX, LOC691644 
8307 - structural constituent of 
muscle 
23  7  5.1e-10  30.43  ACTN3, MLC3, MYL2, 
TPM1, MYBPC2, ASPH, 
PDLIM3 
6936 - muscle contraction  64  6  2.4e-08  9.38  ACTN3, TRDN, ACTA1, 
TPM1, MYBPC1, 
MYBPC2 
3774 - motor activity  74  5  1.2e-06  6.76  MYH4, MLC3, MYL2, 
ACTA1, MYH1 
16459 – myosin  35  4  1.8e-06  11.43  MYH4, MLC3, MYL2, 
MYH1 
5863 - striated muscle thick 
filament 
16  4  5.4e-06  25.00  MYH4, MYH1, MYBPC1, 
LOC691644 
6937 – regulation of muscle 
contraction 
18  3  8.8e-06  16.67  TNNC2, ATP2A1, TPM1 
7517 - muscle development  62  4  1.9e-05  6.45  MLC3, CHODL, ACTA1, 
MYL1 
5865 - striated muscle thin 
filament 
4  2  2.1e-05  50.00  ACTN3, ACTA1 
5859 - muscle myosin  10  3  5.0e-05  30.00  MLC3, MYH1, 
LOC691644 
16529 - sarcoplasmic reticulum  8  2  5.5e-05  25.00  TRDN, ATP2A1 
45214 - sarcomere organization  6  2  8.4e-05  33.33  ABRA, TTN 
5232 - serotonin-activated cation-
selective channel activity 
2  2  9.1e-05  100.00  HTR3A, HTR3B  132 
Table 5-14: Top upregulated ontological groups identified by IGA 6 weeks after dorsal root 
crush 
TOP CHANGED GROUPS    NO. 
GROUP 
MEMBERS  
 NO. CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
MEMBERS
CHANGED 
GENES 
INVOLVED 
5833 - hemoglobin complex  7  3  3.4e-07  42.86  HBB, MGC72973, 
HBA-A1 
IPR008435 - Corticotropin-releasing 
factor binding 
2  2  4.0e-07  100.00  LOC689064, 
MGC72973 
5344 - oxygen transporter activity  8  3  5.4e-07  37.50  HBB, MGC72973, 
HBA-A1 
6956 - complement activation  10  4  8.4e-07  40.00  C4A, C1S, C3, 
CFB 
15671 - oxygen transport  10  3  1.2e-06  30.00  HBB, MGC72973, 
HBA-A1 
IPR000961 - Protein kinase C-
terminal domain 
3  2  1.2e-06  66.67  LOC689064, 
MGC72973 
IPR002075 - Nuclear transport 
factor 2 (NTF2) 
3  2  1.2e-06  66.67  LOC689064, 
MGC72973 
6957 - complement activation, 
alternative pathway 
6  3  1.0e-05  50.00  CFD, C3, CFB 
45087 - innate immune response  27  4  1.4e-05  14.81  CFD, C4A, C1S, 
C3 
19825 - oxygen binding  31  3  4.2e-05  9.68  HBB, MGC72973, 
HBA-A1 
3823 - antigen binding  24  4  6.9e-05  16.67  LOC500180, 
IGHA, 
RGD1359202, 
RT1-BB 
50766 - positive regulation of 
phagocytosis 
12  3  6.9e-05  25.00  C3, FCGR2B, 
FCGR3 
Table 5-15: Top downregulated ontological groups identified by IGA 6 weeks after dorsal 
root crush 
TOP CHANGED GROUPS   NO. 
MEMBERS  
NO. 
CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
MEMBERS 
CHANGED 
GENES INVOLVED 
Striated_muscle_contraction - 
GenMAPP 
26  7  5.3e-11  26.92  ACTN3, MYL2, MYL1, 
TNNI2, TPM1, TTN, 
MYBPC1 
8307 - structural constituent of 
muscle 
23  9  6.7e-11  39.13  ACTN3, MYL2, MLC3, 
TPM1, MYBPC2, MYH6, 
ACTN2, MYOM1, PDLIM3 
6941 - striated muscle 
contraction 
22  8  7.8e-11  36.36  MYH4, MYH1, PGAM2, 
KTBD10, MYBPC1, 
LOC691644, MYH6, 
MYH8 
5863 - striated muscle thick 
filament 
16  7  9.5e-11  43.75  MYH4, MYH1, MYBPC1, 
LOC691644, MYH6, 
MYOM1, MYH8 
6936 - muscle contraction  64  9  4.4e-10  14.06  ACTN3, ACTA1, TRDN, 
TPM1, MYBPC2, CHRNE, 
MYBPC1, TMOD4, 
ACTN2 
3774 - motor activity  73  5  1.9e-09  6.85  MYL2, MLC3, MYH4, 
MYH1, ACTA1 
16459 - myosin  34  4  6.8e-09  11.76  MYL2, MLC3, MYH4, 
MYH1 
7517 - muscle development  62  4  1.5e-07  6.45  MLC3, CHODL, MYH1, 
ACTA1 
5859 - muscle myosin  10  4  3.3e-07  40.00  MLC3, MYH1, 
LOC691644, MYH6 
5865 - striated muscle thin 
filament 
4  3  1.1e-06  75.00  ACTN3, ACTA1, ACTN2 
6937 - regulation of muscle 
contraction 
18  4  3.4e-06  22.22  TNNC2, ATP2A1, TPM1, 
HSPB6 
146 - microfilament motor 
activity 
11  3  4.2e-05  27.27  MYH1, LOC691644, 
MYH6 
45214 - sarcomere organization  6  2  1.1e-04  33.33  ABRA, TTN 
16529 - sarcoplasmic reticulum  8  2  1.1e-04  25.00  TRDN, ATP2A1  133 
 
Table 5-16: Top upregulated ontological groups identified by IGA 6 weeks after spinal nerve 
crush 
TOP CHANGED GROUPS   NO.  GROUP 
MEMBERS  
 NO. 
CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
 % 
MEMBERS
CHANGED 
GENES INVOLVED 
5201 - extracellular matrix 
structural constituent 
59  9  1.3e-09  15.25  FN1, COL9A1, COL1A1, 
FBN1, COL3A1, COL1A2, 
COL5A2, TFPI2, COL6A1 
5833 - hemoglobin complex  7  3  6.8e-09  42.86  HBB, MGC72973, HBA-A1 
6817 - phosphate transport  51  8  7.6e-09  15.69  COL9A1, COL1A1, 
CTHRC1, COL6A3, 
COL3A1, COL1A2, 
COL5A2, COL6A1 
5344 - oxygen transporter 
activity 
8  3  1.1e-08  37.50  HBB, MGC72973, HBA-A1 
15671 - oxygen transport  10  3  2.3e-08  30.00  HBB, MGC72973, HBA-A1 
5581 - collagen  17  5  2.0e-07  29.41  COL1A1, COL3A1, 
COL1A2, COL5A2, COL6A1 
IPR008435 - Corticotropin-
releasing factor binding 
2  2  2.8e-07  100.00  LOC689064, MGC72973 
IPR002075 - Nuclear 
transport factor 2 (NTF2) 
3  2  8.5e-07  66.67  LOC689064, MGC72973 
IPR000961 - Protein kinase 
C-terminal domain 
3  2  8.5e-07  66.67  LOC689064, MGC72973 
19825 - oxygen binding  31  3  8.6e-07  9.68  HBB, MGC72973, HBA-A1 
Inflammatory_Response_Path
way - GenMAPP 
30  4  3.5e-05  13.33  FN1, COL1A1, COL3A1, 
COL1A2 
5584 - collagen type I  2  2  3.9e-05  100.00  COL1A1, COL1A2 
45087 - innate immune 
response 
27  3  9.2e-05  11.11  MX2, CFD, C1S 
30278 - regulation of 
ossification 
6  2  9.2e-05  33.33  BEST5, GDF10 
 
Table 5-17: Top downregulated ontological groups identified by IGA 6 weeks after spinal 
nerve crush 
TOP CHANGED GROUPS   NO. GROUP 
MEMBERS  
NO. 
CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
MEMBERS 
CHANGED 
GENES INVOLVED 
Striated_muscle_contraction - 
GenMAPP 
26  6  3.9e-11  23.08  ACTN3, MYL2, MYH1, TPM1, 
TTN, TNNI2 
6936 - muscle contraction  64  9  2.1e-10  14.06  ACTN3, TRDN, ACTA1, TPM1, 
MYBPC2, CHME, ASPH, 
MYBPC1, TMOD4 
8307 - structural constituent of 
muscle 
23  6  2.7e-10  26.09  ACTN3, MLC3, MYL2, TPM1, 
MYBPC2, ASPH 
6941 - striated muscle 
contraction 
22  7  3.0e-10  31.82  MYH4, MYH1, KBTBD10, 
PGAM2, MYBPC1, MYH6, 
LOC91644 
16459 - myosin  35  4  3.8e-09  11.43  MYH4, MLC3, MYL2, MYL1 
3774 - motor activity  74  5  2.0e-08  6.76  MYH4, MLC3, MYL2, MYL1, 
ACTA1 
5863 - striated muscle thick 
filament 
16  5  1.1e-07  31.25  MYH4, MYH1, MYBPC1, MYH6, 
LOC691644 
5859 - muscle myosin  10  4  7.1e-07  40.00  MLC3, MYH1, MYH6, 
LOC691644 
6937 - regulation of muscle 
contraction 
18  3  5.8e-06  16.67  TNNC2, ATP2A1, TPM1 
5865 - striated muscle thin 
filament 
4  2  8.8e-06  50.00  ACTN3, ACTA1 
16529 - sarcoplasmic 
reticulum 
8  2  5.5e-05  25.00  TRDN, ATP2A1 
7517 - muscle development  62  3  5.7e-05  4.84  MLC3, MYH1, ACTA1 
45214 - sarcomere 
organization 
6  2  7.1e-05  33.33  ABRA, TTN 
146 - microfilament motor 
activity 
11  3  7.3e-05  27.27  MYH1, MYH6, LOC691644  134 
Table 5-18: Top upregulated ontological groups identified by IGA 2 weeks after dorsal 
column transection 
TOP CHANGED GROUPS   NO. GROUP 
MEMBERS  
 NO. 
CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
MEMBERS 
CHANGED 
GENES INVOLVED 
19886 - antigen processing, 
exogenous antigen via MHC class II 
9  5  3.2e-10  55.56  RT1-DA, RT1-BA, RT1-DB1, 
CD74, RT1-BB 
42613 - MHC class II protein 
complex 
5  4  2.7e-09  80.00  RT1-DA, RT1-BA, RT1-DB1, 
RT1-BB 
19884 - antigen presentation, 
exogenous antigen 
9  4  6.6e-08  44.44  RT1-DA, RT1-BA, RT1-DB1, 
RT1-BB 
6956 - complement activation  10  4  5.3e-07  40.00  C3, C4A, C1S, C2 
6958 - complement activation, 
classical pathway 
20  5  1.0e-06  25.00  C3, C4A, C1S, C2, C1QA 
5184 - neuropeptide hormone 
activity 
19  3  3.6e-06  15.79  NPY, GA1, VGF 
45087 - innate immune response  27  5  5.0e-06  18.52  C3, C4A, MX2, C1S, C1QA 
3823 - antigen binding  24  4  5.2e-06  16.67  RT1-DA, RT1-BA, RT1-DB1, 
RT1-BB 
16064 - humoral defense 
mechanism (sensu Vertebrata) 
13  3  6.2e-06  23.08  CD74, FCGR2B, C4A 
Complement and coagulation 
cascades – KEGG 
7  3  1.3e-05  42.86  C3, C1S, C2 
Complement_Activation_Classical – 
GenMAPP 
10  3  4.3e-05  30.00  C3, C7, C2 
Folate biosynthesis - KEGG  3  2  5.6e-05  66.67  DHFR, GCH 
42591 - antigen presentation, 
exogenous antigen via MHC class II 
5  2  6.6e-05  40.00  CD74, FCGR2B 
1664 - G-protein-coupled receptor 
binding 
20  2  7.5e-05  10.00  NPY, GAL 
51258 - protein polymerization  13  3  1.5e-04  23.08  TUBB6, C7, TUBB2B 
Table 5-19: Top downregulated ontological groups identified by IGA 2 weeks after dorsal 
column transection 
TOP CHANGED GROUPS   NO. GROUP 
MEMBERS  
NO. 
CHANGED 
MEMBERS  
 P-VALUE 
CHANGED  
% 
MEMBERS
CHANGED 
GENES INVOLVED 
5230 – extracellular ligand-gated ion 
channel activity 
38  6  2.6e-10  15.79  HTR3B, GABRA1, CHRNA3, 
HTR3A, CHRNB4, CHRNE 
45211 – postsynaptic membrane  92  8  8.6e-10  8.70  HTR3B, GABRA1, CHRNA3, 
HTR3A, CHRNB4, CHRNE, 
SHANK1 
5267 - potassium channel activity  65  8  1.8e-08  12.31  KCND3, KCND1, KCND2, 
KCNC1, KCNS3, CSEN, 
GRIA2, KCNA4 
Striated_muscle_contraction – 
GenMAPP 
26  6  3.4e-08  23.08  ACTN3, MYL2, MYL1, TTN, 
TPM1, TNNI2 
30955 - potassium ion binding  94  9  1.0e-07  9.57  KCND3, KCND1, KCND2, 
KCNC1, KCNS3, CSEN, 
KCNA4, SLC24A2, KCNJ6 
8076 - voltage-gated potassium 
channel complex 
59  7  1.9e-07  11.86  KCND3, KCND1, KCND2, 
KCNC1, KCNS3, KCNA4, 
KCNJ6 
8307 – structural constituent of 
muscle 
23  5  1.7e-06  21.74  MLC3, ACTN3, MYL2, TPM1, 
MYBPC2 
6936 - muscle contraction  64  7  1.7e-06  10.94  ACTN3, CHRNE, P2RXL1, 
ACTA1, TRDN, TPM1, 
MYBPC2 
16459 – myosin  33  4  2.0e-06  12.12  MYH4, MLC3, MYL2, MYH1 
5232 - serotonin-activated cation-
selective channel activity 
2  2  2.6e-06  100.00  HTR3B, HTR3A 
15464 – acetylcholine receptor 
activity 
13  3  3.1e-06  23.08  CHRNA3, CHRNB4, CHRNE 
3774 - motor activity  72  5  7.9e-06  6.94  MYH4, MLC3, MYL2, MYH1, 
ACTA1 
4890 - GABA-A receptor activity  30  3  2.9e-05  10.00  GABRA1, CHRNA3, CHRNB4 
15459 – potassium channel 
regulator activity 
15  3  3.9e-05  20.00  KCNS1, KCNS3, CSEN 
7517 – muscle development  62  5  7.4e-05  8.06  NRG1, MLC3, MYH1, ACTA1, 
CHODL  135 
5.5.2 Ingenuity canonical pathway analysis 
The canonical pathways that are affected by the various injury models were analysed using 
Ingenuity pathways analysis software (IPA) (Ingenuity Systems).  In each case, genes regulated 
within 50% FDR were uploaded to the programme but a 5% FDR cut-off was set for inclusion of a 
gene in a canonical pathway. 
5.5.2.1  Canonical pathways analysis of 2DR data set 
In the 2DR injury a total of 2256 of the 3505 inputted transcript IDs (genes regulated within the 
50% FDR cut-off) could be mapped in the analysis, 285 of which were within the predefined cut-off 
of 5% FDR.   Of these 285 genes, 271 were align-able with functions/pathways.  We defined a 
deregulation in only two canonical pathways with a p value ≤ 0.05 (Figure 5-7).   The affected 
pathways were ‘complement and coagulation cascades’ (p = 8.71E
-5) and ‘Il-6 signalling’ (p= 
0.033).  Since any one gene can be mapped to various pathways in this analysis, we identified the 
differentially upregulated gene A2M (Alpha-2-microglobulin, 2.19 fold change, FDR <0.001 %) as a 
gene participating in both canonical pathways.  Additionally, upregulation of a number of other 
genes (C2, C3, C1QA, C1R, C1S, C4A, CFH, F3, PROS1, SERPING1 and THBD) were features 
of the complement and coagulation cascade pathway while upregulation of the immediate-early 
genes FOS and JUN and the precollagen COL1A contributed to the Il-6 signalling. 
5.5.2.2  Canonical pathways analysis of 6DR data set 
On analysis of the 6DR data set (1941 transcript IDs) a total of 1285 could be mapped and 120 of 
127 genes falling within the 5% FDR cut-off were align-able with functions/pathways.   Six 
significant canonical pathways were identified (Figure 5-7); ‘Calcium signallling’ (p = 5.97E
-10), 
‘Complement and coagulation cascades” (p = 7.014E
-8), ‘Actin cytoskeleton signalling’ (p = 
0.0001), ‘Leukocyte extravasation signalling’ (p = 0.0169), ‘Il-10 signalling” (p=0.0169) and ‘TGF-β 
signalling” (p = 0.045).  The downregulation of ACTA1 (actin alpha 1, 4.79 fold change, FDR=0.08 
%) was a major contributor in three of the six identified canonical pathways (calcium signalling, 
actin signalling and leukocyte extravasation signalling).  The downregulation of 13 other genes; 
ATP2A1, CHRNE, MYH1, MYH2, MYH4, MYL1, RYR1, TNNI, TNNT3, TPM1, TRDN and the 
upregulation of NFATC1 and TNNT2 were features of the calcium signalling.   In the actin 
cytoskeleton signalling pathway the downregulation of ACTN3, MYH1, MYH2, MYH4, MYL1, TTN 
and the upregulation of EGFR, LBP were features.  The downregulation of ACTN3 and 
upregulation of CLDN1, CXCL12, CYBB characterise the leukocyte extravasation signalling. The 
complement and coagulation pathway consisted of 8 upregulated genes; C3, C1S, C4A, CFB, 
CFD, F3, SERPING1, THBD.  The Il-10 signalling pathway consisted of 3 upregulated genes 
FCGR2B, FOS, LBP while the TGF-β signalling consisted of upregulated genes EGFR and FOS 
and downregulated INHBB.  136 
5.5.2.3  Canonical pathways analysis of 6SN data set 
The 6SN data set (3068 transcript IDs) had a total of 1993 transcript IDs that could be mapped and 
154 of 168 of these falling within the 5% FDR cut-off were align-able with functions/pathways.  Four 
significant canonical pathways were identified (Figure 5-7); ‘Calcium signalling’ (p = 3.45E
-5),   
‘Actin cytoskeleton signalling’ (p = 0.0003),  ‘Complement and coagulation cascades’ (p = 0.001) 
and ‘Nitric oxide signalling in the cardiovascular system’ (p = 0.0058).  As in 2DR, the 
downregulation of ACTA1 was important in defining significant canonical pathways in this analysis, 
featuring in two out of four of the pathways.   Calcium signalling was again characterised by a 
number of other downregulated genes ASPH, ATPSA1, CALM3, CHRNE, HTR3A, MYH1, MYH4, 
MYL1, PRKAR2A, RYR1, TN1, TNNT3, TPM1, TRDN along with the upregulation of MYH11, 
TPM2.  Equally, actin cytoskeleton signalling consisted of downregulations of ACTN3, MYH1, 
MYH4, MYL1, TTN but also upregulations of 6 genes ACTN1, FN1, MYH11, MYLK, PDGFRA, 
VCL.  The complement and coagulation pathway consisted entirely of upregulated genes; C15, 
C4A, CFD, F3, F5, F13A1, SERPING1, THBD while ‘nitric oxide signalling’ consisted of 
downregulated genes ATP2A1, CALM3, HSP90AB1, PRKAR2A and one upregulated gene 
GUCY1B3. 
5.5.2.4  Canonical pathways analysis of 2DC data set 
Six significant canonical pathways (Figure 5-7) were identified within the DC data set (6128 
transcript IDs, 3892 of which were mapped, 485 of 504 genes falling with 5% FDR were align-able 
with functions); ‘Complement and coagulation cascades’ (p = 0.0012),  ‘Calcium signalling’ (p = 
0.003), ‘Urea cycle and metabolism of amino groups’ (p = 0.0099), ‘Serotonin receptor signalling’ 
(p=0.0122), ‘Antigen presentation pathway’ (p = 0.0322) and ‘One carbon pool by folate’ (p = 
0.0392).  No one gene could be identified as a main player in multiple pathways.   The 14 genes 
contributing to Complement and coagulation cascades (C2, C3, C1QA, C1QB, C1QC, C1R, C1S, 
C4A, CFB, CFD, CFH, F3, SERPING1, THBD) were all upregulated whilst genes contributing to 
the Calcium signalling canonical pathway were mainly downregulated (ACTA1, ASPH, ATP2A1, 
ATP2B3, CACNA1H, CACNA2D1, CACNG2 CHRNA3, CHRNB4, CHRNE, DSCR1L1, GRIA2, 
GRIKA2, GRIK1, GRIN1, HTR3A, MYH1, MYH2, MYH4, MYL1, RYR1, TNNI2, TNNT3, TPM1, 
TRDN and TRPC3) with only three upregulated genes; CAMK2D, CHRNA1 and NFATC1.  Urea 
cycle and metabolism of amino acid was characterised by the downregulation of ASS1, CKM and 
CKMT1B and the upregulation of ARG1. ‘Serotonin receptor signalling’ featured downregulation of 
genes encoding serotonin receptor subunits (HTR3, HTR7, HTR1D, HTR3A and HTR3B) and 
upregulation of GCH1 and MAOA.  The antigen presentation pathway consisted entirely of the 
upregulated genes CD74, HLA-DMB, HLA-DQA1, HLA-DQB2, HLA-DRA and HLA-DRB1 while 
‘One carbon pool by folate’ consisted only three molecules, one of which was upregulated (DHFR) 
while the other two were downregulated  (DMGDH and GART). 
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Figure 5-7: IPA analysis of canonical pathways affected after injuries. Fisher’s exact test was 
used to calculate a p value (shown as blue bars) determining the probability that each biological 
function assigned to the network is due to chance alone.  The ratio (shown as yellow squares) 
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6DR 
6SN 
2DC  138 
represents the number of differentially expressed genes in a given pathway relative to the total 
number of genes that make up that canonical pathway.  The threshold line is set at p=0.05. 
 
5.5.3 Identification of biologically relevant networks using 
Ingenuity network generation 
To further investigate the global expression response in the DRG to different injuries, and to define 
how individual regulated genes interact to have a coordinated role in specific pathways, we 
identified potential networks of interacting genes using IPA’s network generation function. The 
methodology integrates genomic data with mining techniques to predict protein networks that 
comprise protein-protein interactions and other functional linkages (section 2.9.3.2.1). Each 
potential network is given a score, which is a probabilistic fit between the networks and a list of 
biological functions stored in the Ingenuity Pathways Knowledge Base. The score takes into 
account the number of focus genes (from 5% FDR lists) in the network, and the size of the 
network, to approximate how relevant it is to the original list of genes.  IPA uses a right-tailed 
Fisher’s test to calculate the P value for networks.  A score of 10, for example, would mean that 
there is a P=10
-10 chance that the genes in that network are associated solely by chance. A score 
of 3 or greater was therefore considered significant (p < 0.001). The scores are used to rank the 
networks and the top ranked network is presented as a graph indicating the molecular relationships 
between gene/gene products.  Genes or gene products are represented as nodes and the 
biological relationship between two nodes is represented as an edge (line).  All edges are 
supported by at least one literature reference of direct physical, transcriptional and enzymatic 
interactions or from canonical information stored in the Ingenuity Pathways Knowledge Base.  The 
colour intensity of the node represents the degree of up (red) or downregulation (green).  Nodes 
are displayed with various shapes that represent the functional class of the gene product.  Keys to 
the network nodes and edges for Figure 5-8 to Figure 5-12 can be found in appendix B.  Functional 
analysis of a network then identified the biological functions/diseases that were most significant to 
the genes in the network. 
5.5.3.1  Networks of genes regulated at 2 weeks after dorsal root crush 
We identified 14 networks of potentially interacting genes from the genes regulated at the 5% FDR 
level 2 weeks post-DR crush; the top 5 networks are provided in Table 5-20.  One of the highest 
ranked networks identified by IPA (Figure 5-8) contains genes associated with cell-to-cell signalling 
and interaction, cellular movement and dermatological diseases while the other (Figure 5-9) 
contains genes associated with cell morphology, cellular growth and proliferation and carbohydrate 
metabolism.  139 
 
Table 5-20:  Top 5 networks of genes regulated (all p<0.001) at 2 weeks after dorsal root 
crush 
 
 
  NETWORK GENES (FOCUS GENES IN COLOUR)  SCORE  FOCUS 
GENES 
TOP FUNCTIONS 
1  ADAMTS1, ATP2A1, C1QA, C1R, C1S, CHGA, CKM, 
COL18A1, COL1A1, COL1A2, COL2A1, COL3A1, CSPG2, 
DCN, EGFR, F3, FAP, FBN1, FN1, HLA-DQA1, IGF1, 
IGFBP5, IGFBP6, LOX, MMP2, NID1, PCOLCE, SERPINA3, 
SERPING1, SFRP2, SNED1, TFPI2, TNNT3, TWIST1, 
WISP2 
 
57  35  Cell-To-Cell Signaling and 
Interaction, Dermatological 
Diseases and Conditions, 
Cellular Movement 
 
2  ACP5, ADCYAP1, ATF3, BDNF, CART, CCND2, CDKN1C, 
DAB2, EGR1, FOS, GPC3, HMGB2, KBTBD10, KCNIP3, 
LEPR, MYH4, NPY, NRG1, NTS (includes EG:4922), 
PGAM2, POU3F1, PRRX1, PTGER4, PVR, PVRL3, RAB3A, 
RBP1, SERPINF1, SFRP4, SOAT1, SST, TGFBI, TGFBR1, 
TUBB2B, VGF 
 
57  35  Cell Morphology, Cellular 
Growth and Proliferation, 
Carbohydrate Metabolism 
 
3  A2M, ANXA1, AXL, C7, CA3, CCL13, CD68, CTSK, CXCL9, 
CXCL12, CYP1B1, CYP2J2, ERCC1, HRC, ITGAD, ITGAL, 
JDP2, JUN, LTBP1, MAP3K8, MEOX2, MOG, NFATC1, 
P2RY2, PCSK1, PKD1, PLA2G4A, PPIC, PTX3, RYR1, 
RYR2 (includes EG:6262), SMARCA2, THBS2, TRDN, 
VCAM1 
 
26  22  Cell-To-Cell Signaling and 
Interaction, Hematological 
System Development and 
Function, Immune and 
Lymphatic System 
Development and Function 
 
4  ADAMTS4, C5ORF13, CLDN1, CLOCK, COL11A1, 
COL8A1, COMP, CP, DAPK1, EPB41L1, FBLN1, FKBP5, 
FN1, GCNT1, GJB2, ITGAE, ITGB6, ITGB8, LOXL2, MGP, 
MTPN, MYH1, MYLK, MYLPF, NOV, OCLN, PDGFC, 
PDGFRA, PLEKHC1, TEF, TGFB1, TGFBI, TJP2, TJP3, 
TPM3 
 
18  17  Cancer, Tumor Morphology, 
Cell Morphology 
 
5  ASPH, ATP1A3, CHUK, COL5A2, CPT1A, CSRP2, 
CXCL13, CXCL14, DYRK1A, FGF2, FZD2, GBP4, GDF10, 
GNA15, GPNMB, HRAS, ID2, KCNC1, KLF5, LOX, 
MRPL12, NOV, PDLIM5, PGK1, PLOD1, PTEN, PTGS1, 
SOX4, SPRY1, SPRY2, TMSB10, TOM1, TOP2A, VEGFB, 
VEGFC 
16  16  Cardiovascular System 
Development and Function, 
Organismal Development, 
Cellular Assembly and 
Organization 
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Figure 5-8: Ingenuity pathways analysis identifies a network of genes centred around EGFR, 
FN1 and IGF1 and that is regulated in the DRG 2 weeks after dorsal root crush relative to 
naïve control.  This is one of the two top regulated networks for this condition (Table 5-20). For 
comparison, the network is also shown overlaid with expression information from the other data 
sets.  Nodes are coloured according to expression (upregulated=red, downregulated=green). 
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Figure 5-9: Ingenuity pathways analysis identifies a network of genes centred around FOS 
that is regulated in the DRG 2 weeks after dorsal root crush relative to naïve control. This is 
one of the top upregulated networks for this data set (Table 5-20). For comparison, the 
network is also shown overlaid with expression information from the other data sets.  Nodes are 
coloured according to expression (upregulated=red, downregulated=green). 
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5.5.3.2  Networks of genes regulated at 6 weeks after a dorsal root crush  
We identified 6 significant networks from the genes regulated at the 5% level 6 weeks after dorsal 
root crush.  The top 5 networks are described in Table 5-21.  The top ranked network (Figure 5-12) 
contains 33 genes involved in Skeletal and Muscular System Development and Function, Tissue 
Morphology and Cardiovascular System Development and Function. 
 
 
Table 5-21: Top 5 networks of genes regulated (all p<0.001) at 6 weeks after a dorsal root 
crush. 
  NETWORK GENES (FOCUS GENES IN COLOUR)  SCORE  FOCUS 
GENES 
TOP FUNCTIONS 
1  ACP5, ACTA1, ACTN3, ADIPOQ, AR, BDNF, C3, C1S, 
C4A, CART, CDKN1C, CFB, CFD, CHRNE, CXCL12, DAB2, 
EGFR, F3, FOS, GAS5, HBA2, HBB (includes EG:3043), 
HRC, KBTBD10, LTK, MEOX2, MYOZ1, NRG1, PCK1, 
PGAM2, RYR1, SERPING1, TNNT3, TRDN, VGF 
 
65  33  Skeletal and Muscular 
System Development and 
Function, Tissue 
Morphology, Cardiovascular 
System Development and 
Function 
 
2  ALAS2, ATP2A1, CD40LG, CKB, CKM, CXADR, DDX42, 
FLOT2, FMO3, FYN, HDLBP, ID2, IGF1, IL15, KRAS, 
MS4A1, MSC, MYLPF, MYOD1, OGN, PAWR, PDLIM5, 
RYR1, SLA, SP1, TCF23, TEAD2, THBD, TNNI2, TNNT2, 
TPM3, WNT11, WT1, YARS, ZFP36L1 
 
24  17  Cellular Growth and 
Proliferation, Hematological 
System Development and 
Function, Immune 
Response 
 
3  C19ORF10, CCKAR, CD68, CD244, CLDN1, CSNK1A1, 
CTNNB1, CX3CR1, CYBA, CYBB, DBP, ERBB2, GAD1, 
GJB2, HIRA, HOXA9, HOXA10, IFNG, JUN, LMO7, 
MAP3K8, NFATC1, NLK, OCLN, PBXIP1, PCSK1, PKD2 
(includes EG:5311), PTCH, PTPRG, RT1-AW2, S100A8, 
SDPR, TAX1BP3, TJP2, TJP3 
 
21  15  Cancer, Tumor Morphology, 
Genetic Disorder 
 
4  ACTN1, CEBPA, CFD, COL8A1, CPS1, CPT1A, CYP3A5, 
ENO3, FABP3, FCAR, FGF19 (includes EG:9965), GFPT1, 
HK3, LEP, LTC4S, MGP, MTPN, MYF6, MYH1, ORM2, 
PARD6G, PCTK2, PRKAA1, PTGDS, RAC1, RATNP-3B, 
S100A8, S100A9, S100G, SC5DL, TGFB1, THBD, TTN, 
UCP1, VCL 
 
19  14  Cellular Growth and 
Proliferation, Skeletal and 
Muscular System 
Development and Function, 
Developmental Disorder 
 
5  ALCAM, APLN, CALD1, CHST4, COCH, CP, CXCL13, 
DDX11, DSTN, FCGR2B, GBP2, GFAP, HK2, HMGN2, 
HPSE, HTATIP2, KLF10, LBP, LIF, MAP4K2, MBP, MYC, 
NOS3, ORM2, PRPH, PYGM, QKI, RBP1, RPS13, SLK, 
SPARC, STEAP4, THBS4, TNF, TPM1 
 
15  14  Connective Tissue 
Development and Function, 
Tissue Morphology, Cellular 
Movement 
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Figure 5-10: Ingenuity pathways analysis identifies a network of genes that is centred 
around FOS and that is regulated in the DRG 6 weeks after dorsal root crush relative to 
naïve control.  This is the top upregulated network for this data set (Table 5-21) The intensity of 
the node colour indicates the degree of up (red)- or down (green)- regulation. For comparison, the 
network is also shown overlaid with expression information from the other data sets. 
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5.5.3.3  Networks of genes regulated at 6 weeks after a spinal nerve crush  
We identified 10 significant networks from the genes regulated at the 5% FDR level at 6 weeks 
after a spinal nerve crush.  The top 5 networks are presented in Table 5-22. The top ranked 
network (Figure 5-11) contains 26 genes involved in Cellular Movement, Cell-To-Cell Signaling and 
Interaction and Tissue Development. 
 
 
Table 5-22: Top 5 networks regulated (all at p<0.001) at 6 weeks after a spinal nerve crush. 
  NETWORK GENES (FOCUS GENES IN COLOUR)    SCORE  FOCUS 
GENES 
TOP FUNCTIONS 
1  ADAMTS1, ANXA1, Ap1, CAMP, COL1A1, DAB2, DCN, 
ENTPD1, F3, F5, FBN1, FCGR2B, FN1, IL33, Integrin, 
ITGB1BP1, MEOX2, MYLPF, OMD, P38 MAPK, Pdgf, 
PDGF BB, PDGFRA, PI3K, Pkc(s), PPP2R2A, RTK, 
S100A8, S100A9, TAGLN, TFPI2, Tgf beta, VCAM1, VCAN, 
WISP2 
 
48  26  Cellular Movement, 
Cell-To-Cell Signaling 
and Interaction, Tissue 
Development 
 
2  ACTA1, Actin, ACTN1, ADH1C (includes EG:126), Akt, 
AMPD1, ASPH, Calcineurin protein(s), CALM3, Calmodulin, 
CaMKII, CKM, DBP, F Actin, LMO7, MB, MEF2, MYH1, 
MYH11, MYL1, MYLK, Myosin, P8, PER2, PER3, Ryr, 
RYR1, TEF, TNNT3, TPM1, TPM2, TRDN, Tropomyosin, 
TTN, VCL 
 
45  25  Skeletal and Muscular 
System Development 
and Function, Tissue 
Morphology, Cell 
Signaling 
 
3  ACTA1, ARID1B, CARTPT, CCNE2 (includes EG:9134), 
CDH11, CES1 (includes EG:1066), COL6A1, COL6A2, 
COL6A3, COL6A MAPPED, CTSH, ENO3, ERBB2, FIGF, 
FOS, GAS1, KBTBD10, KIFC3, LTBP2, LUM, MAP1B, 
MYH4, NF2, NRP1, PGAM2, PRRX1, SERPINE2, SFRP, 
SFRP4, SFRP5, SMARCA4, SMARCD1, TNNI2, TNNT3, 
TPM1 
 
26  17  Genetic Disorder, 
Skeletal and Muscular 
Disorders, Cancer 
 
4  ACADVL, ALAS2, ATP2A1, C4A, CD163, CIAA1, CIAA2, 
CLEC4A, COL10A1, COL1A2, COL3A1, CTSS, 
dihydrotestosterone, F13A1, G0S2, ganglioside GM4, 
GPNMB, GPX4, GUCY1B3, H2-Q10, Hsp70, HSP90AB1, 
HSPA1L, IL13, IL13RA2, IL1B, IL3RA, LOX, MBP, PYGM, 
RSAD2, S100A8, STAT3, TMF1, UGDH 
 
26  17  Gene Expression, 
Viral Function, Cell-
To-Cell Signaling and 
Interaction 
 
5  C1q, C1R, C1S, CD74, CD81, CFD, CHRNE, CHRNG, 
COL15A1, CPT2, CPT1A, CTSC, CTSS, DEFB103A, 
DEFB4 (includes EG:1673), HLA-DRA, IDH1, IFITM1, IFNK, 
IGK@, IGKC, malonyl-coenzyme A, MAP3K7IP2, MX1, 
NCOR1, NID1, NR1D1, NR1D2, OGN, PANK2, RFX5, 
SERPINE2, SERPING1, STEAP4, TNF 
 
22  15  Immunological 
Disease, Lipid 
Metabolism, Small 
Molecule Biochemistry 
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Figure 5-11: Ingenuity pathways analysis identifies a network of genes regulated in the DRG 
6 weeks after spinal nerve crush relative to naïve control.  This is the top regulated network for 
this condition (Table 5-22).  For comparison, the network is also shown overlaid with expression 
information from the other data sets.  Nodes are coloured according to expression 
(upregulated=red, downregulated=green). 
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5.5.3.4  Networks of genes regulated at 2 weeks after a dorsal column transection 
28 significant networks were identified from the genes regulated at the 5% FDR level 2 weeks after 
a dorsal column transection. The top ranked network (Figure 5-12) contains 30 focus genes 
involved in Immune Response, Cell Signaling and Immunological Disease. 
 
 
Table 5-23:  Top 5 networks regulated (all at p<0.001) at 2 weeks after a dorsal column 
transection. 
  NETWORK GENES (FOCUS GENES IN COLOUR)  SCORE  FOCUS 
GENES 
TOP FUNCTIONS 
1  ASPH, ATP2A1, C1q, C1QA, C1QB, C1QC, C1R, C1S, 
CAMK2D, CCKBR, CD63, CD74, CDKN1A, CFH, CTSS, 
CXADR, DCN, HLA-DMB, HLA-DQA1, HLA-DQB2, HLA-
DRA, HLA-DRB1, IRF2, KLF10, MHC Class II, MHC II-
&beta;, Phosphoinositide phospholipase C, PLCD1, PLCD4, 
RACGAP1, RFX4, Ryr, RYR1, TGM1, TRDN 
 
44  30  Immune Response, Cell 
Signaling, 
Immunological Disease 
 
2  Ap1, ARRB1, CACYBP, CLDN1, DUSP5, EGFR, F3, 
FABP7, GABAR-A, GABRA1, GABRA5, GABRB1, 
GABRG2, GBP2 (includes EG:14469), GJB2, HBD, MEOX2, 
OCLN, OMD, Pdgf, PDGF BB, Phospholipase C, Pkc(s), 
PLAC8, PLSCR1, POSTN, PRKCE, PTGER4, RGS2, 
SLC1A1, STAT5a/b, THBD, UGDH, XDH, ZFP36L1 
 
39  28  Neurological Disease, 
Developmental 
Disorder, Psychological 
Disorders 
 
3  ACTN3, BCL2L2, CHGA, CP, CUGBP2, ERK1/2, FLNC, 
FOS, FREQ, Gpcr, GTF2F2, HRK, KBTBD10, KCNAB1, 
KCND3, KCNIP3, Mek1/2, MET, MYH2, MYOT, MYOZ1, 
Ngf, NMB, NPY, P2RY1, PDGF-AA, PGAM2, PP1/PP2A, 
PP2A, PPP2R2A, PPP2R5C, SLC40A1, STAT, TGFBI, UCN 
 
37  27  Molecular Transport, 
Behavior, Carbohydrate 
Metabolism 
 
4  AEBP1, ASS1, DRD2, ENTPD1, FCGR2B, G alphai, G 
protein beta gamma, GADD45A, GADD45G, GFRA1, 
GFRA2, Gi-coupled receptor, GRM4, HTR1D, IL24, KCNJ6, 
KLF13 (includes EG:51621), Mapk, MYLPF, P2RX3, P2RX5, 
P2RXL1, P38 MAPK, Pak, Plc beta, PLC gamma, PLEK, 
PTPN6, PTPRH, RET, RGS3, RGS4, S100A9, SST, TRPV1 
 
37  27  Cell Signaling, Digestive 
System Development 
and Function, Organ 
Morphology 
 
5  C2, C3, C3-Cfb, CASP3, CASP7, Caspase, Caspase 3/7, 
CD24, CFB, CFD, CYBB, DSP, DUSP1, EMP1, Fibrin, FN1, 
GZMB, HAPLN1, Igfbp, IGFBP3, INCENP, Integrin, IRF8, 
LYZ, Mmp, MMP3, MMP16, P2RX7, Rap1, SERPINA3, 
SERPINI1, SNED1, Sod, TAC1, VIP 
 
35  26  Inflammatory Disease, 
Connective Tissue 
Disorders, Skeletal and 
Muscular Disorders 
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Figure 5-12: Ingenuity pathways analysis identifies a network of genes regulated in the DRG 
2 weeks after dorsal column transection relative to naïve control. This is the top regulated 
network for this data set (Table 5-23).  For comparison, the network is also shown overlaid with 
expression information from the other data sets.  The nodes are coloured according to expression 
(upregulated=red, downregulated=green). 
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5.6 Discussion (for sections 5.4 and 5.5) 
5.6.1 Centrally or peripherally axotomised DRG neurons respond 
to injury by altering their gene expression programmes 
All the injury models elicited changes in the expression of genes within the DRG.  Whilst there 
have been previous studies that examine gene changes in the DRG following injury to the spinal 
nerve or dorsal root, this is the first study that examines changes in the DRG after an injury within 
the CNS, namely dorsal column transection.  This injury elicited the largest changes and changes 
in more genes than the other injuries. Indeed transection of the dorsal columns elicited a 
transcriptional response which was more dramatic than that elicited at the same time-point 
following injury to the dorsal root (Table 5-2). This is perhaps surprising given that transcriptional 
activation has been shown to diminish as a function of the distance of a lesion from the cell body 
(Rossi et al. 2007).  Dorsal column transection also differed from the other injuries in that it caused 
mainly downregulation of genes as opposed to upregulation.  The complete separation of this injury 
from the other injury models on the basis of principle components analysis and correlation analysis, 
further suggests that dorsal column transection activates a transcriptional programme that is 
different to that elicited by injuries out-with the CNS, in either the peripherally or centrally projecting 
branches of the DRGN. This difference may be attributed to the fact that unlike in dorsal root and 
spinal nerve crush, dorsal column transected axons retain a supply of target derived factors 
through their intact central terminals. 
 
5.6.2 Genes regulated after dorsal column transection include 
known RAGs 
The transcriptional response to CNS injury included upregulation of genes that are known to 
stimulate neurite outgrowth.  Some of these were among the top 20 upregulated genes after dorsal 
column transection (Table 5-9) and included: FLRT3; a cell surface molecule which is expressed in 
sensory neurons after sciatic nerve injury and which promotes neurite outgrowth in vitro (Robinson 
et al. 2004; Tsuji et al. 2004); GAL, which has already been reported to be upregulated after dorsal 
column transection (Zvarova et al. 2004) and which been suggested to have a trophic role in 
regeneration as neuronal outgrowth after a sciatic nerve crush injury is reduced by 35% in Gal-KO 
mice (Holmes et al. 2000); ARG1 and SPRR1A (see section 1.4.2); and ATF3 (see also 3.3.3.2).  
Indeed, the top upregulated genes showed many overlaps with those regulated after sciatic nerve 
transection (Chapter 3 table). This can be interpreted in one of two ways.  This could suggest that 
even after the period of spontaneous sprouting (at 6-24 hours (Kerschensteiner et al. 2005)) after 
CNS injury, genes that are conducive to neurite regeneration are upregulated in the DRG.  This 
has relevance to clinical interventions as it suggests that the appropriate transcriptional  149 
programmes for regeneration may still be in place up to 2 weeks after injury and as such provides 
a window of opportunity for manipulation of the lesion zone. Alternatively, the commonalities that 
exist between the pilot microarray and dorsal column transection could reflect the fact that these 
are both transection injuries and differ from the other conditions in that the continuity of the basal 
lamina is disrupted. 
5.6.3 Dorsal column injury triggers changes that are associated 
with neuropathic pain after peripheral nerve injury 
Neuropathic pain is defined as pain initiated or caused by primary lesions or dysfunction in the 
nervous system.  Unlike physiological pain, which is transient, neuropathic pain can be persistent 
and is associated with changes in the excitability of primary afferent neurons that leads to 
weakened presynaptic inhibition (Zimmermann 2001).   Presynaptic inhibition of primary afferent 
input is a mechanism by which sensory information from the periphery is filtered. Negative 
feedback control on activated primary afferents by intraspinal inhibitory neurons results in primary 
afferent depolarisation (PAD), a mechanism that decreases transmitter from primary afferents and 
that is known to occur in the main, through activation of ionotrophic GABAergic, glutaminergic and 
serotonergic receptors.  The overall effect is reduced sensory synaptic transmission.  These 
normal inhibitory mechanisms are perturbed in neuropathic pain situations. 
 
 
Figure 5-13: Schematic representation of a presynaptic inhibitory axon producing primary 
afferent depolarisation in a primary afferent fibre. Adapted from Rudomin and Schmidt 
(1999). 
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Ontological analysis highlighted another feature of the transcriptional response to dorsal column 
transection that is also a feature of the response to peripheral nerve injury models of neuropathic 
pain described by (Wang et al. 2002). This was the dramatic downregulation of GABA1A receptors, 
potassium channels, nicotinic acetycholine receptors, 5HT3 receptors  (Table 5-19) and glutamate 
receptors (Figure 5-14). These changes are associated with increased axonal excitability and 
neuropathic pain of peripheral nerves or with changes in central pain processing: GABAA receptor 
subunits are downregulated in the DRG in the chronic constriction injury (CCI) model of 
neuropathic pain (Obata et al. 2003) and also in chronic pain states (Naik et al. 2008); there is loss 
of functional neuronal nicotinic acetylcholine receptors in DRGs of rats with spinal nerve ligation 
and neuropathic pain (Dube et al. 2005);   axotomy of DRG neurons decreases expression of 
potassium channel subunits leading to a 50-60% decrease in potassium currents and neuronal 
hyperexcitability (Ishikawa et al. 1999; Yang et al. 2004) and, 5HT3 receptors are expressed in 
dorsal horn of the spinal cord where they mediate antinociception (Bardin et al. 2000; Sasaki et al. 
2001).  They are also expressed in the DRG (Morales et al. 2001).  In peripheral nerve injury the 
downregulation of all these receptors and ion channels in the DRG leads to increased excitability of 
peripheral nerves and decreased presynaptic inhibition at central terminals. This presynaptic 
plasticity can modulate neuropathic pain development and maintenance.  After dorsal column 
transection these changes may contribute to the development of chronic spinal pain by causing 
changes in the effectiveness of transmission in the intact central terminals of the afferent fibres or 
by modulating the excitability of peripheral branches.   
 
Figure 5-14: Glutamate signalling KEGG pathway illustrating downregulation (green) of 
glutamate receptors after dorsal column transection.  151 
 
 
 
 
 
5.6.4 Dorsal column transection activates MHC class II antigen 
processing in the DRG 
A dominating feature of the IGA analysis for dorsal column transection was activation of genes 
involved in MHC class II antigen processing (Table 5-18, Figure 5-7 and Figure 5-12).  This was 
specific to this condition and, interestingly, also sciatic nerve transection.  DRGs are not protected 
by the blood brain barrier and are known to undergo invasion by MHC II - expressing macrophages 
after peripheral nerve lesions (Hu and McLachlan 2002).  Macrophage recruitment is stimulated by 
TNF-α originating from the lesion site which is transported retrogradely, inducing the expression of 
two monocyte chemoattractants in the DRG (MCP-1 (Tanaka et al. 2004) and ICAM-1 (Schafers et 
al. 2002)). It can be envisioned that differences in macrophage recruitment to the DRG and hence 
levels of MHC II class molecules may result from various types of axon injury if the levels of TNF-
alpha that are produced are different.  Indeed, recruitment of MHC II+ macrophages has been 
shown to be greater after a transection injury than after a chronic constriction injury (Hu et al. 
2007).  This may account for the similarities in MHC II activation that we see in the sciatic and 
dorsal column transection injury models. 
5.6.5 Expression of RAGs, neurotrophic factors, growth factors 
and collagen subunits is depressed in the regeneration 
arrested dorsal root compared to regenerating dorsal root 
At 2 weeks post- dorsal root crush there is the presence of regeneration-associated genes (ATF3, 
ADAMTS1) and regeneration-promoting neurotrophic factors and growth factors (BDNF and VGF) 
among the top upregulated genes.  This is reflected in the IGA ontological analysis that identifies 
neuropeptide hormone activity as an important theme at this timepoint (Table 5-3).  At 6 weeks 
after injury these genes no longer appear among the top upregulated genes and there is a general 
reduction in gene expression changes (Table 5-2). 
A striking difference between gene expression in the regenerating and regeneration-arrested 
dorsal root is the expression of procollagens.  IGA identifies ontological groups containing a 
number of procollagens as significantly upregulated 2 weeks post-dorsal root injury and these are 
not a feature for the oncological analysis of genes regulated at 6 weeks post injury.  IPA network 
analysis illustrates this difference (Figure 5-15).  The fact that the upregulation of procollagens is 
seen at 6 weeks post- spinal nerve injury suggests that downregulation of these genes at 6 weeks 
post dorsal root injury is not purely a time dependent effect and may be due to signals encountered 
at the DREZ.  Furthermore, upregulation of procollagens is not a significant feature of the dorsal  152 
column transection injury suggesting that their upregulation is only associated with the 
regenerating conditions. 
In the injured peripheral nerve the secretion of collagen by epineurial fibroblasts is associated with 
scar formation at the lesion zone and inhibition of regeneration (Siironen et al. 1992; Siironen et al. 
1996; Nath et al. 1997).  The expression of collagen can be reduced by neutralisation of TGF-beta 
(Nath et al. 1998; Davison et al. 1999) suggesting that this growth factor stimulates collagen 
production.  There is less known about collagen production in the DRG itself.  DRGs contain non-
neuronal cells including fibroblasts (Mudge 1981) and it is possible that it is these cells that are 
responsible for the regulation of procollagens in our microarray.  Macrophage have however been 
recently shown to express almost every known collagen mRNA (Schnoor et al. 2008).  The 
regulation in collagen could therefore be due to resident DRG macrophage or due to infiltration of 
macrophage. The mechanism and function of this regulation is however unknown.  TGF-beta is not 
significantly upregulated in the DRG in the 2DR and 6SN conditions and as such it can be 
envisioned that TNF-beta may be retrogradely transported to signal from the lesion zone in a 
similar manner to TNF-alpha (Section 5.6.4).   
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Figure 5-15: IPA identifies a network of genes involved in ‘Cellular movement’, ‘cell-cell 
signalling and interaction’ and ‘cell morphology’ that is regulated between 2DR and 6DR.  
The network has a highly significant score of 72 (p<0.001).   For comparison, the network is also 
shown overlaid with expression information from the 2DR vs. ctrl and 6DR vs. ctrl data sets.   The 
intensity of the node colour indicates the degree of up (red)- or down (green) regulation. This 
2DR vs. ctrl  6DR vs. ctrl 
 6DR vs. 2DR  154 
network highlights the downregulation of procollagens and growth promoting factors such as BDNF 
in regeneration-blocked dorsal root fibres. 
5.6.6 Activation of complement is a feature of all the conditions 
A salient feature of the IGA and IPA canonical pathways analysis for all conditions was the 
activation of complement within the DRG (Figure 5-7). This activation of complement appears to 
be long lasting as it is a feature at both 2 and 6 weeks after an injury.  Complement mediates a 
large variety of processes including neuronal cell death, cell adhesion and chemotaxis (Morgan 
and Gasque 1996).  Activation of complement can also lead to inflammation with loss of neurons 
(Speth et al. 2002).  In addition, mice null for the C5 component of complement have reduced 
neuropathic pain sensitivity suggesting that complement may have a role in modulation of 
neuropathic pain. Indeed, increased biosynthesis of complement components by dorsal horn 
microglia in animal models of neuropathic pain has also been reported (Griffin et al. 2007). 
Complement is also active in the PNS during neuropathic pain states and components of 
complement have been reported as upregulated in the DRG at 4 weeks after spinal nerve ligation 
with neuropathic pain (Levin et al. 2008).  These authors also show that depletion of the 
complement cascade by treatment with cobra venom factor alleviates neuropathic pain 
demonstrating a causal link between the two.  The mechanism through which components of 
complement modulate neuropathic pain are currently unknown however inhibitors of microglia have 
been used to manipulate complement regulation and have potential therapeutic value for treatment 
of neuropathic pain (Mika 2008). Our finding that central injury also induces complement activation 
in the DRG has implications for treatment of the chronic pain that is associated with SCI. 
5.6.7 All the injuries produce an apparent downregulation of 
genes involved in the contraction of striated muscle 
The downregulation of actin and myosin components that are involved in striated muscle 
contraction featured in the IGA ontological analysis for all the conditions. This is a previously 
unreported finding.  Some actin and myosin subtypes are found associated with the growth cone 
and axonal cytoskeleton and IPA canonical pathways analysis suggested that for 6DR and 6SN, 
the downregulation of these genes was a feature of actin cytoskeleton signalling. Myosin II (MYL2), 
one of the muscle components found downregulated in this study, is thought to have a role in 
cytoskeleton disassembly (Medeiros et al. 2006; Haviv et al. 2008) and actin bundle turnover at the 
growth cone (Medeiros et al. 2006).  Indeed, downregulation of this myosin gene has been shown 
to increase filopodial extension due to decreased rates of actin bundle severing in the growth cone 
transitional zone  (see section 1.2.2.1) (Medeiros et al. 2006; Haviv et al. 2008).  This may explain 
why this gene is downregulated under injury conditions when there is growth cone activity.  It does 
not however explain the concominant decrease in expression of other muscle components.  The 
expression of these genes on a chip-to-chip basis was therefore investigated using Genespring.  155 
Hierarchical clustering revealed a group of ten muscle genes that clustered closely on the basis of 
their expression across all chips and that showed an unusual pattern of expression (Figure 5-4). 
The expression of these genes was extremely variable within chip triplicates; nine of the 10 genes 
in this cluster showed a very high level of expression on two of the three control chips and elevated 
expression on one chip out of each of the experimental triplicates.  Seven of these genes appeared 
in at least one of the top 20 downregulated genes lists for each condition however their pattern of 
expression suggests that their apparent downregulation may be artifactual and due to random error 
such as varying degrees of contamination from muscle tissue. 
 
 
 
Figure 5-16: Heatmap illustrating across-chip signal intensities of a cluster of muscle 
related genes.  Cells are coloured by normalised signal intensities for each chip. 
 
5.6.8 The top upregulated IPA functional networks for the 
regenerating conditions show overlaps in a number of 
genes with putative roles in regeneration 
One of the top functional networks identified as regulated at 2 weeks following a dorsal root crush 
(Figure 5-8) was centred around the epidermal growth factor receptor (EGFR1), fibronectin 1 (FN1) 
and insulin-like growth factor (IGF1) and was associated with cell-to-cell signalling and cellular 
movement.  The involvement of procollagens in this network also led to an association of this 
network with dermatological diseases.  The top network identified for the other regenerating 
condition, 6 week spinal nerve crush, was also associated with cellular movement and cell-to-cell 
3.0 
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signalling and showed overlap with the 2DR network with the inclusion of ADAMTS1, COL1A1, F3, 
FBN1, FN1, TFPI2 and WISP (Figure 5-11).  Interestingly, some of these genes have been 
previously shown to have roles in axon regeneration. 
Cell adhesion molecules are thought to play an important role in regeneration (reviewed in 
Kiryushoko et al. 2004). The adhesion molecule thromboplastin (F3) belongs to the Ig superfamily 
and is expressed on PNS axons.    It has been shown to interact with a receptor on Schwann cells 
and mediates neuron-glial cross talk during development and regeneration (Thomaidou et al. 
2001).  In agreement with a possible role in regeneration this gene has been shown to be 
upregulated in neurons after peripheral nerve injury (Daniloff et al. 1986). 
ADAMTS1 is a metalloproteinase and like ECEL1, which was investigated in Chapter 3 (see 
section 3.3.3.1), has been suggested to have a role in neuronal regeneration.  It is upregulated in 
the hypoglossal nerve after injury (Sasaki et al. 2001) and has been shown to have proteolytic 
activity on the proteoglycan, aggrecan (Kuno et al. 2000).  This has led to the suggestion that 
ADAMTS1 secreted at axonal terminals may cleave CSPGs (see also section 1.4.1.2) in the 
extracellular matrix to make way for axonal outgrowth.  Fibronectin (FN1) is also a 
metalloproteinase and so could be envisioned to have a similar role. 
5.6.9 The top IPA network for 6DR reveals a gene that is 
antagonistically regulated between 2 and 6 weeks after 
dorsal root crush 
Differences in gene expression between 2 and 6 weeks after dorsal root crush has relevance to 
dorsal root avulsion injury as they may give insight to the intrinsic reasons as to why dorsal root 
neurons can not regenerate through the DREZ to reinstate functional connections in the spinal 
cord.  The top upregulated network for 6DR (Figure 5-10) is centred around the immediate early 
gene FOS and is associated with skeletal and muscular system and tissue morphology, 
cardiovascular system development and function.  The network highlights neuregulin (NRG1) as a 
gene that is upregulated at 6 weeks following dorsal root crush but which is downregulated at 2 
weeks after this injury. NRG is an EGF-like growth factor that is thought to be important in the 
regulation of glial cell function and survival.    It has been reported that the expression of this gene 
in sensory neurons is reduced immediately after peripheral axotomy and returns to normal levels 
after target reinnervation (Bermingham-McDonogh et al. 1997).  Another study suggested that a 
higher level of NRG1 in optic nerves compared to sciatic nerves could contribute to the poor 
regenerative ability of the former (Martinez et al. 2004).  Reduction in NRG1 expression is 
therefore correlated with periods of axon outgrowth whilst overexpression of this gene is 
associated with reduced regenerative capacity.  The upregulation of NRG1 at 6 weeks after dorsal 
root crush could therefore contribute to the regenerative block of these axons at the DREZ.  
Conversely, the downregulation of this gene after dorsal column transection could lend further 
support to the idea that this injury elicits a transcriptional programme conducive to regeneration.  157 
5.7 Question-led analyses and discussion 
5.7.1 Is the expression of receptors consistent with a 
regenerative or non-regenerative phenotype? 
Axon outgrowth depends in part, on how well a growth cone can detect and respond to factors in 
its environment (see also section 1.2.2.1).  Neurotrophic factors, growth factors (such as BDNF 
and GDNF) and laminin have all been shown to be important to the positive regulation of 
outgrowth.   The expression of receptors for these molecules is therefore important in determining 
growth cone responsiveness.  The data was therefore examined for changes in regulation of 
neurotrophin receptors (Ntrks), growth factor receptors (GFRs) and receptors for laminin 
(integrins).  It might be expected that in the conditions where regeneration is successful  (2DR and 
6SN) there might be greater upregulation of such receptors than in the non-regenerating conditions 
however this pattern was only seen for one growth factor receptor, ‘platelet-derived growth factor 
receptor, alpha polypeptide (PDGFRA) which was upregulated 1.48 fold in both 6SN and 2DR (at 
3.16 % and 2.1 % FDR, respectively).   
 
5.7.2 Is the expression of putative regeneration associated genes 
(RAGs) restricted to the regenerating conditions? 
Studies of peripheral nerve regeneration have identified 11 consistently upregulated genes (see 
section 1.5.2.3), suggestive of these genes being important to the process of axonal regeneration.  
A number of other genes that have been identified through microarray studies as putative RAGs 
have been overexpressed in DRG neurons in vitro, and have stimulated neurite outgrowth. The 
expression of these genes in our injury conditions was compared (Table 5-24).  The upregulation of 
these genes does not appear to correlate with neuronal regeneration.  In fact, these genes are 
most consistently upregulated in the dorsal column transection condition, a condition in which 
regeneration is blocked.  Regulation of these genes is almost completely absent at 6 weeks after 
spinal nerve injury in which there is ongoing regeneration, suggesting that they are not necessary 
for maintenance of axon outgrowth.   158 
Table 5-24: Comparison of changes in expression of putative RAGs after all conditions.  
Cells are coloured according to expression. 
 
 
 
 
 
 
 
 
 
 
 
5.7.3 Is regeneration a recapitulation of development? 
It is known that during its development, the CNS undergoes a critical period during which plasticity-
related genes are expressed.  This is thought to account for the regenerative capacity of the 
mammalian CNS in embryogenesis that is lost developmentally with the expression of plasticity-
restricting molecules such as the myelin-associated inhibitors of regeneration. There is 
contradictory evidence for developmental genes being re-expressed during regeneration (reviewed 
in (Emery et al. 2003)). There was however evidence from the pilot microarray of increased 
expression of developmental genes after sciatic nerve transection (see section 3.5.2.1). 
IPA functional analysis was used to interrogate the data sets for genes that are involved in nervous 
system development to search for evidence of re-expression of developmental genes in the 
regenerating conditions. Genes involved in nervous system development and function were 
significantly represented in all the data sets apart from 6SN (Figure 5-17).   
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Figure 5-17:  IPA analysis of the level of representation of genes involved in 'nervous 
system development and function' in each data set. 
5.7.3.1  The 2DR data set  
In the 2DR dataset ‘nervous system development and function’ was significantly represented (p 
value)=2.06E
-2-4.83E
-2) by 24 genes.  The list featured genes involved in the activation of neuroglia 
and neurons (upregulation of BDNF, CYBB, FN1, IGF1, FOS and NTS and the downregulation of 
CHGA), ensheathment of neurons (upregulation of CLN11 and POU3F1), migration of neuroglia 
(upregulation of BDNF, CCL13, CLDN11, FN1, ITGAL and downregulation of NRG1), circadian 
rhythm (upregulation of DBP, FOS, PER2 and PER3 and downregulation of RAB3A), quantity of 
CNS cells (upregulations of ADCYAP1, CCND2, EGFR, IGF1, IGFBP6), excitation of neurons 
(upregulation of BDNF, FOS and NPY) and  survival of granule cells (upregulation of ADCYAP1, 
BDNF and IGF1). 
5.7.3.2  The 6DR data set 
12 genes contributed to the significant representation of ‘nervous system development and 
function’ in the 6DR data set  ((p value)=3.95E
-4- 2.3E
-2).  These were genes involved in; 
chemotaxis of granule cells and granule cell precursors, survival of cells (both associated with 
upregulation of BDNF and CXCL12), activation of neurons and neuroglia (upregulation of BDNF, 
FOS, CYBB and GFA, and downregulation of APLN), long term potentiation (upregulation of 
BDNF, GFAP and NRG1), excitation of neurons and granule cells (upregulation of BDNF and 
FOS), maturation of neurons (upregulation of BDNF and CDKN1C), binding of axon terminals, 
branching of peripheral nerves, cell cycle progression, defasiculation, extension of schwann cells, 
morphology of axon terminals, remyelination and retraction of axon terminals and conduction of 
axons (all associated with the upregulation of NRG1), generation of action potential, chemokinesis, 
discharge of granule cells, formation of cells, innervation, rearrangement of axons, generation of  160 
the excitatory post synaptic potential of dorsal root (all associated with upregulation of BDNF),  
development of motor endplates (downregulation of CHRNE), growth of peripheral nerve and 
neurons (upregulation of BDNF and NRG1),  withdrawal of sensory nerves, quantity of neuroglia 
and axon branches (upregulation of BDNF, EGFR and NRG1), migration (upregulation of BDNF 
and NRG1), myelination (upregulation of BDNF, CLDN1 and NRG1), cell to cell contact,  
(upregulation of CXCL12) and reactivation of astrocytes (upregulation of GFAP). 
5.7.3.3  The 2DC data set 
80 genes contributed to the significant representation of ‘nervous system development and 
function’ in the DC data set ((p value)=8.89E-
4- 4.51E
-2).  Specifically, 16 genes involved in 
neurogenesis were downregulated (ACSL6, AMIGO3, CNR1, DPYSL4, DRGX, FABP7, GFRA2, 
GRIK1, LGI1, LSAMP, MT3, NOG, NRG1, RET, SCRG1 and TRPV1) while 17 genes were 
upregulated (BDNF, CDKN1C, CRIM1, DLX5, DRD2, FRF2, GAL, GFAP, GFRA1, HHIP, MAOA, 
MET, SOX11, SYN3, TGFBR1, THBS4 and SEM).  Other genes contributing to the functional 
classification were involved in; innervation of neurons and cells (upregulation of BDNF, GAP43 and 
VCAM1 and downregulation of GFRA2, GRIA2 and NOG), maturation of neurons (upregulation of 
BDNF, CDKN1C and FGF2), quantity of neurons (upregulation of ADCYAP1, BDNF, CASP3, 
CCND2, CYBB, DRD2, FGF2, GAL, GFRA1, IRX3 and SERPING1 and downregulation of GFRA2, 
NOG and RET), quantity of ganglion cells (downregulation of GFRA2 and NOG), quantity of 
neurites (upregulation of BDNF, GAL and MAOA and downregulation of GFRA2, HTR7 and 
MAPK10), activation  of nerves (upregulation of ADCYAP1 and downregulation of CALCA and 
TAC1), activation of neurons (upregulation of BDNF and FOS and downregulation of CNR1, 
PTGER3, RET and TAC1), depolarisation of dorsal horn cells (upregulation of VIP and 
downregulation of TAC1), depolarisation of neurons (upregulation of ADYCYAP1 and VIP and 
downregulation of P2RX3 and TAC1), paired-pulse facilitation (upregulation of BDNF and 
downregulation of UNC13C), patterning of axons (CASP3 and MAOA), recruitment of medium 
spiny neurons (upregulation of BDNF and FGF2), regeneration of neurons (upregulation of ARG1 
and FGF2), synaptic fatigue of synapse (upregulation of BDNF and SYN3), growth of axons 
(upregulation of BDNF, FGF2, GFRA1, MAOA, MET and SYN3 and downregulation of NRG1 and 
RET), synaptic transmission (upregulation of BDNF, DRD2, FGF2, FREQ, GABRA5, GAL, 
KCNMB4, NPY, SLC1A1 and XDH and downregulation of CHRNB4, CHRNE, DLGAP1, GABRG2, 
GLRB, GRIA2, GRIK1, GRI1, GRM4, HTR7, HTR1D, HTR3A, PCDH8, RIT2 and UNC13C),  
neuritogenesis  (upregulation of ADCYAP1 and FGF2 and downregulation of CACNA1H and 
GFRA2), survival of motor neurons (upregulation of BDNF, GFRA1 and REG3A and 
downregulation of GFRA2) and pain behaviour (upregulation of ARRB1 and SCN3A and 
downregulation of KCNIP3, SCN11A, TAC1 and TRPV1). 
5.7.3.4  The 6SN data set 
Within the 6SN data set only 2 genes contributed  ((p value)=4.94E
-2).  Both the genes (DBP and 
PER2) were upregulated and are known to be involved in circadian rhythm.  161 
5.7.3.5  Discussion 
The analysis did not provide evidence for a re-expression of developmental genes in the 
regenerating conditions and regulated genes in the 2DR and 6SN condition appeared to belong to 
subcategories pertaining to nervous system function rather than nervous system development.   
Indeed dorsal column transection was the only condition in which genes belonging to 
developmental subcategories were changed.  For example in the neurogenesis category, 17 genes 
were upregulated including; SOX11, a developmentally expressed transcription factor that is 
required for neuron survival and outgrowth (Jankowski et al. 2006); synapsin III (SYN3), which is 
highly expressed in growth cones in early development and is required for axonal differentiation 
(Ferreira et al. 2000); cysteine rich motor neuron 1 (CRIM1), a transmembrane protein with a role 
in CNS development via growth factor binding (Kolle et al. 2000) and DLX5, a transcription factor 
which is required for normal neuronal differentiation during development (Perera et al. 2004). 
 
5.7.4 What do the regenerating conditions have in common? 
In order to reveal genes that are common to the regenerating conditions, and thus potentially 
important to the regenerative process, genes were filtered in two ways.  Differentially expressed 
genes identified by ANOVA (p<0.05) were filtered using Venn diagrams in Genespring.  In addition, 
genes that were identified by RPA as differentially expressed (<5% FDR) were filtered by Excel 
based data sorting. 
5.7.4.1  Gene filtering using Venn Diagrams 
Intuitively, genes that are regulated in the regenerating conditions and not in the non-regenerating 
conditions are interesting as putative regeneration-associated genes.  Venn diagrams were 
generated using Genespring GX and were used to identify genes that were differentially expressed 
specifically to the regenerating conditions (2DR and SN).    At the 5% significance level 1011 
genes are changed after 2DR, genes changed after 6DR and 466 genes changed after 2DC 
transection were plotted (Figure 5-18a).  This allowed the identification of 190 genes that were 
specific to the regenerating condition (2DR).  This process was repeated with the other 
regenerating condition (6SN) (Figure 5-18b).  This identified 101 genes regulated specifically in 
6SN. These 101 genes and the 190 genes specific to 2DR were plotted on a third Venn diagram 
(Figure 5-18c).  This allowed the identification of 44 genes that were specifically regulated at the 
5% significance level in the regenerating conditions but not in the non-regenerating conditions 
(Figure 5-19).  GO analysis of this list of genes categorised them as belonging to a number of gene 
categories including development and response to stimulus (Figure 5-18d).  No ‘GO’ categories 
were significantly overrepresented.   162 
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Figure 5-18:  Identifying regeneration-associated genes using Venn diagrams. Number of 
regulated genes (p<0.05) (in bold) specific to a) 2DR and b) 6SN are identified.  c) 44 genes 
common to 2DR and SN are identified and d) analysed by GO.  The number in brackets represents 
the number of regulated genes that changed >1.5-fold. 
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Figure 5-19:  Heatmap with hierarchical clustering (centroid or average linkage method) 
showing the 44 genes identified by Genespring showing differential regulation (at the 5% 
significance level) in only the regenerating conditions.  Cells are coloured by mean normalised 
signal intensity for each condition.  Degree of trust is indicated by the brightness of the cells. 
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5.7.4.2  Identification of regeneration-associated genes using excel data sorting 
Rank products-analysed data files containing fold change values and FDRs for all genes that 
appeared within a 50% FDR cut-off were merged into a single excel spreadsheet that allowed the 
data to be sorted and filtered according to a number of different criteria. 
When data was filtered to leave only those genes regulated in the regenerating conditions at the 
50% FDR level and not in the non- regenerating conditions this yielded a list of 272 genes.  A 50% 
FDR cut-off is however extremely liberal and when these genes were filtered to leave only those 
that were regulated at the 5% FDR level in at least one of the two conditions, 35 genes remained 
(Table 5-25) and 11 of which showed an overlap with the list generated by Genespring (Figure 
5-16).  Of these 35 genes only 3 were regulated within 5% FDR in both the conditions (highlighted 
in red).  These represent candidate regeneration-associated genes. 
 
Table 5-25: Genes regulated within 50% FDR in regenerating conditions but absent at 50% 
FDR in non-regenerating conditions. 
                2DR      SN 
Affy ID    Gene symbol        FC  FDR    FC  FDR 
1369484_at    Wisp2        1.43  4.01    1.58  1.23 
1370333_a_at    Igf1        1.31  10.8    1.53  1.65 
1373062_at    Sulf1        1.22  30.4    1.63  0.67 
1373314_at    ---        1.44  4.01    1.36  7.84 
1373914_at    Shank1        1.21  31.21    1.54  1.8 
1376734_at    ---        1.4  8.4    2.01  0.09 
1377168_at    Cpne9        -1.16  47.33    -1.38  2.34 
1377340_at    Tfpi2        1.49  1.83    1.66  0.53 
1378094_at    RGD1308084      1.37  6.35    1.44  3.97 
1379362_at    ---        1.23  28.48    1.4  4.98 
1379444_at    ---        1.3  11.4    1.54  1.37 
1380726_at    LOC306805      1.29  17.06    1.8  0.25 
1381556_at    RGD1560014_predicted    1.58  2.25    1.22  36.12 
1381819_at    ---        1.24  29.88    1.51  1.89 
1382599_at    ---        1.41  5.53    1.52  1.68 
1383875_at    Upk1b        1.21  32.72    1.42  4.7 
1384211_at    Col11a1        1.29  14.78    1.6  1.07 
1385053_at    ---        1.4  7.17    1.73  0.37 
1385082_at    ---        1.29  15.83    1.44  4.73 
1385973_at    ---        1.52  1.96    1.37  8.41 
1386946_at    Cpt1a        1.18  40.01    1.47  3.66 
1387313_at    Myoc        1.36  5.52    1.5  2.16 
1388469_at    ---        1.38  6.11    1.45  4.07 
1388569_at    Serpinf1        1.3  11.71    1.44  3.88 
1388936_at    Cdh11        1.27  16.79    1.44  3.36 
1389905_at    ---        1.47  2.2    1.39  5.99 
1390119_at    Sfrp2        1.38  7.09    2.41  0 
1390518_at    LOC685462      1.21  33.06    1.56  1.07 
1390632_at    RGD1563246_predicted    1.28  15.22    1.44  3.39 
1390989_at    RGD1563952_predicted    1.21  32.77    1.45  4.01 
1392140_at    Cdh11        1.42  3.18    1.48  2.26 
1393346_at    RGD1561673_predicted    1.26  19.63    1.43  3.9 
1393809_at    Traf6_predicted      -1.21  36.85    1.48  3.8 
1396152_s_at    Igfbp5        1.21  31.36    1.44  3.38 
1399069_at    RGD1310351_predicted    1.21  40.1    1.52  1.68  165 
 
5.7.4.3  Investigating the functions of WISP2 and TFPI2 
Two of these putative regeneration associated genes, WISP2 and TFPI2 feature in the top 
networks identified for the regenerating conditions along with genes that have previously been 
implicated in regeneration (Figure 5-8 and Figure 5-11).  WISP2 and TFPI2 have not been 
described previously as having functions in axonal injury and regeneration. In an effort to 
investigate the function of these genes Genespring was used to select genes with a highly similar 
pattern of expression across all conditions (Pearson correlation coefficient r
2>0.95) which thus 
show co-regulation, and may function in concert, with the genes of interest.  165 genes passed this 
criteria for WISP2 and this list was uploaded for analysis by IPA.  Of these 165 genes, 114 genes 
could be mapped to IDs and 86 were network eligible while 82 were function/network eligible. Two 
significant canonical pathways could be identified as relevant to the list of genes identified as being 
similar in regulation to WISP2 by Genespring (Figure 5-20a).  These were ‘Phospholipid 
degradation’ (p =0.0021) and ‘Glycerophospholipid metabolism’ (p=0.0077).  Three genes 
contributed to both these pathways (PLA1A, PPAP2A, RNF111) 167 genes clustered with TFPI2 in 
terms of cross-condition expression and were analysed by IPA.  Of these 167 genes, 117 genes 
could be mapped to IDs and 87 were network eligible while 78 were function/network eligible. Four 
significant canonical pathways (Figure 5-20b) could be identified as relevant to the list of genes 
identified as being similar in regulation to TFPI2 by Genespring.  These were ‘Phospholipid 
degradation’ (p=0.0019) (contributed by IGF1, PPP2CB, RNF111, WISP2), ‘Glycerophospholipid 
metabolism’ (p=0.0069) (contributed by PLA1A, PPAP2A, RNF111, WISP2), ‘Synaptic long term 
depression’ (p=0.0143) (contributed by IGF1, PPP2CB, RNF111, WISP2) and ‘Wnt/β-catenin 
signalling’ (p=0.0229) (contributed by FRZB, NLK, PPP2CB, SFRP4). 
Genes that cluster with TFPI2 and WISP2 are known to be involved in phospholipid degradation 
and gylcerophospholipid metabolism.  This is perhaps interesting as decreased 
glycerophospholipid synthesis can lead to suppression of axonal outgrowth (Ikemoto et al. 1997).  
TFPI2 also clusters with genes associated with Wnt/β catenin signalling.  This is interesting as   
activation of this signalling pathway has been shown to promote regeneration in the adult retina 
after injury (Osakada et al. 2007) and is thought to have diverse roles in nervous system 
development, microtubule dynamics, modulation of synaptic plasticity and regulation of gene 
expression (Speese and Budnik 2007).  Among the genes that are regulated within this pathway is: 
soluble frizzle-related protein 4 (SFRP4), one of the secreted regulators of wnt that can act to 
antagonise or enhance its signalling (Nakanishi et al. 2006; Bovolenta et al. 2008); Neuroleukin 
(NLK), a neurotrophic factor that promotes the survival of spinal and sensory neurons in culture 
(Gurney et al. 1986);  protein phosphatase 2CB  (PPP2CB), which can act as an inhibitor of cellular 
stress signalling (Lammers and Lavi 2007) and,  frizzled-related protein (FRZB), a receptor for Wnt.  
WISP2 and TFPI2 may therefore support neuronal regeneration by participation in Wnt/β catenin 
signalling. 
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Figure 5-20: IPA analysis of canonical pathways significantly represented by genes with 
similar regulatory pattern to a) WISP2 and b) TFPI2.  Fisher’s exact test was used to calculate a 
p value (shown as blue bars) determining the probability that each biological function assigned to 
the network is due to chance alone.  The ratio (shown as yellow squares) represents the number of 
differentially expressed genes in a given pathway relative to the number of genes that make up that 
canonical pathway. 
a) 
b)  167 
5.7.5 Summary 
We wished to determine the transcriptional profiles associated with axonal outgrowth in vivo.  We 
were particularly interested in finding genes whose expression is generally associated with the 
process of regeneration rather than time point or specific injuries.  Thus in order to avoid focussing 
on transcripts unique to one injury or one time point and another, we used a comparative strategy 
to look for changes that were common to two different regenerating conditions and were therefore 
more likely to be involved in the general process of regeneration.  We examined global gene 
expression changes in DRG at 6 weeks after spinal nerve crush and 2 weeks after dorsal root 
crush (regenerating conditions) and compared this to a 2 week dorsal column transection and a 6 
week dorsal root crush (non-regenerating conditions). 
The gene expression changes in the DRG after the injuries were associated with both regeneration 
and neuropathic pain.  A number of observations were made that were common to all the injuries 
such as the activation of complement.  Other changes were specific to injury type.  Dorsal column 
transection elicited a transcriptional programme that was quite different from the other injuries but 
also upregulated known RAGs suggesting that these neurons are primed for growth and that 
appropriate manipulation of the lesion zone could be beneficial.  This injury also elicited a 
downregulation of neurotransmitter receptors that leads to neuronal hyperexcitability and 
neuropathic pain after peripheral nerve injury.   
The most striking commonality for the regenerating conditions was the upregulation of 
procollagens, presumably by the non-neuronal cells in the DRG that was not time point dependent.  
This suggests that factors secreted by non-neuronal cells in the vicinity of a neuron may play an 
important role in modulating its outgrowth.   
Filtering of genes regulated in each condition identified a number of genes associated with 
regeneration.  Two of these genes, WISP2 and TFPI2 are co-regulated with genes involved in 
gycerophospholipid metabolism while TFPI2 also clusters with genes involved in Wnt/β catenin 
signalling.  These genes were chosen for validation with qRT-PCR (Chapter 6) as putative 
regeneration associated genes.   168 
 
6  qRT-PCR validation of microarray data 
6.1 Introduction and Aims 
Validation is a crucial component of any microarray study.  Although commercial microarrays are 
now generally regarded as reliable and consistent (Barnes et al. 2005; Dallas et al. 2005; Larkin et 
al. 2005; Petersen et al. 2005; Zhu et al. 2005; de Reynies et al. 2006; Wang et al. 2006), they can 
still generate a large number of false positive and negative results by virtue of the large number of 
gene expression results they yield.  It is therefore still considered good practice that microarray 
findings are confirmed by an independent gene expression method.    
The large quantity of RNA required for Northern blots normally precludes their use in validation and 
as such qRT-PCR (section 2.10) has become the ‘gold standard’ for the validation of microarrays.  
A selection of genes that were differentially expressed within the microarray experiment were 
therefore validated using qRT-PCR assays using SYBR green chemistry (Section 2.10).  qRT-PCR 
also presented the opportunity to include sham controls for each of the injuries.  This allowed us to 
confirm that gene changes seen in the microarray were due to the injury itself and not some non-
specfic effect of anaesthesia and/or tissue damage.  In addition, qRT-PCR was performed on RNA 
extracted from the DRG of individual animals allowing the degree of biological variation in the 
expression of a given gene to be assessed.  This was made possible by pooling samples after 
RNA extraction for the microarray and reserving RNA from separate animal for qRT-PCR.  A 6 
week time point after dorsal column transection (6DC) that was not investigated using microarrays 
was also assessed by qRT-PCR to allow temporal changes in gene expression after dorsal column 
injury to be examined.  For the naïve control and all injury conditions (excluding the 6DC condition), 
the same RNA that was used for the microarray was also used in the qRT-PCR.  Additional 
animals were required for the generation of sham controls and the 6DC injury condition. 
Quantitect primer assays for each gene of interest were purchased from Qiagen (Table 2-3).  Good 
quality, total RNA samples were extracted from rat DRG (n=8 rats per condition) (2.8.4.2 , DNase 
treated and reverse transcribed to cDNA using quantitect RT kit (section 2.8.9.2).  qRT-PCR 
assays were performed in triplicate on each sample using the Opticon 2 real-time thermocycler 
(section 2.10). Following qRT-PCR, outliers were removed (section 2.10.4.3), and REST-MCS was 
used to analyse the mean Ct values.  Gene expression changes were normalised to a factor 
calculated from three housekeeping genes whose stability in these injury models was confirmed. 
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6.1.1 Genes chosen for validation 
It is not feasible to validate all the results of a microarray, therefore a small number of genes were 
selected for further investigation. A number of criteria can be used to select these genes.  Many 
studies have used a 2-fold difference as the cut-off for significance (Miron et al. 2006). However, 
this choice can lead to a loss of a large number of smaller expression changes and fails to 
eliminate false-positive results (Costigan et al. 2002).  A cut-off between 1.2 and 1.5-fold combined 
with statistical significance (p<0.05 or, in our case <5% FDR) has been suggested as an improved 
criteria for gene selection (Li and Wong 2001).  Genes selected for validation were therefore not 
necessarily changed over 2-fold, but changed within the 5% FDR level in at least one of the 
conditions. 
We were particularly interested in genes that were regulated specifically in the regenerating 
conditions as these represent putative regeneration-associated genes (section 5.7.4).  Two of 
these genes, WISP2 and TFPI2, were regulated at the 5% FDR level in both the regenerating 
conditions but not regulated within 50% FDR in the non-regenerating conditions and hence were 
chosen for validation.  IGF1 also showed this pattern of regulation but just missed the 5% FDR in 
the SN injury. IGF1 did however appear in the top IPA network identified for 2DR along with TFPI2 
and WISP2 suggesting that these genes may somehow interact.  Furthermore, as will be discussed 
in more detail later, IGF1 has been suggested to have a role in the promotion of axonal outgrowth 
and regeneration (Thanos et al. 1999; Rabinovsky 2004; Salie and Steeves 2005; Koriyama et al. 
2007) and was therefore also picked for validation.  
In a recent comparative study of the neuronal response to dorsal root and sciatic nerve crush 
(Stam et al. 2007) described Ankrd1, a new putative regeneration associated gene, which, when 
overexpressed in PC12 cells induced neurite outgrowth.  This gene did not show expression in our 
microarray that was consistent with it being associated with regeneration and was therefore further 
investigated with qRT-PCR as a test of this hypothesis. 
Dorsal column transection elicited changes in genes that had also been seen after sciatic nerve 
transection.  This was interesting as it suggested that injuries within the spinal cord could induce 
the same intrinsic transcriptional programmes that are elicited by peripheral nerve injury. Among 
the genes that showed regulation only in dorsal column and sciatic nerve transection were 
SEMA6A (described in section 3.3.3.5) and protein tyrosine phosphatase 5 (PTPN5 or STEP).  
PTPN5 overexpression in PC12 cells leads to increased cAMP-induced neurite outgrowth 
suggesting that this gene may have a role in the conditioning lesion effect (see also section 
1.4.2.1) (Okamura et al. 1999).  
Also chosen for validation were two genes that have been well studied in models of nervous 
system injury.  ATF3 (described in section 3.3.3.2) was only significantly induced (within 5% FDR) 
in the 2 week injury conditions suggesting that this gene is part of the general early response to 
injury and not a regeneration-associated gene.  This hypothesis was therefore tested by qRT-PCR.   170 
BDNF1 was significantly induced in all the conditions except 6 weeks after spinal nerve crush.  It 
has been shown that peripherally derived BDNF1 (resulting from a conditioning lesion) can 
promote regeneration of ascending sensory neurons after spinal cord injury (Song et al. 2008).  It is 
therefore slightly surprising that BDNF is induced in dorsal column transection where regeneration 
is abortive and in central axotomy at a time-point when regeneration is not occurring, but not in 
spinal nerve crush at a time-point when axons are still regenerating.  qRT-PCR was used to check 
this unexpected result. 
 
6.2 Results 
6.2.1 Precision of real-time RT-PCT 
The technical precision or reproducibility of qRT-PCR measurements was assessed by calculation 
of inter- and intra-assay variations and operator error according to methods described in Section 
2.10.3.  Linearised threshold values (Ct) were obtained and used to calculate experimental 
variations.   qRT-PCR produces logarithmic data and as such linearised values give a better 
indication of the true experimental variation. 
Table 6-1 : Intra-assay and inter-assay precision. 
RUN 1  RUN 2  RUN 3  SAMPLE 
REPLICATE  Ct  Linearised 
Ct (x10
-8) 
Ct  Linearised 
Ct (x10
-8) 
Ct  Linearised 
Ct (x10
-8) 
1  26.56  1.01  27.27  0.62  26.72  0.90 
2  26.13  1.36  26.90  0.80  26.52  1.04 
3  26.33  1.19  27.30  0.61  26.06  1.42 
4  25.97  1.52  26.67  0.94  26.32  1.19 
5  26.17  1.32  26.14  1.35  26.51  1.04 
6  26.38  1.15  27.01  0.74  26.74  0.89 
7  26.19  1.31  26.58  1.00  26.48  1.07 
8  26.55  1.02  27.04  0.73  26.35  1.17 
9  25.93  1.56  27.00  0.75  26.90  0.80 
10  27.03  0.73  26.73  0.90  26.47  1.08 
11  26.66  0.94  27.42  0.56  27.04  0.72 
12  26.12  1.37  27.34  0.59  26.49  1.06 
13  26.74  0.89  27.15  0.67  26.50  1.05 
14  26.55  1.02  27.18  0.58  26.45  1.09 
15  25.97  1.52  26.94  0.78  26.90  0.80 
Mean Ct 
SD 
CVexp 
26.352 
0.312 
1.18% 
1.19 
0.26 
21.33% 
26.978 
0.328 
1.22% 
0.79 
0.21 
26.38% 
26.563 
0.255 
0.92% 
1.02 
0.18 
17.51% 
                                                                                                           
Intra-assay variations were 21.33% (Run 1, SD=0.26) and 26.38% (Run 2, SD=0.21).   Inter-assay 
(Run 1- Run 2) and operator-associated experimental variation (Average of Run1 and Run 2) –  171 
Run 3) were 5.05 % and 6.34 % respectively. 0.03 % (Run 1- Run 2).  These data suggest that the 
machine and reagent- associated variation was less than the variation generated through operator 
associated pipetting errors and indicates good reproducibility between runs. 
6.2.2 Validation of qRT-PCR reference genes  
The CVexp of several potential reference genes was calculated from the log2normalised data from 
each of the 15 microarray chips in the main microarray experiment (Table 6-2). Of these genes 
UBC was the most variable in the pilot experiment validation.  The next four least variable genes 
(CANX, ATP5B, GAPDH and B2M) were therefore chosen to be assessed independently by qRT-
PCR. 
Table 6-2: CVexp for selected housekeeping genes calculated across all chips 
GENE ID  AFFY. ID  CVEXP 
UBC  1398767_at  0.541 
CANX  1371686_at  0.579 
ATP5B  1380070_at  0.708 
GAPDH  1367557_s_a  0.936 
B2M  1371440_at  1.114 
YWAZ  1395893_at  2.031 
TOP1  1369421_at  2.662 
  
The stability and hence their suitability as reference genes for qRT-PCR normalisation was 
assessed for GAPDH, ATP5B, CANX and B2M using geNorm and Normfinder (section 2.10.4.1).   
B2M, CANX and ATP5B were found to be the most stable of the 4 genes analysed (Figure 6-1 and 
Figure 6-2) and these were therefore used to calculate a composite normalisation factor in later 
analyses in REST-MCS.   172 
 
 
Figure 6-1: HKG evaluation by GeNorm.  Of the 4 genes evaluated only 3 were suitable for use 
as reference genes (M value< 1.5). 
 
Figure 6-2: HKG evaluation by Normfinder.  Genes were ranked in order of stability with B2M as 
the most stable. 
  ←decreasing stability        increasing stability→ 
  ←decreasing stability        increasing stability→  173 
6.2.3 LinReg analysis of well-well reaction efficiencies 
LinReg was described in (Sections 2.10.4.4 and 3.3.2).  The average reaction efficiency for each 
gene assay with standard deviation is recorded in Table 6-3 below.  These gene specific 
efficiencies were integrated into the relative expression analysis in REST MCS.  
Table 6-3: Gene reaction efficiencies as calculated by LinRegPCR. 
GENE SYMBOL  MEAN REACTION EFFICIENCY  STANDARD DEVIATION  
B2M  1.782  0.181 
CANX  1.762  0.173 
GAPDH  1.713  0.135 
ATP5B  1.753  0.163 
ANKRD1  1.717  0.184 
ATF3  1.685  0.203 
SLIT3  1.720  0.185 
BDNF1  1.735  0.142 
IGF1  1.765  0.158 
WISP2  1.746  0.206 
PTPN5  1.797  0.225 
SEMA6A  1.728  0.184 
TFPI2  1.766  0.186 
   
6.2.4  qRT-PCR validation of selected genes 
qRT-PCR was used to quantify expression changes in selected genes from the microarray 
experiment.   Expression in the DRG after injury was calculated relative to a naïve control and for 
all groups apart from 6DC, a sham condition appropriate to the injury (section 2.2.7).  Each gene 
validated in this way is dealt with separately in the ensuing sections.  Microarray fold-change data 
was converted to Log2 expression ratios and for each gene, displayed on a single graph with the 
Log2 expression ratios generated by REST-MCS for the qRT-PCR data (Figure 6-3 to Figure 
6-10).  Mean Ct values and CVexp values (as calculated by REST-MCS) are presented for each 
experimental group and each gene in appendix C. 
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6.2.4.1  Wnt-1 inducible signalling pathway protein-2 (WISP2) expression 
In the microarray WISP2 (1369484_at) was significantly upregulated in both the 6SN (1.6-fold 
change, 4.01%FDR) and 2DR (1.58-fold change, 1.23% FDR) data sets.  This change was 
validated by qRT-PCR in the 2DR vs. naïve comparison, which showed a significant upregulation 
in WISP2 expression (p=0.042, pair-wise fixed reallocation test in REST-MCS) (Figure 6-3).  
Upregulation of the gene was also seen in the 2DR vs. sham comparison although this was 
insignificant (p=0.127).  In the SN vs. naïve and SN vs. sham comparisons qRT-PCR detected a 
small but insignificant upregulation and downregulation, respectively (p>0.05).   
 
 
 
Figure 6-3: qRT-PCR validation of changes in WISP2 expression -comparison of microarray 
and qRT-PCR data.  Red columns show microarray data (*FDR<5%) and blue columns show 
qRT-PCR data (mean ± S.E.M, n=6-8/group) (*p<0.05 for plotted comparison).  Blank columns 
indicate no change (i.e. ratio=1). 
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6.2.4.2  Tissue factor pathway inhibitor 2 (TFPI2) expression 
The microarray detected changes in TFPI2  (1377340_at) within 50% FDR only for the 6SN (1.49 
fold change, 1.83% FDR) and 2DR (1.66 fold change, 0.53% FDR) data sets.  This change was 
validated by qRT-PCR in the 2DR vs. naïve comparison which showed a highly significant 
upregulation in TFPI2 (p=0.01).  This upregulation was also observed in the 2DR vs. sham, 6DR 
vs. naïve and sham, 6SN vs. naive and sham, and 2DC vs. sham comparisons although 
insignificant (p>0.05).    The upregulation in the 6DR vs. naïve comparison was however significant 
before normalisation (p=0.028). 
 
 
 
Figure 6-4: qRT-PCR validation of changes in TFPI2 expression -comparison of microarray 
and qRT-PCR data. Red columns show microarray data (*FDR<5%) and blue columns show qRT-
PCR data (mean ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before normalisation for plotted 
comparison).   
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6.2.4.3  Insulin-like growth factor 1 (IGF1) expression 
IGF1 (probe set 1370333_a_at) was upregulated in both the regenerating conditions (1.31-fold, 
10.8% FDR in SN and 1.53-fold 1.65% FDR in 2DR).  qRT_PCR detected upregulations in 2DR vs. 
both naïve and sham although these were not significant (p<0.05).  Small insignificant 
downregulations of the gene were detected in the SN vs. naïve and sham conditions as well as in 
2DC vs. sham.  qRT-PCR also detected small and insignificant upregulations of IGF1 in 6DR vs. 
sham and naïve, 2DC vs. naïve and 6DC vs. naïve conditions.  In the 6DR vs. sham condition this 
change was significant before normalisation to the reference genes (p=0.007). 
 
 
 
Figure 6-5: qRT-PCR validation of changes in IGF1 expression -comparison of microarray 
and qRT-PCR data.  Red columns show microarray data (*FDR<5%) and blue columns show 
qRT-PCR data (mean ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before normalisation for plotted 
comparison). 
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6.2.4.4  Activating transcription factor 3 (ATF3) expression 
In our microarray, ATF3 (probe set 1369268_at) was upregulated in all the conditions but within the 
5% FDR cut-off only in the 2DR vs. naïve (2.45-fold change, <0.01% FDR) and 2DC vs. naïve 
(11.13-fold change, <0.01% FDR) comparisons.  qRT-PCR validated the change in the 2DR 
microarray, detecting a significant upregulation in ATF3 in the 2DR vs. sham comparison 
(p=0.015).  This upregulation was also seen in the 2DR vs. naïve condition although this was not 
significant (p=0.367).  Small, insignificant upregulations were detected in the 6DR vs. naïve and 
6DR vs. sham conditions (p=0.984 and p=0.123, respectively) and the 6DR vs. sham comparison 
was significant before normalisation to reference genes (p=0.001).   Changes seen in the SN 
microarray were also validated, a significant upregulation in the SN vs. naïve comparison was 
detected by qRT-PCR analysis (p=0.037) although the upregulation seen in SN vs. sham just 
misses significance (p=0.059).  qRT-PCR detected a small upregulation in the 2DC vs. naïve and 
2DC vs. sham comparisons although these were not significant (p=0.968 and p=0.241, 
respectively). A downregulation in ATF3 was detected for 6DC vs. naïve but this was insignificant 
(p=0.639). 
 
Figure 6-6: qRT-PCR validation of changes in ATF3 expression -comparison of microarray 
and qRT-PCR data. Red columns show microarray data (*FDR<5%) and blue columns show qRT-
PCR data (mean ± S.E.M, n=5-8/group) (*p<0.05, *p<0.05 before normalisation for plotted 
comparison).    
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6.2.4.5  Ankyrin repeat domain 1 (ANKRD1) expression 
The microarray detected a change in ANKRD1 (probe set 1367664_at) expression in only the 2DC 
condition (1.77-fold change, 1.77% FDR).  This change was also seen in qRT-PCR in the 2DC vs. 
naïve and 6DC vs. naive comparisons (p=0.004 and p=0.001, respectively) although these were 
not significant after normalisation to the reference genes (p=0.252 and p=0.368, respectively). In 
addition, upregulation in ANKRD1 expression was not detected when 2DC was compared to its 
sham control (p=0.693).  qRT-PCR did however detect significant upregulation of ANKRD1 in the 
2DR vs. naïve, SN vs. naïve and SN vs. sham comparisons (p=0.001, p=0.002 and p=0.004, 
respectively).  A small upregulation was also seen in the 6DR vs. naïve comparison (p=0.033) but 
this was insignificant after normalisation (p=0.871).  
 
 
 
Figure 6-7: qRT-PCR validation of changes in ANKRD1 expression -comparison of 
microarray and qRT-PCR data. Red columns show microarray data (*FDR<5%) and blue 
columns show qRT-PCR data (mean ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before normalisation 
for plotted comparison). 
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6.2.4.6  Semaphorin 6A (SEMA6A) expression 
In the microarray SEMA6A (probe set 1376601_at) was significantly upregulated in the 2DC data 
(3.85-fold change, <0.01% FDR).   A small but insignificant upregulation was also detected in the 
2DR data set (1.32-fold change, 12.19% FDR) that was reflected in the 2DR vs. naïve and 2DR vs. 
sham comparisons  (p=0.436 and 0.308, respectively).  qRT-PCR did not however validate the 
microarray result for the 2DC data set and instead detected small but insignificant downregulations 
of the gene in both the 2DC vs. naïve and 2DC vs. sham comparisons (p=0.939 and p=0.076, 
respectively).  A small and insignificant upregulation was however detected for the 6DC vs. naïve 
comparison (p=0.692).  Where the microarray did not detect any difference in the gene for the SN 
data set, a significant upregulation was detected by qRT-PCR for the SN vs. sham comparison 
(p=0.038) but the upregulation in the 2DR vs. naïve comparison misses significance (p=0.099).  In 
addition, qRT-PCR detected upregulations in the SN vs. naive and 6DR vs. sham that were 
significant before normalisation to the reference genes (p<0.05). 
 
 
 
Figure 6-8: qRT-PCR validation of changes in SEMA6A expression -comparison of 
microarray and qRT-PCR data. Red columns show microarray data (*FDR<5%) and blue 
columns show qRT-PCR data (log2expression ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before 
normalisation for plotted comparison).  180 
6.2.4.7  Protein tyrosine phosphatase, non-receptor type 5 (PTPN5) expression 
In the microarray PTPN5 (probe set 1368421_at) was regulated within the 50% FDR level in only 
the 2DC data set (2.96-fold change, 0.05% FDR).  This change was not validated by qRT-PCR and 
there was small, insignificant downregulation of this gene in the 2DC vs. sham and 6DC vs. naïve 
comparisons (p>0.05).  qRT-PCR did however detect upregulations in this gene in the 2DR and SN 
comparisons.  This change was significant in the SN vs. sham comparison (p=0.03) and highly 
significant before normalisation to reference genes in the SN vs. naïve comparison (p=0.004) 
although just misses significance after nomalisation (p=0.054).  The upregulation of PTPN5 in the 
2DR vs. naïve comparison was significant (p=0.022) but the upregulation in the 2DR vs. sham 
comparison misses significance (p=0.054). 
 
 
 
Figure 6-9: qRT-PCR validation of changes in PTPN5 expression -comparison of microarray 
and qRT-PCR data. Red columns show microarray data (*FDR<5%) and blue columns show qRT-
PCR data (log2expression ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before normalisation for 
plotted comparison). 
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6.2.4.8  Brain-derived neurotrophic factor (BDNF) expression 
In the microarray BDNF (probe set 1368677_at) was significantly upregulated in the 2DR (2.86-fold 
change, <0.01% FDR), 6DR (1.48-fold change, 1.69% FDR) and 2DC (1.57-fold change, 4.7% 
FDR) data sets.  By qRT-PCR, upregulation of this gene was seen in all comparisons except the 
2DC vs. naïve and sham and 6DC vs. naïve comparisons that showed small insignificant 
decreases in BDNF.   None of the changes were significant however (p>0.05) although the 
upregulation in the 6DR vs. sham comparison was significant before normalisation (p=0.013). 
 
 
 
Figure 6-10: qRT-PCR validation of changes in BDNF expression -comparison of microarray 
and qRT-PCR data.  Red columns show microarray data (*FDR<5%) and blue columns show 
qRT-PCR data (log2expression ± S.E.M, n=6-8/group) (*p<0.05, *p<0.05 before normalisation for 
plotted comparison).  182 
6.2.5 Section discussion 
6.2.5.1  Interpretation of qRT-PCR data 
On the whole, the qRT-PCR was consistent with the microarray experiment in that when changes 
were significant, they were in the same direction and of similar magnitude.  Changes in the dorsal 
column transection microarray were generally not validated however. In addition, qRT-PCR 
detected regulation in some genes that had not been detected by microarray, consistent with qRT-
PCR being a more sensitive technique.  
WISP2 and TFPI2 were selected as attractive regeneration associated genes, as they were two of 
only three genes that were upregulated in the regenerating conditions (<5% FDR) but not regulated 
(>50% FDR) in the non-regenerating conditions.  In addition, IPA provided evidence that they are 
regulated in two different functional gene networks that are active in the regenerating conditions 
that also contain IGF1 (Figure 5-8 and Figure 5-11). qRT-PCR however only validated the 
changes in these genes in the 2DR condition and hence brings into question whether these genes 
are truly regeneration associated.   
Three genes that did not show a regeneration-associated expression in the microarrays (SEMA6A, 
PTPN5 and ANKRD1) appeared to show this pattern of expression in the qRT-PCR analysis.  
Overexpression of ANKRD1 has been shown to stimulate neurite outgrowth in PC12 cells and has 
been suggested as a candidate transcriptional modulator of regeneration (Stam et al. 2007).  The 
results of the qRT-PCR support this.  PTPN5 also stimulates neurite growth in vitro and hence the 
results of the qRT-PCR are consistent with this.  For SEMA6A, the link to promotion of 
regeneration appears more tenuous as SEMA6A is known to act as a repulsive signal during 
development and can cause growth cone collapse (see also section 1.2.2.2).  More recent 
evidence however suggests that this gene may have a role in microtubule dynamics (see also 
section ) (Prislei et al. 2008).  Additionally, accumulating evidence suggests that class VI 
semaphorins can act as receptors as well as ligands and thus function in retrograde signalling.  
The SEMA6A cytoplasmic domain can bind ENA/VASP-like protein (EVL) (Klostermann et al. 
2000) that can promote actin polymerisation when receptor-bound (Lambrechts et al. 2000). 
ENA/VASP proteins (see also section 1.2.2.1) are concentrated at filopodial tips and are involved 
in translating extrinsic guidance cues into changes in cytoskeleton and filopodia (Drees and Gertler 
2008).  The upregulation in SEMA6A in the DRG could therefore result in changes in fillopodial 
dynamics through retrograde signalling at the growth cone.   
The qRT-PCR data also lends support to ATF3 being a regeneration-associated gene.  This is in 
contrast to the microarray results which suggested a timepoint-dependent expression of this gene, 
consistent with a general immediate-early response to stress as has been reported previously (Hai 
et al. 1999).  Also consistent with the idea that ATF3 is a general response to any injury, and not 
only in injuries where regeneration is successful, is the observation that this gene was upregulated 
in DRG neurons after spinal cord transection (Huang et al. 2006).   Other studies have however  183 
suggested that this gene is induced in DRG after peripheral and not after central axonal injury and 
is downregulated after target innervation (Tsujino et al. 2000; Bloechlinger et al. 2004).  This is 
consistent with a regeneration-associated expression and also with the qRT-PCR results of this 
study. 
The expression of BDNF was confirmed for the 2 and 6 weeks dorsal root injuries but the relatively 
large upregulation seen in the microarray for dorsal column transection was not detected.  The 
pattern of regulation for this gene as assessed by qRT-PCR is highly suggestive of it having a time-
dependent response to injury out-with the CNS whilst injury within the CNS does not appear to 
induce its expression. 
6.2.5.2  Methodological considerations 
In the microarray experiment, samples were pooled to smooth biological variability.  In the qRT-
PCR cDNA was generated from individual animals to allow biological variability to be assessed.  
Standard errors were large indicating a high degree of inter-animal variability in gene expression.  
This may reflect true differences in gene expression levels between animals and could indicate 
heterogeneity between animals in the severity of the injury although care was taken to be 
consistent in the length of time that the nerve was crushed and in the distance of the crush from 
the DRG.  In the case of the dorsal column transection injury, care was taken that the placement of 
the wire knife was consistent.  The samples for each group were however usually split between 
three plates as all samples could not fit on one and an even mix of samples from each condition 
were placed on each plate to potentially allow direct comparisons between all groups.  This may 
have increased within-group variability and reduced the power of the experiment.  An improved 
design would have all samples for an experimental group, its sham control and the naïve control on 
a single plate as comparisons between experimental groups were not necessary. 
The power of the experiment could have been further improved by increasing the number of 
samples in each group.  In the pilot experiment, gene changes as low as 2.45 fold were validated 
using a group size of 5-6.  Some of the genes that were chosen for validation of the main 
experiment did however show only a very modest fold change (often less than 2 fold) in the 
microarray.  In hindsight, a power calculation based on the pilot experiment could have been used 
to predict the sample size required to detect <2-fold changes.  
Four HKGs were assessed for general stability over all the injury models, sham control and naïve 
groups.  Although the most stable in the sciatic nerve transection/ naïve and sciatic 
transection/sham groups, GAPDH was found to be the least stable across all our new injury 
models.  This highlights the importance of validating HKGs for the specific model in question.  
Indeed, the experiment could have been further improved by performing a separate GeNorm 
analysis for each of the injury models and its control, providing an injury-specific set of stably 
expressed housekeeping genes for each model.  For a number of the target genes, normalisation 
against the reference genes resulted in a change in the P-value of the results (orange asterix on 
figures).  This demonstrates the necessity of normalisation of qRT-PCR data to a stably expressed  184 
reference gene or genes in avoiding erroneous conclusions due to differences in starting template 
amount. 
6.3 Preliminary results in human DRGs  
We wished to determine if genes that are expressed within the DRG of rats with dorsal root crush 
are also present at a similar level in human avulsed DRGs to give an indication as to whether the 
candidate genes revealed by our microarray experiment based on animal injury models are likely to 
be relevant to dorsal root avulsion (see also sections 1.3.2 and 1.4.1.3) as seen in human patients. 
DRGs from three patients who had suffered a dorsal root avulsion injury were obtained at the time 
of corrective surgery.  The details of the patient material are noted in Table 6-4.   All patients were 
young males and this represents the demographic that most commonly presents with dorsal root 
avulsion injury.  Since control human material was unavailable (the acquisition of age-matched 
post mortem DRGs is difficult and samples of inappropriate age have been used in the past 
(Rabert et al. 2004)), the expression of two genes in dorsal root avulsed human DRGs and dorsal 
root crush rat DRGs was compared by qRT-PCR.  From the injury models available to us, dorsal 
root crush is the injury that most closely resembles dorsal root avulsion.   The 2 genes that were 
chosen were upregulated at 5% FDR specifically in the 2DR (chondroitin sulphate proteoglycan 2 
(CSPG2), 1.99 fold-change, 0.06 % FDR)) and 6DR (high density lipid binding protein (HDLBP), 
1.38 fold-change, 4.26 % FDR)) models.  qRT-PCR data was normalised using the most stable 
reference gene from before (B2M).  
 
Table 6-4: Details of human DRG material. 
PATIENT 
ID 
AGE  SEX  CAUSE OF 
INJURY 
TIME FROM INJURY 
TO OPERATION 
NOTES 
050093  27  Male  Car road traffic 
accident 
6 months  C8 root found in 
posterior triangle of 
neck, completely 
avulsed from spinal 
cord. 
060060  24  Male  Dive from bridge  4 months  C6, C7, C8 and T1 
roots found in posterior 
triangle of the neck, 
completely avulsed from 
the spinal cord. 
050082  18  Male  Motorbike road 
traffic accident 
3 months  C8 root found in 
posterior triangle of the 
neck, completely 
avulsed from the spinal 
cord. 
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6.3.1 Results and discussion 
All samples for one target gene and the housekeeping were run in triplicate on a single plate.  As 
before, triplicate Ct values were averaged and REST-MCS was used to quantitate human DRG 
gene expression relative to the 2DR and 6DR animal tissue.  Reaction efficiencies for the human 
and rat primer assays were calculated using LinReg as before and were used to determine if there 
was any difference in efficiency between the rat and human primer assays (Table 6-5).  The values 
could not however be used in REST-MCS as only one reaction efficiency per primer assay can be 
entered.  The reaction efficiency for all three genes was therefore set to the default of 2.  
 
Table 6-5: Reaction efficiencies of rat and human primer assays. 
GENE  B2M  CSPG2  HDLBP 
Species (n=3/group)  Human   Rat  Human  Rat  Human  Rat 
Average efficiency (to 3 s.f.)  1.784  1.710  1.716  1.718  1.732  1.761 
Standard deviation (to 3 s.f.)  0.143  0.148  0.128  0.124  0.149  0.163 
 
The expression of CSPG2 and HDLBP was expressed relative to the reference gene B2M for both 
the rat and human DRGs (Figure 6-11).  The difference in the expression of the two genes in 
human tissue relative to 2DR and 6DR, normalised by B2M, was also quantified (Figure 6-12).  The 
relative expression of both CSPG2 and HDLBP was lower in the human patient material than in the 
2DR and 6DR DRGs.  This difference was ~4.4-fold and significant for CSPG2 (p=0.001 and 
p=0.048 for comparison to 2DR and 6DR, respectively).   
The difference in CSPG2 expression in the human and rat material is not attributed to differences 
in primer efficiencies between the human and rat assays as these were not significantly different 
(p>0.05, 1-way ANOVA).  Indeed, it is unsurprising to find that the human DRGs had lower 
expression of these injury-induced genes given that they were harvested at a much later time point 
after injury than the rat DRGs (3-6 months vs. 2-6 weeks).  These very preliminary data suggest 
that there is a turning down of injury-induced genes at a late time point after injury and a return to 
steady state gene expression, possibly due to failed regenerative attempts.   Alternatively, these 
differences could merely represent variation in the constitutive expression of these genes between 
lumbar and cervical ganglia.  Inclusion of a rat control would have allowed confirmation that these 
two genes are truly injury induced. 
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Figure 6-11:  Expression of HDLBP and CSPG2 in human avulsed DRG compared to rat DRG 
with dorsal root crush expressed relative to B2M expression such that a lower expression 
ratio equates to a lower expression. * significantly different from 2DR and from 6DR (p<0.05).  
Mean ± S.E.M, n=3/group. 
 
Figure 6-12: Log2 Expression of HDLBP and CSPG2 in human avulsed DRGs relative to rat 
DRGs (mean ± S.E.M, *p<0.05, n=3/group).  Data are normalised to the housekeeping gene 
B2M. 
HDLBP 
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6.4 Chapter summary 
The attempted qRT-PCR validation of the microarray data met with mixed success.  Improvements 
could have been made to the design of the experiment to minimise intergroup variability and hence 
increase the power for detection of small fold changes. The qRT-PCR results for the dorsal column 
transection animals showed little similarity to the microarray resullts bringing into question the 
validity of the changes in gene expression detected by these chips. The mixed success of the qRT-
PCR validation highlights the importance of validation on a gene-to-gene basis and the dangers of 
applying a validated status to a whole microarray data set on the basis of a only a few validated 
genes. 
The very preliminary data from the human tissue suggests that two genes that are expressed in rat 
DRG after injury are also expressed in human avulsed DRGs, albeit at a slightly lower level.  As 
there were was no human control tissue available, the level of gene expression was compared to a 
rat injury model with relevance to dorsal root avulsion and normalised for differences in starting 
template to a housekeeping gene.  This approach may be useful for future investigations where 
human control material is unavailable.   188 
7  Final Discussion and future directions 
A number of extrinsic and intrinsic factors are thought to contribute to the failure of the CNS to 
regenerate after injury (section1.4). This project aimed to reveal transcriptional programmes 
intrinsic to successful neuronal regeneration by examining neuronal gene expression associated 
with regenerating and regeneration-blocked/arrested DRG neurons. This project also, to the best of 
our knowledge, represents the first global survey of gene expression changes in the DRG following 
dorsal column injury, or indeed after any other spinal cord injury. 
One of the biggest challenges presented by this, and indeed any other, microarray study is data 
analysis.  Microarrays generate massive volumes of data and as such the application of 
appropriate analyses methods is of paramount importance.  Discrepancies between results of 
different microarrays may be partially attributed to the diverse range of software available to store 
and analyse microarray data (Holloway et al. 2002; Slonim 2002). Tistone (2003) highlighted the 
dangers of drawing faulty conclusions from microarray data due to inadequate or inappropriate 
statistical analysis methods. This project utilised the data analysis facilities at the Sir Henry 
Wellcome Functional Genomics Facility (SHWGF) and Bioinformatics Research Centre (BRC) at 
the University of Glasgow.  This facility has developed a robust microarray analysis pipeline that 
consists of three major steps: data normalisation, identification of differentially expressed genes 
and automated functional interpretation.  Data normalisation is an important step that accounts for 
factors such as differing intensities of dye incorporation; minor irregularities in probe distribution 
during hybridisation; topographical slide variation or scanner introduced bias (Yang et al. 2002).  At 
the SHWFGF, data normalisation is performed using the Robust Multichip Average (RMA) method 
(Irizarry et al. 2003).  RMA performs a probe-specific background correction that compensates for 
non-specific binding, a probe-level multi-chip quantile normalisation to unify perfect match 
distributions across all chips, and a probe-set summary of the log-normalised probe-level data by 
median polishing.   
Following data normalisation, the SHWFGF utilises the Rank Products (RP) method (Breitling et al. 
2004), to identify differentially expressed genes. This method has been shown to perform more 
reliably and consistently than Tusher et al.’s (2001) Significance Analysis of Microarrays (SAM) 
and is particularly useful for small and noisy data sets (Breitling et al. 2004b). The method has now 
been widely adopted and a number of studies published recently have utilised this analysis to 
reveal differentially regulated genes (Cironi et al. 2008; Figueiredo et al. 2008; Kozul et al. 2008). 
RP ranks genes according to their expression changes and also provides statistical confidence 
levels.  The final stage of analysis at the SHWFGF, automated functional interpretation, uses 
Iterative Group Analysis (iGA) (Breitling et al. 2004a)  to produce a robust biological summary of 
the physiological processes affected in a given experiment.  This method was particularly useful as 
an aid in the interpretation of the microarray data. 
In addition to this pipeline analysis, the microarray data was also analysed using ‘Genespring’ 
software, a ‘gold standard’ proprietary software for microarray analysis, and ‘Ingenuity pathways  189 
analysis’, a relatively new approach for functional analysis of microarray data.  These programmes 
offered visualisation aids that were not provided with the RPA and IGA analysis and in addition, 
cross-validation of the analysis methods was achieved by use of multiple analysis tools.  Indeed, 
the two functional analyses (IPA and IGA) showed overlaps in their functional classification of the 
data. 
Ontology based analyses do inevitably have their limitations however.  IGA is reliant on existing 
‘GO ontology’ functional annotations where, for virtually every organism only a subset of known 
genes are annotated (King et al. 2003).  Both IGA and IPA are reliant on the manual curation of 
information from published papers and are as such subject to human error in the interpretation of 
facts.   It was also evident that IGA was heavily influenced by genes that appeared in more than 
one GO category and there was a good deal of redundancy as parent terms and all subordinate 
daughter terms were represented.  
7.1 Main observations 
All the injury models elicited changes in hundreds of genes both at 5% FDR and the 5% 
significance level.  The number of genes that were specific to the regenerating conditions was fairly 
low however.  This may reflect the fact that the two regenerating conditions were at two very 
different time points after injury and it is conceivable that genes which are responsible for initiation 
of regeneration are not required for maintenance of regeneration and vice versa. This analysis also 
assumes that regeneration of the central branch of the DRG neuron after dorsal root injury involves 
activation of the same genes and mechanisms as regeneration after a sciatic or spinal nerve injury. 
Evidence from a recent study of the response of peripherally and centrally axotomised DRG 
neurons did however suggest that injuries in these two branches are very different, even at an 
early time point when regeneration would be taking place in the dorsal root (Stam et al. 2007).  
Taking this into account it is perhaps unsurprising that the degree of overlap in the two 
regenerating condition is so small. 
There was however one striking commonality in the regenerating conditions.  This was the 
upregulation of procollagens. Collagens are usually produced by fibroblasts and are indicative of 
fibrosis.  In the normal sciatic nerve collagen fibrils form part of the perineurium and epineurium, 
the outer connective tissue sheaths that lend structural support and elasticity to the nerve (Stolinski 
1995).  After injury, epineurial fibroblasts are known to upregulate collagen mRNAs (Siironen et al. 
1996).   The results from the microarray suggest that procollagens are also upregulated within the 
DRG during times of axon regeneration.  It is unclear however if procollagens upregulated within 
the DRG could contribute to distal ensheathment of axons during regeneration but the fact that 
procollagens were not generally upregulated in all injuries suggests that this is not simply a feature 
of an inflammatory response to injury. 
Dorsal column transection elicited a robust transcriptional response in the DRG.  This included a 
large number of genes that were not regulated (>50% FDR) in the other injury models (2827 genes  190 
<50% FDR, 244 <5% FDR).  The complete separation of this injury from the others in principal 
components and correlational analysis further highlighted the uniqueness of the transcriptional 
response to this type of injury.  This may be explained by the fact that dorsal column transection 
severs mainly ascending large-diameter Aβ fibres whilst leaving the smaller diameter C fibres that 
make central contacts in the dorsal horn intact.  The DRG therefore retains a supply of target-
derived factors and remains functional.  The difference in the transcriptional response may also be 
due to the fact that it involved transection rather than crushing of the axons and differences in the 
response of DRGs to crushing and axotomy has already been demonstrated (Cho et al. 1998) and 
differences in cell death are discussed later.    
An interesting finding regarding the neuronal response to dorsal column transection was that a 
number of known RAGs were expressed.   While some of these genes have been demonstrated to 
promote neurite outgrowth in vitro, others have only been associated with regeneration because 
they are upregulated after a peripheral nerve injury- i.e. they have not been shown to be 
unregulated in non-regenerating conditions.  So does the upregulation of these RAGs mean that 
dorsal column injury elicits a regenerative transcriptional response or does this mean these genes 
have nothing to do with regeneration after all?  If the former is true, these data may have important 
implications for treatment of spinal cord injury as it suggests that the neurons may be already 
intrinsically primed for regeneration given the appropriate extrinsic factors. 
7.1.1 Observations with relevance to dorsal root avulsion 
Dorsal root avulsion is an intractable injury due to the failure of dorsal root fibres to regenerate 
though the barrier of the DREZ to enter the spinal cord (see also section 1.4.1.3).  It was therefore 
interesting to compare the neuronal response to dorsal root regeneration to that associated with 
dorsal root block at the DREZ.  Many of the genes that were activated at 2 weeks following dorsal 
root crush had returned to pre-injury levels at 6 weeks post-injury.  IPA network analysis did 
however reveal one gene that was downregulated at 2 weeks but later upregulated at 6 weeks.  
This gene was neuregulin 1 (NRG1) (see section 5.6.9).  This gene was one of a very few genes 
that showed an antagonistic pattern of expression at 2 and 6 weeks post-injury (only two others 
were identified using Excel data sorting) and reduced expression of this gene has been previously 
shown to correlate with periods of regeneration (Bermingham-McDonogh et al. 1997) while 
elevated levels of this gene has been suggested to contribute to the poor regenerative capacity of 
optic nerves (Martinez et al. 2004). Upregulation of this gene in neurons that are blocked at the 
DREZ may therefore represent one of the intrinsic factors that contribute to the failure of dorsal root 
axons to overcome the barrier of the DREZ and may represent an attractive candidate for genetic 
manipulation. 
7.1.2 Putative regeneration associated genes 
Wnt-1-inducible signalling pathway protein 2 (WISP2) and tissue factor pathway inhibitor 2 (TFPI2) 
were identified from the microarray as being novel regeneration-associated genes as they were  191 
common and specific to the regenerating conditions.  Further investigation of their function using 
cluster analysis revealed that they are co-regulated in the injury conditions with genes involved in 
glycerophospholipid metabolism.  In addition, TFPI2 clustered with genes involved in Wnt/β catenin 
signalling, a pathway that has been implicated in a number of functions including axonal outgrowth 
(Endo and Rubin 2007).  Although the expression of these genes was not fully validated by the 
qRT-PCR experiments, further investigation of their function and their possible involvement in this 
pathway would be interesting. 
7.1.3 Observations with relevance to neuropathic pain 
Although the main focus of the project was the identification of genes that may have a putative role 
in neuronal regeneration, the study also had relevance to neuropathic pain injury.  Chronic spinal 
pain is a significant problem after spinal cord injury and neuropathic pain is associated with 
peripheral nerve injuries.  An interesting finding was that dorsal column injury elicited many of the 
changes in ion channels and neurotransmitter receptors that are associated with neuropathic injury 
models.  In addition, a feature of all the injuries was gene expression changes indicative of immune 
cell infiltration and there was activation of complement in the DRG after all the injuries.  The 
complement pathway has been recently suggested as a novel target for treatment of neuropathic 
pain (Levin et al. 2008). 
7.2 Interpretational considerations 
 
Interpretation of the microarray data from this experiment was made extremely complex by the 
multitude of factors at play in the in vivo milieu.  Injury to an axon initiates retrograde signalling 
(section 1.5.2.1) that causes changes in the transcription of many genes within the DRG.  The 
transcriptional programmes that are active at any one time in a neuron will be determined by a 
number of factors such as nature of the injury (eg. crush or transection), distance and position of 
injury in relation to the cell body, time from injury and extrinsic signals at the lesion zone.  In 
addition, the DRG is a heterogeneous tissue that contains non-neuronal cells such as macrophage 
and fibroblasts that are also influenced by injury to neurons in their vicinity.  Gene expression 
changes can therefore also be associated with these non-neuronal cells. Attempts have been 
made to reveal the factors that are intrinsic to regeneration by dissociating neurons from the 
extrinsic factors acting on them in vivo and studying them in culture (Szpara et al. 2007).  Whilst 
this allows the environmental conditions to be carefully controlled, there are questions as to how 
valid in vitro observations are to the in vivo situation.  Ultimately, extrinsic and intrinsic factors are 
coupled in the animal, both influencing the other- remove one and you change the other and as 
such in vitro approaches may not accurately reflect the in vivo situation. 
Given also that the nature of the injury has such an influence on the transcriptional response of the 
DRG, we have to ask how clinically relevant animal injury models are.  Animal models need to be  192 
reproducible and hence there is a trade off with how clinically relevant they are (it can be argued 
that it is easier to do a reproducible dorsal column transection than a contusion, easier to do a 
reproducible dorsal root crush than an avulsion). Indeed it has been shown that there is a 
difference in cell death after dorsal root avulsion and dorsal root axotomy (Chew et al. 2008). 
This also highlights another interpretational problem for this project in the fact that different injury 
models may induce varying levels of cell death. An apparent downregulation in a gene could 
therefore be attributed to loss of a certain cell subtype relative to control and this loss may be 
different in each injury. There have been reports of preferential loss of large cells (Bondok and 
Sansone 1984) whilst others report preferential loss of  small cells (Rich et al. 1989). Cell death is 
also thought to vary according to distance of axotomy from the ganglion with injuries that are closer 
to the cell body producing more rapid and pronounced cell death (Watson 1968).  The delay in cell 
death after very distal injuries could be attributed to the delay for retrograde injury signals (section 
1.5.2.1) to reach the cell body.   An investigation of the time course and level of cell death after 
each of our injury models using techniques such as optical dissection would allow us to ascertain 
to what extent gene expression changes were due to cell death.  Information from this would also 
have relevance to regenerative strategies.  If substantial cell death occurs following injury one must 
first improve neuronal survival (e.g. by providing adequate neurotrophic support) before 
regeneration can be encouraged via other strategies. 
7.3 Methodological considerations 
Microarray experiments are expensive and therefore experimental design is constrained by costs.  
Had resources been available, it would have been possible to hybridise chips with samples from 
sham-operated controls for each condition.  This would have removed genes that were regulated 
by systemic changes due to tissue damage during surgery. The inclusion of sham-operated 
samples in the qRT-PCR validation experiments did however provide a compromise that was more 
financially feasible and allowed us to test surgery effects on a gene-to-gene basis.   
Chip costs also dictated the number of replicates that could be performed. For each condition the 
minimum requirement of three replicates was performed and pooling of samples was applied in 
order to smooth variation, as recommended for experiments with a small number of chips 
(Kendziorski et al. 2005). 
Finally, whilst the dorsal column transection is an injury model which has been well optimised and 
which produces a reproducible lesion without damage to overlying blood vessels, it is not easily 
comparable to a crush lesion.  There are several spinal cord contusion injury models (Kuhn and 
Wrathall, 1998; Metz et al. 2000; Young, 2002) which may have been used as an alternative to 
transection but, as discussed, may not be so reproducible although arguably, more clinically 
relevant.   
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7.4 Future directions 
A number of aspects of the microarray data provided by this project were interesting and could 
have been investigated further had there been sufficient time and resources. The qRT-PCR 
validation could have been expanded to include a larger set of genes and the group size could 
have been increased to enhance the power of assay to detect smaller gene expression changes.  
Given the heterogeneity of the DRG, it would have been interesting to determine the locus of the 
gene expression changes by in situ hybridisation on DRG sections.  Validated gene expression 
changes detected in the DRG after injury may not necessarily translate to protein changes in the 
axon however so further validation using protein techniques such as Western blotting and 
immunohistochemical analysis of nerve sections is needed. Proteins that localise to growth cones 
in axon terminals would be of particular interest as regeneration associated genes. 
Following confirmation that a gene is translated and expressed at an appropriate location in the 
neuron, candidate regeneration associated genes may be tested for their ability to stimulate 
regeneration in in vitro assays of DRG neuron growth or in vivo using gene silencing technology 
and transgenic animals. Short interfering RNAs (siRNA) have been successful in silencing a 
number of target genes in vitro thus demonstrating their role in regeneration and neuropathic pain 
(Jankowski et al. 2006; Williams et al. 2006; Murray and Shewan 2008; Toth et al. 2008).   In vivo 
gene silencing is more difficult because of possible off-target effects.  Intrathecal and paratracheal 
administration of siRNA in vivo has been shown to relieve chronic neuropathic pain by reducing 
expression of cation channels in the DRG and their subsequent translocation to the dorsal horn of 
the spinal cord (Dorn et al. 2004; Kasama et al. 2007).  HSV vectors have been used recently to 
target short-hairpin RNA to silence genes in the DRG of mice and this may represent a more 
efficient and targeted method of gene silencing in vivo (Anesti et al. 2008).   
Another interesting line of investigation would be to investigate how manipulations of the lesion 
zone that promote regeneration in the spinal cord (such as cell grafts), affect gene expression in 
the DRG after dorsal column transection.  This may reveal how the extrinsic factors influence 
neuronal transcriptional programmes to promote regeneration.   In addition, this study provided 
only a snapshot of gene expression at 2 weeks after dorsal column transection.  It would be 
interesting therefore to examine temporal DRG gene expression after injury.  In particular a 
comparison of very early gene expression (during the period of abortive sprouting) with gene 
expression at a later time point would be of interest to the identification of regeneration associated 
genes. 
To summarise, this project revealed a number of interesting aspects of the neuronal response to 
central and peripheral branch injuries and a small number of putative regeneration-associated 
genes.  Further work is however needed to validate these, to elucidate the locus of the observed 
changes within the DRG and to establish a causal link between their expression and axonal 
regeneration.  The study also provided the first genome-wide study of gene expression after dorsal 
column transection, which suggested that even after injury within the CNS, DRGs are primed for  194 
regeneration.  This has implications for the treatment of SCI and suggests that early interventions 
to manipulate extrinsic factors at the lesion zone could potentially lead to regeneration and 
functional recovery.  
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Appendices 
 
a) Differentially expressed genes (Rank Products 
Analysis) 
i)  Pilot microarray 
Table 7-1:  Genes upregulated (<1% FDR) in the DRG 8 days after sciatic nerve transection. 
AFFY. ID.  FDR  MEAN 
FC 
ACC. NO.  GENE 
SYMBOL 
GENE TITLE 
1387154_at  0  45.88  NM_012614  Npy  neuropeptide Y 
1377146_at  0  28.51  AI412212  RGD:621647  vasoactive intestinal polypeptide 
1369268_at  0  14.32  NM_012912  Atf3  activating transcription factor 3 
1387088_at  0  12  NM_033237  Gal  galanin 
1398243_at  0  8.71  NM_057144  ---  --- 
1368238_at  0  8.82  NM_053289  Pap  pancreatitis-associated protein 
1371248_at  0  7.15  BI286387  RGD:1310042  small proline-rich protein 1A (predicted) 
1376601_at  0  6.35  BF397526  ---  Similar to semaphorin 6A1; semaphorin 6A-1 
1368224_at  0  6.62  NM_031531  Spin2c  Serine protease inhibitor 
1387396_at  0  5.8  NM_053469  Hamp  hepcidin antimicrobial peptide 
1369202_at  0  5.35  NM_017028  Mx2  myxovirus (influenza virus) resistance 2 
1377334_at  0  4.8  BG378249  RT1-Ba  RT1 class II, locus Ba 
1388451_at  0  3.76  AA817802  ---  Transcribed locus 
1370883_at  0.07  4.03  Y00480  ---  --- 
1368947_at  0.07  4.12  NM_024127  Gadd45a  growth arrest and DNA-damage-inducible 45 alpha 
1368266_at  0.06  3.69  NM_017134  Arg1  arginase 1 
1370315_a_at  0.06  3.56  AF026530  Stmn4  stathmin-like 4 
1371450_at  0.11  3.02  BE117330  Sox11  SRY-box containing gene 11 
1367973_at  0.11  3.2  NM_031530  Ccl2  chemokine (C-C motif) ligand 2 
1372734_at  0.1  3.44  AI408095  RGD:727777  small cell adhesion glycoprotein 
1386967_at  0.1  3.04  NM_053522  Rhoq  ras homolog gene family, member Q 
1388385_at  0.09  3.28  BG371710  Cryba2  crystallin, beta A2 
1368421_at  0.09  3.01  NM_019253  Ptpn5  protein tyrosine phosphatase, non-receptor type 5 
1367930_at  0.08  2.77  NM_017195  Gap43  growth associated protein 43 
1371015_at  0.2  2.73  X52711  Mx1  myxovirus (influenza virus) resistance 1 
1388944_at  0.19  2.59  BE109016  Sox11  SRY-box containing gene 11 
1367679_at  0.19  3.15  NM_013069  Cd74  CD74 antigen (invariant polpypeptide of major 
histocompatibility class II antigen-associated) 
1368892_at  0.25  2.88  NM_016989  Adcyap1  adenylate cyclase activating polypeptide 1 
1370177_at  0.28  2.81  AI548856  PVR  poliovirus receptor 
1376836_at  0.27  2.67  BF419655  ---  --- 
1369788_s_at  0.26  2.68  NM_021835  Jun  v-jun sarcoma virus 17 oncogene homolog (avian) 
1370383_s_at  0.34  2.97  BI279526  ---  --- 
1370051_at  0.36  2.83  NM_031659  Tgm1  transglutaminase 1 
1367664_at  0.38  2.82  L81174  Ankrd1  ankyrin repeat domain 1 (cardiac muscle) 
1389006_at  0.4  2.53  AI170394  Mpeg1  Macrophage expressed gene 1 
1375951_at  0.47  2.65  AA818521  Thbd  thrombomodulin 
1388433_at  0.46  2.63  BI279605  Krt1-19  keratin complex 1, acidic, gene 19 
1372042_at  0.53  2.51  BI294844  ---  Similar to RIKEN cDNA 9430096L06 
1389373_at  0.56  2.42  AI029555  Smad1  SMAD, mothers against DPP homolog 1 (Drosophila) 
1367874_at  0.65  2.7  NM_053522  Rhoq  ras homolog gene family, member Q 
1371245_a_at  0.93  4.11  BI287300  ---  --- 
1368210_at  0.9  2.31  NM_133311  Il24  interleukin 24 
1374280_at  0.95  2.67  AA817812  ---  --- 
1388711_at  0.93  2.42  BF282650  ---  Transcribed locus, strongly similar to NP_598751.3 
interleukin 13 receptor, alpha 1 [Mus musculus] 
1370215_at  1  2.39  AW434057  C1qb  complement component 1, q subcomponent, beta 
polypeptide 
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Table 7-2: Genes downregulated (<1% FDR) in the DRG 8 days after sciatic nerve 
transection. 
AFFY. ID.  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1368751_at  0  -3.6  NM_031778  Kcns3  potassium voltage-gated channel, delayed-
rectifier, subfamily S, member 3 
1393933_at  0  -3.25  AW144823  RGD:1310938  sortilin-related receptor, L(DLR class) A 
repeats-containing (predicted) 
1371108_a_at  0  -3.82  M74494  Atp1a1  ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
1374046_at  0  -3.03  BG376092  ---  --- 
1368506_at  0  -3.37  U27767  Rgs4  regulator of G-protein signaling 4 
1368821_at  0  -3.23  BI290885  Fstl1  follistatin-like 1 
1370556_at  0  -3.06  M24104  ---  --- 
1370517_at  0  -2.88  U18772  RGD:628894  neuronal pentraxin 1 
1377457_a_at  0  -2.8  AA850618  RGD:1310938  sortilin-related receptor, L(DLR class) A 
repeats-containing (predicted) 
1377095_at  0  -2.91  BG380409  LOC287847  similar to ataxin 2-binding protein 1 isoform 1; 
hexaribonucleotide binding protein 1 
1369390_a_at  0  -2.82  NM_022850  Dpp6  dipeptidylpeptidase 6 
1371077_at  0  -2.63  AI575989  Htr3b  5-hydroxytryptamine (serotonin) receptor 3b 
1369428_a_at  0  -2.65  U28430  Htr3a  5-hydroxytryptamine (serotonin) receptor 3a 
1371211_a_at  0  -2.78  U02315  Nrg1  neuregulin 1 
1369001_at  0  -2.57  NM_052805  Chrna3  cholinergic receptor, nicotinic, alpha 
polypeptide 3 
1388000_at  0  -2.65  AF021923  Slc24a2  solute carrier family 24 
(sodium/potassium/calcium exchanger), 
member 2 
1369116_a_at  0  -2.5  NM_017338  Calca  calcitonin/calcitonin-related polypeptide, 
alpha 
1370572_at  0  -2.43  AY030276  Gpr149  G protein-coupled receptor 149 
1375242_at  0.05  -2.39  BI296440  ---  --- 
1384132_at  0.05  -2.63  H31111  RGD:1310999  immunoglobulin superfamily, member 4A 
(predicted) 
1369144_a_at  0.05  -2.49  U75448  Kcnd3  potassium voltage gated channel, Shal-
related family, member 3 
1387065_at  0.32  -2.37  NM_080688  Plcd4  phospholipase C, delta 4 
1387309_a_at  0.3  -2.34  AI111480  Grik1  glutamate receptor, ionotropic, kainate 1 
1368044_at  0.38  -2.42  NM_022669  Scg2  secretogranin 2 
1371003_at  0.36  -2.66  BG378086  Map1b  microtubule-associated protein 1b 
1376736_at  0.38  -2.49  BG375419  ---  Transcribed locus 
1369816_at  0.37  -2.47  NM_013018  Rab3a  RAB3A, member RAS oncogene family 
1368182_at  0.36  -2.33  NM_130739  Acsl6  acyl-CoA synthetase long-chain family 
member 6 
1383499_at  0.34  -2.29  BG371995  ---  Transcribed locus 
1387602_a_at  0.37  -2.26  NM_022189  Htr3b  5-hydroxytryptamine (serotonin) receptor 3b 
1370146_at  0.42  -2.54  NM_053296  Glrb  glycine receptor, beta subunit 
1393480_at  0.56  -2.38  AW919998  Ppp1r2  protein phosphatase 1, regulatory (inhibitor) 
subunit 2 
1369210_at  0.58  -2.26  NM_030875  Scn1a  sodium channel, voltage-gated, type 1, alpha 
polypeptide 
1374743_at  0.74  -2.27  BE115056  ---  --- 
1376311_at  0.71  -2.22  BM391312  ---  Transcribed locus 
1390097_at  0.69  -2.36  BI281738  RGD:1306653  TSPY-like 4 (predicted) 
1390672_at  0.68  -2.29  BG381258  ---  Transcribed locus 
1372345_at  0.66  -2.18  AA894210  ---  Transcribed locus 
1373658_at  0.64  -2.13  AI409259  ---  Similar to Rac GTPase-activating protein 
1375026_at  0.62  -2.16  AI105369  RGD:1309714  ceroid-lipofuscinosis, neuronal 6 (predicted) 
1368853_at  0.61  -2.37  AI227991  Vsnl1  visinin-like 1 
1392607_at  0.64  -2.46  BF391141  ---  Transcribed locus 
1372300_at  0.74  -2.22  BI288838  ---  Similar to Polymerase (RNA) II (DNA 
directed) polypeptide C 
1390146_at  0.75  -2.2  BF414998  ---  Similar to RIKEN cDNA 2610318G18 
1368505_at  0.73  -2.28  U27767  Rgs4  regulator of G-protein signaling 4 
1370406_a_at  0.72  -2.31  AB032395  Daf1  decay accelarating factor 1 
1369627_at  0.7  -2.31  BG672437  Sv2b  synaptic vesicle glycoprotein 2b 
1376842_at  0.71  -2.19  BF395964  ---  Transcribed locus 
1376987_at  0.73  -2.21  AW523375  RGD1309466_predicted  similar to hypothetical protein FLJ20156 
(predicted) 
1368822_at  0.72  -2.22  BI290885  Fstl1  follistatin-like 1 
1367959_a_at  0.71  -2.41  AF182949  Scn1b  sodium channel, voltage-gated, type I, beta 
polypeptide  197 
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1367835_at  0.69  -2.39  NM_019279  Pcsk1n  proprotein convertase subtilisin/kexin type 1 
inhibitor 
1369000_at  0.91  -2.23  NM_021589  Ntrk1  neurotrophic tyrosine kinase, receptor, type 1 
1387235_at  0.89  -2.08  NM_021655  Chga  chromogranin A 
1368696_at  0.95  -2.21  NM_022008  Fxyd7  FXYD domain-containing ion transport 
regulator 7 
1376657_at  0.98  -2.27  BE117767  ---  Similar to RA175 
1368768_at  0.96  -2.08  NM_019265  Scn11a  sodium channel, voltage-gated, type11, alpha 
polypeptide 
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ii) Main microarray 
Table 7-3: Genes upregulated (<1% FDR) in the DRG 2 weeks after dorsal root crush. 
AFFY. ID  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1368238_at  0  13.64  NM_053289  Pap  pancreatitis-associated protein 
1387930_at  0  4.55  L10229  Reg3a  regenerating islet-derived 3 alpha 
1368187_at  0  3.71  NM_133298  Gpnmb  glycoprotein (transmembrane) nmb  
1387154_at  0  3.18  NM_012614  Npy  neuropeptide Y 
1368677_at  0  2.86  NM_012513  Bdnf  brain derived neurotrophic factor 
1368359_a_at  0  2.83  NM_030997  Vgf  VGF nerve growth factor inducible 
1375010_at  0  2.53  AI177761  Cd68  CD68 antigen 
1384063_at  0  2.49  AA958001  Cthrc1  collagen triple helix repeat containing 1  
1395126_at  0  2.45  AI011393  Msr2_predicted  macrophage scavenger receptor 2 (predicted) 
1369268_at  0  2.45  NM_012912  Atf3  activating transcription factor 3  
1373386_at  0  2.49  AI179953  Gjb2  gap junction membrane channel protein beta 
2 
1390119_at  0  2.41  BF396602  Sfrp2  secreted frizzled-related protein 2 
1376750_at  0  2.32  AA963477  ---  Transcribed locus 
1385751_at  0  2.38  BF408413  Thbs2  thrombospondin 2 
1377092_at  0  2.33  BF389682  ---  Transcribed locus 
1368224_at  0  2.34  NM_031531  Serpina3n  serine (or cysteine) peptidase inhibitor, clade 
A, member 3N  
1392965_a_at  0  2.25  AI028877  Smoc2_predicted  SPARC related modular calcium binding 2 
(predicted) 
1385248_a_at  0  2.25  AA997590  Ogn_predicted  osteoglycin (predicted) 
1370892_at  0  2.27  BI285347  C4a /// C4-2  complement component 4a /// complement 
component 4, gene 2 ///  
1367973_at  0  2.33  NM_031530  Ccl2  chemokine (C-C motif) ligand 2 
1384707_at  0  2.25  AI600020  ---  Transcribed locus 
1392515_at  0  2.24  AI177403  Ly49i9   Ly49 inhibitory receptor 9  
1375917_at  0  2.24  BF282961  Gp49b /// LOC499078  glycoprotein 49b /// similar to GP49B1 
1367794_at  0  2.19  NM_012488  A2m  alpha-2-macroglobulin  
1371057_at  0  2.12  AW520967  Gabra5  gamma-aminobutyric acid (GABA-A) 
receptor, subunit alpha 5 
1390525_a_at  0  2.11  BI284420  Stra6  stimulated by retinoic acid gene 6 homolog 
(mouse) 
1387868_at  0  2.21  BF289368  Lbp  lipopolysaccharide binding protein 
1393708_at  0.07  2.07  BE115766  Bhlhb5_predicted  basic helix-loop-helix domain containing, 
class B5 (predicted) 
1382692_at  0.07  2.1  AI045955  RGD1565140_predicted  similar to Clecsf12 protein (predicted)  
1388485_at  0.07  2.14  BG380414  Cxcl14  chemokine (C-X-C motif) ligand 14  
1370234_at  0.06  2.05  AA893484  Fn1  fibronectin 1 
1391435_at  0.06  2.12  BI278687  Pltp_predicted  phospholipid transfer protein (predicted) 
1371447_at  0.06  2.01  BG378630  Plac8_predicted  placenta-specific 8 (predicted) 
1397889_at  0.06  2  BF402043  ---  Transcribed locus 
1369947_at  0.06  2.01  NM_031560  Ctsk  cathepsin K 
1388142_at  0.06  1.99  AA850991  Cspg2  chondroitin sulfate proteoglycan 2 
1373911_at  0.05  2.05  BM389026  Postn_predicted  periostin, osteoblast specific factor 
(predicted)  
1391812_at  0.05  1.99  AI145876  RGD1309172_predicted  Similar to RIKEN cDNA E330026B02 
(predicted) 
1391106_at  0.05  1.97  BM385061  ---  Transcribed locus 
1393508_at  0.05  1.98  AI043805  ---  Transcribed locus 
1382205_at  0.1  1.93  AW527509  ---  Transcribed locus 
1390866_at  0.1  1.97  AI168981  ---  Transcribed locus 
1385475_a_at  0.09  1.94  AI030451  Stra6  stimulated by retinoic acid gene 6 homolog 
(mouse) 
1376734_at  0.09  2.01  BI279030  ---  Transcribed locus 
1387893_at  0.09  1.91  D88250  C1s /// 
RGD1561715_predicted 
complement component 1, s subcomponent  
1368459_at  0.09  1.95  NM_024375  Gdf10  growth differentiation factor 10 
1394109_at  0.09  2.02  BF558056  Thbs1  Thrombospondin 1 
1381504_at  0.12  1.91  AI639412  LOC306805  similar to asporin precursor 
1374273_at  0.12  1.88  BG665433  Cxadr  Coxsackie virus and adenovirus receptor 
1373628_at  0.12  1.88  AA818342  ---  Transcribed locus 
1379344_at  0.12  1.88  AI176057  Cybb  Cytochrome b-245, beta polypeptide 
1374529_at  0.12  1.89  AI406660  Thbs1  Thrombospondin 1 
1368303_at  0.11  1.86  NM_031678  Per2  period homolog 2 (Drosophila) 
1368202_a_at  0.17  1.86  NM_024159  Dab2  disabled homolog 2 (Drosophila)  199 
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1383786_at  0.16  1.84  AW915417  ---  Transcribed locus 
1389006_at  0.16  1.85  AI170394  ---  Transcribed locus, moderately similar to 
NP_035543.1 sex-limited protein [Mus 
musculus] 
1383210_at  0.21  1.84  BF554576  ---  Transcribed locus 
1372013_at  0.21  1.86  BG380285  Ifitm1_predicted  interferon induced transmembrane protein 1 
(predicted)  
1388557_at  0.2  1.83  BF284922  C7 /// Tubb2c  complement component 7 /// tubulin, beta 2c  
1398387_at  0.2  1.8  AI009530  MGC72614  Unknown (protein for MGC:72614) 
1387348_at  0.21  1.88  BE113270  Igfbp5  insulin-like growth factor binding protein 5 
1372254_at  0.23  1.8  AW915763  Serping1  serine (or cysteine) peptidase inhibitor, clade 
G, member 1  
1382108_at  0.22  1.8  AA900536  ---  Transcribed locus  
1390798_at  0.22  1.81  BF288130  Ptprc  protein tyrosine phosphatase, receptor type, 
C  
1380318_at  0.22  1.81  BF401102  ---  Transcribed locus, strongly similar to 
XP_579933.1 PREDICTED: hypothetical 
protein XP_579933 [Rattus norvegicus]  
1368422_at  0.24  1.82  NM_017149  Meox2  mesenchyme homeobox 2  
1370282_at  0.24  1.82  U44948  Csrp2  cysteine and glycine-rich protein 2 
1388939_at  0.25  1.79  AA800298  Col15a1  procollagen, type XV  
1380726_at  0.25  1.8  BI290633  LOC306805  Similar to asporin precursor 
1371245_a_at  0.24  1.91  BI287300  LOC689064  similar to Hemoglobin beta-2 subunit 
(Hemoglobin beta-2 chain) (Beta-2-globin)  
1371102_x_at  0.28  1.9  X05080  MGC72973  beta-glo 
1382398_at  0.28  1.77  BF291169  RGD1565710_predicted  similar to MGC68837 protein (predicted) 
1381798_at  0.29  1.77  BE114958  LMO7  LIM domain only protein 7 
1368223_at  0.31  1.75  NM_024400  Adamts1  a disintegrin-like and metallopeptidse 
(reprolysin type) with thrombospondin type 1 
motif, 1  
1369182_at  0.31  1.76  NM_013057  F3  coagulation factor III 
1371079_at  0.32  1.79  X73371  Fcgr2b  Fc receptor, IgG, low affinity IIb 
1379331_at  0.31  1.78  AA965084  Tnn_predicted  tenascin N (predicted) 
1388138_at  0.31  1.8  X89963  Thbs4  thrombospondin 4 
1382305_at  0.32  1.76  AI236814  Zfp364_predicted  Zinc finger protein 364 (predicted) 
1393351_at  0.31  1.74  BE109501  ---  Transcribed locus 
1373923_at  0.35  1.73  BF283756  ---  Transcribed locus 
1387874_at  0.34  1.84  AI230048  Dbp  D site albumin promoter binding protein  
1385031_at  0.35  1.73  AI144913  ---  Transcribed locus 
1391412_at  0.35  1.84  AA996841  Xrn2_predicted  5'-3' exoribonuclease 2 (predicted) 
1379766_at  0.34  1.74  AI500952  Sla  Src-like adaptor 
1375661_at  0.34  1.74  BE104180  ---  Transcribed locus 
1368883_at  0.33  1.83  NM_030868  Nov  nephroblastoma overexpressed gene 
1393672_at  0.33  1.72  BE117954  Hmcn1_predicted  hemicentin 1 (predicted) 
1374726_at  0.35  1.74  AI411941  Fndc1  fibronectin type III domain containing 1 
1368419_at  0.36  1.73  AF202115  Cp  ceruloplasmin 
1378140_at  0.35  1.74  BI296317  Arl11  ADP-ribosylation factor-like 11  
1382431_at  0.36  1.72  AI103530  ---  Transcribed locus, strongly similar to 
XP_520163.1 PREDICTED: similar to ATP-
binding cassette transporter 1 [Pan 
troglodytes] 
1372818_at  0.37  1.72  BI284441  Colec12  collectin sub-family member 12 
1383946_at  0.37  1.75  AI137640  Cldn1  claudin 1 
1390715_at  0.38  1.71  BF396448  Igfbpl1_predicted  insulin-like growth factor binding protein-like 1 
(predicted) 
1373175_at  0.38  1.72  BI285951  RGD1308734  similar to RIKEN cDNA 1100001H23 
1385053_at  0.37  1.73  BE108648  ---  Transcribed locus 
1370830_at  0.37  1.79  M37394  Egfr  epidermal growth factor receptor  
1378057_at  0.38  1.69  BE103354  Flrt3_predicted  fibronectin leucine rich transmembrane 
protein 3 (predicted) 
1367942_at  0.38  1.71  NM_019144  Acp5  acid phosphatase 5, tartrate resistant 
1370072_at  0.44  1.69  NM_012608  Mme  membrane metallo endopeptidase  
1389754_at  0.45  1.73  AI555295  ---  Transcribed locus, moderately similar to 
XP_529632.1 PREDICTED: hypothetical 
protein XP_529632 [Pan troglodytes] 
1390835_at  0.46  1.76  AI013568  RGD1311123  similar to 1300013J15Rik protein 
1375951_at  0.48  1.7  AA818521  Thbd  thrombomodulin 
1388459_at  0.48  1.68  AI101782  Col18a1  procollagen, type XVIII, alpha 1 
1393891_at  0.49  1.7  BE128699  Col8a1_predicted  procollagen, type VIII, alpha 1 (predicted) 
1382153_at  0.5  1.69  AI171821  Clecsf6  C-type (calcium dependent, carbohydrate 
recognition domain) lectin, superfamily 
member 6  
1368172_a_at  0.5  1.69  BI304009  Lox  lysyl oxidase 
1368420_at  0.5  1.69  NM_012532  Cp  ceruloplasmin   200 
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1398258_at  0.49  1.69  NM_012777  Apod  apolipoprotein D  
1392863_at  0.49  1.66  AA817953  Flrt3_predicted  fibronectin leucine rich transmembrane 
protein 3 (predicted) 
1374730_at  0.5  1.7  AI102519  Txnrd3_predicted  Thioredoxin reductase 3 (predicted) 
1383391_a_at  0.5  1.71  AI716125  C2  complement component 2 
1376799_a_at  0.51  1.68  AA925924  Crlf1_predicted  cytokine receptor-like factor 1 (predicted) 
1368395_at  0.53  1.66  NM_012774  Gpc3  glypican 3 
1370895_at  0.53  1.67  AI179399  Col5a2  procollagen, type V, alpha 2 
1377340_at  0.53  1.66  AI179507  Tfpi2  tissue factor pathway inhibitor 2  
1387029_at  0.55  1.67  NM_130409  Cfh  complement component factor H 
1375378_at  0.55  1.66  BE108882  LOC499022 /// 
LOC684079 
similar to quaking homolog, KH domain RNA 
binding isoform HQK-6 /// similar to quaking 
homolog, KH domain RNA binding isoform 
HQK-5 
1394908_at  0.58  1.65  AW529671  Adcyap1  Adenylate cyclase activating polypeptide 1 
1379404_at  0.58  1.66  AI598327  ---  Transcribed locus 
1395372_at  0.57  1.67  BG668993  Itgb8_predicted  Integrin beta 8 (predicted) 
1392557_at  0.57  1.66  BF389151  Bicc1_predicted  Bicaudal C homolog 1 (Drosophila) 
(predicted) 
1393064_at  0.58  1.68  AI709766  RGD1564108_predicted  Similar to hedgehog-interacting protein 
(predicted)  
1387005_at  0.59  1.64  NM_017320  Ctss  cathepsin S  
1385397_at  0.6  1.65  AA859085  LOC499991  Ab1-219  
1370432_at  0.6  1.64  M72711  Pou3f1  POU domain, class 3, transcription factor 1 
1379995_at  0.63  1.64  BE113173  Tubb2b  Tubulin, beta 2b 
1367553_x_at  0.65  1.77  NM_033234  Hbb  hemoglobin beta chain complex 
1368418_a_at  0.65  1.63  AF202115  Cp  ceruloplasmin 
1381145_at  0.66  1.64  BE112469  ---  Transcribed locus 
1388742_at  0.66  1.63  AA945877  ---  --- 
1373062_at  0.67  1.63  BM388650  ---  Transcribed locus 
1383291_at  0.66  1.64  BF282631  C7 /// Tubb2c  complement component 7 /// tubulin, beta 2c 
1370959_at  0.66  1.64  BI275716  Col3a1  procollagen, type III, alpha 1  
1368990_at  0.68  1.62  NM_012940  Cyp1b1  cytochrome P450, family 1, subfamily b, 
polypeptide 1  
1372299_at  0.67  1.63  AI013919  Cdkn1c  cyclin-dependent kinase inhibitor 1C (P57)  
1368171_at  0.67  1.64  NM_017061  Lox  lysyl oxidase  
1389020_at  0.7  1.62  BM389149  LOC686539  similar to immunoglobulin superfamily 
containing leucine-rich repeat  
1371527_at  0.71  1.61  BI275741  Emp1  epithelial membrane protein 1 
1370301_at  0.72  1.62  U65656  Mmp2  matrix metallopeptidase 2  
1385229_at  0.72  1.64  AW524146  Pcdh20_predicted  protocadherin 20 (predicted) 
1375043_at  0.71  1.63  BF415939  Fos  FBJ murine osteosarcoma viral oncogene 
homolog  
1380692_at  0.72  1.61  BM387127  LOC683869  similar to Retinoblastoma-like protein 1 (107 
kDa retinoblastoma-associated protein) 
(PRB1) (P107) 
1376368_at  0.75  1.65  BE095878  Cuedc2_predicted  CUE domain containing 2 (predicted) 
1372273_at  0.75  1.61  AA944212  Gypc  glycophorin C (Gerbich blood group) 
1371450_at  0.78  1.6  BE117330  ---  Transcribed locus 
1387767_a_at  0.77  1.65  AF305418  Col2a1  procollagen, type II, alpha 1 
1394039_at  0.77  1.62  BM382886  Klf5  Kruppel-like factor 5 
1369422_at  0.76  1.61  NM_138850  Fap  fibroblast activation protein 
1396872_at  0.77  1.6  AI555260  ---  --- 
1368270_at  0.77  1.62  NM_012907  Apobec1  apolipoprotein B editing complex 1 
1394490_at  0.78  1.63  AI502114  Abca1  ATP-binding cassette, sub-family A (ABC1), 
member 1  
1381262_at  0.77  1.66  BG374101  Pbxip1  Pre-B-cell leukemia transcription factor 
interacting protein 1 
1384035_at  0.77  1.62  AW536030  LOC685277 /// 
LOC686794 
similar to liver-specific bHLH-Zip transcription 
factor  
1370240_x_at  0.81  1.69  AI179404  Hba-a1 /// LOC360504  hemoglobin alpha, adult chain 1  
1370810_at  0.85  1.6  L09752  Ccnd2  cyclin D2  
1367749_at  0.84  1.6  NM_031050  Lum  lumican 
1378745_at  0.87  1.6  BG374483  Tmem14a_predicted  Transmembrane protein 14A (predicted)  
1387566_at  0.87  1.59  NM_133551  Pla2g4a  phospholipase A2, group IVA (cytosolic, 
calcium-dependent) 
1371349_at  0.92  1.59  AI598402  Col6a1_predicted  procollagen, type VI, alpha 1 (predicted) 
1368394_at  0.92  1.63  AF140346  Sfrp4  secreted frizzled-related protein 4 
1367902_at  0.98  1.59  NM_022396  Gng11  guanine nucleotide binding protein (G 
protein), gamma 11 
1389966_at  0.97  1.58  AI176126  Col6a3_predicted  procollagen, type VI, alpha 3 (predicted) 
1381070_at  0.96  1.59  AI233106  Synpr  Synaptoporin /// Transcribed locus, strongly 
similar to NP_082328.2 synaptoporin   201 
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1371913_at  0.98  1.57  BG379319  Tgfbi  transforming growth factor, beta induced 
1379696_at  0.98  1.59  BI291833  ---  Transcribed locus, moderately similar to 
XP_576460.1 PREDICTED: similar to 
hypothetical protein PB402898.00.0 [Rattus 
norvegicus] 
1376905_at  0.97  1.58  BI304147  ---  Transcribed locus 
1392946_at  0.97  1.57  AI029194  ---  Transcribed locus 
1389553_at  0.96  1.58  BF393825  Dcir3  dendritic cell inhibitory receptor 3 
1378389_at  0.98  1.58  BM385157  ---  Transcribed locus, strongly similar to 
XP_225713.3 PREDICTED: similar to nuclear 
factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 [Rattus norvegicus] 
1374531_at  0.99  1.58  AA926305  ---  Transcribed locus 
 
Table 7-4: Genes downregulated (<1% FDR) in the DRG at 2 weeks after dorsal root crush. 
AFFY. ID.  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1387133_at  0  -2.44  NM_053988  Calb2  calbindin 2 
1394297_at  0  -2.31  BG670107  Hoxd1_predicted  homeo box D1 (predicted) 
1390881_at  0  -2.25  AI172339  Abra  actin-binding Rho activating protein 
1370900_at  0.25  -9.32  BM391169  Myh4  myosin, heavy polypeptide 4, skeletal muscle 
1367962_at  0.4  -7.31  NM_133424  Actn3  actinin alpha 3  
1384269_at  0.5  -1.77  BF386887  ---  Transcribed locus 
1377163_at  0.57  -1.74  BM385741  Inhbb  inhibin beta-B  
1372195_at  0.5  -6.72  BG663128  Tnnc2  troponin C type 2 (fast) 
1370033_at  0.44  -5.55  NM_020104  Mlc3  fast myosin alkali light chain 
1391575_at  0.4  -1.67  BG380566  ---  --- 
1380306_at  0.36  -1.96  AW435415  ---  Transcribed locus 
1367626_at  0.42  -5.3  NM_012530  Ckm  creatine kinase, muscle 
1391305_at  0.46  -1.62  AI576233  ---  --- 
1387787_at  0.43  -5.11  NM_012605  Myl2  myosin, light polypeptide 2  
1368585_at  0.53  -1.66  NM_017110  Cart  cocaine and amphetamine regulated transcript 
1395714_at  0.5  -1.53  AT005664  ---  --- 
1388349_at  0.71  -1.75  AA799557  ---  --- 
1367762_at  0.67  -1.58  NM_012659  Sst  somatostatin  
1371247_at  0.68  -4.33  BF521859  Ap2a1_predicted /// 
Ptov1 /// 
Med25_predicted 
Adaptor protein complex AP-2, alpha 1 subunit 
(predicted) /// Prostate tumor over expressed 
gene 1 /// Mediator of RNA polymerase II 
transcription, subunit 25 homolog (yeast) 
(predicted) 
1370198_at  0.65  -2.86  AJ243304  Trdn  triadin 
1386907_at  0.67  -2.96  NM_012949  Cpd  Carboxypeptidase D 
1368108_at  0.64  -4.05  NM_058213  Atp2a1  ATPase, Ca++ transporting, cardiac muscle, 
fast twitch 1 
1387235_at  0.61  -1.51  NM_021655  Chga  chromogranin A  
1378252_at  0.71  -1.62  AI029745  Chodl_predicted  chondrolectin (predicted) 
1390355_at  0.68  -2.14  AI575442  Ryr1  ryanodine receptor 1, skeletal muscle 
1391153_at  0.73  -1.52  BE101678  ---  Transcribed locus 
1368554_at  0.7  -1.56  NM_013161  Pnlip  pancreatic lipase  
1374677_at  0.97  -2.91  AI577508  LOC684425  similar to Adenylosuccinate synthetase 
isozyme 1  
1376227_at  0.94  -2.08  AI716887  RGD1561064_predicted  similar to myozenin 1 (predicted) 
1374934_at  0.91  -1.54  BF405151  Gpr39  G protein-coupled receptor 39 
1372296_at  0.88  -1.59  AA800892  RGD1563599_predicted  similar to putative SH3BGR protein (predicted) 
1395327_at  0.91  -1.91  AW522341  ---  Transcribed locus, weakly similar to 
XP_580018.1 PREDICTED: hypothetical 
protein XP_580018 [Rattus norvegicus] 
1367896_at  0.89  -3.45  AB030829  Ca3  carbonic anhydrase 3  
1370550_at  0.89  -1.48  U31554  Lsamp  limbic system-associated membrane protein 
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Table 7-5: Genes upregulated (<1% FDR) in the DRG at 6 weeks after dorsal root crush. 
AFFY. ID  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1387902_a_at  0  2.67  L22655  LOC500180 /// 
LOC500183 
similar to IG KAPPA CHAIN V-V REGION K2 
PRECURSOR /// similar to IG KAPPA CHAIN V-V 
REGION K2 PRECURSOR /// similar to NGF-
binding Ig light chain /// similar to NGF-binding Ig 
light chain 
1371447_at  0  1.98  BG378630  Plac8_predicted  placenta-specific 8 (predicted) 
1368187_at  0  2.11  NM_133298  Gpnmb  glycoprotein (transmembrane) nmb  
1371245_a_at  0  1.94  BI287300  LOC689064  similar to Hemoglobin beta-2 subunit (Hemoglobin 
beta-2 chain) (Beta-2-globin) (Hemoglobin beta 
chain, minor-form)  
1390798_at  0  1.87  BF288130  Ptprc  protein tyrosine phosphatase, receptor type, C  
1373386_at  0  2.05  AI179953  Gjb2  gap junction membrane channel protein beta 2 
1367553_x_at  0  1.81  NM_033234  Hbb  hemoglobin beta chain complex 
1371102_x_at  0  1.8  X05080  MGC72973  beta-glo 
1387125_at  0  2.29  NM_053587  S100a9  S100 calcium binding protein A9 (calgranulin B)  
1388602_at  0  1.87  AI237358  Cfd  complement factor D (adipsin) 
1369705_at  0  2.03  AI169634  Xtrp3  X transporter protein 3 
1370967_at  0.08  1.71  BG374683  Cldn10_predicted  Claudin 10 (predicted)  
1382083_at  0.15  1.82  BF287593  Coch_predicted  coagulation factor C homolog (Limulus 
polyphemus) (predicted)  
1391446_at  0.29  1.68  AA817742  Ms4a1_predicted  membrane-spanning 4-domains, subfamily A, 
member 1 (predicted) 
1374334_at  0.27  1.87  AI412189  Igha_mapped  immunoglobulin heavy chain (alpha polypeptide) 
(mapped) 
1382305_at  0.25  1.65  AI236814  Zfp364_predicted  Zinc finger protein 364 (predicted) 
1368422_at  0.24  1.7  NM_017149  Meox2  mesenchyme homeobox 2  
1395126_at  0.28  1.71  AI011393  Msr2_predicted  macrophage scavenger receptor 2 (predicted) 
1367985_at  0.26  1.65  NM_013197  Alas2  aminolevulinic acid synthase 2  
1397999_at  0.5  1.61  BF386502  Irs2  Insulin receptor substrate 2 
1395209_at  0.52  1.6  BM387740  Pank2_predicted  Pantothenate kinase 2 (Hallervorden-Spatz 
syndrome) (predicted) 
1385974_at  0.5  1.92  BM384723  Pard6g_predicted  par-6 partitioning defective 6 homolog gamma (C. 
elegans) (predicted) 
1369182_at  0.52  1.69  NM_013057  F3  coagulation factor III 
1368494_at  0.58  2.06  NM_053822  S100a8  S100 calcium binding protein A8 (calgranulin A)  
1376750_at  0.72  1.6  AA963477  ---  Transcribed locus 
1370240_x_at  0.73  1.63  AI179404  Hba-a1 /// 
LOC360504 
hemoglobin alpha, adult chain 1  
1375519_at  0.7  1.58  AI237401  LOC287167  globin, alpha  
1381997_at  0.71  1.64  BM386227  Adipoq  adiponectin, C1Q and collagen domain containing 
1394283_at  0.72  1.57  AW144132  Luc7l2_predicted  LUC7-like 2 (S. cerevisiae) (predicted) 
1372264_at  0.7  1.69  BI277460  Pck1  phosphoenolpyruvate carboxykinase 1  
1370892_at  0.68  1.62  BI285347  C4a /// C4-2  complement component 4a /// complement 
component 4, gene 2 
1375917_at  0.66  1.61  BF282961  Gp49b /// 
LOC499078 
glycoprotein 49b /// similar to GP49B1 
1374122_at  0.73  1.57  BM386808  Myo5c_predicted  myosin VC (predicted) 
1379766_at  0.71  1.64  AI500952  Sla  Src-like adaptor 
1381798_at  0.77  1.56  BE114958  LMO7  LIM domain only protein 7 
1395716_at  0.75  1.58  AW919386  ---  --- 
1370239_at  0.76  1.59  AI179404  Hba-a1 /// 
LOC360504 
hemoglobin alpha, adult chain 1  /// hemoglobin 
alpha 2 chain  
1390777_at  0.74  1.58  AI710051  Sc5d  sterol-C5-desaturase (fungal ERG3, delta-5-
desaturase) homolog (S. cerevisae)  
1385248_a_at  0.82  1.68  AA997590  Ogn_predicted  osteoglycin (predicted) 
1380050_at  0.8  1.58  AA819428  ---  Transcribed locus 
1388608_x_at  0.83  1.54  AI577319  Hba-a1 /// 
LOC360504 
hemoglobin alpha, adult chain 1  
1370607_a_at  0.81  1.54  U02323  Nrg1  neuregulin 1 
1370428_x_at  0.84  1.5  AJ249701  RT1-Aw2 /// RT1-
A2 /// RT1-A3 
RT1 class Ib, locus Aw2 /// RT1 class Ia, locus A2 
/// RT1 class I, A3 
1367847_at  0.95  1.62  NM_053611  Nupr1  nuclear protein 1  
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Table 7-6: Genes downregulated (1% FDR) in the DRG at 6 weeks after a dorsal root crush. 
AFFY. ID.  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1387133_at  0  -1.86  NM_053988  Calb2  calbindin 2 
1367962_at  0  -9.27  NM_133424  Actn3  actinin alpha 3  
1387787_at  0  -8.39  NM_012605  Myl2  myosin, light polypeptide 2  
1370033_at  0  -9.08  NM_020104  Mlc3  fast myosin alkali light chain 
1384269_at  0  -1.72  BF386887  ---  Transcribed locus 
1370900_at  0  -14.12  BM391169  Myh4  myosin, heavy polypeptide 4, skeletal 
muscle 
1377106_at  0  -5.94  AW533050  ---  Transcribed locus 
1372195_at  0  -8.73  BG663128  Tnnc2  troponin C type 2 (fast) 
1378252_at  0  -1.66  AI029745  Chodl_predicted  chondrolectin (predicted) 
1370971_at  0  -6.99  BI277545  Myh1 /// LOC691644  myosin, heavy polypeptide 1, skeletal 
muscle, adult  
1388604_at  0  -3.1  BI276959  LOC679341 /// 
LOC686019 
similar to Calsequestrin-1 precursor 
(Calsequestrin, skeletal muscle isoform)  
1369928_at  0.08  -4.79  NM_019212  Acta1  actin, alpha 1, skeletal muscle  
1367626_at  0.08  -6.48  NM_012530  Ckm  creatine kinase, muscle 
1387414_at  0.07  -1.58  NM_024141  Duox2  dual oxidase 2 
1390881_at  0.4  -1.66  AI172339  Abra  actin-binding Rho activating protein 
1370198_at  0.38  -3.15  AJ243304  Trdn  triadin 
1390355_at  0.41  -2.21  AI575442  Ryr1  ryanodine receptor 1, skeletal muscle 
1368554_at  0.39  -1.58  NM_013161  Pnlip  pancreatic lipase  
1395327_at  0.37  -3.09  AW522341  ---  Transcribed locus, weakly similar to 
XP_580018.1 PREDICTED: hypothetical 
protein XP_580018 [Rattus norvegicus] 
1371247_at  0.45  -5.61  BF521859  Ap2a1_predicted /// 
Ptov1 /// 
Med25_predicted 
Adaptor protein complex AP-2, alpha 1 
subunit (predicted) /// Prostate tumor over 
expressed gene 1 /// Mediator of RNA 
polymerase II transcription, subunit 25 
homolog (yeast) (predicted) 
1386907_at  0.52  -3.23  NM_012949  Cpd  Carboxypeptidase D 
1374677_at  0.59  -3.22  AI577508  LOC684425  similar to Adenylosuccinate synthetase 
isozyme 1 (Adenylosuccinate synthetase, 
muscle isozyme) (IMP--aspartate ligase 1) 
(AdSS 1) (AMPSase 1) 
1395406_at  0.7  -1.54  BF552212  Sbno1  Sno, strawberry notch homolog 1 
(Drosophila) 
1372296_at  0.67  -1.58  AA800892  RGD1563599_predicted  similar to putative SH3BGR protein 
(predicted) 
1394297_at  0.88  -1.46  BG670107  Hoxd1_predicted  homeo box D1 (predicted) 
1368788_at  0.85  -1.6  NM_019164  Chad  chondroadherin 
1367964_at  0.85  -3.21  NM_017185  Tnni2  troponin I type 2 (skeletal, fast) 
1384737_at  0.86  -2.11  BF555973  Trdn  Triadin 
1368108_at  0.9  -4.15  NM_058213  Atp2a1  ATPase, Ca++ transporting, cardiac muscle, 
fast twitch 1 
1371241_x_at  0.87  -3.57  AF370889  Tpm1  Tropomyosin 1, alpha 
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Table 7-7: Genes upregulated (<1% FDR) in the DRG at 6 weeks after spinal nerve crush. 
AFFY. ID  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1387125_at  0  3.26  NM_053587  S100a9  S100 calcium binding protein A9 (calgranulin 
B)  
1371245_a_at  0  2.88  BI287300  LOC689064  similar to Hemoglobin beta-2 subunit  
1367553_x_at  0  2.58  NM_033234  Hbb  hemoglobin beta chain complex 
1370913_at  0  2.57  AI409634  Best5  Best5 protein  
1368494_at  0  2.85  NM_053822  S100a8  S100 calcium binding protein A8 (calgranulin 
A)  
1371102_x_at  0  2.51  X05080  MGC72973  beta-glo 
1382031_at  0.14  2.38  AA859079  ---  Transcribed locus 
1370240_x_at  0.12  2.32  AI179404  Hba-a1 /// LOC360504  hemoglobin alpha, adult chain 1 /// 
hemoglobin alpha 2 chain 
1367985_at  0.11  2.34  NM_013197  Alas2  aminolevulinic acid synthase 2  
1368021_at  0.1  2.23  NM_130780  Adh1  alcohol dehydrogenase 1 (class I) 
1370239_at  0.09  2.28  AI179404  Hba-a1 /// LOC360504  hemoglobin alpha, adult chain 1 /// 
hemoglobin alpha 2 chain  
1375519_at  0.08  2.26  AI237401  LOC287167  globin, alpha  
1371447_at  0.08  2.1  BG378630  Plac8_predicted  placenta-specific 8 (predicted) 
1388142_at  0.14  2.05  AA850991  Cspg2  chondroitin sulfate proteoglycan 2 
1385248_a_at  0.13  2.38  AA997590  Ogn_predicted  osteoglycin (predicted) 
1370791_at  0.12  2.46  U16683  Hgfac  Hepatocyte growth factor activator 
1385229_at  0.18  2.42  AW524146  Pcdh20_predicted  protocadherin 20 (predicted) 
1388608_x_at  0.17  2.07  AI577319  Hba-a1 /// LOC360504  hemoglobin alpha, adult chain 1 /// 
hemoglobin alpha 2 chain 
1387943_at  0.16  2.19  U16686  Defa  defensin, alpha 5, Paneth cell-specific 
1374334_at  0.2  2.21  AI412189  Igha_mapped  immunoglobulin heavy chain (alpha 
polypeptide) (mapped) 
1387902_a_at  0.24  2.08  L22655  LOC500180 /// 
LOC500183 
similar to IG KAPPA CHAIN V-V REGION K2 
PRECURSOR /// similar to NGF-binding Ig 
light chain 
1369182_at  0.23  1.85  NM_013057  F3  coagulation factor III 
1373628_at  0.3  1.85  AA818342  ---  Transcribed locus 
1370234_at  0.29  1.79  AA893484  Fn1  fibronectin 1 /// fibronectin 1 
1370428_x_at  0.28  2.03  AJ249701  RT1-Aw2 /// RT1-A2 /// 
RT1-A3 
RT1 class Ib, locus Aw2 /// RT1 class Ia, 
locus A2 /// RT1 class I, A3 
1387134_at  0.31  1.86  NM_053687  Slfn3  schlafen 3 
1375917_at  0.33  1.73  BF282961  Gp49b /// LOC499078  glycoprotein 49b /// similar to GP49B1 
1393210_at  0.36  1.7  AI070116  ---  --- 
1389486_at  0.34  1.8  BE108354  ---  Transcribed locus  
1388557_at  0.4  1.69  BF284922  C7 /// Tubb2c  complement component 7 /// tubulin, beta 2c  
1369202_at  0.39  1.78  NM_017028  Mx2  myxovirus (influenza virus) resistance 2 
1393508_at  0.38  1.69  AI043805  ---  Transcribed locus 
1386641_at  0.36  1.7  BF546770  ---  Transcribed locus 
1392557_at  0.35  1.69  BF389151  Bicc1_predicted  Bicaudal C homolog 1 (Drosophila) 
(predicted) 
1381145_at  0.34  1.68  BE112469  ---  Transcribed locus 
1387874_at  0.33  1.78  AI230048  Dbp  D site albumin promoter binding protein  
1368459_at  0.32  1.81  NM_024375  Gdf10  growth differentiation factor 10 
1388602_at  0.34  1.71  AI237358  Cfd  complement factor D (adipsin) 
1381859_at  0.33  1.67  BE097018  LOC684063 /// 
LOC689997 
similar to F33H2.2  
1382153_at  0.4  1.68  AI171821  Clecsf6  C-type (calcium dependent, carbohydrate 
recognition domain) lectin, superfamily 
member 6  
1384707_at  0.39  1.68  AI600020  ---  Transcribed locus 
1392842_at  0.38  1.64  AI072951  ---  Transcribed locus, strongly similar to 
XP_220775.2 PREDICTED: similar to 
schlafen 5 [Rattus norvegicus] 
1368422_at  0.4  1.64  NM_017149  Meox2  mesenchyme homeobox 2  
1388138_at  0.39  1.63  X89963  Thbs4  thrombospondin 4 
1368304_at  0.4  1.67  NM_053433  Fmo3  flavin containing monooxygenase 3 
1387985_a_at  0.39  1.64  AB039825  Obp3  alpha-2u globulin PGCL4 
1391428_at  0.38  1.68  AI639162  ---  Transcribed locus 
1381504_at  0.38  1.65  AI639412  LOC306805  similar to asporin precursor 
1390450_a_at  0.39  1.63  AA945955  Ogn_predicted  osteoglycin (predicted) 
1387893_at  0.42  1.63  D88250  C1s /// 
RGD1561715_predicted 
complement component 1, s subcomponent  
1393064_at  0.43  1.69  AI709766  RGD1564108_predicted  Similar to hedgehog-interacting protein 
(predicted) 
1382587_at  0.46  1.62  AA901257  RGD1307084  Similar to RIKEN cDNA 1110001A07 gene  205 
Table 7-7 continued. 
1368474_at  0.53  1.6  NM_012889  Vcam1  vascular cell adhesion molecule 1  
1382108_at  0.52  1.59  AA900536  ---  Transcribed locus  
1390798_at  0.51  1.6  BF288130  Ptprc  protein tyrosine phosphatase, receptor type, 
C  
1388973_at  0.52  1.81  BM388861  Col9a1  procollagen, type IX, alpha 1  
1393603_at  0.6  1.76  AA998531  Camp  cathelicidin antimicrobial peptide 
1368303_at  0.64  1.81  NM_031678  Per2  period homolog 2 (Drosophila) 
1378745_at  0.64  1.64  BG374483  Tmem14a_predicted  Transmembrane protein 14A (predicted)  
1388116_at  0.63  1.61  BI285575  Col1a1  procollagen, type 1, alpha 1  
1395209_at  0.64  1.59  BM387740  Pank2_predicted  Pantothenate kinase 2 (Hallervorden-Spatz 
syndrome) (predicted) 
1393252_at  0.65  1.68  AA996804  ---  Transcribed locus 
1370810_at  0.65  1.56  L09752  Ccnd2  cyclin D2  
1387319_at  0.67  1.56  NM_019205  Ccl11  chemokine (C-C motif) ligand 11  
1381262_at  0.69  1.59  BG374101  Pbxip1  Pre-B-cell leukemia transcription factor 
interacting protein 1 
1388880_at  0.7  1.62  BI278962  ---  Transcribed locus 
1394940_at  0.72  1.56  BI294811  RGD1311381_predicted  similar to hypothetical protein FLJ20037 
(predicted) 
1367847_at  0.74  1.6  NM_053611  Nupr1  nuclear protein 1  
1368187_at  0.72  1.78  NM_133298  Gpnmb  glycoprotein (transmembrane) nmb  
1387756_s_at  0.76  1.65  NM_133294  Hemgn  hemogen 
1383708_at  0.82  1.56  BI303923  LOC498564  similar to integrin, beta-like 1 
1384063_at  0.85  1.65  AA958001  Cthrc1  collagen triple helix repeat containing 1  
 
 
Table 7-8:  Genes downregulated (<1% FDR) in the DRG at 6 weeks after spinal nerve crush. 
AFFY. ID  % 
FDR 
MEAN 
FC 
ACC. NO.  GENE SYMBOL  GENE TITLE 
1377106_at  1  -5.79  AW533050  ---  Transcribed locus 
1370900_at  0.67  -6.6  BM391169  Myh4  myosin, heavy polypeptide 4, skeletal 
muscle 
1372195_at  0.5  -6.89  BG663128  Tnnc2  troponin C type 2 (fast) 
1370033_at  0.4  -5.94  NM_020104  Mlc3  fast myosin alkali light chain 
1383827_at  0.5  -1.61  AI059119  Tlk1_predicted  tousled-like kinase 1 (predicted) 
1387787_at  0.43  -6.72  NM_012605  Myl2  myosin, light polypeptide 2  
1370971_at  0.62  -5.37  BI277545  Myh1 /// LOC691644  myosin, heavy polypeptide 1, skeletal 
muscle, adult /// similar to Myosin heavy 
chain, skeletal muscle, adult 2 (Myosin 
heavy chain IIa) (MyHC-IIa) 
1370198_at  0.56  -3.27  AJ243304  Trdn  triadin 
1384717_at  0.7  -1.55  AA894199  ---  --- 
1367626_at  0.64  -5.08  NM_012530  Ckm  creatine kinase, muscle 
1370550_at  0.75  -1.5  U31554  Lsamp  limbic system-associated membrane protein 
1388604_at  0.69  -2.82  BI276959  LOC679341 /// 
LOC686019 
similar to Calsequestrin-1 precursor 
(Calsequestrin, skeletal muscle isoform)  
1385491_at  0.64  -1.71  BF403514  RGD1560435_predicted  similar to KIAA1183 protein (predicted) 
1371247_at  0.6  -5.01  BF521859  Ap2a1_predicted /// Ptov1 
/// Med25_predicted 
Adaptor protein complex AP-2, alpha 1 
subunit (predicted) /// Prostate tumor over 
expressed gene 1 /// Mediator of RNA 
polymerase II transcription, subunit 25 
homolog (yeast) (predicted) 
1369928_at  0.62  -4.4  NM_019212  Acta1  actin, alpha 1, skeletal muscle  
1399073_at  0.65  -1.55  BI274378  Otub1_predicted  OTU domain, ubiquitin aldehyde binding 1 
(predicted) 
1387133_at  0.61  -1.48  NM_053988  Calb2  calbindin 2 
1374677_at  0.68  -3.21  AI577508  LOC684425  similar to Adenylosuccinate synthetase 
isozyme 1 (AdSS 1) (AMPSase 1) 
1368108_at  0.75  -4.04  NM_058213  Atp2a1  ATPase, Ca++ transporting, cardiac muscle, 
fast twitch 1 
1386907_at  0.86  -2.99  NM_012949  Cpd  Carboxypeptidase D 
1380695_at  0.82  -1.49  BM386352  ---  Transcribed locus, strongly similar to 
XP_580081.1 PREDICTED: hypothetical 
protein XP_580081 [Rattus norvegicus] 
1393555_at  0.78  -1.68  BG153357  Hspcb   similar to heat shock protein 1, beta  
1393615_at  0.75  -1.48  AI059603  RGD1561030_predicted  similar to DEP domain containing 6 
(predicted) 
1390630_at  0.76  -1.48  BE112446  ---  Transcribed locus 
1382441_at  0.85  -1.53  AI556402  Arid1b  AT rich interactive domain 1B (Swi1 like) 
1390881_at  0.93  -1.6  AI172339  Abra  actin-binding Rho activating protein  206 
Table 7-9:  Genes upregulated (<1% FDR) in the DRG at 2 weeks after dorsal column 
transection. 
 
AFFY. ID  % 
FDR 
MEAN FC  ACC. NO.  GENE SYMBOL  GENE TITLE 
1377146_at  0  87.59  AI412212  Vip  vasoactive intestinal polypeptide 
1387154_at  0  29.13  NM_012614  Npy  neuropeptide Y 
1368238_at  0  13.01  NM_053289  Pap  pancreatitis-associated protein 
1369268_at  0  11.13  NM_012912  Atf3  activating transcription factor 3  
1398243_at  0  9.65  NM_057144  Vsnl1  Visinin-like 1 
1384035_at  0  7.67  AW536030  LOC685277 /// 
LOC686794 
similar to liver-specific bHLH-Zip 
transcription factor  
1387088_at  0  6.14  NM_033237  Gal  galanin  
1368266_at  0  5.87  NM_017134  Arg1  arginase 1  
1392863_at  0  5.69  AA817953  Flrt3_predicted  fibronectin leucine rich 
transmembrane protein 3 (predicted) 
1393573_at  0  5.23  AI575628  Pde6b_predicted  phosphodiesterase 6B, cGMP, rod 
receptor, beta polypeptide (predicted) 
1381070_at  0  4.99  AI233106  Synpr  Synaptoporin  
1371450_at  0  5.03  BE117330  ---  Transcribed locus 
1383210_at  0  4.95  BF554576  ---  Transcribed locus 
1375661_at  0  4.76  BE104180  ---  Transcribed locus 
1371248_at  0  4.8  BI286387  LOC499660  similar to Cornifin A (Small proline-rich 
protein 1A) (SPR1A) (SPRR1) 
1382868_at  0  4.33  BM387083  Sema6a_predicted  sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6A (predicted)  
1378057_at  0  4.24  BE103354  Flrt3_predicted  fibronectin leucine rich 
transmembrane protein 3 (predicted) 
1392862_at  0  4.25  AA859389  Sema6a_predicted  Sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6A (predicted) 
1378700_at  0  3.85  BF403674  ---  Transcribed locus 
1376601_at  0  3.85  BF397526  Sema6a_predicted  sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6A (predicted) 
1374276_at  0  3.79  BE104102  LOC685277  Similar to liver-specific bHLH-Zip 
transcription factor 
1373513_at  0  3.61  AI012419  ---  Transcribed locus 
1371057_at  0  3.56  AW520967  Gabra5  gamma-aminobutyric acid (GABA-A) 
receptor, subunit alpha 5 
1368947_at  0  3.52  NM_024127  Gadd45a  growth arrest and DNA-damage-
inducible 45 alpha  
1388433_at  0  3.34  BI279605  Krt1-19  keratin complex 1, acidic, gene 19 
1393477_at  0  3.35  AI548924  ---  --- 
1370883_at  0  3.35  Y00480  RT1-Da  RT1 class II, locus Da  
1369649_at  0  3.32  AF400662  Cacna2d1  calcium channel, voltage-dependent, 
alpha2/delta subunit 1 
1368359_a_at  0  3.35  NM_030997  Vgf  VGF nerve growth factor inducible 
1384803_at  0  3.42  BI283351  RGD1565626_predicted 
/// 
RGD1561089_predicted 
/// LOC686064 /// 
LOC686125 
RGD1565626 (predicted) /// 
hypothetical protein LOC686125 
1386552_at  0  3.24  BF284027  ---  Transcribed locus 
1388451_at  0  3.16  AA817802  ---  Transcribed locus 
1368000_at  0  3.14  NM_016994  C3  complement component 3  
1382692_at  0  3.04  AI045955  RGD1565140_predicted  similar to Clecsf12 protein (predicted)  
1377334_at  0  3.07  BG378249  RT1-Ba  RT1 class II, locus Ba 
1370383_s_at  0  3.04  BI279526  RT1-Db1  RT1 class II, locus Db1 
1388944_at  0  2.9  BE109016  ---  Transcribed locus 
1368421_at  0.05  2.96  NM_019253  Ptpn5  protein tyrosine phosphatase, non-
receptor type 5 
1382017_at  0.05  2.83  AI012949  Rbp2  retinol binding protein 2, cellular 
1368657_at  0.05  2.96  NM_133523  Mmp3  matrix metallopeptidase 3  
1368188_at  0.05  2.76  NM_017233  Hpd  4-hydroxyphenylpyruvic acid 
dioxygenase 
1376390_at  0.05  2.76  BF395317  Ms4a11_predicted  membrane-spanning 4-domains, 
subfamily A, member 11 (predicted 
1367679_at  0.05  2.73  NM_013069  Cd74  CD74 antigen (invariant polypeptide of 
major histocompatibility complex, 
class II antigen-associated)   207 
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1397823_at  0.05  2.72  BE117531  Cacna2d1  Calcium channel, voltage-dependent, 
alpha2/delta subunit 1 
1371079_at  0.04  2.75  X73371  Fcgr2b  Fc receptor, IgG, low affinity IIb 
1377168_at  0.04  2.74  AI412673  Cpne9  copine family member IX 
1370315_a_at  0.04  2.66  AF026530  Stmn4  stathmin-like 4  
1389528_s_at  0.04  2.71  BI288619  Jun  Jun oncogene 
1370892_at  0.04  2.66  BI285347  C4a /// C4-2  complement component 4a /// 
complement component 4, gene 2 ///  
1383536_at  0.08  2.63  AI712541  Dhfr  Dihydrofolate reductase 
1384036_s_at  0.08  2.6  AW536030  ---  --- 
1398390_at  0.08  2.53  AA892854  LOC498335  similar to Small inducible cytokine B13 
precursor (CXCL13) (B lymphocyte 
chemoattractant) (CXC chemokine 
BLC)  
1387908_at  0.13  2.6  AF239157  Rasd1  RAS, dexamethasone-induced 1 
1369788_s_at  0.13  2.41  NM_021835  Jun  Jun oncogene 
1381190_at  0.13  2.45  AI598833  Prpf8  Pre-mRNA processing factor 8 
1370177_at  0.12  2.43  AI548856  PVR  poliovirus receptor  
1389696_at  0.12  2.44  BF409820  ---  Transcribed locus 
1381798_at  0.12  2.4  BE114958  LMO7  LIM domain only protein 7 
1387283_at  0.12  2.68  NM_134350  Mx2  myxovirus (influenza virus) resistance 
2  
1370249_at  0.12  2.34  AI008680  Bzrp  benzodiazepine receptor, peripheral 
1387930_at  0.11  2.62  L10229  Reg3a  regenerating islet-derived 3 alpha 
1382638_at  0.11  2.3  AI058645  Flrt3_predicted  Fibronectin leucine rich 
transmembrane protein 3 (predicted) 
1388711_at  0.13  2.31  BF282650  Il13ra1  interleukin 13 receptor, alpha 1 
1376100_at  0.12  2.35  BI274903  Tubb6  tubulin, beta 6 
1382960_at  0.14  2.3  BE108047  ---  Transcribed locus 
1371913_at  0.14  2.29  BG379319  Tgfbi  transforming growth factor, beta 
induced 
1376750_at  0.13  2.29  AA963477  ---  Transcribed locus 
1388557_at  0.13  2.25  BF284922  C7 /// Tubb2c  complement component 7 /// tubulin, 
beta 2c 
1379957_at  0.13  2.23  BE107457  Slfn8  schlafen 8 /// schlafen 8 
1383805_at  0.14  2.33  BG666454  RGD1561817_predicted  similar to Traf2 and NCK interacting 
kinase, splice variant 4 (predicted) 
1368353_at  0.14  2.23  NM_017009  Gfap  glial fibrillary acidic protein 
1377092_at  0.14  2.26  BF389682  ---  Transcribed locus  
1374404_at  0.14  2.3  BI288619  Jun  Jun oncogene  
1397400_at  0.14  2.25  BM391846  ---  Transcribed locus, moderately similar 
to XP_580018.1 PREDICTED: 
hypothetical protein XP_580018 
[Rattus norvegicus] 
1373368_at  0.15  2.22  BI279680  LOC684050  similar to procollagen C-
endopeptidase enhancer 2  
1370822_at  0.16  2.39  AF307302  RT1-Ba  RT1 class II, locus Ba  
1387221_at  0.16  2.27  NM_024356  Gch  GTP cyclohydrolase 1  
1376799_a_at  0.15  2.19  AA925924  Crlf1_predicted  cytokine receptor-like factor 1 
(predicted) 
1390687_at  0.15  2.2  AI556803  Plek  pleckstrin 
1383946_at  0.16  2.24  AI137640  Cldn1  claudin 1 
1380100_at  0.17  2.16  AW526268  RGD1561817_predicted  similar to Traf2 and NCK interacting 
kinase, splice variant 4 (predicted)  
1372734_at  0.17  2.16  AI408095  Smagp  small cell adhesion glycoprotein 
1368419_at  0.17  2.15  AF202115  Cp  ceruloplasmin 
1368923_at  0.17  2.14  AB023896  Ecel1  endothelin converting enzyme-like 1 
1390282_at  0.16  2.22  BI274639  LOC687052  similar to cytochrome P450, family 2, 
subfamily s, polypeptide 1 
1371033_at  0.17  2.44  AI715202  RT1-Bb  RT1 class II, locus Bb 
1382619_at  0.17  2.13  AI072460  ---  Transcribed locus 
1370428_x_at  0.17  2.83  AJ249701  RT1-Aw2 /// RT1-A2 /// 
RT1-A3 
RT1 class Ib, locus Aw2 /// RT1 class 
Ia, locus A2 /// RT1 class I, A3 
1384013_at  0.17  2.12  BF524215  Chl1  cell adhesion molecule with homology 
to L1CAM 
1388496_at  0.16  2.18  AI103600  Flnc_predicted  filamin C, gamma (actin binding 
protein 280) (predicted) 
1392946_at  0.2  2.1  AI029194  ---  Transcribed locus  
1370391_at  0.19  2.15  U23407  Crabp2  cellular retinoic acid binding protein 2 
1378531_at  0.19  2.09  AI555775  ---  Transcribed locus 
1376911_at  0.19  2.12  BM386385  ---  Transcribed locus 
1368224_at  0.19  2.18  NM_031531  Serpina3n  serine (or cysteine) peptidase 
inhibitor, clade A, member 3N   208 
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1369904_at  0.2  2.06  NM_012956  Gabrb1  gamma-aminobutyric acid (GABA-A) 
receptor, subunit beta 1 
1387893_at  0.2  2.06  D88250  C1s /// 
RGD1561715_predicted 
complement component 1, s 
subcomponent  
1367930_at  0.22  2.05  NM_017195  Gap43  growth associated protein 43 
1376562_at  0.24  2.11  BI291396  RGD1561817_predicted  similar to Traf2 and NCK interacting 
kinase, splice variant 4 (predicted) 
1372359_at  0.24  2.07  BI291423  RGD1310090  similar to 2310043K02Rik protein 
1393679_at  0.26  2.04  BE102362  ---  Transcribed locus 
1387005_at  0.26  2.03  NM_017320  Ctss  cathepsin S  
1379766_at  0.27  2.02  AI500952  Sla  Src-like adaptor 
1381145_at  0.27  2.02  BE112469  ---  Transcribed locus 
1390713_at  0.26  2.01  BF410051  ---  Transcribed locus 
1390798_at  0.28  1.99  BF288130  Ptprc  protein tyrosine phosphatase, 
receptor type, C  
1374280_at  0.28  2.01  AA817812  Cbln2  cerebellin 2 precursor protein 
1388547_at  0.34  2.01  BE328951  Cldn4  claudin 4  
1372516_at  0.35  1.98  AI317842  Kif22  kinesin family member 22 
1388045_a_at  0.35  1.96  D83348  Cdh22  cadherin 22 
1371447_at  0.35  1.96  BG378630  Plac8_predicted  placenta-specific 8 (predicted) 
1370830_at  0.35  2.1  M37394  Egfr  epidermal growth factor receptor  
1389579_at  0.34  1.97  BI284372  ---  Transcribed locus 
1368412_a_at  0.34  2  D45412  Ptpro  protein tyrosine phosphatase, 
receptor type, O 
1381341_at  0.34  2.01  BE111796  Gabbr1  Gamma-aminobutyric acid (GABA) B 
receptor 1 
1369029_at  0.34  1.96  NM_057194  Plscr1  phospholipid scramblase 1 
1383234_at  0.35  1.98  BF405850  ---  Transcribed locus 
1390525_a_at  0.34  1.94  BI284420  Stra6  stimulated by retinoic acid gene 6 
homolog (mouse) 
1393508_at  0.4  1.96  AI043805  ---  Transcribed locus 
1391605_at  0.4  2  BG666431  ---  Transcribed locus, strongly similar to 
XP_342569.2 PREDICTED: similar to 
protein tyrosine phosphatase, 
receptor type, T isoform 1 precursor 
[Rattus norvegicus] 
1370913_at  0.39  2  AI409634  Best5  Best5 protein  
1388742_at  0.39  1.95  AA945877  ---  --- 
1381331_at  0.39  2.01  AI638953  Cklfsf1  chemokine-like factor super family 1 
1383391_a_at  0.4  1.93  AI716125  C2  complement component 2 
1390450_a_at  0.4  1.95  AA945955  Ogn_predicted  osteoglycin (predicted) 
1372254_at  0.4  1.91  AW915763  Serping1  serine (or cysteine) peptidase 
inhibitor, clade G, member 1 G,  
1368590_at  0.4  1.96  NM_080776  Mmp16  matrix metalloproteinase 16 
1382031_at  0.4  2  AA859079  ---  Transcribed locus 
1388419_at  0.4  1.95  AW915005  Acly  ATP citrate lyase 
1389373_at  0.4  1.93  AI029555  Smad1  MAD homolog 1 (Drosophila)  
1396451_at  0.41  1.96  BF393275  ---  Transcribed locus 
1373357_at  0.41  1.91  BI291467  ---  Transcribed locus 
1392110_at  0.4  2.08  AA818585  ---  Transcribed locus 
1367847_at  0.45  1.92  NM_053611  Nupr1  nuclear protein 1  
1383936_at  0.45  1.9  BM386842  Emilin2_predicted  Elastin microfibril interfacer 2 
(predicted) 
1394908_at  0.45  1.94  AW529671  Adcyap1  Adenylate cyclase activating 
polypeptide 1 
1394940_at  0.44  1.9  BI294811  RGD1311381_predicted  similar to hypothetical protein 
FLJ20037 (predicted) 
1395126_at  0.44  1.99  AI011393  Msr2_predicted  macrophage scavenger receptor 2 
(predicted) 
1368892_at  0.44  1.94  NM_016989  Adcyap1  adenylate cyclase activating 
polypeptide 1  
1379995_at  0.45  1.94  BE113173  Tubb2b  Tubulin, beta 2b 
1379573_at  0.45  1.88  AA818730  Ctps_predicted  Cytidine 5'-triphosphate synthase 
(predicted) 
1369182_at  0.45  1.91  NM_013057  F3  coagulation factor III 
1370382_at  0.45  2.01  BI279526  RT1-Bb  RT1 class II, locus Bb 
1369705_at  0.46  1.94  AI169634  Xtrp3  X transporter protein 3 
1374273_at  0.47  1.88  BG665433  Cxadr  Coxsackie virus and adenovirus 
receptor 
1375043_at  0.46  1.88  BF415939  Fos  FBJ murine osteosarcoma viral 
oncogene homolog  
1368418_a_at  0.46  1.88  AF202115  Cp  ceruloplasmin 
1396208_at  0.46  1.9  BM389807  Ggtla1  gamma-glutamyltransferase-like 
activity 1  209 
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1368422_at  0.47  1.9  NM_017149  Meox2  mesenchyme homeobox 2  
1381089_at  0.49  1.93  BE114458  ---  Transcribed locus 
1391630_at  0.5  1.86  BF420033  ---  Transcribed locus, strongly similar to 
XP_236458.3 PREDICTED: similar to 
T-box transcription factor TBX18 
[Rattus norvegicus] 
1396263_at  0.51  1.86  BI301147  ---  Transcribed locus, strongly similar to 
XP_234584.3 PREDICTED: similar to 
RIKEN cDNA 4831426I19 [Rattus 
norvegicus] 
1389006_at  0.5  1.88  AI170394  ---  Transcribed locus, moderately similar 
to NP_035543.1 sex-limited protein 
[Mus musculus] 
1375056_at  0.51  1.87  AA943310  ---  --- 
1371527_at  0.57  1.84  BI275741  Emp1  epithelial membrane protein 1 
1393469_at  0.56  1.84  BE102340  ---  --- 
1382153_at  0.6  1.84  AI171821  Clecsf6  C-type (calcium dependent, 
carbohydrate recognition domain) 
lectin, superfamily member 6  
1367974_at  0.6  1.84  NM_012823  Anxa3  annexin A3 
1387134_at  0.63  2.06  NM_053687  Slfn3  schlafen 3 
1385475_a_at  0.64  1.83  AI030451  Stra6  stimulated by retinoic acid gene 6 
homolog (mouse) 
1371245_a_at  0.65  1.87  BI287300  LOC689064  similar to Hemoglobin beta-2 subunit 
(Hemoglobin beta-2 chain) (Beta-2-
globin) (Hemoglobin beta chain, 
minor-form)  
1371988_at  0.65  1.82  AA892549  Man1a_predicted  mannosidase 1, alpha (predicted) 
1376652_at  0.71  1.85  BF418957  C1qa  complement component 1, q 
subcomponent, alpha polypeptide 
1379404_at  0.71  1.82  AI598327  ---  Transcribed locus 
1367849_at  0.72  1.84  NM_013026  Sdc1  syndecan 1  
1393638_at  0.71  1.82  AI549199  Ptger4  Prostaglandin E receptor 4 (subtype 
EP4) 
1393210_at  0.72  1.81  AI070116  ---  --- 
1397361_x_at  0.74  1.84  AI407549  ---  --- 
1387113_at  0.74  1.81  NM_053335  Ctbp2  C-terminal binding protein 2 
1370075_at  0.74  1.86  NM_130400  Dhfr  dihydrofolate reductase  
1381682_at  0.78  1.83  BE106750  ---  --- 
1387007_at  0.8  1.82  NM_012959  Gfra1  glial cell line derived neurotrophic 
factor family receptor alpha 1 
1396835_at  0.81  1.79  BE095505  ---  Transcribed locus, strongly similar to 
XP_579880.1 PREDICTED: 
hypothetical protein XP_579880 
[Rattus norvegicus] 
1375270_at  0.81  1.8  BM384026  ---  Transcribed locus 
1391383_at  0.81  1.84  BF413778  Crtac1  cartilage acidic protein 1 
1372042_at  0.81  1.82  BI294844  Cmtm3_predicted  CKLF-like MARVEL transmembrane 
domain containing 3 (predicted) 
1389496_at  0.82  1.8  BI300893  Akap7  A kinase (PRKA) anchor protein 7 
1382305_at  0.82  1.8  AI236814  Zfp364_predicted  Zinc finger protein 364 (predicted) 
1385248_a_at  0.81  1.79  AA997590  Ogn_predicted  osteoglycin (predicted) 
1388674_at  0.84  1.78  AI010427  Cdkn1a  cyclin-dependent kinase inhibitor 1A  
1368834_at  0.84  1.78  AA894330  Camk2d  calcium/calmodulin-dependent protein 
kinase II, delta 
1386529_at  0.85  1.85  BF564309  ---  Transcribed locus  
1388792_at  0.9  1.81  AI599423  Gadd45g  growth arrest and DNA-damage-
inducible 45 gamma  
1375825_at  0.89  1.86  BM382867  ---  --- 
1368021_at  0.9  1.82  NM_130780  Adh1  alcohol dehydrogenase 1 (class I) 
1374171_at  0.9  1.78  AI170507  ---  Transcribed locus 
1370234_at  0.92  1.77  AA893484  Fn1  fibronectin 1  
1375145_at  0.94  1.79  AI548036  RGD1565886_predicted  RGD1565886 (predicted) 
1373575_at  0.94  1.76  BE111722  LOC498279  similar to NADH dehydrogenase 
(ubiquinone) Fe-S protein 2 
1374557_at  0.94  1.76  BF394235  LOC362065  CG6210-like 
1381755_x_at  0.94  1.76  BI288309  RGD1304563_predicted  similar to RIKEN cDNA 4831426I19 
(predicted) 
1377161_at  0.94  1.78  BG378317  ---  Transcribed locus 
1368332_at  0.94  1.77  NM_133624  Gbp2  guanylate nucleotide binding protein 2 
1385751_at  0.93  1.77  BF408413  Thbs2  thrombospondin 2 
1391660_at  0.93  1.78  AI412900  ---  Transcribed locus, moderately similar 
to XP_576460.1 PREDICTED: similar 
to hypothetical protein PB402898.00.0   210 
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1370628_at  0.93  1.88  M34097  Gzmb  granzyme B 
1376204_at  0.93  1.76  AW531412  ---  Transcribed locus 
1373975_at  0.94  1.8  AI232716  LOC368066  similar to indolethylamine N-
methyltransferase 
1375917_at  0.94  1.75  BF282961  Gp49b /// LOC499078  glycoprotein 49b /// similar to GP49B1 
1390937_at  0.94  1.75  AW523875  RGD1309051  similar to chromosome 14 open 
reading frame 50 
1383291_at  0.96  1.77  BF282631  C7 /// Tubb2c  complement component 7 /// tubulin, 
beta 2c 
1368708_a_at  0.97  1.76  NM_012547  Drd2  dopamine receptor 2  
1389368_at  0.97  1.77  AW253242  Cnksr3  Cnksr family member 3 
1369713_at  0.98  1.77  M99418  Cckbr  cholecystokinin B receptor 
1374065_at  0.99  1.74  BG378920  Met  Met proto-oncogene 
1373911_at  1  1.91  BM389026  Postn_predicted  periostin, osteoblast specific factor 
(predicted)  
 
 
Table 7-10: Genes downregulated (<1% FDR) in the DRG at 2 weeks after dorsal column 
transection. 
AFFY. ID.  % 
FDR 
MEAN FC  ACC. NO.  GENE SYMBOL  GENE TITLE 
1387133_at  0  -4.94  NM_053988  Calb2  calbindin 2 
1388349_at  0  -5.16  AA799557  ---  --- 
1374787_at  0  -4.04  BI282169  ---  Transcribed locus 
1377163_at  0  -3.81  BM385741  Inhbb  inhibin beta-B  
1376980_at  0  -3.72  BF285539  ---  Transcribed locus 
1391575_at  0  -3.49  BG380566  ---  --- 
1382914_at  0  -3.36  AA924097  ---  Transcribed locus 
1370900_at  0  -9.97  BM391169  Myh4  myosin, heavy polypeptide 4, skeletal 
muscle 
1368407_at  0  -3.09  NM_022605  Hpse  heparanase 
1374035_at  0  -3.08  BI296482  ---  Transcribed locus 
1385731_at  0  -3.07  BE113552  ---  Transcribed locus 
1390530_at  0  -3.14  AI169239  ---  Transcribed locus 
1387065_at  0  -2.95  NM_080688  Plcd4  phospholipase C, delta 4  
1371077_at  0  -2.92  AI575989  Htr3b  5-hydroxytryptamine (serotonin) 
receptor 3b 
1394297_at  0  -3.03  BG670107  Hoxd1_predicted  homeo box D1 (predicted) 
1396366_at  0  -3.07  BF409020  ---  Transcribed locus 
1370214_at  0  -2.83  AI175539  Pvalb  parvalbumin 
1391563_at  0  -2.95  AA963184  RGD1565148_predicted  similar to melanoma associated 
antigen (mutated) 1-like 1 (predicted) 
1384269_at  0  -2.93  BF386887  ---  Transcribed locus 
1377106_at  0  -6.9  AW533050  ---  Transcribed locus 
1393952_at  0  -2.74  BI278833  RGD1561424_predicted  similar to CTCL tumor antigen se57-1 
(predicted) 
1396676_at  0  -2.87  BF394718  ---  Transcribed locus 
1380828_at  0  -2.69  AI145413  Gabra1  gamma-aminobutyric acid A receptor, 
alpha 1 
1371211_a_at  0  -2.61  U02315  Nrg1  neuregulin 1 
1382439_at  0  -2.72  AI070686  Itgb6  integrin, beta 6  
1387309_a_at  0  -2.64  AI111480  Grik1  glutamate receptor, ionotropic, 
kainate 1 
1393299_at  0  -2.68  BF567794  Dpp10  dipeptidylpeptidase 10 
1369001_at  0  -2.6  NM_052805  Chrna3  cholinergic receptor, nicotinic, alpha 
polypeptide 3  
1369144_a_at  0  -2.6  NM_031739  Kcnd3  potassium voltage gated channel, 
Shal-related family, member 3 
1370033_at  0  -8.31  NM_020104  Mlc3  fast myosin alkali light chain 
1367962_at  0  -7.24  NM_133424  Actn3  actinin alpha 3  
1369428_a_at  0  -2.58  U28430  Htr3a  5-hydroxytryptamine (serotonin) 
receptor 3a 
1381499_at  0  -2.57  BM390226  ---  Transcribed locus 
1391764_at  0  -2.58  BE119571  ---  Transcribed locus 
1372195_at  0  -8.75  BG663128  Tnnc2  troponin C type 2 (fast) 
1370404_at  0  -2.49  AF440736  LOC266776  cystatin TE-1 
1386695_at  0.03  -2.45  BF565756  ---  --- 
1394252_at  0.03  -2.48  BG668764  Spock3_predicted  sparc/osteonectin, cwcv and kazal-
like domains proteoglycan 3 
(predicted)  211 
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1398623_at  0.03  -2.46  AI454607  Chrnb4  cholinergic receptor, nicotinic, beta 
polypeptide 4 
1390958_at  0.12  -2.43  AW528339  ---  Transcribed locus 
1378288_at  0.12  -2.36  BI292167  RGD1311100_predicted  similar to RIKEN cDNA D630035O19 
(predicted)  
1371049_at  0.12  -2.37  BF413467  Dpysl4  dihydropyrimidinase-like 4 
1369137_at  0.12  -2.36  NM_017194  Chrne  cholinergic receptor, nicotinic, epsilon 
polypeptide 
1396276_at  0.11  -2.34  BG662898  ---  Transcribed locus 
1394097_at  0.11  -2.38  AA849706  ---  Transcribed locus 
1382123_at  0.11  -2.33  AI574734  ---  --- 
1387787_at  0.11  -7.08  NM_012605  Myl2  myosin, light polypeptide 2  
1385491_at  0.1  -2.46  BF403514  RGD1560435_predicted  similar to KIAA1183 protein 
(predicted) 
1368749_at  0.1  -2.35  NM_053954  Kcns1  K+ voltage-gated channel, subfamily 
S, 1 
1386310_at  0.1  -2.38  AI412779  ---  Transcribed locus  
1381233_at  0.1  -2.29  AW528010  ---  Transcribed locus 
1371212_at  0.1  -2.41  U02315  Nrg1  neuregulin 1 
1388604_at  0.11  -3.41  BI276959  LOC679341 /// 
LOC686019 
similar to Calsequestrin-1 precursor 
(Calsequestrin, skeletal muscle 
isoform) 
1382924_at  0.11  -2.31  AA850195  Pank1_predicted  pantothenate kinase 1 (predicted) 
1370971_at  0.11  -5.96  BI277545  Myh1 /// LOC691644  myosin, heavy polypeptide 1, skeletal 
muscle, adult /// similar to Myosin 
heavy chain, skeletal muscle, adult 2  
1378470_at  0.11  -2.26  BM384409  Paqr5  progestin and adipoQ receptor family 
member V 
1393933_at  0.11  -2.25  AW144823  Sorl1_predicted  sortilin-related receptor, L(DLR class) 
A repeats-containing (predicted) 
1384393_at  0.1  -2.27  BE120370  ---  Transcribed locus 
1390362_at  0.1  -2.24  BF394081  ---  Transcribed locus 
1370439_a_at  0.1  -2.29  M34052  Kcnc2  potassium voltage gated channel, 
Shaw-related subfamily, member 2  
1371247_at  0.11  -5.89  BF521859  Ap2a1_predicted /// 
Ptov1 /// 
Med25_predicted 
Adaptor protein complex AP-2, alpha 
1 subunit (predicted) /// Prostate 
tumor over expressed gene 1 /// 
Mediator of RNA polymerase II 
transcription, subunit 25 homolog 
(yeast) (predicted) 
1378310_at  0.11  -2.24  BG669018  RGD1562710_predicted  similar to neuromedin B precursor - 
rat (predicted) 
1388968_at  0.13  -2.2  BF402642  ---  Transcribed locus 
1386907_at  0.12  -3.69  NM_012949  Cpd  Carboxypeptidase D 
1395333_at  0.12  -2.21  AW533483  LOC679370 /// 
LOC688790 
similar to Myelin P2 protein  
1367626_at  0.12  -5.55  NM_012530  Ckm  creatine kinase, muscle 
1396040_at  0.13  -2.23  BE108568  Shank1  SH3 and multiple ankyrin repeat 
domains 1 
1386119_at  0.13  -2.3  BE110033  LOC689147  Hypothetical protein LOC689147 
1368958_at  0.13  -2.16  NM_017294  Pacsin1  protein kinase C and casein kinase 
substrate in neurons 1 
1395487_at  0.13  -2.19  BF400826  ---  Transcribed locus 
1368740_at  0.13  -2.2  NM_012721  P2rxl1  purinergic receptor P2X-like 1, orphan 
receptor 
1387058_at  0.12  -2.17  NM_017225  Pctp  phosphatidylcholine transfer protein 
1385043_at  0.12  -2.19  AA924649  RGD1565362_predicted  similar to channel-interacting PDZ 
domain protein isoform 1 (predicted) 
1387602_a_at  0.12  -2.17  NM_022189  Htr3b  5-hydroxytryptamine (serotonin) 
receptor 3b 
1392221_at  0.12  -2.18  BE114215  RGD1562371_predicted  Similar to GREB1 protein isoform a 
(predicted) 
1379458_at  0.12  -2.18  AW533900  RGD1566178_predicted  similar to Kelch-like protein 14 
(predicted) 
1394837_at  0.13  -2.2  BF405797  ---  --- 
1369928_at  0.14  -4.76  NM_019212  Acta1  actin, alpha 1, skeletal muscle  
1378876_at  0.14  -2.13  BE114024  ---  Transcribed locus 
1378111_at  0.14  -2.14  AI576002  ---  Transcribed locus 
1367762_at  0.14  -2.15  NM_012659  Sst  somatostatin  
1368524_at  0.13  -2.16  NM_012856  Kcnc1  potassium voltage gated channel, 
Shaw-related subfamily, member 1 
1371089_at  0.13  -2.13  AA945082  ---  Transcribed locus  
1374743_at  0.13  -2.16  BE115056  RGD1565362_predicted  similar to channel-interacting PDZ 
domain protein isoform 1 (predicted)  212 
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1370198_at  0.14  -3.34  AJ243304  Trdn  triadin 
1368751_at  0.15  -2.14  NM_031778  Kcns3  potassium voltage-gated channel, 
delayed-rectifier, subfamily S, 
member 3 
1396542_at  0.15  -2.14  BF393011  ---  Transcribed locus 
1369677_at  0.15  -2.21  X55812  ---  --- 
1368853_at  0.16  -2.16  NM_012686  Vsnl1  visinin-like 1 
1375518_at  0.16  -4.07  AI104533  Ttn  titin 
1376225_at  0.16  -2.11  BF411924  Csen  Calsenilin, presenilin binding protein, 
EF hand transcription factor 
1393626_at  0.16  -2.11  BF562507  Sorl1_predicted  sortilin-related receptor, L(DLR class) 
A repeats-containing (predicted) 
1368561_at  0.17  -2.11  NM_033352  Abcd2  ATP-binding cassette, sub-family D 
(ALD), member 2  
1383582_at  0.18  -2.1  BG377582  Tmem54  transmembrane protein 54 
1379894_at  0.18  -2.09  AI501165  RGD1310110_predicted  similar to 3632451O06Rik protein 
(predicted) 
1368108_at  0.21  -4.61  NM_058213  Atp2a1  ATPase, Ca++ transporting, cardiac 
muscle, fast twitch 1 
1374677_at  0.21  -3.33  AI577508  LOC684425  similar to Adenylosuccinate 
synthetase isozyme 1  
1393253_at  0.2  -2.13  BF408799  Zfp365  zinc finger protein 365 
1367733_at  0.2  -2.14  NM_019291  Ca2  carbonic anhydrase 2  
1375026_at  0.2  -2.07  AI105369  LOC688757  Hypothetical protein LOC688757 
1372423_at  0.22  -2.07  BI286396  Perp_predicted  PERP, TP53 apoptosis effector 
(predicted)  
1378136_at  0.23  -2.06  BF403749  ---  --- 
1376944_at  0.22  -2.08  AI407163  Prlr  Prolactin receptor 
1375066_at  0.25  -2.05  H33003  RGD1563319_predicted  similar to RIKEN cDNA 6330512M04 
gene (predicted) 
1380455_at  0.25  -2.04  BM389422  ---  Transcribed locus, moderately similar 
to XP_853274.1 PREDICTED: 
hypothetical protein XP_848181 
[Canis familiaris] 
1384866_at  0.25  -2.04  AI070096  Entpd3  ectonucleoside triphosphate 
diphosphohydrolase 3 
1377857_at  0.25  -2.08  BF291163  ---  Transcribed locus 
1369953_a_at  0.25  -2.05  BI285141  Cd24  CD24 antigen 
1392880_at  0.26  -2.04  BG665051  ---  --- 
1370517_at  0.26  -2.03  U18772  Nptx1  neuronal pentraxin 1 
1391153_at  0.27  -2.04  BE101678  ---  Transcribed locus 
1394412_at  0.27  -2.06  AI144648  Tmem16c_predicted  transmembrane protein 16C 
(predicted) 
1381575_at  0.28  -3.1  AI638986  ---  Transcribed locus 
1368506_at  0.28  -2.01  U27767  Rgs4  regulator of G-protein signaling 4 
1384080_at  0.28  -2.06  AA924955  ---  Transcribed locus 
1385633_at  0.28  -2.03  AA817878  ---  Transcribed locus 
1368554_at  0.29  -2.03  NM_013161  Pnlip  pancreatic lipase  
1394821_at  0.29  -2.04  BF399731  ---  Transcribed locus 
1394578_at  0.29  -2.04  BI299761  Gria2  Glutamate receptor, ionotropic, 
AMPA2  
1383566_at  0.29  -2  AW527690  ---  Transcribed locus 
1395546_at  0.29  -2.02  AW529685  ---  Transcribed locus 
1391656_at  0.29  -2.03  AI101416  ---  --- 
1390652_at  0.28  -2.02  BF390059  ---  Transcribed locus  
1371162_at  0.28  -2.01  AJ311952  Mrga10  nuclear receptor MrgA10 RF-amide G 
protein-coupled receptor 
1394577_at  0.29  -2.02  BI279384  ---  Transcribed locus 
1388060_at  0.29  -1.98  U71294  Syt12  synaptotagmin XII 
1377773_at  0.29  -2  AW522872  ---  Transcribed locus, weakly similar to 
NP_766020.1 RIKEN cDNA 
C030002O17 [Mus musculus] 
1384737_at  0.29  -2.32  BF555973  Trdn  Triadin 
1370625_at  0.3  -1.99  AF044201  Faim2  Fas apoptotic inhibitory molecule 2 
1392189_at  0.3  -2.01  BE105136  RGD1562092_predicted  similar to regulatory factor X 4 variant 
(predicted) 
1398649_at  0.3  -1.98  AA819827  Slitrk3_predicted  SLIT and NTRK-like family, member 3 
(predicted)  
1385321_at  0.29  -2.04  AW532713  LOC683275 /// 
LOC688502 
similar to heterogeneous nuclear 
ribonucleoprotein methyltransferase-
like 4 /// similar to Protein arginine N-
methyltransferase 4  
1386120_at  0.31  -1.99  BF393607  LOC679389 /// 
LOC689147 
hypothetical protein LOC679389 /// 
hypothetical protein LOC689147  213 
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1384236_at  0.3  -1.97  BI281089  ---  CDNA clone IMAGE:7315883 
1377457_a_at  0.31  -1.97  AA850618  Sorl1_predicted  sortilin-related receptor, L(DLR class) 
A repeats-containing (predicted) 
1380865_at  0.31  -1.96  BM385284  ---  Transcribed locus  
1390707_at  0.32  -1.95  BI281632  Rgs10  regulator of G-protein signalling 10 
1395327_at  0.32  -2.31  AW522341  ---  Transcribed locus, weakly similar to 
XP_580018.1 PREDICTED: 
hypothetical protein XP_580018 
[Rattus norvegicus] 
1369035_a_at  0.32  -1.96  AB073753  Kcnj6  potassium inwardly-rectifying channel, 
subfamily J, member 6 
1370124_at  0.32  -1.94  NM_053968  Mt3  metallothionein 3  
1375242_at  0.32  -1.96  BI296440  LOC687797  similar to tumor suppressor candidate 
5 
1378026_at  0.31  -1.95  BE109912  ---  Transcribed locus 
1373637_at  0.32  -1.97  BG372823  ---  --- 
1378105_at  0.34  -1.93  BF289201  ---  Transcribed locus 
1397497_at  0.34  -1.96  BF391164  ---  Transcribed locus 
1367745_at  0.33  -1.92  NM_031143  Dgkz  diacylglycerol kinase zeta 
1371241_x_at  0.33  -3.05  AF370889  Tpm1  Tropomyosin 1, alpha 
1394295_at  0.36  -1.97  BG672252  ---  Transcribed locus 
1370556_at  0.35  -1.95  M24104  Vamp1  vesicle-associated membrane protein 
1 
1383014_at  0.35  -1.94  AI639078  ---  Transcribed locus 
1384696_at  0.35  -1.93  BE113106  MGC116197  similar to RIKEN cDNA 1700001E04 
1396023_at  0.35  -1.94  AW522736  ---  Transcribed locus  
1378252_at  0.36  -2.02  AI029745  Chodl_predicted  chondrolectin (predicted) 
1369043_at  0.35  -1.92  NM_012971  Kcna4  potassium voltage-gated channel, 
shaker-related subfamily, member 4 
1390881_at  0.35  -1.95  AI172339  Abra  actin-binding Rho activating protein 
1391246_at  0.36  -1.92  BF390318  RGD1561985_predicted  similar to dystrobrevin alpha isoform 1 
(predicted) 
1390710_x_at  0.35  -1.91  AA850618  Sorl1_predicted  sortilin-related receptor, L(DLR class) 
A repeats-containing (predicted) 
1384923_at  0.35  -1.92  AI137998  ---  Transcribed locus, strongly similar to 
XP_236620.3 PREDICTED: similar to 
RIKEN cDNA 6430571L13 gene 
[Rattus norvegicus] 
1397840_at  0.36  -1.93  BF563826  ---  Transcribed locus 
1369755_at  0.35  -1.9  AF106624  B3gat2  beta-1,3-glucuronyltransferase 2 
(glucuronosyltransferase S) 
1394070_at  0.36  -1.9  AA893087  ---  --- 
1368182_at  0.39  -1.89  NM_130739  Acsl6  acyl-CoA synthetase long-chain family 
member 6  
1382147_at  0.39  -1.88  AI229479  LOC363915  similar to CG14446-PA 
1370546_at  0.39  -1.91  U75361  Unc13c  unc-13 homolog C (C. elegans) 
1367964_at  0.41  -2.79  NM_017185  Tnni2  troponin I type 2 (skeletal, fast) 
1368789_at  0.42  -1.88  NM_020072  Acpp  acid phosphatase, prostate  
1395536_at  0.42  -1.88  BG673248  ---  Transcribed locus 
1379814_at  0.43  -1.9  AW532796  ---  CDNA clone IMAGE:7302159 
1384655_at  0.44  -1.85  AW142820  Kirrel3_predicted  kin of IRRE like 3 (Drosophila) 
(predicted) 
1388506_at  0.46  -1.86  AW144509  Dsp  desmoplakin 
1369116_a_at  0.46  -1.86  NM_017338  Calca  calcitonin/calcitonin-related 
polypeptide, alpha 
1374046_at  0.46  -1.87  BG376092  Hs3st2  heparan sulfate (glucosamine) 3-O-
sulfotransferase 2 
1382965_at  0.45  -1.88  AA996630  Amigo3  Amphoterin induced gene and ORF 3 
1368768_at  0.46  -1.85  NM_019265  Scn11a  sodium channel, voltage-gated, type 
XI, alpha 
1380228_at  0.45  -1.91  BG672066  RGD1306880_predicted  similar to hypothetical protein 
MGC47816 (predicted) 
1386922_at  0.46  -1.88  AI408948  Ca2  carbonic anhydrase 2 
1379054_at  0.47  -1.88  BF391881  Kcnc1  Potassium voltage gated channel, 
Shaw-related subfamily, member 1  
1383642_at  0.46  -1.87  BG374114  ---  --- 
1390355_at  0.47  -2.12  AI575442  Ryr1  ryanodine receptor 1, skeletal muscle 
1390146_at  0.49  -1.86  BF414998  ---  --- 
1378857_at  0.49  -1.86  AI716196  LOC678833  similar to transcription elongation 
factor A (SII)-like 5 
1387375_at  0.52  -1.83  NM_031855  Khk  ketohexokinase 
1388000_at  0.52  -1.83  AF021923  Slc24a2  solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 2  214 
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1371570_at  0.52  -1.85  AI406266  Scrt1_predicted  scratch homolog 1, zinc finger protein 
(Drosophila) (predicted) 
1376928_at  0.53  -1.89  BE106737  RGD1565950_predicted  Similar to A disintegrin-like and 
metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 2 
(predicted) 
1370078_at  0.53  -1.85  NM_021758  ---  Transcribed locus 
1368124_at  0.53  -1.82  NM_133578  Dusp5  dual specificity phosphatase 5 
1369158_at  0.53  -1.82  NM_016996  Casr  calcium-sensing receptor 
1377374_at  0.53  -1.84  AI146055  ---  Transcribed locus 
1391653_at  0.55  -1.83  BE120391  Gabrg2  gamma-aminobutyric acid A receptor, 
gamma 2 
1377924_at  0.57  -1.84  BE113414  ---  Transcribed locus 
1373697_at  0.57  -2.36  BG378588  Mybpc2_predicted  myosin binding protein C, fast-type 
(predicted)  
1372755_at  0.57  -1.83  AI102073  Mal2  mal, T-cell differentiation protein 2 
1394786_at  0.58  -1.85  AW526631  Sorl1_predicted  sortilin-related receptor, L(DLR class) 
A repeats-containing (predicted) 
1378163_at  0.58  -1.83  AA817956  ---  Transcribed locus 
1380011_at  0.57  -1.81  BM383573  ---  Transcribed locus, moderately similar 
to XP_576460.1 PREDICTED: similar 
to hypothetical protein PB402898.00.0  
1393040_at  0.58  -1.83  BE097656  ---  Transcribed locus 
1398099_at  0.58  -1.82  AW527241  ---  --- 
1393262_at  0.61  -1.84  BG379771  ---  Transcribed locus, strongly similar to 
XP_574942.1 PREDICTED: similar to 
regulatory factor X-associated protein 
[Rattus norvegicus]  
1376424_at  0.61  -1.82  BF412664  ---  Transcribed locus 
1379510_at  0.62  -1.83  BF546306  ---  Transcribed locus  
1393197_at  0.63  -1.8  BG376055  Abhd8_predicted  abhydrolase domain containing 8 
(predicted) 
1393547_at  0.63  -1.8  BE101549  RGD1560399_predicted  similar to hypothetical protein 
C630023L15 (predicted) 
1375690_at  0.63  -1.84  AI138004  ---  --- 
1376463_at  0.64  -1.81  AA955579  ---  Transcribed locus 
1384202_at  0.64  -1.8  BI287326  RGD1566317_predicted  similar to Tescalcin (predicted) 
1384780_at  0.64  -1.8  BF402747  Cpne4_predicted  copine IV (predicted) 
1372745_at  0.64  -2.14  BE112453  ---  --- 
1370111_at  0.66  -1.81  NM_019314  Kcnn2  potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 2  
1371052_at  0.68  -1.82  AA859752  Nog  noggin 
1374528_at  0.67  -1.79  BF418764  Rgs3  Regulator of G-protein signalling 3 
1378107_at  0.67  -1.81  AI146051  ---  Transcribed locus 
1391013_at  0.67  -1.86  AW523567  Pcdh8  Protocadherin 8 
1383220_at  0.68  -1.8  BE114231  Kcnip4  Kv channel interacting protein 4 
1390815_at  0.68  -1.82  BF282870  Cnnm1_predicted  cyclin M1 (predicted) 
1370550_at  0.68  -1.77  U31554  Lsamp  limbic system-associated membrane 
protein 
1394522_at  0.68  -1.78  AW527950  ---  Transcribed locus, weakly similar to 
XP_508524.1 PREDICTED: similar to 
phospholipase C, beta 3 
(phosphatidylinositol-specific) [Pan 
troglodytes] 
1377828_at  0.68  -1.8  BG672090  Tmem16c_predicted  transmembrane protein 16C 
(predicted) 
1388891_at  0.68  -1.79  BG374285  ---  Transcribed locus 
1374785_at  0.68  -1.78  BG380471  RGD1565373_predicted  similar to CD69 antigen (p60, early T-
cell activation antigen) (predicted) 
1387821_at  0.7  -1.8  NM_017313  Rab3ip  RAB3A interacting protein 
1384158_at  0.69  -1.82  AW522416  ---  Transcribed locus 
1368351_at  0.69  -1.77  NM_017247  Scn10a  sodium channel, voltage-gated, type 
10, alpha polypeptide 
1398306_at  0.69  -2.31  J02811  Ampd1  adenosine monophosphate 
deaminase 1 (isoform M) 
1396459_at  0.69  -1.78  BE096723  Isl2  Insulin related protein 2 (islet 2) 
1382011_at  0.69  -1.78  AI100797  ---  Transcribed locus, strongly similar to 
NP_796210.2 plasma membrane 
calcium ATPase 3 [Mus musculus] 
1389550_at  0.7  -1.77  BM385941  Sh3gl2  SH3-domain GRB2-like 2 
1385826_at  0.72  -1.78  AA860047  ---  Transcribed locus 
1381001_at  0.73  -1.78  BE105897  Kbtbd3_predicted  Kelch repeat and BTB (POZ) domain 
containing 3 (predicted)  215 
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1384756_at  0.75  -1.79  BF394311  Slc43a2_predicted  Solute carrier family 43, member 2 
(predicted) 
1380107_a_at  0.75  -1.76  BM384521  RGD1305719_predicted  similar to putative N-acetyltransferase 
Camello 2 (predicted) 
1385311_at  0.75  -1.8  BI274649  Slco5a1_predicted  solute carrier organic anion 
transporter family, member 5A1 
(predicted)  
1383542_at  0.78  -1.76  BI282819  ---  Transcribed locus 
1381445_at  0.77  -1.79  AA996810  Esrrg  Estrogen-related receptor gamma 
1391521_at  0.78  -1.75  AA858748  Casp12  Caspase 12 
1368255_at  0.78  -1.78  NM_017354  Hnt  neurotrimin 
1368339_at  0.78  -1.78  NM_012521  S100g  S100 calcium binding protein G  
1388802_at  0.78  -1.76  AI579422  Bex1  brain expressed X-linked 1 
1374363_at  0.78  -1.75  AI232693  RGD1306028  similar to hypothetical protein 
FLJ30473 
1376311_at  0.78  -1.78  BM391312  RGD1563465_predicted  similar to netrin G1 (predicted) 
1388543_at  0.81  -1.77  BI291257  RGD1306289_predicted  similar to HTPAP protein (predicted) 
1396127_at  0.8  -1.76  BF288545  ---  --- 
1368801_at  0.81  -1.76  NM_053342  Cxxc4  CXXC finger 4 
1397983_at  0.82  -1.76  BF403330  ---  Transcribed locus 
1391326_at  0.82  -1.75  BE095733  RGD1562292_predicted  similar to homeotic protein Hox B5 - 
mouse (predicted) 
1398298_at  0.82  -1.75  NM_012852  Htr1d  5-hydroxytryptamine (serotonin) 
receptor 1D 
1393404_at  0.81  -1.74  BF554746  ---  Transcribed locus, strongly similar to 
NP_808376.1 reticulon 4 receptor-like 
1 [Mus musculus] 
1391200_at  0.81  -1.76  AW530290  ---  Transcribed locus 
1370606_at  0.81  -1.76  U22830  P2ry1  purinergic receptor P2Y, G-protein 
coupled 1  
1383499_at  0.81  -1.75  BG371995  ---  --- 
1370125_at  0.82  -1.77  NM_019189  Ngef_predicted  Neuronal guanine nucleotide 
exchange factor (predicted) 
1371554_at  0.82  -2.2  AA799471  LOC688173  similar to Telethonin (Titin cap 
protein) 
1394290_at  0.82  -1.77  BG669921  ---  Transcribed locus 
1370944_at  0.82  -1.75  AI230238  Col10a1  procollagen, type X, alpha 1 
1391547_at  0.83  -1.8  AI045669  ---  CDNA clone IMAGE:7320555 
1375032_at  0.83  -1.76  AI412533  RGD1565261_predicted  similar to kinase non-catalytic C-lobe 
domain (KIND) containing 1 isoform b 
(predicted) 
1388741_at  0.85  -2.06  AW533234  LOC683555 /// 
LOC688915 
similar to cardiomyopathy associated 
5  
1388139_at  0.85  -3.66  BI277586  LOC691644  similar to Myosin heavy chain, 
skeletal muscle, adult 2a  
1390123_at  0.85  -1.76  BI279036  Tmem45b  transmembrane protein 45b 
1379374_at  0.85  -1.76  AW526088  Prg1  plasticity related gene 1 
1398182_at  0.86  -1.75  BF411782  ---  Transcribed locus 
1388037_at  0.87  -1.74  J05087  Atp2b3  ATPase, Ca++ transporting, plasma 
membrane 3 
1392865_at  0.87  -1.75  BG371594  ---  --- 
1385445_at  0.89  -1.81  BE119167  ---  Transcribed locus, strongly similar to 
XP_233112.3 PREDICTED: similar to 
extracellular matrix protein QBRICK 
[Rattus norvegicus] 
1391879_at  0.89  -1.74  AA964161  ---  Transcribed locus 
1376893_at  0.9  -1.74  AI406821  Vmp_predicted  vesicular membrane protein p24 
(predicted) 
1367896_at  0.9  -1.49  AB030829  Ca3  carbonic anhydrase 3  
1387799_at  0.9  -1.74  AF129400  Fxyd2  FXYD domain-containing ion transport 
regulator 2 
1383554_at  0.89  -1.76  AW142796  RGD1566282_predicted  similar to RIKEN cDNA D330045A20 
(predicted) 
1392950_at  0.9  -2.31  BF552973  Myot_predicted  myotilin (predicted) 
1395714_at  0.9  -1.73  AT005664  ---  --- 
1374934_at  0.9  -1.79  BF405151  Gpr39  G protein-coupled receptor 39 
1369165_at  0.9  -1.73  NM_021771  Trpc3  transient receptor potential cation 
channel, subfamily C, member 3 
1394545_at  0.9  -1.73  AA998459  Spire2_predicted  spire homolog 2 (Drosophila) 
(predicted) 
1377942_at  0.92  -1.73  AI101595  ---  Transcribed locus 
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b) Ingenuity pathways analysis  
 
Figure 7-1: Key to IPA node types used in networks. 
 
Figure 7-2: Key to IPA edge types used in networks.  217 
c) qRT-PCR descriptive statistics 
i)  Pilot microarray 
Table 7-11: Descriptive statistics for genes investigated in validation of pilot microarray 
GENE  GROUP  FINAL N MEAN CT 
(±S.E) 
CV% 
naïve  5  33.228 (0.259)  0.779 
sham  5  33.580 (0.405)  1.206 
ECEL1 
sciatic trans. 6  29.582 (0.349)  1.180 
naive  5  30.432 (0.283)  0.930 
sham  6  31.033 (0.452)  1.457 
ATF3 
sciatic trans. 6  26.960 (0.250)  0.927 
naive  5  29.690 (0.282)  0.950 
sham  6  30.587 (0.382)  1.249 
MX2 
sciatic trans. 6  29.065 (0.270)  0.929 
naive   6  26.227 (0.363)  1.384 
sham  6  27.720 (0.356)  1.284 
NPTX1 
sciatic trans. 6  29.542 (0.651)  2.204 
naive  6  28.737 (0.359)  1.249 
sham  6  30.683 (0.511)  1.665 
SEMA6A 
sciatic trans  6  28.108 (0.461)  1.640 
 
 
ii) Main microarray  
Table 7-12: ATF3 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  8  29.521 (0.952)  3.225 
2DR  8  27.845 (0.348)  1.250 
2DR sham  7  28.917 (0.296)  1.024 
6DR  7  28.087 (0.344)  1.225 
6DR sham  8  29.528 (0.165)  0.559 
SN  7  25.709 (0.810)  3.151 
SN sham  7  27.603 (0.627)  2.271 
2DC  7  28.926 (0.602)  2.081 
2DC sham  5  29.702 (0.235)  0.791 
6DC  5  29.134 (0.263)  0.903 
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Table 7-13: ANKRD1 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  6  36.175 (0.268)  0.741 
2DR  6  34.513 (0.270)  0.782 
2DR sham  8  34.893 (0.481)  1.378 
6DR  7  34.946 (0.394)  1.127 
6DR sham  8  35.566 (0.380)  1.068 
SN  7  31.503 (0.421)  1.336 
SN sham  8  33.579 (0.567)  1.689 
2DC  7  34.786 (0.244)  0.701 
2DC sham  7  34.371 (0.481)  1.399 
6DC  5  33.656 (0.205)  0.615 
 
Table 7-14: SEMA6A descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  7  31.129 (0.956)  3.071 
2DR  8  30.386 (0.230)  0.757 
2DR sham  8  30.566 (0.287)  0.939 
6DR  8  39.369 (0.269)  0.886 
6DR sham  8  31.778 (0.353)  1.111 
SN  8  28.741 (0.521)  1.813 
SN sham  8  30.224 (0.534)  1.767 
2DC  8  30.728 (0.279)  0.908 
2DC sham  8  29.624 (0.288)  0.927 
6DC  7  29.393 (0.380)  1.293 
 
Table 7-15: PTPN5 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  5  30.988 (0.371)  1.197 
2DR  8  29.881 (0.290)  0.971 
2DR sham  6  30.567 (0.209)  0.684 
6DR  6  30.283 (0.298)  0.984 
6DR sham  7  30.983 (0.456)  1.472 
SN  8  28.754 (0.467)  1.624 
SN sham  8  29.979 (0.369)  1.231 
2DC  7  30.493 (0.369)  1.210 
2DC sham  8  30.213 (0.263)  0.870 
6DC  7  30.061 (0.227)  0.755 
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Table 7-16: BDNF descriptive statistics     
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  8  27.450 (0.770)  2.807 
2DR  7  25.990 (0.455)  1.751 
2DR sham  6  26.542 (0.295)  1.111 
6DR  8  26.124 (0.310)  1.187 
6DR sham  7  27.453 (0.316)   1.151 
SN  8  26.669 (0.435)  1.629 
SN sham  7  26.997 (0.487)  1.804 
2DC  8   27.138 (0.418)  1.540 
2DC sham  8  26.408 (0.366  1.386 
6DC  7  26.603 (0.318)  1.195 
 
 
Table 7-17: IGF1 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  8  26.290 (0.704)  2.678 
2DR  8  25.453 (0.382)  1.501 
2DR sham  8  25.049 (0.240)  0.958 
6DR  7  25.064 (0.249)  0.993 
6DR sham  8  26.195 (0.236)  0.901 
SN  8  25.930 (0.385)  1.485 
SN sham  8  25.490 (0.379)  1.487 
2DC  8  25.630 (0.421)  1.643 
2DC sham  8  24.644 (0.394)  1.599 
6DC  7  24.977 (0.326)  1.305 
 
 
Table 7-18: WISP2 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  8  31.074 (0.405)  1.303 
2DR  8  29.745 (0.476)  1.600 
2DR sham  8  30.425 (0.302)  0.993 
6DR  8  30.145 (0.551)  1.828 
6DR sham  7  31.071 (0.397)  1.278 
SN  8  30.473 (0.408)  1.339 
SN sham  8  29.780 (0.467)  1.568 
2DC  8  30.021 (0.372)  1.239 
2DC sham  8  29.354 (0.416)  1.417 
6DC  6  29.985 (0.365)  1.217  220 
Table 7-19: TFPI2 descriptive statistics 
GROUP  FINAL N  MEAN CT (±S.E)  CV% 
Naïve ctrl  7  33.014 (0.508)  1.539 
2DR  7  31.487 (0.244)  0.775 
2DR sham  8  31.516 (0.230)  0.730 
6DR  7  31.779 (0.152)  0.478 
6DR sham  8  32.565 (0.346)  1.062 
SN  7  31.953 (0.316)  0.989 
SN sham  8  32.320 (0.253)  0.783 
2DC  7  31.884 (0.435)  1.364 
2DC sham  7  31.436 (0.453)  1.441 
6DC  5  32.370 (0.213)  0.658 
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